Document:

exv10w17

 

Exhibit 10.17

LEASE

     THIS LEASE (“Lease”), dated as of October 25, 2005, is made by and between TRIUMPH 1450 LLC, a
Colorado limited liability company (“Landlord”), and REPLIDYNE, INC., a Delaware corporation
(“Tenant”) (collectively, the “Parties,” and individually, a “Party”).

RECITALS

     A. Maxtor Realty Corporation, a Delaware corporation (“Maxtor Realty”), is the fee owner of
certain real property in Boulder County, Colorado, commonly called 1450 Infinite Drive, Louisville,
Colorado 80027, together with the building (“Building”) and other improvements thereon and the
appurtenant parking and landscaped areas (collectively, the “Project”).

     B. Maxtor Realty had leased the Project to Maxtor Corporation, a Delaware corporation
(“Maxtor”), pursuant to that certain Master Lease dated as of September 10, 1996.

     C. Maxtor has subleased the Premises (as defined below) to Tenant pursuant to that certain
Sublease dated as of August 1, 2005 (the “Sublease”).

     D. Maxtor Realty has entered into a purchase agreement with Landlord, pursuant to which Maxtor
Realty has agreed to sell the Project to Landlord and Landlord has agreed to purchase the Project
from Maxtor Realty.

     E. Landlord desires that (i) the parties to the Sublease terminate the Sublease as of the date
hereof, and (ii) Tenant enter into this Lease with Landlord.

     NOW, THEREFORE, in consideration of the mutual promises contained herein, and for other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the
Parties hereby agree as follows:

1. BASIC PROVISIONS (“BASIC PROVISIONS”).

     1.1 Premises: Approximately 3,423 rentable square feet (“RSF”) of clean room space (“Clean
Room Space”) in Section C1 of the Building, approximately 11,851 RSF of office space (“Office
Space”) in Section S1 of the Building, approximately 12,709 RSF of laboratory space (“Lab Space”)
in Section L1 of the Building, approximately 5,725 RSF of office space (“Office Space”) in Section
S2 of the Building, approximately 7,948 RSF of office space (“Office Space”) in Section E2 of the
Building and approximately 765 RSF of storage space (“Storage Space”) in the Building, all as
depicted on Exhibit A hereto, for a total RSF of 42,421 (collectively, the “Premises”).
The portion of the Premises consisting of (a) approximately 5,725 RSF in Section S2 of the
Building, and (b) approximately 7,948 RSF in Section E2 of the Building, as the same are depicted
on Exhibit A hereto are collectively called herein, the “New Office Space”.

 

 

     1.2 Term: The initial term of this Lease (the “Initial Term”) shall commence on the date
hereof (“Commencement Date”) and shall expire on September 30, 2011 (“Initial Expiration Date”).
The Initial Term, along with any extensions thereof, is herein called, the “Term”. The Initial
Expiration Date, as the same may be extended by the Option Term (as defined in Paragraph 53 below)
or sooner terminated in accordance with the provisions of this Lease, is herein called, the
“Expiration Date”.

     1.3 Base Rent; Payment Schedule:

          (a) Base Rent: Tenant shall pay to Landlord a monthly base rent (“Base Rent”), payable in
equal monthly payments according to the payment schedule (“Payment Schedule”) set forth in
Paragraph 1.3(b) below with each such monthly payment due and payable on the first (1st)
day of each month during the Term. The Payment Schedule has been calculated using the following
factors: (1) a rate of $22.00 per RSF for Clean Room Space; (2) a rate of $8.00 per RSF for Office
Space; (3) a rate of $10.00 per RSF for Lab Space; (4) a rate of $3.00 per RSF for Storage Space;
(5) the rentable square footage of the Premises; and (6) the payment terms of the Prior Lease.
Notwithstanding the foregoing, provided that no Default or Breach (as such terms are defined in
Paragraph 13.1 below) has occurred and is continuing, (i) the monthly Base Rent for the New Office
Space (S2 & E2) shall be abated in its entirety for the first six (6) months after August 1, 2005,
(ii) monthly Base Rent for the Clean Room Space (C1) shall be abated in its entirety during the
period from January 1, 2006 through and including September 10, 2006, and (iii) monthly Base Rent
for the Lab Space (L1) and the Office Space (S1) shall be abated in its entirety during the period
from August 1, 2005 through and including October 31, 2005. Beginning on August 1, 2006 and on
each annual anniversary thereafter, Base Rent for the New Office Space (E2 & S2) shall be increased
by seven percent (7%) over the Base Rent for the prior twelve (12) month period. Beginning on
October 1, 2007, and on each annual anniversary thereafter, Base Rent for the Premises leased by
Tenant hereunder (other than with respect to the New Office Space) shall be increased by seven
percent (7%) over the Base Rent for the prior twelve (12) month period.

          (b) Base Rent Payment Schedule: All of the monthly payment amounts set forth below are for
Base Rent only and do not include Additional Rent (as defined in Paragraph 4.1 below):

	 	 	—	August 2005 through October 2005, a monthly payment of
Thirteen Thousand, Seven Hundred and Fifty Two Dollars and Five Cents
($13,752.05);
	 
	 	 	—	November 2005 through December 2005, a monthly payment of
Fifty Two Thousand, Three Hundred Fifty Three Dollars and Forty Six Cents
($52,353.46);
	 
	 	 	—	January 2006, a monthly payment of Forty Three Thousand, Five
Hundred Ten Dollars and Seventy One Cents ($43,510.71);
	 
	 	 	—	February 2006 through July 2006, a monthly payment of Fifty
Two Thousand, Six Hundred Twenty Six Dollars and Four Cents ($52,626.04);

2

 

	 	 	—	August 2006, a monthly payment of Fifty Three Thousand, Two
Hundred Sixty Four Dollars and Twelve Cents ($53,264.12);
	 
	 	 	—	September 2006, a monthly payment of Forty Thousand, Eight
Hundred Ninety Five Dollars and Eighty One Cents ($40,895.81);
	 
	 	 	—	October 2006 through July 2007, a monthly payment of Thirty
Four Thousand, Seven Hundred Eleven Dollars and Sixty Six Cents
($34,711.66);
	 
	 	 	—	August 2007 through September 2007, a monthly payment of
Thirty Five Thousand, Three Hundred Ninety Four Dollars and Forty Cents
($35,394.40);
	 
	 	 	—	October 2007 through July 2008, a monthly payment of Thirty
Seven Thousand, One Hundred Forty One Dollars and Forty Seven Cents
($37,141.47);
	 
	 	 	—	August 2008 through September 2008, a monthly payment of
Thirty Seven Thousand, Eight Hundred Seventy Two Dollars and Zero Cents
($37,872.00);
	 
	 	 	—	October 2008 through July 2009, a monthly payment of Thirty
Nine Thousand, Seven Hundred Forty One Dollars and Thirty Eight Cents
($39,741.38);
	 
	 	 	—	August 2009 through September 2009, a monthly payment of Forty
Thousand, Five Hundred Twenty Three Dollars and Four Cents ($40,523.04);
	 
	 	 	—	October 2009 through July 2010, a monthly payment of Forty Two
Thousand, Five Hundred Twenty Three Dollars and Twenty Seven Cents
($42,523.27);
	 
	 	 	—	August 2010 through September 2010, a monthly payment of Forty
Three Thousand, Three Hundred Fifty Nine Dollars and Sixty Six Cents
($43,359.66);
	 
	 	 	—	October 2010 through July 2011, a monthly payment of Forty
Five Thousand, Four Hundred Ninety Nine Dollars and Ninety Cents
($45,499.90); and
	 
	 	 	—	August 2011 through September 2011, a monthly payment of Forty
Six Thousand, Three Hundred Ninety Four Dollars and Eighty Three Cents
($46,394.83).

     1.4 Security Deposit: Tenant has deposited with Landlord the sum of Thirty Six Thousand, One
Hundred and Fifty Dollars ($36.150.00) as a security deposit (the “Security

3

 

Deposit”) to secure Tenant’s obligations hereunder and otherwise in accordance with the terms
of Paragraph 5 below.

     1.5 Agreed Use: The Premises shall be used for the following uses and no others:
administration, manufacturing, design, research and development to the extent such uses are
permitted by Applicable Requirements (as defined in Paragraph 2.3 below). The Parties hereto
acknowledge that Tenant may use in the Premises certain chemicals, biochemicals and low-level
radiation consistent with a typical operation of a research-focused biotechnology company, provided
that such use complies with the terms of this Lease, including without limitation, the provisions
contained in Paragraph 6.2 below.

     1.6 Insuring Party: Landlord is the “Insuring Party” unless otherwise stated herein.

     1.7 Real Estate Brokers: The following real estate brokers (the “Brokers”) and brokerage
relationships exist in this transaction: None.

     1.8 Exhibits: Attached hereto are Exhibit A through Exhibit G which
constitute a part of this Lease.

2. PREMISES.

     2.1 Leasing. Landlord hereby leases to Tenant, and Tenant hereby leases from Landlord, the
Premises, for the Term, at the rental, and upon all of the terms, covenants and conditions set
forth in this Lease. Any statement regarding the rentable square footage of the Building, the
Premises or any portion thereof as set forth in this Lease, or that may have been used in
calculating Rent (as defined in Paragraph 4.1 below), is an approximation which the Parties agree
is reasonable and Rent based thereon is not subject to revision or re-measurement.

     2.2 Delivery. Tenant shall accept the New Office Space in their condition as of the
Commencement Date. Landlord shall have no obligation for any defects in the Premises. Tenant’s
taking possession of the New Office Space shall be conclusive evidence that Tenant accepts the New
Office Space and that the New Office Space were in good condition at the time possession was taken.
Tenant acknowledges that (a) Tenant shall be responsible, at its sole cost and expense, for any
work required or desirable in preparing the New Office Space for Tenant’s occupancy and/or use
during the Term, and (b) Tenant is in possession of the Premises pursuant to the Sublease.

     2.3 Compliance. Landlord shall be responsible for any non-compliance with any and all laws,
covenants or restrictions of record, building codes, regulations and ordinances (“Applicable
Requirements”) applicable to the Common Areas (as defined in Paragraph 2.5(a) below) and in effect
on the Commencement Date and/or during the Term, provided that all costs and expenses related to
any such non-compliance may be included by Landlord in Operating Expenses (as defined in Paragraph
4.3(c) below) if permitted under Paragraph 4.3 hereof. Landlord shall have no responsibility for
non-compliance with Applicable Requirements arising out of or related to the specific use to which
Tenant will put the Premises and any Alterations or Utility Installations (as such terms are
defined in Paragraph 7.3(a) below) made or to be made by Tenant. Tenant is responsible for
determining whether or not the zoning is appropriate for

4

 

Tenant’s intended use. If the Applicable Requirements are hereafter changed so as to require
during the Term any action in connection with the Premises as a result of Tenant’s specific use of
the Premises or any Alterations or Utility Installations, including without limitation, the
remediation of any Hazardous Substance (as defined in Paragraph 6.2(b) below), Tenant shall be
fully responsible for the cost thereof. Tenant hereby agrees to be responsible for the compliance
of the Premises and Tenant’s use thereof with all Applicable Requirements related thereto during
the term that Tenant had possession of the Premises or any portion thereof.

     2.4 “As Is” Condition. Tenant acknowledges that it is thoroughly familiar with the condition
of the Premises, the Building and the Project; and Tenant agrees that it is leasing the Premises on
an “As Is” basis, subject to all patent defects, without any representation or warranty by Landlord
or any of the Landlord Parties as to the condition of the Premises, the Building or the Project or
their fitness for Tenant’s use or any particular purpose, and subject to all applicable zoning,
municipal, county and state laws, ordinances and regulations governing and regulating the use of
the Premises, and any easements, covenants or restrictions of record.

     2.5 Common Areas; Building Amenities.

          (a) Common Areas. Landlord hereby grants to Tenant the right to non-exclusive use of any
portion of the Building or Project that Landlord designates, in Landlord’s sole discretion, as for
the common use of tenants and others, including without limitation, the shipping/receiving docks
and areas, the common entrances and exits and the elevators (collectively, “Common Areas”).
Landlord shall have the right, in its sole discretion, to change, add to, reduce or regulate the
Common Areas (or the use thereof) from time to time, provided that the same does not have a
material adverse effect on Tenant’s business activities in the Premises.

          (b) Building Amenities. At no Additional Rent to Tenant, Landlord hereby grants to Tenant the
right to non-exclusive use of the Building’s fitness center with men and women’s locker rooms,
shipping/receiving areas and electrical power back-up systems, and outdoor basketball and
volleyball courts (collectively, the “Facilities”), the Building’s cafeteria and full service
kitchen, and the Building’s break rooms (collectively, the “Amenities”), subject to the following
terms and conditions:

               (i) Tenant shall permit only its officers and employees to use the Facilities (“Permitted
Users”).

               (ii) Tenant’s use of the Amenities shall be subject to compliance with such policies and
procedures as Landlord may establish in its sole discretion from time to time regarding such use,
including without limitation, policies relating to use of equipment located therein, hours of
operation, conduct and dress requirements.

               (iii) Tenant covenants, as a condition of the use by each of the Permitted Users of the
Facilities, including without limitation, the outdoor basketball and volleyball courts, to obtain
from each and deliver to Landlord an executed Release in the form attached hereto as Exhibit
B.

5

 

               (iv) Tenant’s use of the Building’s cafeteria and full service kitchen shall require the prior
written approval of Landlord, which Landlord may withhold in its sole discretion, and shall be at
Tenant’s pro-rata cost, including but not limited to, the cost of food, labor, maintenance,
equipment, necessary improvements and any other associated costs.

          (c) Landlord shall have the right, in its sole discretion, to change, add to, reduce or
regulate the Amenities (or the use thereof) from time to time, provided that the same does not have
a material adverse effect on Tenant’s business activities in, and use of, the Premises.

3. TERM.

     3.1 Term. The Commencement Date, Expiration Date and Term of this Lease are as specified in
Basic Provisions above.

4. RENT.

     4.1 Additional Rent; Rent. All sums due under this Lease, other than Base Rent, are called
“Additional Rent”. Tenant shall pay all Additional Rent to Landlord upon demand unless otherwise
provided hereunder. Base Rent and Additional Rent shall be referred to collectively as “Rent.”

     4.2 Payment. Tenant shall cause payment of Base Rent and other Rent, as the same may be
adjusted from time to time, to be received by Landlord in lawful money of the United States,
without offset or deduction (except as specifically permitted in this Lease), on or before the day
on which it is due. Base Rent and other Rent for any period during the Term which is for less than
one (1) full calendar month shall be prorated based upon the actual number of days of said month.
Payment of Base Rent and other Rent shall be made to Landlord at its address stated herein or to
such other persons or place as Landlord may from time to time designate in writing. Acceptance of
a payment which is less than the amount then due shall not be a waiver of Landlord’s rights to the
balance of such Base Rent and other Rent, regardless of Landlord’s endorsement of any check so
stating.

     4.3 Operating Expenses.

          (a) Triple Net Lease. The Base Rent to be paid by Tenant to Landlord is intended to be
absolutely triple net. As such, beginning (i) on the Commencement Date with regard to the New
Office Space, and (ii) on September 11, 2006 with regard to the Premises other than the New Office
Space, and continuing through the Term, Tenant shall pay as Additional Rent an amount equal to
Tenant’s Proportionate Share of Sector Operating Expenses for each Sector (as such terms are
defined in this Paragraph 4.3 below). Landlord’s current non-biding estimates of Additional Rent
for Sector Operating Expenses are as follows: (a) Clean Room Space—$17.53 per RSF; (b) Office
Space—$8.80 per RSF; (c) Lab Space—$9.16 per RSF; and (d) Storage Space —$8.80 per RSF.

          (b) Expense Statements; Categories of Operating Expenses. On or prior to the commencement of
each calendar year after the Commencement Date, or such other accounting period as Landlord may
utilize from time to time, Landlord shall give Tenant a

6

 

written estimate of the Sector Operating Expenses for the coming year and the estimated amount
due from Tenant hereunder. Tenant shall pay such estimated amount of Additional Rent to Landlord
in equal monthly installments, in advance, at the same time the monthly Base Rent is paid. Within
ninety (90) days after the end of each calendar year, or such other annual accounting period as
Landlord shall utilize from time to time, Landlord shall furnish Tenant with a statement (“Expense
Statement”) showing the actual costs incurred by Landlord for Sector Operating Expenses during the
year then ended and Tenant’s Proportionate Share of the same. If such Expense Statement shows an
amount owing by Tenant that is less than the sum of the monthly payments made by Tenant in the year
then ended, such excess shall be credited against the next installment(s) of Additional Rent
payable hereunder by Tenant. If such Expense Statement shows an amount owing by Tenant which is
more than the sum of the monthly payments made by Tenant in the year then ended, Tenant shall pay
such deficiency to Landlord within thirty (30) days after receipt of such Expense Statement. The
obligations of Tenant hereunder shall survive expiration or termination of this Lease.

          (c) Definition of Operating Expenses. As used in this Lease, “Operating Expenses” shall mean
all costs and expenses of every kind and nature incurred by Landlord with respect to the ownership,
maintenance, repair and operation of the Project, without offset for any revenue derived by the
Landlord. Without limiting the generality of the foregoing, the following categories of expenses
are expressly intended to be included: general maintenance and repair costs for sidewalks, the
roof, floors, walls, service areas, foundations, common areas, mechanical rooms, the interior and
exterior of the Building, systems within the Project, and facilities for the use of tenants; all
charges for utilities supplied to the Project (“Utilities”); air-conditioning, ventilating and
heating charges of the Project common areas; security guards and alarm services; elevator
maintenance and other charges; painting, refinishing, decoration and landscaping of common areas;
trash and debris removal; pest control; property management fees; expenses, wages, benefits, and
payroll taxes payable with regard to all on-site and off-site employees engaged in the operation,
maintenance, engineering and security of the Project; legal expenses and the cost of audits by
certified public accountants; all supplies, materials and equipment rentals used in the operation
and maintenance of the Project; amounts paid to contractors or subcontractors for work or services
performed in connection with the operation, maintenance, engineering and security of the Project;
any reserve for repair and replacement of equipment used in the maintenance and operation of the
Project; insurance premiums or similar costs applicable to the Project, including without
limitation, the insurance that Landlord is required to maintain under Paragraph 8 below
(collectively, “Insurance”); amortization (together with reasonable financing charges) of any
capital improvements made to the Project by Landlord which will improve operating efficiency, or
which may be required under any governmental law or regulation; any form of real property tax,
special assessment, license fee, license tax, business license fee, business license tax,
commercial rental tax, levy, or charge, or transit tax, levied by any governmental authority having
the direct power to tax, against any legal or equitable interest of Landlord in the Project or as
against Landlord’s business of leasing the Project (other than Landlord’s federal or state income,
franchise, inheritance or estate taxes) (collectively, “Real Estate Taxes”); and any form of
personal property tax or assessment on the Personal Property (as defined in Paragraph 7.4(d) below)
owned by Tenant (collectively, “Personal Property Taxes”). Tenant agrees that any other cost or
expense that is not mentioned in the foregoing but incurred by Landlord in connection with the
ownership, maintenance, repair and operation of the Project shall be a part of Operating Expenses
hereunder.

7

 

          (d) Exclusions to Operating Expenses. Notwithstanding anything to the contrary contained in
this Lease, none of the following items shall be included in Operating Expenses:

               (i) The overhead and other costs associated with the operation of the business or the
ownership entity which constitutes the sublessor hereunder, unless related solely to Project
operations, provided that if Landlord has costs associated with multiple buildings or projects,
Landlord may include such costs prorated to the extent allocable to the Project;

               (ii) Costs of capital improvements and capital replacements and reserves for capital
replacements, except to the extent expressly provided for in Paragraph 4.3(c) above;

               (iii) Depreciation or amortization, except to the extent specifically provided for in
Paragraph 4.3(c) above;

               (iv) Costs and expenses incurred in connection with leasing or re-leasing space in the
Building such as commissions, space planning, architectural, engineering, attorneys’ fees,
advertising costs, the cost of tenant improvements and tenant improvement allowances, tenant
concessions and promotional expenses;

               (v) Costs and expenses incurred in connection with the termination, modification or
enforcement of leases with tenants in the Building, including without limitation, court costs,
attorneys’ fees and disbursements;

               (vi) Costs of salaries, benefits and other compensation to employees above the grade of senior
property manager, provided that if such costs related to multiple buildings or projects, Landlord
may include such costs prorated to the extent allocable to the Project; and

               (vii) Specific costs incurred for the account of, separately billed to, and paid by specific
tenants of the Building.

          (e) Sector Operating Expenses. Landlord shall segregate Operating Expenses into the following
categories (each, a “Sector”): (i) clean room space; (ii) lab space; (iii) office space; and (iv)
storage space. The Operating Expenses segregated into such categories, as determined by Landlord
in its reasonable discretion, shall constitute “Sector Operating Expenses” hereunder.

          (f) Tenant’s Proportionate Share. As used in this Lease, “Tenant’s Proportionate Share” shall
mean the ratio of dividing (i) RSF for the applicable Sector in the Premises by (ii) the total RSF
for all Sector space in the Building, as the same may be modified by Landlord from time to time.
The initial Tenant’s Proportionate Share for each Sector is as follows: (1) for clean room
space—14.42%, which has been computed by dividing 3,423 RSF (clean room space in the Premises) by
23,740 RSF (total clean space in the Building); (2) for lab space—23.54%, which has been computed
by dividing 12,709 RSF (lab space in the Premises) by 54,001 RSF (total lab space in the Building);
(3) for office space—35.50%, which has been computed by dividing 25,524 RSF (office space in the
Premises) by 71,901 RSF (total office

8

 

space in the Building); and (4) for storage space—17.98%, which has been computed by dividing
765 RSF (storage space in the Premises) by 4,254 RSF (total storage space in the Building).

          (g) Limitation on Certain Operating Expenses. Notwithstanding the foregoing, Landlord agrees
that beginning on August 1, 2006 Tenant’s obligation to pay Tenant’s Proportionate Share of Certain
Operating Expenses (as defined below) shall not be increased by more than five percent (5%) over
the amount payable by Tenant for the same during the prior twelve (12) month period. As used
herein, “Certain Operating Expenses” means Sector Operating Expenses during an applicable period
other than Utilities, Insurance, Real Estate Taxes and Personal Property Taxes allocated by
Landlord (in its sole discretion) to the applicable Sector for such period.

          (h) Audit Right. Tenant, within one hundred eighty (180) days after receiving an Expense
Statement, may give Landlord written notice (“Review Notice”) that Tenant intends to review
Landlord’s records of the Operating Expenses for the calendar year to which the Expense Statement
applies (an “Expense Year”). Within a reasonable time after receipt of the Review Notice, Landlord
shall make all pertinent records available for inspection that are reasonably necessary for Tenant
to conduct its review. If Tenant retains an agent to review Landlord’s records, the agent must be
with a certified public accounting firm (“CPA Firm”) licensed to do business in Colorado and which
shall not be compensated on a contingent fee basis. Tenant shall be solely responsible for all
costs, expenses and fees incurred for the audit; provided, however, if following an Objection
Notice (as defined below), Landlord and Tenant determine that Operating Expenses for the Building,
or the amount charged to Tenant by Landlord, for the year in question were less than stated or
appropriately charged hereunder by more than five percent (5%), Landlord, within sixty (60) days
after its receipt of paid invoices therefor from Tenant, shall reimburse Tenant for the reasonable
amounts paid by Tenant to the CPA Firm in connection with such review by Tenant. Within thirty
(30) days after the records are made available to Tenant, Tenant shall have the right to give
Landlord written notice (an “Objection Notice”) stating in reasonable detail any objection to the
Expense Statement for that Expense Year. If Tenant fails to give Landlord an Objection Notice
within the thirty (30) day period or fails to provide Landlord with a Review Notice within the one
hundred eighty (180) day period described above, Tenant shall be deemed to have approved Landlord’s
Expense Statement and shall be barred from raising any claims regarding the Operating Expenses for
that Expense Year. Notwithstanding anything to the contrary contained herein, if Tenant’s audit of
Operating Expenses with respect to any Expense Year determines that a category or subcategory of
Operating Expenses has been erroneous in any respect in such Expense Year, then Tenant shall have
the right to examine Operating Expenses for the two (2) Expense Years preceding the Expense Year
that was the subject of Tenant’s original Review Notice, provided that Tenant’s examination thereof
shall be in accordance with the procedures described above; and the Parties shall make an
appropriate adjustment in the charges for Operating Expenses or a refund thereof in accordance with
the procedures described above. The records obtained by Tenant shall be treated as confidential.
In no event shall Tenant be permitted to examine Landlord’s records or to dispute any Expense
Statement unless Tenant has paid and continues to pay all rent when due.

9

 

5. SECURITY DEPOSIT.

     5.1 Security Deposit. Any Security Deposit held by Landlord shall be held as security for the
faithful performance by Tenant of all of Tenant’s terms, covenants, and conditions under this
Lease. If Tenant commits a Breach (as defined in Paragraph 13.1 below) hereunder, Landlord may
(but shall not be required to) use, retain and apply all or any part of the Security Deposit for
the payment of any Rent or any other sum in default, or for the payment of any amount which
Landlord may spend or become obligated to spend by reason of Tenant’s Default (as defined in
Paragraph 13.1 below) or Breach, or to compensate Landlord for any other loss or damage which
Landlord may suffer as a result of Tenant’s default. If any portion of the Security Deposit is so
used or applied, Tenant shall, within fifteen (15) days after written demand therefor, deposit with
Landlord in cash or a cashier’s check an amount sufficient to restore the Security Deposit to its
original amount, and Tenant’s failure to do so shall constitute a Breach under this Lease.
Landlord shall not be required to keep the Security Deposit separate from its general funds, and
Tenant shall not be entitled to interest on the Security Deposit or any portion thereof. If Tenant
shall fully and faithfully perform every provision of this Lease, the Security Deposit, or any
balance thereof, shall be returned to Tenant (or, at Landlord’s option, to the last assignee of
Tenant’s interest hereunder) within thirty (30) days following the expiration of the Term or
vacation of the Premises by Tenant, whichever event occurs later. In the event of a termination of
Landlord’s interest in this Lease, the Security Deposit, or any portion thereof not previously
applied, may be released by Landlord to Landlord’s transferee and, if so released, Tenant agrees to
look solely to such transferee for proper application or return of the Security Deposit.

6. USE; HAZARDOUS SUBSTANCES.

     6.1 Use; Direct Entrance to Premises.

          (a) Use. Tenant shall use and occupy the Premises only for the Agreed Use and for no other
purpose. Tenant shall not use or permit the use of the Premises in a manner that is unlawful,
creates damage, waste or a nuisance, or that disturbs owners and/or occupants of, or causes damage
to neighboring properties.

          (b) Direct Entrance to Premises. Landlord agrees that Tenant shall be permitted to continue
to use (i) the existing direct entrance to its Premises (“Direct Entrance”), which is located in
Section S1 of the Building, and (ii) the existing three (3) card readers located at the entrances
to the Premises (“Card Readers”). Tenant acknowledges and agrees that the Direct Entrance and the
Card Readers are part of the Premises, such that Tenant shall keep and maintain the same in good
order, condition and repair, at Tenant’s sole cost and expense, and otherwise in accordance with
the terms of this Lease, including without limitation, the provisions contained in Paragraph 7.1
below.

     6.2 Hazardous Substances.

          (a) Definitions. As used in this Lease, the term “Hazardous Substance” shall mean any
product, substance, or waste whose presence, use, manufacture, disposal, transportation, or
release, either by itself or in combination with other materials expected to be

10

 

on the Premises, is: (i) potentially injurious to the public health, safety or welfare, the
environment or the Premises, (ii) regulated or monitored by any governmental authority, or (iii) a
basis for potential liability of Landlord to any governmental agency or third party under any
applicable statute or common law theory. Hazardous Substances shall include, but not be limited
to, PCB’s, hydrocarbons, petroleum, gasoline, asbestos and/or crude oil or any products,
by-products or fractions thereof. As used in this Lease, the term “Reportable Use” shall mean (i)
the installation or use of any above ground storage tank, (ii) the generation, possession, storage,
use, transportation, release or disposal of a Hazardous Substance that requires a permit from, or
with respect to which a report, notice, registration or business plan is required to be filed with,
any governmental authority, and/or (iii) the presence at the Premises or the Project of a Hazardous
Substance with respect to which any Applicable Requirements requires that a notice be given to
persons entering or occupying the Premises or neighboring properties.

          (b) Reportable Uses and Hazardous Substances Require Consent. Except as otherwise permitted
hereunder, Tenant shall not engage in any activity in or on the Premises or the Project which
constitutes a Reportable Use of Hazardous Substances, nor shall Tenant generate, possess, store,
use, release or dispose of any Hazardous Substances in, on, under or about the Premises, the
Building or the Project, without the express prior written consent of Landlord, which consent may
be given or withheld in Landlord’s sole discretion, and Tenant’s timely compliance (at Tenant’s
expense) with all Applicable Requirements. In addition, Landlord may condition its consent to any
Reportable Use upon receiving such additional assurances as Landlord reasonably deems necessary to
protect itself, the public, the Premises, the Building, the Project and/or the environment against
damage, contamination, injury and/or liability, including, but not limited to, the installation
(and removal on or before Lease expiration or termination) of protective modifications (such as
concrete encasements) and/or increasing the Security Deposit. Landlord hereby consents to Tenant’s
use in and about the Premises of the Hazardous Substances in the quantities listed on Exhibit
C hereto and common cleaning and office supplies in appropriate quantities, provided that
Tenant strictly complies at all times with (A) all Applicable Requirements with respect thereto,
and (B) Tenant’s Hazardous Substance Management Plan attached hereto as Exhibit D (the
“Hazardous Substance Management Plan”), as the same may be modified from time to time. Tenant
shall promptly provide to Landlord all amendments, modifications and supplements to Tenant’s
Hazardous Substance Management Plan.

          (c) Duty to Inform Landlord. If Tenant knows, or has reasonable cause to believe, that a
Hazardous Substance has come to be located in, on, under or about the Premises or the Project that
is not otherwise permitted hereunder or otherwise authorized by Landlord in writing, Tenant shall
immediately give written notice of such fact to Landlord, and provide Landlord with a copy of any
report, notice, claim or other documentation which it has concerning the presence of such Hazardous
Substance.

          (d) Tenant Remediation. Tenant shall not cause or permit any Hazardous Substance to be spilled
or released in, on, under, or about the Premises or the Project (including through the plumbing or
sanitary sewer system) and shall promptly, at Tenant’s sole cost and expense, take all
investigatory and/or remedial action reasonably recommended, whether or not formally ordered or
required, for the cleanup of any contamination of, and for the maintenance, security and/or
monitoring of the Premises, the Project or neighboring properties, that was (i)

11

 

caused by Tenant, or (ii) pertaining to or involving any Hazardous Substance brought onto the
Premises or the Project by or for Tenant, or (iii) pertaining to or involving any Hazardous
Substance brought onto the Premises or the Project or any portion thereof by any third party during
the term that Tenant had possession of the Premises or the Project or any portion thereof. Tenant
shall be solely responsible for the remediation of any condition concerning any Hazardous Substance
in, on, under or about the Premises or the Project to the extent required under this Paragraph 6.2.

          (e) Investigations and Remediations. Tenant shall have responsibility and shall pay for any
investigations or remediation measures required by governmental entities having jurisdiction with
respect to the existence of Hazardous Substances on the Premises or the Project. Tenant shall
cooperate fully in any such activities at the request of Landlord, including allowing Landlord and
Landlord’s agents to have reasonable access to the Premises at reasonable times in order to carry
out any investigative and remedial actions which Landlord may elect to do.

     6.3 Tenant’s Compliance with Applicable Requirements. Tenant shall obtain, maintain and
strictly comply with, at Tenant’s sole cost and expense, any and all Applicable Requirements with
its generation, possession, storage, use, release or disposal of any Hazardous Substance in or
about the Premises, the Building or the Project (if the same is permitted under this Lease),
including without limitation, (i) all Environmental Protection Agency Identification Numbers, and
(ii) all air, wastewater, sewer and other permits and governmental approvals. Except as otherwise
provided in this Lease, Tenant shall, at Tenant’s sole expense, fully, diligently and in a timely
manner comply with all requirements of any applicable fire insurance underwriter or rating bureau,
and the recommendations of Landlord’s engineers and/or consultants which relate in any manner to
the Premises, without regard to whether said requirements are now in effect or become effective
after the Commencement Date. Tenant shall, within ten (10) days after receipt of Landlord’s
written request, provide Landlord with copies of all permits and other documents, and other
information evidencing Tenant’s compliance with any Applicable Requirements specified by Landlord,
and shall immediately upon receipt by Tenant, notify Landlord in writing (and immediately provide
to Landlord copies of any documents involved) of any threatened or actual claim, notice, citation,
warning, complaint or report pertaining to or involving the failure of Tenant or the Premises to
comply with any Applicable Requirements or the provisions of this Paragraph 6.

     6.4 Inspection; Compliance. Landlord and Landlord’s Lender and consultants shall have the
right to enter the Premises at any time, in the case of an emergency, and otherwise at reasonable
times upon reasonable prior notice, which may be verbal, for the purpose of inspecting the
condition of the Premises and for verifying compliance by Tenant with this Lease. The reasonable
cost of any such inspections shall be paid by Tenant.

     6.5 Tenant Indemnification. Tenant shall indemnify, defend and hold harmless each of Landlord
and its shareholders, directors, officers, employees, agents, affiliates, subsidiaries, Lender (as
defined in Paragraph 30.1 below), successors and assigns (the “Landlord Parties”) from and against
any and all damages, losses, liabilities, judgments, claims, causes of action, demands, expenses,
costs, fines, penalties, and attorneys’ and consultants’ fees (collectively, “Claims”) arising out
of or involving (i) any Hazardous Substance brought onto the Premises or

12

 

the Project by or for Tenant, or (ii) pertaining to or involving any Hazardous Substance
brought onto the Premises or the Project or any portion thereof by any third party during the term
that Tenant had possession of the Premises or the Project or any portion thereof. Tenant’s
obligations shall include, but not be limited to, the effects of any contamination or injury to
person, property or the environment created or suffered by Tenant, and the cost of investigation,
removal, remediation, restoration and/or abatement, and shall survive the expiration or termination
of this Lease. No termination, cancellation or release agreement entered into by Landlord and
Tenant shall release Tenant from its obligations under this Lease with respect to Hazardous
Substances, unless Landlord specifically agrees thereto in writing at the time of such agreement
and such agreement specifically identifies this Paragraph 6 of this Lease.

7. MAINTENANCE; REPAIRS; UTILITY INSTALLATIONS; TRADE FIXTURES AND ALTERATIONS.

     7.1 Tenant’s Obligations.

          (a) In General. Subject to the provisions of Paragraphs 7.2 (Landlord’s Obligations), 9
(Damage or Destruction), and 14 (Condemnation), Tenant shall, at Tenant’s sole expense, keep the
Premises, Utility Installations, and Alterations in good order, condition and repair (whether or
not the portion of the Premises requiring repairs, or the means of repairing the same, are
reasonably or readily accessible to Tenant), including, but not limited to, all equipment or
facilities, such as plumbing, heating, ventilating, air-conditioning, electrical, lighting
facilities, boilers, pressure vessels, fire protection system, fixtures, walls (interior and
exterior), ceilings, floors, windows, doors, light bulbs, plate glass or skylights located in or on
the Premises. Tenant, in keeping the Premises in good order, condition and repair, shall exercise
and perform good maintenance practices, specifically including the procurement and maintenance of
the service contracts if required by Landlord pursuant to Paragraph 7.1(b) below. Tenant’s
obligations shall include restorations, replacements or renewals when necessary to keep the
Premises or a part thereof in good order, condition and state of repair.

          (b) Service Contracts. If requested by Landlord, Tenant shall, at Tenant’s sole expense,
procure and maintain contracts, in form and substance reasonably satisfactory to Landlord, with
copies to Landlord, for, and with contractors specializing and experienced in the maintenance of
the following equipment and improvements, if any, if and when installed in the Premises or
elsewhere: (i) heating, ventilation and air conditioning equipment (“HVAC”), (ii) boiler, and
pressure vessels, (iii) fire extinguishing systems, including fire sprinklers, fire alarm and/or
smoke detection, and (iv) any other equipment, if reasonably required by Landlord.

          (c) Landlord’s Election. Notwithstanding the foregoing, if Tenant shall fail to meet any
obligation set forth in this Paragraph 7.1, or if Landlord determines in its sole discretion that
the Premises are not being maintained as required hereunder, Landlord may elect to undertake any
such obligation of Tenant, in which event Tenant shall reimburse Landlord within ten (10) days of
receipt of notice that Landlord has paid for such work and all of Landlord’s costs.

     7.2 Landlord’s Obligations. Subject to the provisions of Paragraphs 9 (Damage or Destruction)
and 14 (Condemnation), and except for Claims caused in whole or in part by any

13

 

act or omission of Tenant or Tenant’s employees, agents, contractors or invitees, Landlord
agrees (i) to keep the foundation, roof and structural supports of the Building in good condition
and repair, (ii) to provide twenty-four (24) hours a day, seven (7) days per week such quantity of
heat and air-conditioning as may be required in Landlord’s reasonable judgment for the comfortable
occupation of the Premises, and (iii) to maintain the HVAC system for the Premises in good
condition and repair (subject to Paragraph 7.1(b) above), provided that all of the foregoing costs
and expenses therefor shall constitute Operating Expenses. It is the intention of the Parties that
the terms of this Lease govern the respective obligations of the Parties as to maintenance and
repair of the Building and the Project, and they expressly waive the benefit of any statute now or
hereafter in effect to the extent it is inconsistent with the terms of this Lease. Landlord hereby
absolutely disclaims any responsibility for any defects in the Premises, the Building or the
Project (or any portion thereof), or for the repair or maintenance of any condition at the
Premises, and Tenant hereby agrees to be responsible for any defects in the Premises, and on-going
maintenance and repair of the Premises and any portion thereof.

     7.3 Utility Installations; Trade Fixtures; Alterations.

          (a) Definitions; Consent Required. The term “Utility Installations” refers to all floor and
window coverings, air lines, power panels, electrical distribution, security and fire protection
systems, communication systems, lighting fixtures, HVAC, plumbing, and fencing in or on the
Premises or the Building. The term “Trade Fixtures” shall mean Tenant’s machinery and equipment
that can be removed without doing material damage to the Premises. The term “Alterations” shall
mean any modification of the improvements, other than Utility Installations or Trade Fixtures,
whether by addition or deletion. “Tenant Owned Alterations and/or Utility Installations” are
defined as Alterations and/or Utility Installations made by Tenant that are not yet owned by
Landlord pursuant to Paragraph 7.4(a). Tenant shall not make any Alterations or Utility
Installations to the Premises or the Building, without Landlord’s prior written consent, which
Landlord may withhold in its reasonable discretion.

          (b) Consent Requirements. Any Alterations or Utility Installations that Tenant shall desire
to make shall be presented to Landlord in written form with detailed plans. Consent shall be
deemed conditioned upon Tenant’s: (i) acquiring all applicable governmental permits, (ii)
furnishing Landlord with copies of both the permits and the plans and specifications prior to
commencement of the work, and (iii) compliance with all conditions of said permits and other
Applicable Requirements in a prompt and expeditious manner. Any Alterations or Utility
Installations shall be performed in a workmanlike manner with good and sufficient materials all at
Tenant’s cost. Tenant shall promptly upon completion furnish Landlord with as-built plans and
specifications for any Alterations or Utility Installations, whether or not Landlord’s consent is
required. In the event that Tenant constructs or installs any Utility Installations or Alterations
to any portion of the Building outside of the Premises, including without limitation, any
modifications or additions to any base Building infrastructure equipment or system (such as the
HVAC), Tenant shall be responsible for, and shall promptly pay or reimburse Landlord as Additional
Rent upon written demand therefor, all costs and expenses related to (A) installing separate
meter(s) as required by Landlord, (B) the utilities and other services furnished to Tenant and/or
the Premises with respect to such Utility Installations or Alterations, and (C) Landlord’s then
current construction management fee with respect to such Utility Installations or Alterations.
Notwithstanding the foregoing, Tenant shall not be required to obtain Landlord’s

14

 

consent to any Alteration or Utility Installation to the Premises if (i) the total cost
(including soft costs) for such Alteration or Utility Installation does not exceed $25,000, (ii)
the total costs (including soft costs) for all Alterations and Utility Installations made by Tenant
to the Premises during the prior twelve (12) month period does note exceed $50,000, (iii) such
Alteration or Utility Installation does not affect the foundation, roof or any structural component
of the Building or any Building system, and (iv) Tenant provides Landlord with not fewer than ten
(10) days’ prior written notice of Tenant’s construction or installation of such Alteration or
Utility Installation.

          (c) Mechanics’ Liens. Tenant shall pay, when due, all claims for labor or materials furnished
or alleged to have been furnished to or for Tenant at or for use on the Premises, which claims are
or may be secured by any mechanic’s or materialmen’s lien against the Premises or any interest
therein. If any mechanic’s lien is recorded for work claimed to have been done for, or on behalf
of, or for materials claimed to be furnished to Tenant or the Premises, then Tenant shall, at its
expense, immediately discharge such lien, by bond or otherwise, on demand of Landlord. Tenant
shall give Landlord not less than ten (10) days’ notice prior to the commencement of any work in,
on or about the Premises, and Landlord shall have the right to post notices of non-responsibility.
If Tenant shall contest the validity of any such lien, claim or demand, then Tenant shall, at its
sole expense defend and protect itself, Landlord and the Premises against the same and shall pay
and satisfy any such adverse judgment that may be rendered thereon before the enforcement thereof.
If Landlord shall require, Tenant shall furnish a surety bond in an amount equal to one and
one-half (1 1/2) times the amount of such contested lien, claim or demand, indemnifying Landlord
against liability for the same. If Landlord elects to participate in any such action, Tenant shall
pay Landlord’s attorneys’ fees and costs.

     7.4 Ownership; Removal; Surrender; Restoration; License of Personal Property.

          (a) Ownership; Required Removal. Subject to Landlord’s right to require removal or elect
ownership as hereinafter provided, all Alterations and Utility Installations made by Tenant shall
be the property of Tenant, but considered a part of the Premises. Unless otherwise instructed per
Paragraph 7.4(b) hereof, all Alterations and Utility Installations made by or for the benefit of
Tenant shall, at the expiration or termination of this Lease, be removed by Tenant from the
Premises.

          (b) Non-Removal. By delivery to Tenant of written notice from Landlord at the time that
Landlord grants its approval, Landlord shall respond to Tenant’s request, if any (by expressly so
stating in such approval), that Tenant shall be permitted to surrender the applicable Alteration or
Utility Installation along with the Premises at expiration or termination of this Lease and shall
not be required to remove the same at such time. Notwithstanding the foregoing, Landlord may
require the removal at any time of all or any part of any Tenant Owned Alterations or Utility
Installations made without the required consent of Landlord.

          (c) Surrender/Restoration. Tenant shall surrender the Premises on or before the Expiration
Date or any earlier termination date, with all improvements, parts and surfaces thereof broom clean
and free of debris, and in good operating order, condition and state of repair, ordinary wear and
tear and insured casualty excepted. “Ordinary wear and tear” shall not include any damage or
deterioration that would have been prevented by good maintenance

15

 

practice or a service contract. Tenant shall repair any damage occasioned by the
installation, maintenance or removal of Trade Fixtures, Alterations and/or Utility Installations,
furnishings, and equipment as well as the removal of any storage tank installed by or for Tenant,
and the removal, replacement, or remediation of any soil, material or groundwater contaminated by
Tenant. Trade Fixtures shall remain the property of Tenant and shall be removed by Tenant. The
failure by Tenant to timely vacate the Premises pursuant to this Paragraph 7.4(c) without the
express written consent of Landlord shall constitute a holdover under the provisions of Paragraph
26 below.

          (d) License of Personal Property. Landlord grants Tenant a license to use in the Premises,
during the Term and at no Additional Rent, the personal property more specifically described in
Exhibit E attached hereto, along with the existing voice/data, CAT5 wiring infrastructure,
available racks, telephone room and cabling in the Premises (collectively, “Personal Property”). As
soon hereafter as reasonably practicable, the Parties shall jointly conduct a walk-through
inspection of the Personal Property (and photograph certain Personal Property, if needed), and note
on Exhibit E pre-existing damage or defective conditions in the Personal Property. TENANT
ACCEPTS THE PERSONAL PROPERTY IN AN “AS IS”, “WHERE IS” CONDITION WITH ALL FAULTS AND WITHOUT
WARRANTIES, EXPRESS OR IMPLIED. LANDLORD DISCLAIMS ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR
FITNESS FOR A PARTICULAR PURPOSE. TENANT SHALL NOT REMOVE THE PERSONAL PROPERTY FROM THE PREMISES
OR TRANSFER ITS RIGHT TO USE THE PERSONAL PROPERTY. TENANT EXPRESSLY ASSUMES ALL RISK AND
RESPONSIBILITY FOR ANY DEFECTS (INCLUDING LATENT DEFECTS) IN THE PERSONAL PROPERTY, AND TENANT
SHALL INDEMNIFY, DEFEND AND HOLD LANDLORD AND THE LANDLORD PARTIES HARMLESS FROM AND AGAINST ANY
AND ALL CLAIMS ARISING FROM TENANT’S USE OF THE PERSONAL PROPERTY. Except for pre-existing damage
or defective conditions to the Personal Property (as mutually agreed by Landlord and Tenant),
Tenant shall maintain the Personal Property in good condition and repair throughout the Term. Upon
the expiration or earlier termination of this Lease, Tenant shall surrender the Personal Property
in the same condition as received, ordinary wear and tear excepted. Except for pre-existing damage
or defective conditions to the Personal Property (as mutually agreed by Landlord and Tenant),
Tenant shall reimburse Landlord, as Additional Rent, for the reasonable cost of (i) repairing any
damage to the Personal Property, ordinary wear and tear and damage due to casualty or condemnation
excepted, or (ii) replacing any missing Personal Property, within thirty (30) days after receipt of
invoices or other satisfactory evidence of such costs. Tenant shall insure the Personal Property
for its full replacement value (which insurance shall name Landlord as the loss payee) and Tenant
shall provide evidence thereof to Landlord in accordance with the requirements of Paragraph 8
below.

8. INSURANCE; INDEMNITY.

     8.1 Liability Insurance.

          (a) Carried by Tenant. Tenant shall obtain and keep in force a Commercial General Liability
Policy of Insurance protecting Tenant, Landlord and Landlord’s property manager, if any, against
claims for bodily injury, personal injury and property damage based upon or arising out of the
ownership, use, occupancy or maintenance of the Premises and all

16

 

areas appurtenant thereto. The initial amount of such insurance shall be not less than
$5,000,000 per occurrence with an “Additional Insured-Manager’s or Lessor’s Premises Endorsement”
and contain the “Amendment of the Pollution Exclusion Endorsement” for damage caused by heat, smoke
or fumes from a hostile fire. The policy shall not contain any intra-insured exclusions as between
insured persons or organizations, but shall include coverage for liability assumed under this Lease
as an “insured contract” for the performance of Tenant’s indemnity obligations under this Lease.
Tenant shall also obtain and keep in force pollution legal liability insurance with a minimum limit
of not less than $2,000,000 per occurrence. The limits of insurance required under this Lease
shall not, however, limit the liability of Tenant nor relieve Tenant of any obligation hereunder.
The commercial general liability and pollution legal liability insurance policies shall insure on
an occurrence and not a claims-made basis. All insurance carried by Tenant shall be primary to and
not contributory with any similar insurance carried by Landlord, whose insurance shall be
considered excess insurance only. Tenant’s policy may be a “blanket policy” with an aggregate per
location endorsement which specifically provides that the amount of insurance shall not be
prejudice by other losses covered by the policy.

          (b) Carried by Landlord. Landlord may, at its option, maintain liability insurance as
described in Paragraph 8.1(a), in addition to, and not in lieu of, the insurance required to be
maintained by Tenant. Tenant shall not be named as an additional insured therein.

     8.2 Property Insurance — Building, Improvements and Rental Value.

          (a) Building and Improvements. The Insuring Party shall obtain and keep in force a policy or
policies in the name of Landlord, with loss payable to Landlord and to any Lender(s) insuring loss
or damage to the Premises. The amount of all risk insurance maintained by the Insuring Party shall
be equal to the full replacement cost of the Building. If Landlord is the Insuring Party, however,
Tenant Owned Alterations and Utility Installations, Trade Fixtures, and Tenant’s personal property
shall be insured by Tenant under Paragraph 8.3 rather than by Landlord. Such policy or policies
shall insure against all risks of direct physical loss or damage (including the perils of flood),
including coverage for debris removal and the enforcement of any Applicable Requirements requiring
the upgrading, demolition, reconstruction or replacement of any portion of the Premises as the
result of a covered loss. Said policy or policies shall also contain an agreed valuation provision
in lieu of any coinsurance clause, waiver of subrogation, and inflation guard protection causing an
increase in the annual property insurance coverage amount by a factor of not less than the adjusted
U.S. Department of Labor Consumer Price Index for All Urban Consumers for the city nearest to where
the Premises are located. If such insurance coverage has a deductible clause, the deductible
amount shall not exceed $25,000 per occurrence and such deductible amount in the event of an
Insured Loss shall be included in Operating Expenses.

          (b) Adjacent Premises. If the Premises are part of a group of buildings owned by Landlord
which are adjacent to the Premises, the Tenant shall pay for any increase in the premiums for the
property insurance of such building or buildings if said increase is caused by Tenant’s acts,
omissions, use or occupancy of the Premises.

     8.3 Tenant’s Property/Business Interruption Insurance.

17

 

          (a) Property Damage. Tenant shall obtain and maintain insurance coverage on all of Tenant’s
personal property, Trade Fixtures, and Tenant Owned Alterations and Utility Installations. Such
insurance shall be full replacement cost coverage. The proceeds from any such insurance shall be
used by Tenant for the replacement of personal property, Trade Fixtures and Tenant Owned
Alterations and Utility Installations. Tenant shall provide Landlord with written evidence that
such insurance is in force.

          (b) Business Interruption. Tenant shall obtain and maintain loss of income and extra expense
insurance in amounts as will reimburse Tenant for direct or indirect loss of earnings attributable
to all perils commonly insured against by prudent tenants in the business of Tenant or attributable
to prevention of access to the Premises as a result of such perils.

          (c) No Representation of Adequate Coverage. Landlord makes no representation that the limits
or forms of coverage of insurance specified herein are adequate to cover Tenant’s property,
business operations or obligations under this Lease.

     8.4 Insurance Policies. Insurance required herein shall be provided by companies duly
licensed or admitted to transact business in the state where the Premises are located, and
maintaining during the policy term a policyholders rating of A- or better and a financial category
rating of at least Class X, or such other rating as may be required by Landlord’s Lender, as set
forth in the most current issue of “Best’s Insurance Guide”. Each policy of insurance required to
be maintained by Tenant hereunder shall name Landlord and Landlord’s Lender as additional insureds.
Tenant shall not do or permit to be done anything which invalidates the required insurance
policies. Tenant shall, prior to the Commencement Date, deliver to Landlord certificates
evidencing the existence and amounts of the required insurance, along with certified copies of the
policies therefor (if requested by Landlord). No such policy shall be cancelable or subject to
modification except after thirty (30) days’ prior written notice to Landlord. Tenant shall, at
least thirty (30) days prior to the expiration of such policies, furnish Landlord with evidence of
renewals or “insurance binders” evidencing renewal thereof, or Landlord may order such insurance
and charge the cost thereof to Tenant, which amount shall be payable by Tenant to Landlord upon
demand. Such policies shall be for a term of at least one (1) year, or the length of the remaining
term of this Lease, whichever is less. If either Party shall fail to procure and maintain the
insurance required to be carried by it, the other Party may, but shall not be required to, procure
and maintain the same.

     8.5 Waiver of Subrogation. Without affecting any other rights or remedies, Tenant and
Landlord each hereby releases and relieves the other, and waives its entire right to recover
damages against the other, for loss of or damage to its property arising out of or incident to the
perils required to be insured against herein. The effect of such releases and waivers is not
limited by the amount of insurance carried or required, or by any deductibles applicable hereto.
The Parties agree to have their respective property damage insurance carriers waive any right to
subrogation that such companies may have against Landlord or Tenant, as the case may be, so long as
the insurance is not invalidated thereby, and to provide evidence thereof.

18

 

     8.6 Indemnities.

          (a) Tenant Indemnity. To the fullest extent permitted by law and except as provided below,
Tenant hereby waives all Claims against Landlord and the Landlord Parties for damage to any
property or injury to or death of any person in, upon or about the Premises, the Building or the
Project arising at any time and from any cause. Except for Claims arising from the gross
negligence or willful misconduct of Landlord or Landlord’s employees or agents with regard to the
Project, Tenant hereby agrees to indemnify, defend and hold harmless each of Landlord and the
Landlord Parties from and against all Claims, including without limitation, any Claims for damage
to any property or injury to or death of any person, arising from or related to (a) any act or
omission by Tenant or Tenant’s employees, agents, contractors, invitees or any other person
claiming under Tenant in, on or about the Premises, the Building or the Project, or (b) the use or
occupancy of the Premises, the Building or the Project by Tenant or Tenant’s employees, agents,
contractors, invitees or any other person claiming under Tenant, or (c) the negligence or willful
misconduct of Tenant or Tenant’s employees, agents, contractors, invitees or any other person
claiming under Tenant, in, on or about the Premises, the Building or the Project, or (d) any breach
or default by Tenant under this Lease. If any action or proceeding is brought against Landlord or
any of the Landlord Parties by reason of any of the foregoing matters, Tenant shall upon notice
defend the same at Tenant’s expense by counsel reasonably satisfactory to Landlord and Landlord
shall cooperate with Tenant in such defense. Landlord need not have first paid any such Claim in
order to be defended or indemnified. All of the obligations of Tenant set forth in this Lease
including, without limitation, the obligations set forth in this Paragraph 8.6 shall survive the
expiration or earlier termination of this Lease.

          (b) Landlord Indemnity. Except for Claims covered by Tenant’s indemnity under Paragraphs 6.5
and 8.6(a) above, Landlord hereby agrees to indemnify, defend and hold harmless Tenant from and
against all Claims arising during the Term from the gross negligence or willful misconduct of
Landlord or Landlord’s employees and agents with regard to the Project. If any action or
proceeding is brought against Tenant by reason of any of the foregoing matters, Landlord shall upon
notice defend the same at Landlord’s expense by counsel reasonably satisfactory to Tenant and
Tenant shall cooperate with Landlord in such defense. Tenant need not have first paid any such
Claim in order to be defended or indemnified. All of the obligations of Landlord set forth in this
Paragraph 8.6 shall survive the expiration or earlier termination of this Lease.

     8.7 Exemption of Landlord from Liability. To the fullest extent permitted by law, Landlord
shall not be liable, and Tenant waives any Claim, for injury or damage to the person or goods,
wares, merchandise, business records or other property of Tenant or Tenant’s employees, agents,
contractors, invitees, or any other person in or about the Premises, the Building or the Project,
whether such damage or injury is caused by or results from fire, steam, electricity, gas, water or
rain, or from the breakage, leakage, obstruction or other defects of pipes, fire sprinklers, wires,
appliances, plumbing, HVAC or lighting fixtures, or from any other cause, whether the said injury
or damage results from conditions arising upon the Premises or upon other portions of the Building
or the Project of which the Premises are a part, or from other sources or places. Landlord shall
not be liable for any Claims arising from any act or omission of any other tenant of Landlord.

19

 

9. DAMAGE OR DESTRUCTION.

     9.1 Definitions.

          (a) “Premises Partial Damage” shall mean damage or destruction to the improvements on the
Premises, other than Tenant Owned Alterations and Utility Installations, which can reasonably be
repaired in twelve (12) months or less from the date of the damage or destruction. Landlord shall
notify Tenant in writing within thirty (30) days from the date of the damage or destruction as to
whether or not the damage is Premises Partial Damage or Premises Total Destruction.

          (b) “Premises Total Destruction” shall mean damage or destruction to the Premises, other than
Tenant Owned Alterations and Utility Installations and Trade Fixtures, which cannot reasonably be
repaired in twelve (12) months or less from the date of the damage or destruction. Landlord shall
notify Tenant in writing within thirty (30) days from the date of the damage or destruction as to
whether or not the damage is Premises Partial Damage or Premises Total Destruction.

          (c) “Insured Loss” shall mean damage or destruction to improvements on the Premises, other
than Tenant Owned Alterations and Utility Installations and Trade Fixtures, which was caused by an
event required to be covered by the insurance described in Paragraph 8.2(a), irrespective of any
deductible amounts or coverage limits involved.

          (d) “Replacement Cost” shall mean the cost to repair or rebuild the improvements owned by
Landlord at the time of the occurrence to their condition existing immediately prior thereto,
including demolition, debris removal and upgrading required by the operation of Applicable
Requirements, and without deduction for depreciation.

          (e) “Hazardous Substance Condition” shall mean the occurrence or discovery of a condition
involving the presence of, or a contamination by, a Hazardous Substance as defined in Paragraph
6.2(a), in, on, or under the Premises.

     9.2 Partial Damage — Insured Loss. Landlord shall, at Landlord’s expense (subject to receipt
of adequate insurance proceeds), repair such damage (but not Tenant’s Trade Fixtures or Tenant
Owned Alterations and Utility Installations) and this Lease shall continue in full force and
effect.

     9.3 Total Destruction. Notwithstanding any other provision hereof, if a Premises Total
Destruction occurs, then either Party may elect to terminate this Lease as of the date that is
sixty (60) days following such Premises Total Destruction. If the damage or destruction was caused
by the gross negligence or willful misconduct of Tenant, Landlord shall have the right to recover
Landlord’s damages from Tenant, to the extent not covered by insurance required to be carried
hereunder. If neither Landlord nor Tenant elects to terminate this Lease, then the Premises Total
Destruction shall be treated as a Premises Partial Damage and the provisions of Paragraph 9.2 above
shall apply.

     9.4 Damage Near End of Term. If at any time during the last twelve (12) months of this Lease
there is damage for which the cost to repair exceeds six (6) month’s Base Rent,

20

 

whether or not an Insured Loss, Landlord may terminate this Lease effective sixty (60) days
following the date of occurrence of such damage by giving written termination notice to Tenant
within thirty (30) days after the date of occurrence of such damage. Notwithstanding the
foregoing, if Tenant at that time has an exercisable option to extend this Lease, then Tenant may
preserve this Lease by, (a) exercising such option and (b) providing Landlord with any shortage in
insurance proceeds (or adequate assurance thereof) needed to make the repairs on or before the
earlier of (i) the date which is ten (10) days after Tenant’s receipt of Landlord’s written notice
purporting to terminate this Lease, or (ii) the day prior to the date upon which such option
expires. If Tenant duly exercises such option during such period and provides Landlord with funds
(or adequate assurance thereof) to cover any shortage in insurance proceeds, Landlord shall, at
Landlord’s commercially reasonable expense, repair such damage as soon as reasonably possible and
this Lease shall continue in full force and effect. If Tenant fails to exercise such option and
provide such funds or assurance during such period, then this Lease shall terminate on the date
specified in the termination notice and Tenant’s option shall be extinguished.

     9.5 Abatement of Rent; Tenant’s Remedies.

          (a) Abatement. In the event of Premises Partial Damage or Premises Total Destruction or a
Hazardous Substance Condition for which Tenant is not responsible under this Lease, Base Rent
payable by Tenant for the period required for the repair, remediation or restoration of such damage
shall be abated in proportion to the degree to which Tenant’s use of the Premises is impaired, but
not to exceed the proceeds received from the Rental Value Insurance. All other obligations of
Tenant under this Lease shall be performed by Tenant, and Landlord shall have no liability for any
such damage, destruction, remediation, repair or restoration except as provided herein.

          (b) Remedies. If Landlord shall be obligated to repair or restore the Premises and does not
commence, in a substantial and meaningful way, such repair or restoration within one hundred eighty
(180) days after such obligation shall arise, Tenant may, at any time prior to the commencement of
such repair or restoration, give written notice to Landlord and to any Lender of which Tenant has
actual notice, of Tenant’s election to terminate this Lease on a date not less than sixty (60) days
following the giving of such notice. If Tenant gives such notice and such repair or restoration is
not commenced within thirty (30) days thereafter, this Lease shall terminate as of the date
specified in said notice. If the repair or restoration is commenced within said thirty (30) days,
this Lease shall continue in full force and effect. “Commence” shall mean either the unconditional
authorization of the preparation of the required plans, or the beginning of the actual work on the
Premises, whichever first occurs.

     9.6 Termination-Advance Payments. Upon termination of this Lease pursuant to this Paragraph
9, an equitable adjustment shall be made concerning advance Base Rent and any other advance
payments made by Tenant to Landlord. Landlord shall, in addition, return to Tenant so much of
Tenant’s Security Deposit as has not been, or is not then required to be, used by Landlord.

     9.7 Waive Statutes. Landlord and Tenant agree that the terms of this Lease shall govern the
effect of any damage to or destruction of the Premises with respect to the termination

21

 

of this Lease and hereby waive the provisions of any present or future statute to the extent
inconsistent herewith.

10. PERSONAL PROPERTY TAXES.

     Tenant shall pay, prior to delinquency, all taxes assessed against and levied upon Tenant
Owned Alterations, Utility Installations and Trade Fixtures and all furnishings, equipment and
personal property owned by Tenant. When possible, Tenant shall cause such property to be assessed
and billed separately from the real property of Landlord. If any of Tenant’s personal property
shall be assessed with Landlord’s real property, Tenant shall pay Landlord the taxes attributable
to Tenant’s property within ten (10) days after receipt of a written statement therefor.

11. UTILITIES.

     Tenant shall pay for all water, gas, heat, light, power, telephone, trash disposal and other
utilities and services supplied to the Premises, together with any taxes thereon. In the event
that Landlord provides any utilities or services to the Premises, Tenant shall pay to Landlord
promptly upon demand, as Additional Rent, all sums therefor. Moreover, in the event that (a) any
utilities or services supplied to the Premises, or (b) any Utility Installations or Alterations
made by Tenant to or for the benefit of the Premises, causes any Building equipment or system to
exceed its capacity or otherwise cause an unsuitable condition to exist, in either case as
determined by Landlord in its reasonable discretion, then Tenant shall be responsible for all
Claims resulting therefrom or related thereto, including without limitation, the cost of repairing
or replacing the applicable Building equipment or system. Landlord shall not be liable for
damages, consequential or otherwise, nor shall there be any Rent abatement arising out of any
curtailment or interruption whatsoever in utility or others services provided to the Premises, the
Building or the Project. Tenant hereby acknowledges and agrees that neither Landlord nor any of
Landlord’s employees, agents or representatives have made any representations or warranties,
express or implied, regarding any Building equipment or system, including without limitation, any
of the foregoing’s fitness for any particular purpose.

12. ASSIGNMENT AND SUBLETTING.

     12.1 Landlord’s Consent Required.

          (a) Tenant shall not voluntarily or by operation of law assign, transfer, mortgage or encumber
(collectively, “assign or assignment”) or sublet all or any part of Tenant’s interest in this Lease
or in the Premises without Landlord’s prior written consent, which consent, subject to the
provisions of this Paragraph 12, shall not be unreasonably withheld or delayed.

          (b) A change in the control of Tenant shall constitute an assignment requiring consent. The
transfer, in any one transaction or in a series of related transactions, of twenty-five percent
(25%) or more of the voting control of Tenant shall constitute a change in control for this
purpose.

          (c) The involvement of Tenant or its assets in any transaction, or series of transactions (by
way of merger, sale, acquisition, financing, transfer, leveraged buy-out or

22

 

otherwise), whether or not a formal assignment or hypothecation of this Lease or Tenant’s
assets occurs, which results or will result in a reduction of the Net Worth of Tenant (as defined
below) as it was represented at the time of the execution of this Lease or at the time of the most
recent assignment to which Landlord has consented, or as it exists immediately prior to said
transaction or transactions constituting such reduction, whichever was or is greater, shall be
considered an assignment of this Lease to which Landlord may withhold its consent. “Net Worth of
Tenant” shall mean the net worth of Tenant (excluding any guarantors) established under generally
accepted accounting principles.

          (d) An assignment or subletting without consent shall, at Landlord’s option, be a Default
curable after notice as set forth in Paragraph 13.1(c), or a noncurable Breach without the
necessity of any notice and grace period. If Landlord elects to treat such unapproved assignment
or subletting as a noncurable Breach, Landlord may terminate this Lease.

          (e) Tenant’s remedy for any Breach of Paragraph 12.1 by Landlord shall be limited to an action
for declaratory relief and/or injunctive relief.

     12.2 Terms and Conditions Applicable to Assignment and Subletting.

          (a) Regardless of Landlord’s consent or whether such consent is required under this Lease, any
assignment or subletting shall not: (i) be effective without the express written assumption by
such assignee or subtenant of the obligations of Tenant under this Lease, (ii) release Tenant of
any obligations hereunder, or (iii) alter the primary liability of Tenant for the payment of Rent
or for the performance of any other obligations to be performed by Tenant.

          (b) Landlord may accept Rent or performance of Tenant’s obligations from any person other than
Tenant pending approval or disapproval of an assignment. Neither a delay in the approval or
disapproval of such assignment nor the acceptance of Rent or performance shall constitute a waiver
or estoppel of Landlord’s right to exercise its remedies for Tenant’s Default or Breach.

          (c) Landlord’s consent to any assignment or subletting shall not constitute a consent to any
subsequent assignment or subletting.

          (d) In the event of any Default or Breach by Tenant, Landlord may proceed directly against
Tenant or anyone else responsible for the performance of Tenant’s obligations under this Lease,
including any assignee or subtenant, without first exhausting Landlord’s remedies against any other
person or entity responsible therefore to Landlord, or any security held by Landlord.

          (e) Each request for consent to an assignment or subletting shall be in writing, accompanied
by information relevant to Landlord’s determination as to the financial and operational
responsibility and appropriateness of the proposed assignee or subtenant, including but not limited
to the intended use and/or required modification of the Premises, if any. Tenant agrees to provide
Landlord with such other or additional information and/or documentation as may be reasonably
requested. Tenant shall reimburse Landlord for all reasonable out of pocket costs actually
incurred by Landlord in connection with the consideration of any request, including attorneys’
fees.

23

 

          (f) Any assignee of, or subtenant under, this Lease shall, by reason of accepting such
assignment or entering into such sublease, be deemed to have assumed and agreed to conform and
comply with each and every term, covenant, condition and obligation herein to be observed or
performed by Tenant during the Term of said assignment or sublease, other than such obligations as
are contrary to or inconsistent with provisions of an assignment or sublease to which Landlord has
specifically consented to in writing.

     12.3 Additional Terms and Conditions Applicable to Subletting. The following terms and
conditions shall apply to any subletting by Tenant of all or any part of the Premises and shall be
deemed included in all subleases under this Lease whether or not expressly incorporated therein:

          (a) Tenant hereby assigns and transfers to Landlord all of Tenant’s interest in all Rent
payable on any sublease, and Landlord may collect such Rent and apply same toward Tenant’s
obligations under this Lease; provided, however, that until a Breach shall occur in the performance
of Tenant’s obligations, Tenant may collect said Rent. Landlord shall not, by reason of the
foregoing or any assignment of such sublease, nor by reason of the collection of Rent, be deemed
liable to the subtenant for any failure of Tenant to perform and comply with any of Tenant’s
obligations to such subtenant. Tenant hereby irrevocably authorizes and directs any such
subtenant, upon receipt of a written notice from Landlord stating that a Breach exists in the
performance of Tenant’s obligations under this Lease, to pay to Landlord all Rent due and to become
due under the sublease. Subtenant shall rely upon any such notice from Landlord and shall pay all
Rents to Landlord without any obligation or right to inquire as to whether such Breach exists,
notwithstanding any claim from Tenant to the contrary.

          (b) In the event of a Breach by Tenant, Landlord may, at its option, require subtenant to
attorn to Landlord, in which event Landlord shall undertake the obligations of the sublandlord
under such sublease from the time of the exercise of said option to the expiration of such
sublease; provided, however, Landlord shall not be liable for any prepaid rents or security deposit
paid by such subtenant to such sublandlord or for any prior Defaults or Breaches of such
sublandlord.

          (c) Any matter requiring the consent of the sublandlord under a sublease shall also require
the consent of Landlord.

          (d) No subtenant shall further assign or sublet all or any part of the Premises without
Landlord’s prior written consent.

          (e) If a sublease, fifty percent (50%) of any sublease rentals or any other economic
consideration received by Tenant as a result of such subletting, whether denominated rentals under
the sublease or otherwise, which in aggregate exceed the total sums which Tenant is obligated to
pay Landlord under this Lease (prorated to reflect obligations allocable to that portion of the
Premises subject to such sublease), after deducting the reasonable and customary costs for tenant
improvements, reasonable attorneys’ fees and brokerage fees incurred by Tenant in connection with
the subletting, shall, provided Tenant has not committed a Default or Breach hereunder, be paid to
Landlord as Additional Rent. If Tenant has committed a Default or Breach under this Lease, then
all such consideration shall be paid to Landlord.

24

 

          (f) If an assignment, fifty percent (50%) of any economic consideration received by Tenant
with respect to the assignment of this Lease, whether denominated as such or otherwise, which in
aggregate exceed the total sums which Tenant is obligated to pay Landlord under this Lease, after
deducting the reasonable and customary costs for tenant improvements, reasonable attorneys’ fees
and brokerage fees incurred by Tenant in connection with the assignment, shall, provided Tenant has
not committed a Default or Breach hereunder, be paid to Landlord as Additional Rent. If Tenant has
committed a Default or Breach under this Lease, then all such consideration shall be paid to
Landlord.

     12.4 Conditions to Consent to Assignment or Subletting. Tenant acknowledges that Landlord’s
agreement to sublease the Premises to Tenant at the rent and upon the terms stated herein is in
material reliance upon Landlord’s evaluation of the original Tenant’s background, experience and
ability, as well as the nature of the use of the Premises by the original Tenant as set forth in
Paragraph 6. In the event that Tenant shall request Landlord’s written consent to assign or
sublease the Premises as required in this Paragraph 12, then each such request for consent shall be
in writing and accompanied by the following:

          (a) Balance sheets, income statements and tax returns of the proposed assignee or subtenant
for the most recent three (3) fiscal years.

          (b) A complete business biography and history of the proposed assignee or subtenant and its
officers, partners and managers, if any.

          (c) A statement of the specific uses for which the Premises will be utilized by the proposed
assignee or subtenant.

          (d) Preliminary plans prepared by an architect or civil engineer for all alterations to the
Premises that are contemplated to be made by the proposed assignee or subtenant.

          (e) A list prepared by the proposed assignee or subtenant of all buildings in which the
proposed assignee or subtenant has been a tenant during the past five (5) years, which list shall
include the address of each such building and the last known name, address and telephone number of
the landlord of each such building.

          (f) A list prepared by the proposed assignee or subtenant of all lawsuits in which the
proposed assignee or subtenant has been a named party, either as plaintiff or defendant, during the
past three (3) years, which list shall include the name and location of the court, the case name
and case number and a brief description of the nature of the action.

          (g) Written approval of the proposed assignment or sublease and a reaffirmation of liability,
in a form satisfactory to Landlord’s counsel, from all guarantors and previous assignors of this
Lease, not previously expressly released by Landlord, if any.

          (h) Landlord may refuse to consent on any commercially reasonable grounds, including without
limitations the potential inability of the proposed assignee to fulfill the terms of this Lease and
the financial irresponsibility or instability of the proposed assignee or subtenant, the lack of
suitability of the Premises for the intended use by the proposed assignee or

25

 

subtenant, the potential for unlawful or undesirable use of the Premises by the subtenant or
assignee, or the character or business reputation of the proposed assignee or subtenant. In any
dispute which arises under this paragraph, Tenant shall pay to Landlord all of Landlord’s costs and
expenses reasonably incurred by Landlord in making the investigation and factual findings provided
for in this paragraph.

     12.5 Standards for Consent to Assignment or Subletting. Once Landlord has received all sums
required under Paragraph 12.2(e) above and all of the information, in satisfactory form, as
required above, together with any additional information which Landlord may reasonably request,
Landlord shall undertake to review Tenant’s request for consent to assign or sublease. In
determining whether to give its consent to such assignment or subletting, Landlord shall consider
all commercially reasonable factors, including, but not limited to, the following:

          (a) The financial responsibility of the proposed assignee or subtenant;

          (b) The nature of the occupancy and of the business to be conducted on the Premises and its
suitability for the Premises, Building and/or the Project; and

          (c) The need for and nature of any indicated alteration of the Premises by the proposed
assignee or subtenant and/or whether Personal Property could be damaged or not adequately
maintained by the proposed assignee or subtenant.

     12.6 Permitted Transfers. Notwithstanding anything to the contrary herein but subject to
compliance with the provisions of Paragraphs 12.2 and 12.3 above, Tenant may, without Landlord’s
consent, (a) assign this Lease or sublease all or any portion of the Premises to any entity with
which Tenant merges, regardless of whether Tenant is the surviving entity, or (b) cause a sale or
transfer of all or substantially all the capital stock or other ownership interests in Tenant
including a “going public” transaction (each successor entity, assignee, purchaser or subtenant in
(a) or (b) being referred to herein as a “Permitted Transferee” and each such transaction a
“Permitted Transfer”), provided that all of the following conditions are satisfied: (x) Tenant is
not in Default under this Lease at the time of such assignment, subletting, sale or transfer; (y)
Tenant shall give Landlord written notice at least five (5) business days’ prior to the effective
date of the Permitted Transfer, and (z) the net worth of the Permitted Transferee shall be equal to
or better than Tenant’s net worth as of the day prior to the proposed assignment, subletting, sale
or transfer, or as of August 1, 2005, whichever is greater.

13. DEFAULT; BREACH; REMEDIES.

     13.1 Default; Breach. A “Default” is defined as a failure by the Tenant to comply with or
perform any of the terms, covenants or conditions under this Lease or any of the Rules. A “Breach”
is defined as the occurrence of one or more of the following Defaults, and the failure of Tenant to
cure such Default within any applicable grace period:

          (a) The abandonment of the Premises; or the vacating of the Premises without apparent intent
to return and without providing a reasonable level of security, or which results in the coverage of
the property insurance described in Paragraph 8.2 above being jeopardized as a result thereof, or
without providing reasonable security to minimize potential vandalism.

26

 

          (b) The failure of Tenant to make any payment of Rent (or to restore the Security Deposit)
when due.

          (c) The failure to provide reasonable evidence of insurance or surety bond, or to fulfill any
other obligation under this Lease which endangers or threatens life or property, where such failure
continues for a period of three (3) business days following written notice to Tenant.

          (d) The failure by Tenant to provide (i) reasonable written evidence of compliance with
Applicable Requirements, (ii) the service contracts, (iii) the rescission of an unauthorized
assignment or subletting, (iv) an Estoppel Certificate (as defined in Paragraph 16 below), (v) a
subordination agreement or other document requested under Paragraph 30 below, (vi) any document
requested under Paragraph 39 below, or (vii) any other documentation or information which Landlord
may reasonably require of Tenant under the terms of this Lease, where any such failure continues
for a period of ten (10) days following written notice to Tenant.

          (e) A Default by Tenant as to the terms, covenants, conditions or provisions of this Lease, or
of the Rules, other than those described in Paragraphs 13.1(a), (b) or (c), above, where such
Default continues for a period of thirty (30) days after written notice; provided, however, that if
the nature of Tenant’s Default is such that more than thirty (30) days are reasonably required for
its cure, then it shall not be deemed to be a Breach if Tenant commences such cure within said
thirty (30) day period and thereafter diligently prosecutes such cure to completion within an
additional thirty (30) day period.

          (f) The occurrence of any of the following events: (i) the making of any general arrangement
or assignment for the benefit of creditors; (ii) becoming a “debtor” as defined in 11 U.S.C. § 101
or any successor statute thereto (unless, in the case of a petition filed against Tenant, the same
is dismissed within sixty (60) days); (iii) the appointment of a trustee or receiver to take
possession of substantially all of Tenant’s assets located at the Premises or of Tenant’s interest
in this Lease, where possession is not restored to Tenant within thirty (30) days; or (iv) the
attachment, execution or other judicial seizure of substantially all of Tenant’s assets located at
the Premises or of Tenant’s interest in this Lease, where such seizure is not discharged within
thirty (30) days; provided, however, in the event that any provision of this subparagraph (e) is
contrary to any applicable law, such provision shall be of no force or effect, and not affect the
validity of the remaining provisions.

          (g) The discovery that any financial statement of Tenant given to Landlord was materially
false.

          13.2 Remedies. If Tenant fails to perform any of its affirmative duties or obligations,
within ten (10) days after written notice (or in case of an emergency, without notice), Landlord
may, at its option, perform such duty or obligation on Tenant’s behalf, including but not limited
to the obtaining of reasonably required bonds, insurance policies, or governmental licenses,
permits or approvals. The costs and expenses of any such performance by Landlord shall be due and
payable by Tenant upon receipt of invoice therefor. If any check given to Landlord by Tenant shall
not be honored by the bank upon which it is drawn, Landlord, at its option, may require all future
payments to be made by Tenant to be by cashier’s check. In the event of a

27

 

Breach, Landlord may, with or without further notice or demand, and without limiting Landlord
in the exercise of any right or remedy which Landlord may have by reason of such Breach:

          (a) give Tenant written notice in accordance with applicable law of its intention to terminate
this Lease on the date of the notice or on any later date specified in the notice, and, on the date
specified in the notice, Tenant’s right to possession of the Premises will cease and this Lease
will be terminated (except as to Tenant’s liability set forth in this Paragraph 13.2(a)), as if the
expiration of the term fixed in the notice were the end of the term of this Lease. If this Lease
is terminated pursuant to the provisions of this Paragraph 13.2(a), Tenant will remain liable to
Landlord for damages in an amount equal to the Rent and other sums that would have been owing by
Tenant under this Lease for the balance of the Term if this Lease had not been terminated, less the
net proceeds, if any, of any reletting of the Premises by Landlord subsequent to the termination,
after deducting all of Landlord’s expenses in connection with the reletting, including without
limitation, the expenses set forth in Paragraph 13.2(b)(2) below. Landlord will be entitled to
collect those damages from Tenant monthly on the days on which the Rent and other amounts would
have been payable under this Lease if this Lease had not been terminated and Landlord will be
entitled to receive those damages from Tenant on those days. Alternatively, at the option of
Landlord, if this Lease is terminated, Landlord will be entitled to recover from Tenant (A) the
worth at the time of award of the unpaid Rent that had been earned at the time of termination; (B)
the worth at the time of award of the amount by which the unpaid Rent that would have been earned
after termination until the time of award exceeds the amount of the Rent loss that Tenant proves
could reasonably have been avoided; (C) the worth at the time of award of the amount by which the
unpaid Rent for the balance of the term of this Lease after the time of award exceeds the amount of
the Rent loss that Tenant proves could reasonably be avoided; and (D) any other amount necessary to
compensate Landlord for all the detriment proximately caused by Tenant’s failure to perform its
obligations under this Lease or that in the ordinary course of things would be likely to result
from that failure. The “worth at the time of award” of the amount referred to in clauses (A) and
(B) above is computed by allowing interest at the rate of eighteen percent (18%) per annum. The
worth at the time of award of the amount referred to in clause (C) is computed by discounting the
amount at the discount rate of the Federal Reserve Bank of San Francisco at the time of award. For
the purpose of determining unpaid rental under clause (C) above, the monthly rent reserved in this
Lease will be deemed to be the sum of the Base Rent due and the amounts last payable by Tenant
under this Lease for the calendar year in which the award is made; or

          (b) (1) after demand, notice and any court order as may be required under applicable law,
re-enter and take possession of the Premises, or any part of the Premises; repossess the Premises
as of Landlord’s former estate; expel Tenant and those claiming through or under Tenant from the
Premises; and remove the effects of both or either, without being deemed guilty of any manner of
trespass and without prejudice to any remedies for arrears of Rent or preceding breach of covenants
or conditions. If Landlord elects to re-enter, as provided in this Paragraph 13.2(b), or if
Landlord takes possession of the Premises pursuant to legal proceedings or pursuant to any notice
provided by law, Landlord may, from time to time, without terminating this Lease, relet the
Premises or any part of the Premises, either alone or in conjunction with other portions of the
Building of which the Premises are a part, in Landlord’s or Tenant’s name but for the account of
Tenant, for such term or terms (which may be greater or less than the period that would otherwise
have constituted the balance of the Term of this Lease)

28

 

and on such terms and conditions (which may include concessions of free rent, and the
alteration and repair of the Premises) as Landlord, in its reasonable discretion, may determine.
Landlord may collect and receive the Rents for the Premises. Landlord will not be responsible or
liable for any failure to relet the Premises, or any part of the Premises, or for any failure to
collect any Rent due upon reletting. No re-entry or taking possession of the Premises by Landlord
will be construed as an election on Landlord’s part to terminate this Lease unless a written notice
of such intention is given to Tenant. No notice from Landlord under this Lease or under a forcible
entry and detainer statute or similar law will constitute an election by Landlord to terminate this
Lease unless the notice specifically says so. Landlord reserves the right following any re-entry
or reletting, or both, to exercise its right to terminate this Lease by giving Tenant written
notice, and, in that event, this Lease will terminate as specified in the notice; and

               (2) if Landlord elects to take possession of the Premises according to this Paragraph 13.2(b)
without terminating this Lease, Tenant will pay Landlord (i) the Rent and other sums that would be
payable under this Lease if such repossession had not occurred, less (ii) the net proceeds, if any,
of any reletting of the Premises, after deducting all of Landlord’s expenses incurred in connection
with such reletting, including without limitation all repossession costs, brokerage commissions,
legal expenses, attorneys’ fees, expenses of employees, alteration, remodeling, repair costs, and
expenses of preparation for reletting. If, in connection with any reletting, the new sublease term
extends beyond the existing Term or the Premises covered by reletting include areas that are not
part of the Premises, a fair apportionment of the rent received from such reletting and the
expenses incurred in connection with such reletting will be made in determining the net proceeds
received from reletting. In addition, in determining the net proceeds from reletting, any rent
concessions will be apportioned over the term of the new sublease. Tenant will pay such amounts to
Landlord monthly on the days on which the Rent and all other amounts owing under this Lease would
have been payable if possession had not been retaken, and Landlord will be entitled to receive the
Rent and other amounts from Tenant on those days; or

          (c) commence one or more suits or suits for the recovery of the Rent and other amounts and
damages set forth in this Paragraph 13 may be brought by Landlord, from time to time, at Landlord’s
election, and nothing in this Lease will be deemed to require Landlord to await the date on which
the Term of this Lease expires. Each right and remedy in this Lease will be cumulative and will be
in addition to every other right or remedy in this Lease or existing at law or in equity or by
statute or otherwise, including without limitation suits for injunctive relief and specific
performance. The exercise or beginning of the exercise by Landlord of any right or remedy will not
preclude the simultaneous or later exercise by Landlord of any other rights or remedies. All
rights and remedies are cumulative and nonexclusive.

     13.3 Late Charges. Tenant hereby acknowledges that late payment by Tenant of Rent will cause
Landlord to incur costs not contemplated by this Lease, the exact amount of which will be extremely
difficult to ascertain. Such costs include, but are not limited to, processing and accounting
charges, and late charges which may be imposed upon Landlord by any Lender. Accordingly, if any
Rent shall not be received by Landlord within five (5) days after such amount shall be due, then,
without any requirement for notice to Tenant, Tenant shall pay to Landlord a late charge equal to
five percent (5%) of each such overdue amount. The Parties hereby agree that such late charge
represents a fair and reasonable estimate of the costs Landlord

29

 

will incur by reason of such late payment. Acceptance of such late charge by Landlord shall
in no event constitute a waiver of Tenant’s Default or Breach with respect to such overdue amount,
nor prevent the exercise of any of the other rights and remedies granted hereunder.

     13.4 Interest. Any monetary payment due Landlord hereunder, other than late charges, not
received by Landlord, when due shall bear interest from the sixth (6th) day after the
date due. The interest (“Interest”) charged shall be equal to eighteen percent (18%) per annum,
but shall not exceed the maximum rate allowed by law. Interest is payable in addition to the
potential late charge provided for in Paragraph 13.3 above.

     13.5 Breach by Landlord. Landlord shall not be deemed in breach of this Lease unless Landlord
fails within a reasonable time to perform an obligation required to be performed by Landlord. For
purposes of this Paragraph, a reasonable time shall in no event be less than thirty (30) days after
receipt by Landlord, and any Lender whose name and address shall have been furnished Tenant in
writing for such purpose, of written notice specifying wherein such obligation of Landlord has not
been performed; provided, however, that if the nature of Landlord’s obligation is such that more
than thirty (30) days are reasonably required for its performance, then Landlord shall not be in
breach if performance is commenced within such thirty (30) day period and thereafter diligently
pursued to completion.

14. CONDEMNATION.

     If the Premises or any portion thereof are taken under the power of eminent domain or sold
under the threat of the exercise of said power (collectively “Condemnation”), this Lease shall
terminate as to the part taken as of the date the condemning authority takes title or possession,
whichever first occurs. If more than twenty-five percent (25%) of the Premises, or more than
thirty-five percent (35%) of the parking is taken by Condemnation, Tenant may, at Tenant’s option,
to be exercised in writing within ten (10) days after Landlord shall have given Tenant written
notice of such taking (or in the absence of such notice, within ten (10) days after the condemning
authority shall have taken possession) terminate this Lease as of the date the condemning authority
takes such possession. If Tenant does not timely terminate this Lease in accordance with the
foregoing, this Lease shall remain in full force and effect as to the portion of the Premises
remaining, except that the Base Rent shall be reduced in proportion to the reduction in utility of
the Premises caused by such Condemnation. Condemnation awards and/or payments shall be the
property of Landlord, whether such award shall be made as compensation for diminution in value of
the leasehold, the value of the part taken, or for severance damages. In the event that this Lease
is not terminated by reason of the Condemnation, Landlord shall repair any damage to the Premises
caused by such Condemnation to the extent of any proceeds actually received by Landlord.

15. BROKERS.

     15.1 Representations and Indemnities of Broker Relationships. Tenant and Landlord each
represent and warrant to the other that it has had no dealings with any person, firm, broker or
finder in connection with this Lease, and that no one is entitled to any commission or finder’s fee
in connection herewith. Tenant and Landlord do each hereby agree to indemnify, protect, defend and
hold the other harmless from and against liability for

30

 

compensation or charges which may be claimed by any such unnamed broker, finder or other
similar party by reason of any dealings or actions of the indemnifying Party, including any costs,
expenses, attorneys’ fees reasonably incurred with respect thereto.

16. ESTOPPEL CERTIFICATES.

     16.1 Each Party (as “Responding Party”) shall within twenty (20) days after written notice
from the other Party (the “Requesting Party”) execute, acknowledge and deliver to the Requesting
Party a statement certifying, if applicable, that Tenant is in possession of the Premises; this
Lease is in full force and effect; this Lease is unmodified (or if there have been modifications,
that this Lease is in full force and effect, as modified, and stating the date and nature of each
modification); Tenant claims no present charge, lien, or claim of offset against Rent; there is no
existing default by reason of some act or omission by Landlord; and such other additional
information, confirmation and/or statements as may be reasonably requested by the Requesting Party,
or Landlord’s Lender, if any (“Estoppel Certificate”).

     16.2 If the Responding Party shall fail to execute or deliver the Estoppel Certificate within
such twenty (20) day period, the Requesting Party may execute an Estoppel Certificate stating that:
(i) this Lease is in full force and effect without modification except as may be represented by the
Requesting Party, (ii) there are no uncured defaults in the Requesting Party’s performance, and
(iii) if Landlord is the Requesting Party, not more than one (1) month’s Base Rent has been paid in
advance. Prospective purchasers and encumbrancers may rely upon the Requesting Party’s Estoppel
Certificate, and the Responding Party shall be estopped from denying the truth of the facts
contained in said Certificate.

     16.3 If Landlord desires to finance, refinance, or sell the Premises, or any part thereof,
Tenant shall deliver to any potential lender or purchaser designated by Landlord such financial
statements as may be reasonably required by such lender or purchaser, including but not limited to
Tenant’s financial statements for the past three (3) years. All such financial statements shall be
received by Landlord and such lender or purchaser in confidence and shall be used only for the
purposes herein set forth

17. LIABILITY AFTER TRANSFER.

     In the event of a transfer of the Landlord’s interest in the Premises or this Lease, Landlord
shall deliver to the transferee or assignee (in cash or by credit) any unused Security Deposit held
by Landlord. Upon such transfer or assignment and delivery of the Security Deposit, if any,
Landlord shall be relieved of all liability with respect to the obligations and/or covenants under
this Lease thereafter to be performed by the same.

18. SEVERABILITY.

     The invalidity of any provision of this Lease, as determined by a court of competent
jurisdiction, shall in no way affect the validity of any other provision hereof.

31

 

19. DAYS.

     Unless otherwise specifically indicated to the contrary, the word “days” as used in this Lease
shall mean and refer to calendar days.

20. LIMITATION ON LIABILITY.

     In consideration of the benefits accruing hereunder, Tenant on behalf of itself and all
successors and assigns of Tenant, covenants and agrees that, notwithstanding anything to the
contrary and notwithstanding any applicable law to the contrary:

          (a) the liability of Landlord under this Lease (including any liability for any actual or
alleged failure, breach or default by Landlord under this Lease and/or negligence of Landlord
hereunder) and any recourse against Landlord shall be limited solely to the interest in the Project
of Landlord, along with the sale and insurance proceeds with regard to the Project, and not any
other assets of Landlord; and

          (b) no director, officer, shareholder, employee, adviser or agent of Landlord shall be
personally liable in any manner or to any extent under or in connection with this Lease, and Tenant
shall not seek recourse against any such person or against any of their personal assets for
satisfaction of any liability with respect to this Lease; and

          (c) Landlord and the Landlord Parties shall not be responsible or liable for any indirect,
incidental, special, consequential or punitive damages in connection with this Lease, including,
without limitation, on account of lost profits or the interruption of Tenant’s business.

     With regard to the provisions of Paragraph 20(a) above, Landlord hereby acknowledges and
agrees that, if Tenant were to obtain a judgment against Landlord in connection with this Lease,
then Tenant shall be entitled to record a judgment lien against the fee interest of the Project
with respect thereto.

21. TIME OF ESSENCE.

Time is of the essence with respect to the performance of all obligations to be performed or
observed by the Parties under this Lease.

22. NO PRIOR OR OTHER AGREEMENTS; COUNTERPARTS.

     This Lease contains all agreements between the Parties with respect to any matter mentioned
herein, and no other prior or contemporaneous agreement or understanding shall be effective. This
Lease may be executed in any number of counterparts, each of which when so executed and delivered
shall be deemed to be an original and all of which counterparts taken together shall constitute but
one and the same instrument.

32

 

23. NOTICES.

     23.1 Notice Requirements. All notices required or permitted by this Lease shall be in writing
and may be delivered in person (by hand or by courier) or may be sent by regular, certified or
registered mail or U.S. Postal Service Express Mail, with postage prepaid, or by facsimile
transmission, and shall be deemed sufficiently given if served in a manner specified in this
Paragraph 23. The addresses noted below shall be that Party’s address for delivery or mailing of
notices. Either Party may by written notice to the other specify a different address for notice.
A copy of all notices to Landlord shall be concurrently transmitted to such party or parties at
such addresses as Landlord may from time to time hereafter designate in writing.

	 	 	 	 	 	 	 	 	 
	 	 	Landlord:	 	Triumph 1450 LLC	 	 
	 	 	 	 	9605 Kingston Court, Suite 160	 	 
	 	 	 	 	Englewood, Colorado 80112	 	 
	 	 	 	 	Attention: Paul J. Ruff	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	with a copy to:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 

	 	 	 	Attention: 	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	Tenant:	 	Replidyne, Inc.	 	 
	 	 	 	 	1450 Infinite Drive	 	 
	 	 	 	 	Louisville, Colorado 80027	 	 
	 	 	 	 	Attention: Jill Clark, Senior Director of Finance
and Administration	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	with a copy to:	 	Holland & Hart LLP	 	 
	 	 	 	 	1800 Broadway, Suite 300	 	 
	 	 	 	 	Boulder, Colorado 80302	 	 
	 	 	 	 	Attention: J. Marcus Painter, Esq.	 	 

     23.2 Date of Notice. Any notice sent by registered or certified mail, return receipt
requested, shall be deemed given on the date of delivery shown on the receipt card, or if no
delivery date is shown, the postmark thereon. If sent by regular mail the notice shall be deemed
given forty-eight (48) hours after the same is addressed as required herein and mailed with postage
prepaid. Notices delivered by United States Express Mail or overnight courier that guarantee next
day delivery shall be deemed given twenty-four (24) hours after delivery of the same to the Postal
Service or courier. Notices transmitted by facsimile transmission or similar means shall be deemed
delivered upon telephone confirmation of receipt, provided a copy is also delivered via delivery or
mail. If notice is received on a Saturday, Sunday or legal holiday, it shall be deemed received on
the next business day.

24. WAIVERS.

     No waiver by Landlord of the Default or Breach of any term, covenant or condition hereof by
Tenant, shall be deemed a waiver of any other term, covenant or condition hereof, or of any
subsequent Default or Breach by Tenant of the same or of any other term, covenant or

33

 

condition hereof. Landlord’s consent to, or approval of, any act shall not be deemed to
render unnecessary the obtaining of Landlord’s consent to, or approval of, any subsequent or
similar act by Tenant, or be construed as the basis of an estoppel to enforce the provision or
provisions of this Lease requiring such consent. The acceptance of Rent by Landlord shall not be a
waiver of any Default or Breach by Tenant. Any payment by Tenant may be accepted by Landlord on
account of monies or damages due Landlord, notwithstanding any qualifying statements or conditions
made by Tenant in connection therewith, which such statements and/or conditions shall be of no
force or effect whatsoever unless specifically agreed to in writing by Landlord at or before the
time of deposit of such payment.

25. RECORDING.

     No recordation of any memorandum of this Lease, or “short form” of this Lease, shall be
permitted without the prior written consent of Landlord, which shall be withheld or given in
Landlord’s sole discretion. The Party requesting recordation shall be responsible for payment of
any fees applicable thereto.

26. NO RIGHT TO HOLDOVER.

     Tenant has no right to retain possession of the Premises or any part thereof beyond the
expiration or termination of this Lease. In the event that Tenant holds over with Landlord’s
express consent, then the Base Rent shall be increased to one hundred fifty percent (150%) of the
Base Rent applicable during the month immediately preceding the expiration or termination. Tenant
agrees to indemnify, defend and hold harmless Landlord and the Landlord Parties from and against
any Claim arising out of such holding over. Nothing contained herein shall be construed as consent
by Landlord to any holding over by Tenant.

27. CUMULATIVE REMEDIES.

     No remedy or election hereunder shall be deemed exclusive but shall, wherever possible, be
cumulative with all other remedies at law or in equity.

28. COVENANTS AND CONDITIONS; CONSTRUCTION OF AGREEMENT.

     All provisions of this Lease to be observed or performed by Tenant are both covenants and
conditions. In construing this Lease, all headings and titles are for the convenience of the
Parties only and shall not be considered a part of this Lease. Whenever required by the context,
the singular shall include the plural and vice versa. This Lease shall not be construed as if
prepared by one of the Parties, but rather according to its fair meaning as a whole, as if both
Parties had prepared it.

29. BINDING EFFECT; CHOICE OF LAW.

     This Lease shall be binding upon the Parties, their personal representatives, successors and
assigns and be governed by the laws of the State in which the Premises are located. Any litigation
between the Parties hereto concerning this Lease shall be initiated in the county in which the
Premises are located.

34

 

30. SUBORDINATION; ATTORNMENT; NON-DISTURBANCE.

     30.1 Subordination. This Lease granted hereby shall be subject and subordinate to any ground
lease, mortgage, deed of trust, or other hypothecation or security device (collectively, “Security
Device”), now or hereafter placed upon the Premises, to any and all advances made on the security
thereof, and to all renewals, modifications, and extensions thereof; provided, however that so long
as there is no Breach or Default hereunder, Tenant’s right to possession of the Premises shall not
be disturbed by Landlord’s Lender. Tenant agrees that the holders of any such Security Devices (in
this Lease together referred to as “Lender” or “Landlord’s Lender”) shall have no liability or
obligation to perform any of the obligations of Landlord under this Lease. Any Lender may elect to
have this Lease superior to the lien of its Security Device by giving written notice thereof to
Tenant, whereupon this Lease shall be deemed prior to such Security Device, notwithstanding the
relative dates of the documentation or recordation thereof.

     30.2 Attornment. Subject to the non-disturbance provisions of Paragraph 30.3, Tenant agrees
to attorn to a Lender or any other party who acquires ownership of the Premises by reason of a
foreclosure of a Security Device, and that in the event of such foreclosure, such new owner shall
not: (i) be liable for any act or omission of any prior Landlord or with respect to events
occurring prior to acquisition of ownership; (ii) be subject to any offsets or defenses which
Tenant might have against any prior Landlord, or (iii) be bound by prepayment of more than one (1)
month’s Base Rent.

     30.3 Non-Disturbance. With respect to Security Devices entered into by Landlord concurrently
with or after the execution of this Lease, Tenant’s subordination of this Lease and/or attornment
shall be subject to receiving a commercially reasonable non-disturbance agreement (a
“Non-Disturbance Agreement”) from Landlord’s Lender which Non-Disturbance Agreement provides that
Tenant’s possession of the Premises, and this Lease, including any options to extend the term
hereof, will not be disturbed so long as Tenant is not in Breach or Default hereunder and attorns
to the record owner of the Premises. Each Party agrees, from time to time during the Term of this
Lease, upon demand of the other Party to execute, acknowledge and deliver such other instruments,
confirming such subordination and non-disturbance, and such instruments of attornment as shall be
requested by a Party’s lender.

     30.4 Self-Executing. The agreements contained in this Paragraph 30 shall be effective without
the execution of any further documents; provided, however, that, upon written request from Landlord
or a Lender in connection with a sale, financing or refinancing of the Premises, Tenant and
Landlord shall execute such further writings as may be reasonably required to separately document
any subordination, attornment and/or Non-Disturbance Agreement provided for herein.

31. ATTORNEYS’ FEES.

     If any Party brings an action or proceeding involving the Premises to enforce the terms hereof
or to declare rights hereunder, the Prevailing Party (as hereafter defined) in any such proceeding,
action, or appeal thereon, shall be entitled to reasonable attorneys’ fees. Such fees may be
awarded in the same suit or recovered in a separate suit, whether or not such action or proceeding
is pursued to decision or judgment. The term, “Prevailing Party” shall include,

35

 

without limitation, a Party who substantially obtains or defeats the relief sought, as the
case may be, whether by compromise, settlement, judgment, or the abandonment by the other Party or
Broker of its claim or defense. The attorneys’ fees award shall not be computed in accordance with
any court fee schedule, but shall be such as to fully reimburse all attorneys’ fees reasonably
incurred. In addition, Landlord shall be entitled to attorneys’ fees, costs and expenses incurred
in the preparation and service of notices of Default and consultations in connection therewith,
whether or not a legal action is subsequently commenced in connection with such Default or
resulting Breach.

32. LANDLORD’S ACCESS; SHOWING PREMISES; REPAIRS.

     Landlord and Landlord’s agents shall have the right to enter the Premises upon reasonable
advance notice to Tenant (except in the case of an emergency or regularly scheduled janitorial
services for which no prior notice shall be required), and otherwise at reasonable times for the
purpose of showing the same to prospective purchasers, lenders, or subtenants, and making such
alterations, repairs, improvements or additions to the Premises as Landlord may deem necessary.
All such activities shall be without abatement of rent or liability to Tenant. Landlord may at any
time place on the Premises any ordinary “For Sale” signs and Landlord may during the last twelve
(12) months of the term hereof place on the Premises any ordinary “For Lease” signs.

33. AUCTIONS.

     Tenant shall not conduct, nor permit to be conducted, any auction upon the Premises without
Landlord’s prior written consent. Landlord shall not be obligated to exercise any standard of
reasonableness in determining whether to permit an auction.

34. SIGNS.

     Tenant shall not place any sign in, on or about the Premises, the Building or the Project
without Landlord’s prior written consent, which consent Landlord may withhold in its sole
discretion; provided, however, Landlord hereby agrees that Tenant shall have the right to use its
proportionate share (with all tenants of the Building) of the monument located in front of the
Building. All signage of Tenant (including any monument signage) shall, at Tenant’s sole cost and
expense, (a) be installed, maintained, repaired and removed by Tenant, and (b) at all times comply
with all Applicable Requirements. At expiration or earlier termination of this Lease, Tenant shall
remove all signs installed by Tenant and repair all damage caused by the removal of such signs.
Landlord hereby grants its consent to all of Tenant’s signage existing at the Premises as of August
1, 2005.

35. TERMINATION; MERGER.

     Unless specifically stated otherwise in writing by Landlord, the voluntary or other surrender
of this Lease by Tenant, the mutual termination or cancellation hereof, or a termination hereof by
Landlord for Breach by Tenant, shall automatically terminate any sublease or lesser estate in the
Premises; provided, however, that Landlord may elect to continue any one or all existing
subtenancies or sub-subtenancies. Landlord’s failure within ten (10) days following any

36

 

such event to elect to the contrary by written notice to the holder of any such lesser
interest, shall constitute Landlord’s election to have such event constitute the termination of
such interest.

36. CONSENTS.

     Except as otherwise provided herein, wherever in this Lease the consent of a Party is required
to an act by or for the other Party, such consent shall not be unreasonably withheld or delayed.
Landlord’s actual reasonable costs and expenses (including but not limited to architects’,
attorneys’, engineers’ and other consultants’ fees) incurred in the consideration of, or response
to, a request by Tenant for any Landlord consent, including but not limited to consents to an
assignment, a subletting or the presence or use of a Hazardous Substance, shall be paid by Tenant
upon receipt of an invoice and supporting documentation therefor. Landlord’s consent to any act,
assignment or subletting shall not constitute an acknowledgment that no Default or Breach by Tenant
of this Lease exists, nor shall such consent be deemed a waiver of any then existing Default or
Breach, except as may be otherwise specifically stated in writing by Landlord at the time of such
consent. The failure to specify herein any particular condition to Landlord’s consent shall not
preclude the imposition by Landlord at the time of consent of such further or other conditions as
are then reasonable with reference to the particular matter for which consent is being given. In
the event that either Party disagrees with any determination made by the other hereunder and
reasonably requests the reasons for such determination, the determining Party shall furnish its
reasons in writing and in reasonable detail within ten (10) business days following such request.

37. QUIET POSSESSION.

     Subject to payment by Tenant of the Rent and performance of all of the covenants, conditions
and provisions on Tenant’s part to be observed and performed under this Lease, Tenant shall have
quiet possession and quiet enjoyment of the Premises during the term hereof.

38. PARKING.

     Tenant shall have the right to use, on a unassigned, non-exclusive basis, one hundred
thirty-two (132) parking spaces in the parking areas designated at the Building, in accordance with
a parking ratio of 3.1 parking spaces per each 1,000 RSF of the Premises. The use of such parking
spaces shall be subject to, and is conditioned upon, compliance by Tenant with all rules and
regulations governing such parking areas promulgated by Landlord from time to time (and Tenant
shall cause all of Tenant’s employees, agents, contractors and invitees that park therein to comply
with the same). Tenant acknowledges that Landlord reserves the right, in its sole discretion, to
designate any of the parking spaces at the Building as exclusive spaces; in which event and after
Landlord has notified Tenant in writing thereof, then Tenant shall cause its employees, agents,
contractors and invitees not to park in such exclusive spaces.

39. RESERVATIONS.

     Landlord reserves to itself the right, from time to time, to grant, without the consent or
joinder of Tenant, such easements (including reciprocal easements affecting the Premises and other
buildings within the Project), rights and dedications that Landlord deems necessary, and to cause
the recordation of parcel maps and restrictions, so long as such easements, rights,

37

 

dedications, maps and restrictions do not unreasonably interfere with the use of the Premises
by Tenant. Tenant agrees to sign any documents reasonably requested by Landlord to effectuate any
such easement rights, dedication, map or restrictions, and to abide by the terms of any such
restrictions and/or agreements.

40. PERFORMANCE UNDER PROTEST.

     If at any time a dispute shall arise as to any amount or sum of money to be paid by one Party
to the other under the provisions hereof, the Party against whom the obligation to pay the money is
asserted shall have the right to make payment “under protest” and such payment shall not be
regarded as a voluntary payment and there shall survive the right on the part of said Party to
institute suit for recovery of such sum. If it shall be adjudged that there was no legal
obligation on the part of said Party to pay such sum or any part thereof, said Party shall be
entitled to recover such sum or so much thereof as it was not legally required to pay.

41. AUTHORITY.

     If either Party hereto is a corporation, trust, limited liability company, partnership, or
similar entity, each individual executing this Lease on behalf of such entity represents and
warrants that he or she is duly authorized to execute and deliver this Lease on its behalf. Tenant
shall deliver to Landlord satisfactory evidence of such authority.

42. CONFLICT.

     Any conflict between the printed provisions of this Lease and the typewritten or handwritten
provisions shall be controlled by the typewritten or handwritten provisions.

43. OFFER.

     Preparation of this Lease by either Party or their agent and submission of same to the other
Party shall not be deemed an offer to sublease to the other Party. This Lease is not intended to
be binding until executed and delivered by all Parties hereto.

44. AMENDMENTS.

     This Lease may be modified only in writing, signed by the Parties in interest at the time of
the modification. As long as they do not materially change Tenant’s obligations hereunder, Tenant
agrees to make such reasonable non-monetary modifications to this Lease as may be reasonably
required by a Lender in connection with the obtaining of normal financing or refinancing of the
Premises.

45. MULTIPLE PARTIES.

     If more than one person or entity is named herein as either Landlord or Tenant, such multiple
Parties shall have joint and several responsibility to comply with the terms of this Lease.

38

 

46. UNAVOIDABLE DELAYS.

     If the performance of Landlord of any act required herein, including, without limitation, the
design, planning, permitting, construction and completion of the Tenant Improvements, is prevented
or delayed by reason of strikes, lockouts, labor disputes, governmental delays, acts of God, fire,
floods, epidemics, freight embargoes, unavailability of materials and supplies, development
moratoriums imposed by any governmental authority, or other causes beyond the reasonable control of
Landlord, Landlord shall be excused from performing that obligation for the period equal to the
period of prevention or delay.

47. [INTENTIONALLY OMITTED].

48. FINANCIAL INFORMATION.

     Tenant shall furnish Landlord with true and complete copies of (i) Tenant’s most recent
audited annual financial statements within one hundred eighty (180) days of the end of each of
Tenant’s fiscal years, (ii) Tenant’s most recent unaudited quarterly financial statements,
certified by Tenant’s Chief Financial Officer as fairly representing the financial condition and
result of operations of Tenant as of the end of such fiscal quarter, within forty-five (45) days of
the end of each of Tenant’s first three (3) fiscal quarters of each of Tenant’s fiscal year, all of
which shall be treated by Landlord as confidential information belonging to Tenant, and (iii) any
other financial information or summaries that Tenant typically provides to its lenders or
shareholders.

49. INTERPRETATION.

     Neither Party hereto nor their respective attorneys shall be deemed the drafter of this Lease
for purposes of interpreting or construing any of the provisions of this Lease in any judicial
proceeding which may hereafter arise between the Parties or their respective assigns or
successors-in-interest. This Lease shall be interpreted in accordance with the fair meaning
thereof, and not strictly for or against any Party hereto. Tenant acknowledges that it has read
this Lease in its entirety and has had the opportunity to freely negotiate any or all of the terms
hereof before executing the same.

50. RULES AND REGULATIONS.

     Tenant shall comply with the rules and regulations attached hereto as Exhibit F with
respect to the Building (including the Common Areas) and the Project, as the same may be amended,
modified and supplemented by Landlord from time to time (the “Rules”). Landlord shall have the
right at all times to amend, modify and/or supplement the Rules in any manner as Landlord may deem
advisable in its sole discretion; provided, that (i) any amendment, modification or supplement to
the Rules shall not materially increase Tenant’s obligations under this Lease or materially
decrease Tenant’s rights under this Lease, and (ii) Landlord will provide Tenant with all
amendments, modifications and supplements to the Rules. Landlord shall not be responsible to Tenant
for the non-compliance by any other tenant or occupant of the Building or the Project with any of
the Rules. In the event of any conflict between any Rule and any provision contained in this
Lease, the provision contained in this Lease shall control.

39

 

51. CONFIDENTIALITY.

     Tenant and Landlord acknowledge that the Premises contain highly confidential and proprietary
information. Accordingly, both Parties agree as follows:

          (i) To use all reasonably appropriate measures to avoid receipt of any information or
materials which either Party know or have reason to know contains confidential trade secrets or
other proprietary information (“Confidential Information”), including but not limited to,
refraining from, receiving or obtaining any Confidential Information from an owner without such
owners consent; and

          (ii) To immediately notify the other if a Party believes it has received Confidential
Information, to prohibit disclosure of such Confidential Information to a third party, and to
immediately return any documents or other tangible evidence of such Confidential Information to the
other; and

          (iv) To put their employees, directors, subcontractors and agents on notice of their
obligations set forth herein.

          Both Parties acknowledge that the unauthorized disclosure of Confidential Information to the
other, or to third parties, would cause irreparable business harm for which damages alone are not
an adequate remedy. Accordingly, both Parties agree that either Party shall be entitled to
injunctive relief to immediately cease any actual or potential misuse or unauthorized disclosure of
Confidential Information.

52. RIGHT OF SECOND REFUSAL.

     52.1 Right of Second Refusal. Tenant shall have a right of second refusal on the Second
Refusal Space (as defined below) during the first three (3) years of the Term subject to the terms
and conditions set forth in this Paragraph 52 (the “Right of Second Refusal”). As used herein,
“Second Refusal Space” shall mean the space constituting approximately 10,476 RSF in Section E1 of
the Building, as depicted on Exhibit G hereto. The Second Refusal Space is presently
vacant, but subject to a right of first refusal (“Right of First Refusal”) in favor of GlobeImmune,
Inc. (“GlobeImmune”), another tenant in the Building. Landlord shall provide written notice to
Tenant (a “Second Refusal Notice”) of any bona fide offer to lease the Second Refusal Space or any
portion thereof that Landlord receives during the Term of this Lease and which Landlord is willing
to accept (an “Offer”), provided that GlobeImmune has declined to exercise its Right of First
Refusal with respect to the same. Tenant shall have five (5) business days after receipt of
Landlord’s notice to exercise its Right of Second Refusal by providing Landlord with an irrevocable
written notice (“Election Notice”) that Tenant elects to lease all of the Second Refusal Space
described in the Offer on the same terms and conditions as set forth in the Offer (and Tenant shall
not be permitted to lease less than all of the Second Refusal Space described in the Offer);
provided, however, if Landlord receives Tenant’s Election Notice on or before August 1, 2006, then
Base Rent for the Second Refusal Space shall be the lesser of (i) the initial Base Rent set forth
in the Offer, and (ii) the Base Rent applicable to the Premises on the date that the Second Refusal
Space becomes part of the “Premises” hereunder. In the event that Landlord does not receive
Tenant’s written election to exercise the Right of Second Refusal

40

 

within five (5) business days after the date of the Second Refusal Notice, then Tenant shall
be deemed to have declined to exercise its Right of Second Refusal with respect thereto and
Landlord shall be free to sublease the space described in the Offer to any third party on the terms
and conditions contained in the Offer or such other economic terms and conditions that (taken as a
whole) are not less favorable (to a tenant) by more than ten percent (10%).

     52.2 Terms and Conditions. In the event Tenant duly and timely delivers its Election Notice
to Landlord, then Landlord shall prepare an amendment to this Lease (or a direct lease, if Landlord
desires), pursuant to which Tenant shall lease the Second Refusal Space from Landlord, upon and
subject to the same terms and conditions contained in this Lease except as follows: (i) Tenant
shall accept the Second Refusal Space in its then “As-built” and “AS IS” condition without any
obligation of Landlord to repaint, remodel, improve or alter the Second Refusal Space for Tenant’s
occupancy or to provide Tenant any allowance therefor; (ii) Landlord shall deliver the Second
Refusal Space to Tenant no later than thirty (30) days after Landlord regains possession of such
space (if such space is not vacant at such time); (iii) the term of Tenant’s lease of the Second
Refusal Space, and obligation to pay Rent therefor, shall commence on such delivery date and
continue for the remaining Term; (iv) upon such delivery, the Second Refusal Space shall be part of
the Premises under this Lease, such that the term “Premises” in this Lease thereafter shall refer
to the space then leased immediately prior to such delivery, plus the Second Refusal Space; and (v)
as otherwise expressly provided in this Paragraph 52.

     52.3 Termination of Right of Second Refusal. Upon the occurrence of any of the following
events, Landlord shall have the option, exercisable at any time prior to the commencement of the
term as to the Second Refusal Space, to terminate all of the provisions of this Paragraph 52,
whereupon all rights of Tenant pursuant to the Right of Second Refusal shall terminate and shall be
of no further force and effect:

          (a) The existence at either (i) the time of exercise of the Right of Second Refusal, or (ii)
the commencement of the term of the Second Refusal Space, of a Default or Breach on the part of
Tenant under this Lease.

          (b) Tenant is not, immediately prior to exercise of the Right of Second Refusal, in occupancy
of at least ninety percent (90%) of the Premises then leased to Tenant.

          (c) Notwithstanding anything to the contrary contained herein, the Right of Second Refusal
shall terminate on August 1, 2008.

     52.4 No Transfer of Right. This Right of Second Refusal is personal to Tenant and shall not
be transferable or assignable, by operation of law or otherwise, voluntarily or involuntarily, to
any assignee of this Lease, or sublessee of all or any part of the Premises, or any other person or
entity, other than any assignee or sublessee to which Landlord has given its consent in accordance
with Paragraph 12 above and other than a Permitted Transferee. Time shall be of the essence with
respect to all of the provisions of this Paragraph 52.

53. OPTION TO EXTEND.

     53.1 Grant of Option. Landlord hereby grants to Tenant an option to extend the Term of this
Lease (“Option”) for a period of five (5) years (“Option Term”), subject to all of the

41

 

provisions of this Lease except that: (i) Base Rent shall be adjusted in accordance with
Paragraph 53.2 below; and (ii) Tenant shall not be permitted to extend the Term beyond the Option
Term. Tenant may exercise the Option if and only if (A) Tenant is not then in Default or in
Breach, and (B) Landlord receives from Tenant an irrevocable written notice exercising the Option
at least nine (9) months, but not sooner than twelve (12) months, before the Expiration Date. If
Tenant commits a Default during the period after the exercise of the Option but prior to the
commencement date of the Option Term, and fails to cure such Default within the applicable cure
period (but no later than the day immediately prior to the commencement of the Option Term if
earlier), then in Landlord’s sole discretion, Landlord may treat Tenant’s election to exercise the
Option as ineffective, in which event this Lease shall expire on the Expiration Date as if Tenant
had not given such notice.

     53.2 Fair Market Rental Value. The Base Rent for the first (1st) year of the
Option Term shall be the then Fair Market Rental Value (as defined below) for comparable space in
the Building and in comparable buildings in Boulder and Broomfield Counties, Colorado (“Comparable
Buildings”). Base Rent for the second (2nd) and third (3rd) year of the
Option Term shall be increased, on the anniversary of the commencement date of the Option Term, by
three percent (3%) over the Base Rent for the prior twelve (12) month period. As used in this
Lease, “Fair Market Rental Value” shall mean one hundred percent (100%) of the rental rate per
rental square foot agreed to be paid by tenants for comparable space in the Building and in
Comparable Buildings, in non-sublease, non-affiliated, arms-length transactions within the prior
ninety (90) day period, with appropriate adjustments for the condition of the premises, length of
lease, age and amenities of Comparable Buildings, any tenant improvement allowances and other
tenant concessions, and the type of lease.

     53.3 Negotiation Period. Within ten (10) business days after receipt of Tenant’s written
notice of its election to exercise the Option, Landlord shall inform Tenant of the Fair Market
Rental Value applicable for the Option Term. Within five (5) days after Tenant’s receipt of
Landlord’s determination of Fair Market Rental Value, Tenant shall either (a) accept Landlord’s
statement of Fair Market Rental Value as the initial Base Rent for the Option Term, or (b) notify
Landlord in writing that Tenant elects to negotiate with Landlord for a period of thirty (30) days
(the “Negotiation Period”) in order to reach a mutually agreeable determination of the initial Base
Rent for the Option Term. Failure on the part of Tenant to notify Landlord in writing that Tenant
elects to negotiate the initial Base Rent for the Option Period within such five (5) day period
shall constitute acceptance of the initial Base Rent for the Option Term as calculated by Landlord.

     53.4 Election for Appraisal. In the event that the Parties fail to mutually determine the
initial Base Rent for the Option Term, Tenant may elect, by written notice to Landlord prior to the
expiration of the Negotiation Period, that the Fair Market Rental Value be determined pursuant to
the appraisal process set forth in Paragraph 53.5 below (the “Appraisal”). Failure on the part of
Tenant to elect such Appraisal process by the end of the Negotiation Period shall constitute
acceptance of the initial Base Rent for the Option Term as calculated by Landlord. If Tenant
elects to determinate the Fair Market Rental Value pursuant to the Appraisal process, the Appraisal
shall be concluded within forty-five (45) days after the date of Tenant’s election, subject to
extension for an additional fifteen (15) day period if a third (3rd) appraiser is
required and does not act in a timely manner. To the extent that the Appraisal has not been
completed

42

 

prior to the expiration of any preceding period for which Base Rent has been determined,
Tenant shall pay Base Rent at the rate calculated by Landlord, with an adjustment to be made once
Fair Market Rental Value is ultimately determined by such Appraisal.

     53.5 Appraisal Procedure. In the event that Tenant elects to determine the Fair Market Rental
Value pursuant to an Appraisal process, the Appraisal shall be conducted as follows:

          (a) Tenant shall make a demand for an Appraisal in writing in accordance with Paragraph 53.4
above, wherein Tenant shall specify the name and address of the person to act as the appraiser on
its behalf. The appraiser shall be either (A) qualified as a real estate appraiser (and shall be a
member of the American Institute of Real Estate Appraisers (MAI) or any comparable successor
organization), or (B) a licensed real estate broker, in either case with at least ten (10) years
professional experience in appraising or leasing (as applicable) commercial properties in Boulder
and Broomfield Counties, Colorado. Failure on the part of Tenant to make a proper appointment in a
timely manner for such Appraisal shall constitute a waiver of the right thereto. Within fifteen
(15) days after the service of the demand for such Appraisal, Landlord shall give notice to Tenant,
specifying the name and address of the person designated by Landlord to act as the appraiser on its
behalf who shall be similarly qualified.

          (b) In the event that two (2) appraisers are chosen pursuant to Paragraph 53.5(a) above, the
appraisers so chosen shall, within fifteen (15) days after the second appraiser is appointed,
determine the Fair Market Rental Value. If the two (2) appraisers are unable to agree upon a
determination of Fair Market Rental Value within such fifteen (15) day period, they, themselves,
shall appoint a third (3rd) appraiser, who shall be a competent and impartial person with
qualifications the same as required of the first two (2) appraisers pursuant to Paragraph 53.5(a)
above. In the event they are unable to agree upon such appointment within seven (7) days after
expiration of said fifteen (15) day period, the third (3rd) appraiser shall be selected by the
Parties themselves, if they can agree thereon, within a further period of ten (10) days. If the
Parties do not so agree, then either Party, on behalf of both, may request appointment of such a
qualified person by the then Presiding Judge of the Superior Court in and for the County of
Boulder, Colorado, acting in his private and not in his official capacity, and the other Party
shall not raise any question as to such Judge’s full power and jurisdiction to entertain the
application for and make the appointment.

          (c) Where the Fair Market Rental Value cannot be resolved by agreement between the two (2)
appraisers selected by Landlord and Tenant or settlement between the Parties during the course of
the Appraisal process, the Fair Market Rental Value shall be determined by the three appraisers
within fifteen (15) days of the appointment of the third (3rd) appraiser in accordance with the
following procedure: The appraiser selected by each of the Parties shall state in writing his or
her determination of the Fair Market Rental Value supported by the reasons therefor with
counterpart copies to each Party. The appraisers shall arrange for a simultaneous exchange of such
proposed resolutions. The role of the third (3rd) appraiser shall be to select which of the two (2)
proposed resolutions more closely approximates his or her determination of the Fair Market Rental
Value. The third (3rd) appraiser shall have no right to propose a middle ground or any modification
of either of the two (2) proposed resolutions. The

43

 

resolution he or she chooses as more closely approximating his or her determination shall
constitute the decision of the appraisers and be final and binding upon the Parties.

          (d) In the event of a failure, refusal or inability of any appraiser to act, his or her
successor shall be appointed by him or her, but in the case of the third (3rd) appraiser, his or
her successor shall be appointed in the same manner as provided for appointment of the third (3rd)
appraiser. Any decision in which the appraiser appointed by Landlord and the appraiser appointed by
Tenant concur shall be binding and conclusive upon the Parties. Each Party shall pay the fee and
expenses of its respective appraiser and both shall share the fee and expenses of the third (3rd)
appraiser, if any.

     53.6 Fees for Appraisal. To the extent that the Appraisal has not been completed prior to the
Expiration Date, Tenant shall pay Base Rent at the rate calculated by Landlord, with an adjustment
to be made once Fair Market Rental Value is ultimately determined.

     53.7 No Transfer of Option. The Option granted to Tenant is personal to Tenant and shall not
be transferable or assignable, by operation of law or otherwise, voluntarily or involuntarily, to
any assignee of this Lease, or sublessee of all or any part of the Premises, or any other person or
entity, other than any assignee or sublessee to which Landlord has given its consent in accordance
with Paragraph 12 above and other than a Permitted Transferee. Time shall be of the essence with
respect to all of the provisions of this Paragraph 53.

44

 

     IN WITNESS WHEREOF, the Parties have executed this Lease as of the date first hereinabove
written.

	 	 	 
	 

	 	LANDLORD:
	 
	 	 
	 

	 	TRIUMPH 1450 LLC,
	 

	 	a Colorado limited liability company

	 	 	 
	 

	 	By: /Ronald D. Boraks/
	 

	 	 
	 

	 	Name:  Ronald D. Boraks
	 

	 	Its:       Manager
	 
	 	 
	 

	 	TENANT:
	 
	 	 
	 

	 	REPLIDYNE, INC.,

	 

	 	a Delaware corporation

	 	 	 	 	 
	 

	 	By:
	 	/Kenneth J. Collins/
	 

	 	 	 	 
	 	 	Name: Kenneth J. Collins
	 	 	Its:       President and CEO

45

 

EXHIBIT A 

DEPICTION OF PREMISES

CLEANROOM 3,423 RSF

OFFICE SPACE 25,576 RSF

LAB SPACE 12,709 RSF

STORAGE SPACE 765 RSF

NEW OFFICE SPACE 13,725 RSF

 

 

EXHIBIT B

RELEASE

          I,
                                        
(print name), hereby acknowledge that I, as
an employee of
                     (insert name of employer), have voluntarily chosen to
make use of some or all of the sports or fitness facilities, including without limitation, the
outdoor basketball and volleyball courts (collectively, the
“Facilities”) made available by
                      
(“Landlord”) and located on the property at 1450 Infinite Drive, Louisville,
Colorado.

     I ACKNOWLEDGE THAT THE FACILITIES ARE NOT SUPERVISED, ARE USED BY OTHERS, AND THAT THEIR USE
MAY BE A HAZARDOUS ACTIVITY. I AM VOLUNTARILY USING THE FACILITIES OFFERED BY LANDLORD, WITH
KNOWLEDGE OF THE DANGER INVOLVED AND HEREBY AGREE TO ASSUME ANY AND ALL RISKS OF DAMAGE, INJURY
AND DEATH ARISING OUT OF MY USE OF THE FACILITIES.

     PLEASE INITIAL:                     

     As a lawful consideration for being permitted by Landlord to make use of the Facilities, I
hereby agree that I, my heirs, distributes, guardians, legal representatives and assigns will not
make a claim against, sue, attach the property of, or prosecute, Landlord and its shareholders,
directors, officers, employees, agents, subsidiaries, affiliates, successors or assigns
(individually, a “Landlord Party” and collectively, the “Landlord Parties”) for any damages,
losses, liabilities, judgments, claims, causes of action, demands, expenses, costs, fines,
penalties and attorneys’ fees (collectively, “Claims”) resulting from or in connection with (i)
the Facilities, (ii) the undersigned’s use of the Facilities, or (iii) any act or omission of any
Landlord Party with respect the Facilities or the undersigned’s use thereof. I hereby release each
and every Landlord Party from all Claims that I, my heirs, distributes, guardians, legal
representatives, or assigns now have or may hereafter have, with respect to (1) the Facilities,
(2) the undersigned’s use of the Facilities, or (3) any act or omission of any Landlord Party with
respect the Facilities or the undersigned’s use thereof.

     I HAVE CAREFULLY READ THIS AGREEMENT AND FULLY UNDERSTAND ITS CONTENTS, I AM AWARE THAT THIS
IS A RELEASE OF LIABILITY AND A CONTRACT BETWEEN MYSELF AND LANDLORD. I SIGN THIS AGREEMENT ON MY
OWN FREE WILL.

	 	 	 	 	 	 	 	 	 
	By:

	 	 	 	 	 	Date:	 	 
	 

	 	 
	 	 	 	 	 	 
	 

	 	(signature)	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 
	(printed name)
	 	 	 	(print name of employer)

 

 

EXHIBIT C

LIST AND QUANTITIES OF HAZARDOUS SUBSTANCES

 

 

Replldyne, Inc.

Active List of Reagents, General Use

August, 2005

	 	 	 
	Reagent Name	 	Amount*
	1 step NBT/BCIP

	 	250 mL
	1-Butanol

	 	500 mL
	2-Mercaptoethanol

	 	250 mL
	2-propanol

	 	2.5 L
	30% Acrylamlde/Bis 37.5:1

	 	1500 mL
	30%Acrylamide/Bis29:1

	 	500 mL
	40% Acrylamide/Bis 19:1

	 	500 mL
	Acetic Acid

	 	8 L
	Acetone

	 	1 L
	Acetonitrile

	 	1 L
	Acrylamide 99.9%

	 	200 g
	Adenosine 5’-Triphosphate

	 	5 g
	Adenosine-5’-O-(3-thiotriphosphate)

	 	200 mmol
	Agarose

	 	750 g
	Albumin, Bovine

	 	200 g
	Alumina

	 	500 g
	Ammonium Bicarbonate

	 	500 g
	Ammonium Chloride

	 	1000 g
	Ammonium Foramte

	 	500 g
	Ammonium Persulfate

	 	200 g
	Ammonium Sulfate

	 	10 kg
	Amonium Formate

	 	500 g
	Ampicillin Sodium Salt

	 	400 g
	Bacto-Argar

	 	500 g
	Bentonlte

	 	500 g
	Benzamldlne

	 	5 g
	Betaine

	 	500 g
	Bis

	 	1500 g
	Blue Dextran

	 	10 g
	Boric Acid

	 	10 g
	Brain Heart Infusion

	 	500 g
	Bromophenol Blue Aqueous

	 	500 g
	Buffer-Saturated Phenol

	 	100 mL
	Calcium Chloride

	 	500 g
	Calcium Sulfate

	 	500 g
	Calf thymus DNA

	 	250 mg
	Carbowax PEG 8000

	 	12 kg
	Casltone Media

	 	500 g
	Cesium Chloride

	 	1 kg
	Chloramphenicol

	 	100 g
	Chloroform

	 	2.5 L
	Citric Acid Anhydrous

	 	2000 g
	Coomassie Plus Protien Assay Reagent

	 	950 mL
	Count Off

	 	2 L
	Crystal Violet

	 	25 g

Page 1

 

Replidyne, Inc.

Active List of Reagents, General Use

August, 2005

	 	 	 
	Reagent Name	 	Amount*
	Cytldine-5’-triphosphate

	 	5 g
	d-Biotin

	 	25 g
	Deoxyadenosine-5’-triphosphate

	 	5 g
	Deoxycholic Acid, Sodium Salt

	 	100 g
	Deoxycytidine-5’-triphosphate

	 	5 g
	Deoxyguanosine-5’-triphosphate

	 	5 g
	Dextrose

	 	500 g
	Dithiothreitol

	 	1 kg
	DMSO

	 	1 L
	DNA replication enzymes

	 	3 g
	DNA, various sources

	 	100 mg
	Dnase I

	 	100 mg
	Drierite

	 	3 kg
	D-Sorbitol

	 	5 kg
	Ecosclnt-O

	 	12 L
	EDTA

	 	500 g
	Ethanol

	 	20 L
	Ethidium bromide

	 	5 g
	Faropenem Medoxomil

	 	250 kg
	Ferric Chloride

	 	250 g
	Formamide

	 	1 L
	Glucose

	 	1 kg
	Glycine

	 	4 kg
	Guanosine-5’-triphosphate

	 	5 g
	Gylcerln

	 	40 L
	HEPES

	 	500 g
	Imidazole

	 	500 g
	IPTG

	 	100 g
	Iso-Amyl Alcohol

	 	500 mL
	Kanamycin

	 	5 g
	L-glutmaic acid

	 	1 kg
	Lysol I.C.

	 	1 gallon
	Lysozyme

	 	100 g
	M13mp18 RF DNA

	 	10 mg
	Magnesium Acelate

	 	1000 g
	Magnesium Chloride

	 	500 g
	Magnesium Sulfate

	 	1000 g
	MES

	 	100 g
	Methanol

	 	20 L
	Mineral Oil

	 	1 L
	Murine IgG Immunoglogulin

	 	1 mL
	Nickel Sulfate

	 	100 g
	No count Radioactive Decontaminant

	 	8 oz
	n-Octyl-B-D-glucopyranoside

	 	5 g
	Nonldet P-40

	 	500 mL
	pH standard Buffers

	 	2000 mL
	Phenylmethyldulfonyl-Fluoride

	 	5 g
	Picogreen

	 	4 mL
	Poly(dA-dC)Poly(dG-dT)

	 	5 units
	Polydeoxyadenylic acid

	 	25 units

Page 2

 

Replidyne, Inc.

Active List of Reagents, General Use

August, 2005

	 	 	 
	Reagent Name	 	Amount*
	polyoxyethylene 20 cetyl Ether

	 	500 g
	Potassium Acetate

	 	3 kg
	Potassium chloride

	 	3 kg
	potassium- phosphate dibasic

	 	3 kg
	potassium- phosphate monobasic

	 	3 kg
	Protamine Sulfate

	 	5 g
	Proteose peptone #3

	 	500 g
	Rabbit IgG Immunoglogulin

	 	1 mL
	Radioactive Decontaminant

	 	8 oz
	Radioactive Isotope C14

	 	1 mCl
	Radioactive Isotope H3

	 	1 mCl
	Radioactive Isotope P32

	 	1 mCi
	Radioactive Isotope S35

	 	1 mCi
	Restriction enzymes

	 	5000 units
	Rifampicin

	 	100 mg
	SDS

	 	500 g
	Silica Gel Desiciant

	 	2.5 kg
	Sodium acetate

	 	500 g
	Sodium Azide

	 	100 g
	Sodium Bicarbonate

	 	500 g
	Sodium Borate

	 	500 g
	Sodium Chloride

	 	3 kg
	Sodium citrate

	 	1500 g
	Sodium Hydroxide

	 	500 g
	Sodium Hydroxide 10 N Soultion

	 	3 L
	Sodium phosphate

	 	1 kg
	Sodium phosphate

	 	1 kg
	Sodium phosphate, dibasic

	 	1 kg
	Sodium Pyrophosphale

	 	9 kg
	Sodium Sulfate

	 	500 g
	Spermidine

	 	200 g
	Streptavidin_alkaline Phosphatase Conjugate

	 	4 mL
	Sucrose

	 	6 kg
	SYBR Gold

	 	1 mL
	T4 Polynucleotide kinase

	 	200 units
	T7 DNA polymerase

	 	200 units
	TEMED

	 	100 gm
	Tetracycline

	 	5 g
	THAM

	 	2 kg
	Thymldine-5’-triphosphate

	 	5 g
	Todd Hewitt Broth

	 	10 kg
	Topoisomerase IV

	 	5 mg
	Trichloroacetic Acid

	 	1 kg
	Trichloroautic Acid

	 	500 g
	Tricine

	 	100 g
	Tricine

	 	500 g
	Triethylamine

	 	500 mL
	Tris

	 	10 kg
	Tris-glycine-SDS

	 	400 g
	Triton X-1 00

	 	500 mL

Page 3

 

Replidyne, Inc.

Active List of Reagents, General Use

August, 2005

	 	 	 
	Reagent Name	 	Amount*
	Trypticase Soy Broth

	 	1000 g
	Tryptone Peptone

	 	3 kg
	Tween-20

	 	500 mL
	Urea

	 	3 kg
	Urldine-5’-triphosphate

	 	5 g
	Xylene Cyanole FF

	 	25 g
	Yeast Extract

	 	10 kg
	Zinc Sulfate

	 	1 kg

 

			
	*	 	Listed amounts represent quantities in actual use or storage on the Premises.
The maximum quantity of each reagent in use or in storage at the Premises at any given
time, is approximately four times the listed amount. The maximum annual quantity of
each reagent used and stored on the Premises is approximately ten times the listed
amount.

Page 4

 

Replidyne, Inc.

Active List of Reagents

August, 2005

	 	 	 
	Reagent Name	 	Amount*
	 	 	 
	((3s)-(3-1,2,3,4-Tetrahydroisoquinolyl))-N-(Tertbutyl)Carboxamide

	 	Research Quantity
	(-)-Menthyl Chloroformate

	 	Research Quantity
	(+)-1-(9-Fluorenyl)Ethyl Chloroformate

	 	Research Quantity
	(1r,2s)-(-)-Ephedrine

	 	Research Quantity
	(1r,2s)-1-Amino-2-lndanol

	 	Research Quantity
	(1s,2r)-(-)-Cis-1-Amino-2-lndanol

	 	Research Quantity
	(2-Bromoethyl)Benzene

	 	Research Quantity
	(2-Methoxy-5-Phenyl)Phenyl Isothlocyanate

	 	Research Quantity
	(2r,8as)-(+)-(Camphorylsulfonyl)Oxaziridine

	 	Research Quantity
	(3-Bromopropoxy)-Tert-Butyldimethylsilane

	 	Research Quantity
	(3s)-2-Carbobenzoxy-1,2,3,4-Tetrahydroisoquinoline-3-Carboxylic Acid

	 	Research Quantity
	(R)-(-)-Epichlorohydrin

	 	Research Quantity
	(S)-(+)-3-Bromo-2-Methyl-1-Propanol

	 	Research Quantity
	(S)-(+)-3-Hydroxytetrahydrofuran

	 	Research Quantity
	(S)-3-Hydroxypyrrolidine

	 	Research Quantity
	[(3s)-4-Azabicyclo[4.4.0]Dec-3-Yl]-N-(Tert-Butyl)Carboxamide

	 	Research Quantity
	[1,1’-Biphenyl]-4,4’-diamine

	 	Research Quantity
	[1,1’-Biphenyl]-4,4’-diamine, 3,3’-dichloro-

	 	Research Quantity
	[1,1’-Biphenyl]-4,4’-diamine, 3,3’-dimethoxy-

	 	Research Quantity
	[1,1’-Biphenyl]-4,4’-diamine, 3,3’-dimethyl-

	 	Research Quantity
	1-(2-Bromo-EthyI)-1h-Pyrazole

	 	Research Quantity
	1-(2-Pyridyl)-2-Thiourea

	 	Research Quantity
	1-(3-Dimethylaminopropyl)-3-Ethylcarbodilmide Hydrochloride

	 	Research Quantity
	1-(4-Chlorophenyl)-1h-Pyrrole-2-Carbaldehyde

	 	Research Quantity
	1-(Bromomethyl)lsoquinoline Hydrobromide

	 	Research Quantity
	1-(o-Chlorophenyl)thiourea

	 	Research Quantity
	1,1,1,2-Tetrachloroethane

	 	Research Quantity
	1,1,2,2-Tetrachloroethane

	 	Research Quantity
	1,1,2-Trichloroethane

	 	Research Quantity
	1,1-Dichloroethyiene

	 	Research Quantity
	1,1-Dimethylhydrazine

	 	Research Quantity
	1,2,3,4-Tetrahydroisoquinoline-3-Carboxylic Acid

	 	Research Quantity
	1,2,3,4-Tetrahydroisoquinoline-3-Carboxylic Acid Hydrochloride

	 	Research Quantity
	1,2,4,5-Tetrachlorobenzene

	 	Research Quantity
	1,2,4,5-Tetrazine, 3,6-Di-2-Pyridinyl-

	 	Research Quantity
	1,2:3,4-Diepoxybutane

	 	Research Quantity
	1,2-Benzenedicarboxylic acid, bis(2-ethylhexyl) ester

	 	Research Quantity
	1,2-Benzenedicarboxylic acid, dibutyl ester

	 	Research Quantity
	1,2-Benzenedicarboxylic acid, diethyl ester

	 	Research Quantity
	1,2-Benzenedicarboxylic acid, dimethyl ester

	 	Research Quantity
	1,2-Benzenedicarboxylic acid, dioctyl ester

	 	Research Quantity
	1,2-Benzenediol, 4-[1-hydroxy-2-(methylamino)ethyl]-, (R)-

	 	Research Quantity
	1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide, & salts

	 	Research Quantity
	1,2-Dibromo-3-chloropropane

	 	Research Quantity

Page 1

 

Replidyne, Inc.

Active List of Reagents

August, 2005

	 	 	 
	Reagent Name	 	Amount*
	 	 	 
	1,2-Dichloroethylene

	 	Research Quantity
	1,2-Dimethylhydrazine

	 	Research Quantity
	1,2-Diphenylhydrazine

	 	Research Quantity
	1,2-Ethanediamine

	 	Research Quantity
	1,2-Oxathiolane, 2,2-dioxide

	 	Research Quantity
	1,3,5-Trichlorobenzene

	 	Research Quantity
	1,3,5-Trinitrobenzene

	 	Research Quantity
	1,3,5-Trioxane, 2,4,6-trimethyl-

	 	Research Quantity
	1,3-Benzenediol

	 	Research Quantity
	1,3-Benzodioxol-4-ol, 2,2-dimethyl-

	 	Research Quantity
	1,3-Benzodioxol-4-ol, 2,2-dimethyl-, methyl carbamate

	 	Research Quantity
	1,3-Benzodioxole, 5-(1-propenyl)-

	 	Research Quantity
	1,3-Benzodioxole, 5-(2-propenyl)-

	 	Research Quantity
	1,3-Benzodioxole, 5-propyl-

	 	Research Quantity
	1,3-Butadiene, 1,1,2,3,4,4-hexachloro-

	 	Research Quantity
	1,3-Cyclopentadiene, 1,2,3,4,5,5-hexachloro-

	 	Research Quantity
	1,3-Diaminopropane

	 	Research Quantity
	1,3-Diaminopropane Trityl Resin

	 	Research Quantity
	1,3-Dibromopropane

	 	Research Quantity
	1,3-Dichloro-5,5-Dimethylhydantoin

	 	Research Quantity
	1,3-Dichloropropene

	 	Research Quantity
	1,3-Isobenzofurandione

	 	Research Quantity
	1,3-Pentadiene

	 	Research Quantity
	1,3-Propane sultone

	 	Research Quantity
	1,4-Benzodioxan-6-YI Methyl Ketone

	 	Research Quantity
	1,4-Dichloro-2-butene

	 	Research Quantity
	1,4-Diethyleneoxide

	 	Research Quantity
	1,4-Dioxane

	 	Research Quantity
	1,4-Naphthalenedione

	 	Research Quantity
	1,4-Naphthoquinone

	 	Research Quantity
	1,5-Pentanediol

	 	Research Quantity
	10741sodium Hydrotris (3,5-Dimethylpyrazol-1-YI)Borate

	 	Research Quantity
	18-Crown-6

	 	Research Quantity
	1-Acetyl-2-thiourea

	 	Research Quantity
	1-Benzothiophen-2-Ylmethylamine

	 	Research Quantity
	1-Boc-3-Hydroxypiperidine

	 	Research Quantity
	1-Boc-3-Hydroxy-Pyrrolidine

	 	Research Quantity
	1-Boc-Indoline

	 	Research Quantity
	1-Bromo-3-Methoxypropane

	 	Research Quantity
	1-Bromo-3-Methyl-2-Butene

	 	Research Quantity
	1-Bromo-3-Methylbutane

	 	Research Quantity
	1-Bromoadamantane

	 	Research Quantity
	1-Butanamine, N-butyl-N-nitroso-

	 	Research Quantity
	1-Butanol

	 	Research Quantity

Page 2

 

Replidyne, Inc.

Active List of Reagents

August, 2005

	 	 	 
	Reagent Name	 	Amount*
	 	 	 
	1-Eth-1-Ynyl-4-Methoxybenzene

	 	Research Quantity
	1-Ethoxyvinyltri-N-Butyltin

	 	Research Quantity
	1-Formylindoline

	 	Research Quantity
	1H-1,2,4-Triazol-3-amine

	 	Research Quantity
	1h-Imidazole-4-Carboxylic Acid

	 	Research Quantity
	1 -Hydroxybenzotriazole

	 	Research Quantity
	1-Hydroxyethylethoxypiperazine

	 	Research Quantity
	1-lodopentane

	 	Research Quantity
	1-Methyl-1h-Imidazole-5-Carbonyl Chloride Hydrochloride

	 	Research Quantity
	1-Methyl-1h-Imidazole-5-Carboxaldehyde

	 	Research Quantity
	1-Methyl-4-Piperidone

	 	Research Quantity
	1-Methylbutadiene

	 	Research Quantity
	1-Methylimidazole

	 	Research Quantity
	1-Methylpyrrole-2-Carboxaldehyde

	 	Research Quantity
	1-Naphthalenamine

	 	Research Quantity
	1-Naphthalenesulfonyl Chloride

	 	Research Quantity
	1-Naphthalenol, methylcarbamate

	 	Research Quantity
	1-Naphthol

	 	Research Quantity
	1-Naphthyl Isocyanate

	 	Research Quantity
	1-Naphthyl Isothiocyanate

	 	Research Quantity
	1-Propanamine

	 	Research Quantity
	1-Propanamine, N-nitroso-N-propyl-

	 	Research Quantity
	1-Propanamine, N-propyl-

	 	Research Quantity
	1-Propanol, 2,3-dibromo-, phosphate (3:1)

	 	Research Quantity
	1-Propanol, 2-methyl-

	 	Research Quantity
	1-Propene, 1,1,2,3,3,3-hexachloro-

	 	Research Quantity
	1-Propene, 1,3-dichloro-

	 	Research Quantity
	1-Pyrrolidinecarbonyl Chloride

	 	Research Quantity
	2 ,4 -Dimethoxyacetophenone

	 	Research Quantity
	2
-Methoxy-Biphenyl-2-Carbaldehyde

	 	Research Quantity
	2-Trifluoromethyl-Biphenyl-2-Carbaldehyde

	 	Research Quantity
	2-(3-TrifluoromethyIphenoxy)-5-Nitrobenzaldehyde

	 	Research Quantity
	2-(4-Chlorophenoxy)Benzenecarbaldehyde

	 	Research Quantity
	2-(4-Chlorophenyl)Malondialdehyde

	 	Research Quantity
	2-(4-Fluorophenoxy)Benzenecarbaldehyde

	 	Research Quantity
	2-(4-Methylphenoxy)Benzenecarbaldehyde

	 	Research Quantity
	2-(4-Trifluoromethylphenoxy)-5-Nitrobenzaldehyde

	 	Research Quantity
	2-(Chloromethyl)-3,5-Dimethyl-4-Pyridinyl Methyl Ether, Hcl Salt

	 	Research Quantity
	2-(Chloromethyl)Quinoline Hydrochloride

	 	Research Quantity
	2-(Cyclohexylthio)-5-Nitrobenzaldehyde

	 	Research Quantity
	2-(Difluoromethoxy)-5-Nitrobenzaldehyde

	 	Research Quantity
	2,2

	 	Research Quantity
	2,2’-Bioxirane

	 	Research Quantity
	2,2-Dimethoxypropane

	 	Research Quantity

Page 3

 

Replidyne, Inc.

Active List of Reagents

August, 2005

	 	 	 
	Reagent Name	 	Amount*
	 	 	 
	2,2-Dimethyl-1,3-Propanediamine

	 	Research Quantity
	2,3,4,6-Tetrachlorophenol

	 	Research Quantity
	2,3-Diaminopyridine

	 	Research Quantity
	2,3-Dicyanopyrazine

	 	Research Quantity
	2,3-Difluorobenzaldehyde

	 	Research Quantity
	2,4 -Dibromoacetophenone

	 	Research Quantity
	2,4-(1H,3H)-Pyrimidinedione, 5-[bis(2- chloroethyl)amino]-

	 	Research Quantity
	2,4,5-Trichlorophenol

	 	Research Quantity
	2,4,5-Trifluorobenzaldehyde

	 	Research Quantity
	2,4,6-Tribromophenol

	 	Research Quantity
	2,4,6-Trichlorophenol

	 	Research Quantity
	2,4-Dichloro-6,7-Dimethoxyquinazoline

	 	Research Quantity
	2,4-Dichlorophenol

	 	Research Quantity
	2,4-Difluorobenzaldehyde

	 	Research Quantity
	2,4-Dihydroxybenzaldehyde

	 	Research Quantity
	2,4-Dihydroxybenzoic Acid

	 	Research Quantity
	2,4-Dimethoxybenzylamine
Hydrochloride

	 	Research Quantity
	2,4-Dimethylphenol

	 	Research Quantity
	2,4-Dinitrophenol

	 	Research Quantity
	2,4-Dinitrophenylhydrazine

	 	Research Quantity
	2,4-Dinitrotoluene

	 	Research Quantity
	2,4-Lutidine

	 	Research Quantity
	2,4-Quinolinediol

	 	Research Quantity
	2,4-Thiazolidinedione

	 	Research Quantity
	2,5-Cyclohexadiene-1,4-dione

	 	Research Quantity
	2,5-Difluorobenzaldehyde

	 	Research Quantity
	2,5-Dihydroxybenzaldehyde

	 	Research Quantity
	2,5-Dihydroxybenzoic Acid

	 	Research Quantity
	2,5-Diiodobenzoic Acid

	 	Research Quantity
	2,5-Dimethoxybenzaldehyde

	 	Research Quantity
	2,5-Furandione

	 	Research Quantity
	2,6-Dichloro-4-(Chloromethyl)Pyridine

	 	Research Quantity
	2,6-Dichlorobenzaldehyde

	 	Research Quantity
	2,6-Dichlorophenol

	 	Research Quantity
	2,6-Difluorobenzaldehyde

	 	Research Quantity
	2,6-Dimethylbenzaldehyde

	 	Research Quantity
	2,6-Dinitrotoluene

	 	Research Quantity
	2,7-Naphthalenedisulfonic acid,

	 	Research Quantity
	2-[4-(Tert-Butyl)Phenoxy]-5-Nitrobenzaldehyde

	 	Research Quantity
	2-[4-(Trifluoromethyl)Phenyl]Benzaldehyde

	 	Research Quantity
	2-Acetamidophenol

	 	Research Quantity
	2-Acetylaminofluorene

	 	Research Quantity
	2-Acetylbutyrolactone

	 	Research Quantity
	2-Amino-3,5-Dimethylbenzoic Acid

	 	Research Quantity

Page 4

 

Replidyne, Inc.

Active List of Reagents

August, 2005

	 	 	 
	Reagent Name	 	Amount*
	 	 	 
	2-Amino-3-Bromo-5-Methylbenzoic Acid

	 	Research Quantity
	2-Amino-3-Methylpyridine

	 	Research Quantity
	2-Amino-5-Fluorobenzoic Acid Methyl Ester

	 	Research Quantity
	2-Amino-5-Methoxybenzoic Acid

	 	Research Quantity
	2-Amino-6-Fluorobenzoic Acid

	 	Research Quantity
	2-Aminopyridine

	 	Research Quantity
	2-Azetidinone

	 	Research Quantity
	2-Bromo-1-Indanol

	 	Research Quantity
	2-Bromo-2-Methylpropane

	 	Research Quantity
	2-Bromo-4-Nitrotoluene

	 	Research Quantity
	2-Bromobenzylamine Hydrochloride

	 	Research Quantity
	2-Bromomethyl-1,3-Dioxolane

	 	Research Quantity
	2-Bromopropane

	 	Research Quantity
	2-Bromopropionic Acid

	 	Research Quantity
	2-Butanone

	 	Research Quantity
	2-Butanone, 3,3-dimethyl

	 	Research Quantity
	2-Butanone, peroxide

	 	Research Quantity
	2-Butenal

	 	Research Quantity
	2-Butene, 1,4-dichloro-

	 	Research Quantity
	2-Chloro-4,6-Dimethoxy-1,3,5-Triazine

	 	Research Quantity
	2-Chloro-4,6-Dimethylpyrimidine

	 	Research Quantity
	2-Chloro-5-Chloromethylpyridine

	 	Research Quantity
	2-Chloro-5-Nitrobenzaldehyde

	 	Research Quantity
	2-Chloro-6-Fluorobenzaldehyde

	 	Research Quantity
	2-Chloro-6-Nitrobenzaldehyde

	 	Research Quantity
	2-Chloroacetanilide

	 	Research Quantity
	2-Chloroethyl vinyl ether

	 	Research Quantity
	2-Chloromethyl-3,4-Dimethoxy Pyridine Hcl

	 	Research Quantity
	2-Chloropyrimidine

	 	Research Quantity
	2-Chloroquinoxaline

	 	Research Quantity
	2-Cyanopyridine

	 	Research Quantity
	2-Cyclohexyl-4,6-dinitrophenol

	 	Research Quantity
	2-Cyclohexylethyl Bromide

	 	Research Quantity
	2-Dimethylaminoethyl Chloride Hydrochloride

	 	Research Quantity
	2-Ethyl-5-Formylimidazole

	 	Research Quantity
	2-Ethylhexanoic Acid

	 	Research Quantity
	2-Fluoro-3-(Trifluoromethyl)Benzaldehyde

	 	Research Quantity
	2-Fluoro-3-Methoxybenzaldehyde

	 	Research Quantity
	2-Fluoro-5-(Trifluoromethyl)Benzaldehyde

	 	Research Quantity
	2-Fluoro-5-lodobenzaldehyde

	 	Research Quantity
	2-Fluoro-5-Methoxybenzaldehyde

	 	Research Quantity
	2-Fluoro-5-Nitrobenzaldehyde

	 	Research Quantity
	2-Fluoro-5-Nitrobenzoic Acid

	 	Research Quantity
	2-Fluorobenzoic Acid

	 	Research Quantity

Page 5

 

Replidyne, Inc.

Active List of Reagents

August, 2005

	 	 	 
	Reagent Name	 	Amount*
	 	 	 
	2-Fluorobenzonitrile

	 	Research Quantity
	2-Furancarboxaldehyde

	 	Research Quantity
	2-Guanidinobenzimidazole

	 	Research Quantity
	2-Hydroxy-4-Methoxyaniline Hydrochloride

	 	Research Quantity
	2-Hydroxy-6-Methoxybenzaldehyde

	 	Research Quantity
	2-Hydroxyethyl Vinyl Ether

	 	Research Quantity
	2-Hydroxypyridine N-Oxide

	 	Research Quantity
	2-Hydroxypyrimidine

	 	Research Quantity
	2-Imidazolidinethione

	 	Research Quantity
	2-Indanamine Hydrochloride

	 	Research Quantity
	2-Iodo-2-Methylpropane

	 	Research Quantity
	2-Iodopropane

	 	Research Quantity
	2-Isopropoxyethanol

	 	Research Quantity
	2-Ketobutyric Acid

	 	Research Quantity
	2-Mercaptothiazoline

	 	Research Quantity
	2-Methoxy-4-Nitro-5-Methyl Aniline

	 	Research Quantity
	2-Methoxy-5-Nitrobenzaldehyde

	 	Research Quantity
	2-Methoxyacetophenone

	 	Research Quantity
	2-Methoxybenzylamine

	 	Research Quantity
	2-Methoxyethylamine

	 	Research Quantity
	2-Methoxyphenyl Isothiocyanate

	 	Research Quantity
	2-Methyl-1 ,5-Diphenyl-1h-Pyrrole-3-Carboxylic Acid

	 	Research Quantity
	2-Methyl-1h-Imidazole-4-Carbaldehyde

	 	Research Quantity
	2-Methyl-3-Butyn-2-OI

	 	Research Quantity
	2-Methyllactonitrile

	 	Research Quantity
	2-Morpholino-5-Nitrobenzaidehyde

	 	Research Quantity
	2-Naphthalenamine

	 	Research Quantity
	2-Nitro-4-(Trifluoromethyl)Benzoic Acid

	 	Research Quantity
	2-Nitropropane

	 	Research Quantity
	2-Phenyl-1h-Imidazole-4-Carbaldehyde

	 	Research Quantity
	2-Phenylbenzaldehyde

	 	Research Quantity
	2-Phenylethylamine

	 	Research Quantity
	2-Phenylindene

	 	Research Quantity
	2-Picoline

	 	Research Quantity
	2-Picolinonitrile-N-Oxide

	 	Research Quantity
	2-Propanone

	 	Research Quantity
	2-Propenamide

	 	Research Quantity
	2-Propenenitrile

	 	Research Quantity
	2-Propenenitrile, 2-methyl-

	 	Research Quantity
	2-Propenoic acid

	 	Research Quantity
	2-Propenoic acid, 2-methyl-, ethyl ester

	 	Research Quantity
	2-Propenoic acid, 2-methyl-, methyl ester

	 	Research Quantity
	2-Propenoic acid, ethyl ester

	 	Research Quantity
	2-Pyrrolidone

	 	Research Quantity

Page 6

 

Replidyne, Inc.

Active List of Reagents

August, 2005

	 	 	 
	Reagent Name	 	Amount*
	 	 	 
	2-Quinoxalinecarbonyl Chloride

	 	Research Quantity
	3-Chloro-Biphenyl-2-Carbaldehyde

	 	Research Quantity
	3-(2-Hydroxyethyl)Pyridine

	 	Research Quantity
	3,3 ,3 -Phosphinidynetris(Benzenesulfonic Acid) Trisodium Salt

	 	Research Quantity
	3,3 -Diethyloxadicarbocyanine Iodide

	 	Research Quantity
	3,3’-Dichlorobenzidine

	 	Research Quantity
	3,3’-Dimethoxybenzidine

	 	Research Quantity
	3,3-Dimethyl-1-Butanol

	 	Research Quantity
	3,3’-Dimethylbenzidine

	 	Research Quantity
	3,4-Dibromobenzaldehyde

	 	Research Quantity
	3,4-Dichlorobenzaldehyde

	 	Research Quantity
	3,4-Dichlorobenzylamine

	 	Research Quantity
	3,4-Difluorobenzaldehyde

	 	Research Quantity
	3,4-Dihydroxy-6-Nitrobenzaldehyde

	 	Research Quantity
	3,4-Dihydroxybenzaldehyde

	 	Research Quantity
	3,4-Dihydroxybenzoic Acid

	 	Research Quantity
	3,4-Dimethoxyaniline

	 	Research Quantity
	3,4-Dimethoxyphenethyl Isothiocyanate

	 	Research Quantity
	3,4-Methylenedioxyaniline

	 	Research Quantity
	3,5-Dibromo-2-Methoxybenzaldehyde

	 	Research Quantity
	3,5-Dibromobenzaldehyde

	 	Research Quantity
	3,5-Dibromosalicylaldehyde

	 	Research Quantity
	3,5-Dichloro-2-Methoxyacetophenone

	 	Research Quantity
	3,5-Dichloroaniline

	 	Research Quantity
	3,5-Dihydroxybenzoic Acid

	 	Research Quantity
	3,5-Dimethoxybenzylamine

	 	Research Quantity
	3,6-Pyridazinedione, 1,2-dihydro-

	 	Research Quantity
	3-Amino-4-Cyanopyrazole

	 	Research Quantity
	3-Amino-5-Methylisoxazole

	 	Research Quantity
	3-Aminoisonicotinic Acid

	 	Research Quantity
	3-Aminophenol

	 	Research Quantity
	3-Aminopyridine

	 	Research Quantity
	3-Bromo-4-Methylaniline

	 	Research Quantity
	3-Bromofuran

	 	Research Quantity
	3-Bromopropionic Acid

	 	Research Quantity
	3-Bromopropionitrile

	 	Research Quantity
	3-Butynyl P-Toluenesulfonate

	 	Research Quantity
	3-Chloro-2,2-Dimethylpropionic Acid

	 	Research Quantity
	3-Chloro-2-Fluorobenzaldehyde

	 	Research Quantity
	3’-Chloroacetanilide

	 	Research Quantity
	3-Chloroperoxybenzoic Acid

	 	Research Quantity
	3-Chloropropionitrile

	 	Research Quantity
	3-Cyano-4-Dimethylamino-2-Fluorobenzaldehyde

	 	Research Quantity
	3-Cyclohexyl-1-Propyne

	 	Research Quantity

Page 7

 

Replidyne, Inc.

Active List of Reagents

August, 2005

	 	 	 
	Reagent Name	 	Amount*
	 	 	 
	3-Ethyl-4-Methylaniline

	 	Research Quantity
	3-Ethynylpyridine

	 	Research Quantity
	3-Hexyn-2-One

	 	Research Quantity
	3-Hydroxy-2-Methylbenzoic Acid

	 	Research Quantity
	3-Hydroxypropionitrile

	 	Research Quantity
	3-Indoleacrylic Acid

	 	Research Quantity
	3-Iodo-4-Methylanilinc

	 	Research Quantity
	3-Iodobenzylamine Hydrochloride

	 	Research Quantity
	3-Isopropylphenyl N-methylcarbamate

	 	Research Quantity
	3-Methoxyacetophenone

	 	Research Quantity
	3-Methoxybenzylamine

	 	Research Quantity
	3-Methoxyphenyl Isocyanate

	 	Research Quantity
	3-Methoxyphenyl Isothiocyanate

	 	Research Quantity
	3-Methoxypropylamine

	 	Research Quantity
	3-Methylcholanthrene

	 	Research Quantity
	3-Methylindene-2-Carboxylic Acid

	 	Research Quantity
	3-Methylthiophene-2-Carboxaldehyde

	 	Research Quantity
	3-Nitro-6-(Piperidin-1-YI)Benzaldehyde

	 	Research Quantity
	3-Oxo-3-Thiophen-2-YI-Propionic Acid Ethyl Ester

	 	Research Quantity
	3-Phenyl-1-Propyne

	 	Research Quantity
	3-Phenylpropionaldehyde

	 	Research Quantity
	3-Picolyl Isothiocyanate Hydrobromide

	 	Research Quantity
	3-Picolylamine

	 	Research Quantity
	3-Pyridyl Isothiocyanate

	 	Research Quantity
	3-Tert-ButoxycarbonyIamino-Pyrrolidine-3-Carboxylic Acid

	 	Research Quantity
	4-Chloro-Biphenyl-2-Carbaldehyde

	 	Research Quantity
	4(1H)-Pyrimidinone, 2,3-dihydro-6-methyl-2-thioxo-

	 	Research Quantity
	4-(2-Formyiphenoxy)Benzenecarbonitrile

	 	Research Quantity
	4-(4-Fluorophenoxy)-3-Nitrobenzenecarbaldehyde

	 	Research Quantity
	4-(4-Morpholino)-3-Nitrobenzaldehyde

	 	Research Quantity
	4-(6-Methyl-2-Benzothiazolyl)Phenyl Isocyanate

	 	Research Quantity
	4(7)-Bromo-7(4)-Methyl-1-Indanone

	 	Research Quantity
	4-(Dimethylamino)Phenyl Isothiocyanate

	 	Research Quantity
	4-(Methylmercapto)Aniline

	 	Research Quantity
	4,4 -Dimethoxytrityl Chloride

	 	Research Quantity
	4,4’-Methylenebis(2-chloroaniline)

	 	Research Quantity
	4,5-Dibromothiophene-2-Carboxaldehyde

	 	Research Quantity
	4,6-Dichloro-1h-Indole-2-Carbonyl Chloride

	 	Research Quantity
	4,6-Dinitro-o-cresol, & salts

	 	Research Quantity
	4,7-Methano-1H-indene, 1,2,4,5,6,7,8,8-octachloro-2,3,3a,4,7,7a-hexahydro-

	 	Research Quantity
	4-Acetamido-2-Methylacetophenone

	 	Research Quantity
	4-Aminobenzotrifluoride Hydrochloride

	 	Research Quantity
	4-Aminophenol

	 	Research Quantity
	4-Aminopyridine

	 	Research Quantity

Page 8

 

Replidyne, Inc.

Active List of Reagents

August, 2005

	 	 	 
	Reagent Name	 	Amount*
	 	 	 
	4-Aminopyrimidine-5-Carbonitrile

4-Azidoaniline Hydrochloride

4-Bromo-1-Methyl-1h-Imidazole-5-Carboxaldehyde

4-Bromo-2-Thiophenecarboxaldehyde

4-Bromophenyl phenyl ether

4-Bromopyrole-2-Carboxaldehyde

4-Chloro-2-Nitrobenzaldehyde

4-Chloro-3-Nitrobenzaldehyde

4-Chloro-o-toluidine, hydrochloride

4-Chlorophenylacetylene

4-Chlorothiophenol

4-Cyanophenyl Isothiocyanate

4-Dimethylamino-2-Nitrobenzaldehyde

4-Dimethylaminopyridine

4-Ethylaniline

4-Ethynylaniline

4-Fluoroaniline

4-Fluorobenzaldehyde

4-Fluorobenzyl Bromide

4-Formylimidazole

4-Hydroxy-3-Nitrobenzaldehyde

4-Hydroxyphthalic Acid

4-Hydroxyquinoline

4-Iodobenzoic Acid

4-Iodophenyl Isothiocyanate

4-Methoxy-2-Methylaniline

4-Methoxy-3-Nitrobenzaldehyde

4-Methoxybenzylamine

4-Methoxyphenol

4-Methoxyphenyl Isocyanate

4-Methoxyphenyl Isothiocyanate

4-Methyl-2-pentanone

4-Methyl-5-Thiazoleethanol

4-Methylacetanilide

4-Methylamino-1,1-Dioxo-Tetrahydro-1 lambda6-Thiophen-3-OI

4-Morpholinylcarbonyl Chloride

4-Nitrophenyl Isothiocyanate

4-Pentynoic Acid

4-Phenylurazole

5-(Aminomethyl)-3-isoxazolol

5,5 -Dithiobis(2-Nitrobenzoic Acid)

5-Acetamidoanthranilic Acid

5-Aminoisoquinoline

5-Aminoquinoline

	 	Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Research Quantity

Page 9

 

Replidyne, Inc.

Active List of Reagents

August, 2005

	 	 	 	 	 
	Reagent Name	 	Amount*	 
	 	 	 
	5-Bromo-2,2-Bithiophene-5-Carboxaldehyde
	 	Research Quantity
	5-Bromo-2-Fluorobenzaldehyde
	 	Research Quantity
	5-Bromo-2-Furaldehyde
	 	Research Quantity
	5-Chloro-2-Furaldehyde
	 	Research Quantity
	5-Chloro-2-Methoxyacetophenone
	 	Research Quantity
	5-Chloro-2-Nitrobenzaldehyde
	 	Research Quantity
	5-Chloro-2-Thiophenecarboxaldehyde
	 	Research Quantity
	5-Chloroisatoic Anhydride
	 	Research Quantity
	5-Cyano-1-Pentyne
	 	Research Quantity
	5-Fluoro-1-Indanone
	 	Research Quantity
	5-Fluoro-2-Nitrobenzaldehyde
	 	Research Quantity
	5-Hydroxyisophthalic Acid
	 	Research Quantity
	5-Iodo-2-Furaldehyde
	 	Research Quantity
	5-Iodosalicylic Acid
	 	Research Quantity
	5-Methoxy-2-Methylaniline
	 	Research Quantity
	5-Methoxyindole
	 	Research Quantity
	5-Methylimidazole-4-Carboxaldehyde
	 	Research Quantity
	5-Nitro-2-(1-Pyrrolidinyl)Benzaldehyde
	 	Research Quantity
	5-Nitro-2-Furaldehyde
	 	Research Quantity
	5-Nitro-o-toluidine
	 	Research Quantity
	5-Norbornene-2,3-Dicarboxylic Anhydride
	 	Research Quantity
	6-(4-Chlorophenylthio)Imidazo[2,1-B]Thiazole-5-Carboxaldehyde
	 	Research Quantity
	6-Chloro-1-Hexyne
	 	Research Quantity
	6-Chloro-2,4-Dimethoxypyrimidine
	 	Research Quantity
	6-Chloroimidazo[2,1-B]Thiazole-5-Carboxaldehyde
	 	Research Quantity
	6-Chlorouracil
	 	Research Quantity
	6-Fluoroveratraldehyde
	 	Research Quantity
	6-Nitropiperonal
	 	Research Quantity
	6-Nitroveratraldehyde
	 	Research Quantity
	7,12-Dimethylbenz[a]anthracene
	 	Research Quantity
	7-Benzofuranol, 2,3-dihydro-2,2-dimethyl
	 	Research Quantity
	7-Oxabicyclo[4.1.0]Heptan-2-One
	 	Research Quantity
	8-(Bromomethyl)Quinoline
	 	Research Quantity
	8-Quinolinesulfonyl Chloride
	 	Research Quantity
	9-Fluorenylmethanol
	 	Research Quantity
	9-Fluorenylmethyl Succinimidyl Carbonate
	 	Research Quantity
	Acetaldehyde
	 	Research Quantity
	Acetaldehyde, chloro-
	 	Research Quantity
	Acetaldehyde, trichloro-
	 	Research Quantity
	Acetamide, 2-fluoro-
	 	Research Quantity
	Acetamide, N-(4-ethoxyphenyl)-
	 	Research Quantity
	Acetamide, N-(aminothioxomethyl)-
	 	Research Quantity
	Acetamide, N-9H-fluoren-2-yl-
	 	Research Quantity
	Acetic acid ethyl ester
	 	Research Quantity

Page 10

 

Replidyne, Inc.

Active List of Reagents

August, 2005

	 	 	 
	Reagent Name	 	Amount*
	 	 	 
	Acetic acid, (2,4,5-trichlorophenoxy)-

	 	Research Quantity
	Acetic acid, (2,4-dichlorophenoxy)-, salts & esters

	 	Research Quantity
	Acetic acid, fluoro-, sodium salt

	 	Research Quantity
	Acetic acid, lead(2+) salt

	 	Research Quantity
	Acetic acid, thallium(1+) salt

	 	Research Quantity
	Acetic-D3 Acid-D

	 	Research Quantity
	Acetone

	 	Research Quantity
	Acetonitrlle

	 	Research Quantity
	Acetophenone

	 	Research Quantity
	Acetyl chloride

	 	Research Quantity
	Acetylsuccinic Acid Dimethyl Ester

	 	Research Quantity
	Acrylamide

	 	Research Quantity
	Acrylic acid

	 	Research Quantity
	Acrylonitrlle

	 	Research Quantity
	Agmatine Sulfate

	 	Research Quantity
	Allyl alcohol

	 	Research Quantity
	Allyl Bromide

	 	Research Quantity
	Allyloxy-Tert-Butyldimethylsilane

	 	Research Quantity
	Alpha,Alpha -Dibromo-P-Xylene

	 	Research Quantity
	alpha,alpha-Dimethylbenzylhydroperoxide

	 	Research Quantity
	alpha,alpha-Dimethylphenethylamine

	 	Research Quantity
	alpha-Naphthylamine

	 	Research Quantity
	Aluminum Chloride

	 	Research Quantity
	Aluminum phosphide

	 	Research Quantity
	Amidinothiourea

	 	Research Quantity
	Aminoacetonitrile Hydrochloride

	 	Research Quantity
	Aminomethylcyclohexane

	 	Research Quantity
	Amitrole

	 	Research Quantity
	Ammonia, 2.0 M In 2-Propanol

	 	Research Quantity
	Ammonium Acetate

	 	Research Quantity
	Ammonium Molybdate

	 	Research Quantity
	Ammonium vanadate

	 	Research Quantity
	Anlline

	 	Research Quantity
	Anlsole

	 	Research Quantity
	Anthranilic Acid

	 	Research Quantity
	Arsinic acid, dimethyl-

	 	Research Quantity
	August, 2005
	 	 
	Auramine

	 	Research Quantity
	Azaserine

	 	Research Quantity
	Aziridine

	 	Research Quantity
	Aziridine, 2-methyl-

	 	Research Quantity
	Barban

	 	Research Quantity
	Barbituric Acid

	 	Research Quantity
	Bendiocarb

	 	Research Quantity

Page 11

 

Replidyne, Inc.

Active List of Reagents

August, 2005

	 	 	 
	Reagent Name	 	Amount*
	Bendiocarb phenol

	 	Research Quantity
	Benomyl

	 	Research Quantity
	Benz[a]anthracene

	 	Research Quantity
	Benz[a]anthracene, 7,12-dimethyl-

	 	Research Quantity
	Benz[c]acridine

	 	Research Quantity
	Benzal chloride

	 	Research Quantity
	Benzenamine

	 	Research Quantity
	Benzenamine, 2-methyl-

	 	Research Quantity
	Benzenamine, 2-methyl-, hydrochloride

	 	Research Quantity
	Benzenamine, 2-methyl-5-nitro-

	 	Research Quantity
	Benzenamine, 4,4’-methylenebis[2-chloro-

	 	Research Quantity
	Benzenamine, 4-chloro-

	 	Research Quantity
	Benzenamine, 4-chloro-2-methyl-, hydrochloride

	 	Research Quantity
	Benzenamine, 4-methyl-

	 	Research Quantity
	Benzenamine, 4-nitro-

	 	Research Quantity
	Benzenamine, N,N-dlmethyl-4-(phenylazo)-

	 	Research Quantity
	Benzene

	 	Research Quantity
	Benzene, (1-methylethyl)-

	 	Research Quantity
	Benzene, (chloromethyl)-

	 	Research Quantity
	Benzene, (dichloromethyl)-

	 	Research Quantity
	Benzene, (trichloromethyl)-

	 	Research Quantity
	Benzene, 1,1’-(2,2,2-trichloroethylidene)bis[4- methoxy-

	 	Research Quantity
	Benzene, 1,1’-(2,2,2-trichloroethylidene)bis[4-chloro-

	 	Research Quantity
	Benzene, 1,1’-(2,2-dichloroethylidene)bis[4-chloro-

	 	Research Quantity
	Benzene, 1,2,4,5-tetrachloro-

	 	Research Quantity
	Benzene, 1,2-dichloro-

	 	Research Quantity
	Benzene, 1,3,5-trinitro-

	 	Research Quantity
	Benzene, 1,3-dichloro-

	 	Research Quantity
	Benzene, 1,3-diisocyanatomethyl-

	 	Research Quantity
	Benzene, 1,4-dichloro-

	 	Research Quantity
	Benzene, 1-bromo-4-phenoxy-

	 	Research Quantity
	Benzene, 1-methyl-2,4-dinitro-

	 	Research Quantity
	Benzene, 2-methyl-1,3-dinitro-

	 	Research Quantity
	Benzene, chloro-

	 	Research Quantity
	Benzene, dimethyl-

	 	Research Quantity
	Benzene, hexachloro-

	 	Research Quantity
	Benzene, hexahydro-

	 	Research Quantity
	Benzene, methyl-

	 	Research Quantity
	Benzene, nitro-

	 	Research Quantity
	Benzene, pentachloro-

	 	Research Quantity
	Benzene, pentachloronitro-

	 	Research Quantity
	Benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]-

	 	Research Quantity
	Benzenediamine, ar-methyl-

	 	Research Quantity
	Benzeneethanamine, alpha,alpha-dimethyl-

	 	Research Quantity

Page 12

 

Replidyne, Inc.

Active List of Reagents

August, 2005

	 	 	 
	Reagent Name	 	Amount*
	Benzenesulfonic acid chloride

	 	Research Quantity
	Benzenesulfonyl chloride

	 	Research Quantity
	Benzenethiol

	 	Research Quantity
	Benzhydrylamine

	 	Research Quantity
	Benzidine

	 	Research Quantity
	Benzo[a]pyrene

	 	Research Quantity
	Benzo[rst]pentaphene

	 	Research Quantity
	Benzotrichloride

	 	Research Quantity
	Benzoyl Isocyanate

	 	Research Quantity
	Benzoyl Isothiocyanate

	 	Research Quantity
	Benzoyl Peroxide

	 	Research Quantity
	Benzyl 2,2,2-Trichloroacetimidate

	 	Research Quantity
	Benzyl chloride

	 	Research Quantity
	Benzyl Chloroformate

	 	Research Quantity
	Benzyltriethylammonium Chloride

	 	Research Quantity
	Benzyltrimethylammonium Chloride

	 	Research Quantity
	Beta-Alanine

	 	Research Quantity
	beta-Chloronaphthalene

	 	Research Quantity
	beta-Naphthylamine

	 	Research Quantity
	Bis(1,5-Cyclooctadiene)Nickel(0)

	 	Research Quantity
	Bis(Triphenylphosphine)Copper(I) Borohydride

	 	Research Quantity
	Boc-Arg-Oh Hcl H2o

	 	Research Quantity
	Borane-Tetrahydrofuran Complex

	 	Research Quantity
	Boron Tribromide

	 	Research Quantity
	Bromoacetone

	 	Research Quantity
	Bromoform

	 	Research Quantity
	Brucine

	 	Research Quantity
	Cacodylic acid

	 	Research Quantity
	Cadmium Chloride

	 	Research Quantity
	Calcium chromate

	 	Research Quantity
	Calcium Hydride

	 	Research Quantity
	Carbamic acid, 1H-benzimidazol-2-yl, methyl ester

	 	Research Quantity
	Carbamic acid, ethyl ester

	 	Research Quantity
	Carbamic acid, methylnitroso-, ethyl ester

	 	Research Quantity
	Carbamic acid, phenyl-, 1-methylethyl ester

	 	Research Quantity
	Carbamic chloride, dimethyl-

	 	Research Quantity
	Carbamodithioic acid, 1,2-ethanediylbis-, salts & esters

	 	Research Quantity
	Carbamothioic acid, bis(1-methylethyl)-, S-(2,3-dichloro-2-propenyl) ester

	 	Research Quantity
	Carbamothioic acid, dipropyl-, S-(phenylmethyl) ester

	 	Research Quantity
	Carbaryl

	 	Research Quantity
	Carbendazim

	 	Research Quantity
	Carbofuran

	 	Research Quantity
	Carbofuran phenol

	 	Research Quantity
	Carbon disulfide

	 	Research Quantity

Page 13

 

Replidyne, Inc.

Active List of Reagents

August, 2005

	 	 	 
	Reagent Name	 	Amount*
	Carbon oxyfluoride

	 	Research Quantity
	Carbon tetrachloride

	 	Research Quantity
	Carbonic acid, dithallium(1+) salt

	 	Research Quantity
	Carbonic dichloride

	 	Research Quantity
	Carbonic difluoride

	 	Research Quantity
	Carbonochloridic acid, methyl ester

	 	Research Quantity
	Carbosulfan

	 	Research Quantity
	Ceric Sulfate

	 	Research Quantity
	Cerium(III) Sulfate N-Hydrate

	 	Research Quantity
	Cerium(iv) Sulfate Tetrahydrate

	 	Research Quantity
	Cesium Carbonate

	 	Research Quantity
	Chloral

	 	Research Quantity
	Chlorambucil

	 	Research Quantity
	Chlordane, alpha & gamma isomers

	 	Research Quantity
	Chlordecone

	 	Research Quantity
	Chlornaphazin

	 	Research Quantity
	Chloroacetaldehyde

	 	Research Quantity
	Chloroacetic Anhydride

	 	Research Quantity
	Chlorobenzene

	 	Research Quantity
	Chlorobenzilate

	 	Research Quantity
	Chlorocarbonylsulfenyl Chloride

	 	Research Quantity
	Chloroform

	 	Research Quantity
	Chloromethyl methyl ether

	 	Research Quantity
	Chromic acid H2CrO4, calcium salt

	 	Research Quantity
	Chrysene

	 	Research Quantity
	Cis-2-Butene-1,4-Diol

	 	Research Quantity
	Copper

	 	Research Quantity
	Copper (II) Sulphate, 5 H2o

	 	Research Quantity
	Copper(I) Cyanide

	 	Research Quantity
	Copper(I) Iodide

	 	Research Quantity
	Copper(II) Oxide

	 	Research Quantity
	Copper(lI) Sulfate

	 	Research Quantity
	Creosote

	 	Research Quantity
	Cresol (Cresylic acid)

	 	Research Quantity
	Crotonaldehyde

	 	Research Quantity
	Cumene

	 	Research Quantity
	Cupric Sulfate Pentahydrate

	 	Research Quantity
	Cuprous Chloride

	 	Research Quantity
	Cyanides (soluble cyanide salts), not otherwise specified

	 	Research Quantity
	Cyanogen

	 	Research Quantity
	Cyanogen bromide (CN)Br

	 	Research Quantity
	Cyanogen chloride

	 	Research Quantity
	Cyclohexane

	 	Research Quantity
	Cyclohexanecarbonyl Chloride

	 	Research Quantity

Page 14

 

Replidyne, Inc.

Active List of Reagents

August, 2005

	 	 	 
	Reagent Name	 	Amount*
	Cyclohexanone

	 	Research Quantity
	Cyclohexene

	 	Research Quantity
	Cyclopentanecarbonyl Chloride

	 	Research Quantity
	Cyclophosphamide

	 	Research Quantity
	Cyclopropyl Acetylene

	 	Research Quantity
	Cyclotrimethylenemethylchlorosilane

	 	Research Quantity
	Daunomycin

	 	Research Quantity
	Daunorubicin

	 	Research Quantity
	D-Glucose, 2-deoxy-2-[[(methylnitrosoamino)- carbonyl]amino]-

	 	Research Quantity
	Diallate

	 	Research Quantity
	Dibenz[a,h]anthracene

	 	Research Quantity
	Dibenzo[a,i]pyrene

	 	Research Quantity
	Dibenzyl Phosphite

	 	Research Quantity
	Dibutyl phthalate

	 	Research Quantity
	Dichlorodifluoromethane

	 	Research Quantity
	Dichloroethyl ether

	 	Research Quantity
	Dichloroisopropyl ether

	 	Research Quantity
	Dichloromethoxy ethane

	 	Research Quantity
	Dichloromethyl ether

	 	Research Quantity
	Dicyclopentadiene

	 	Research Quantity
	Diethyl 1,4-Dihydro-2,6-Dimethyl-3,5-Pyridinedicarboxylate

	 	Research Quantity
	Diethyl Aminomalonate Hydrochloride

	 	Research Quantity
	Diethyl Azodicarboxylate

	 	Research Quantity
	Diethyl Chloromethylphosphonate

	 	Research Quantity
	Diethyl Chlorophosphate

	 	Research Quantity
	Diethyl Malonate

	 	Research Quantity
	Diethyl Phosphite

	 	Research Quantity
	Diethyl phthalate

	 	Research Quantity
	Diethyl Succinate

	 	Research Quantity
	Diethyl[2-Hydroxypropyl]Aminoethyl Sephadex

	 	Research Quantity
	Diethylene Glycol Diethyl Ether

	 	Research Quantity
	Diethylene glycol, dicarbamate

	 	Research Quantity
	Diethylhexyl phthalate

	 	Research Quantity
	Diethyl-p-nitrophenyl phosphate

	 	Research Quantity
	Diethylstilbesterol

	 	Research Quantity
	Dihydrosafrole

	 	Research Quantity
	Diisobutylaluminum Hydride 1m In Toluene

	 	Research Quantity
	Diisobutylamine

	 	Research Quantity
	Diisopropylamine

	 	Research Quantity
	Diisopropylfluorophosphate

	 	Research Quantity
	Diketene

	 	Research Quantity
	Dimethoate

	 	Research Quantity
	Dimethyl Fumarate

	 	Research Quantity
	Dimethyl Maleate

	 	Research Quantity

Page 15

 

Replidyne, Inc.

Active List of Reagents

August, 2005

	 	 	 
	Reagent Name	 	Amount*
	Dimethyl phthalate

	 	Research Quantity
	Dimethyl sulfate

	 	Research Quantity
	Dimethyl Sulfide

	 	Research Quantity
	Dimethylamine

	 	Research Quantity
	Dimethylamine 2.0m In Thf

	 	Research Quantity
	Dimethylcarbamoyl chloride

	 	Research Quantity
	Dimethylcyanamide

	 	Research Quantity
	Dimethylsulfamoyl Chloride

	 	Research Quantity
	Dimetilan

	 	Research Quantity
	Di-n-octyl phthalate

	 	Research Quantity
	Dinoseb

	 	Research Quantity
	Di-n-propylnitrosamine

	 	Research Quantity
	Diphenyl Cyanocarbonimidate

	 	Research Quantity
	Diphenylacetic Acid

	 	Research Quantity
	Diphenylamine

	 	Research Quantity
	Diphenylphosphinic Chloride

	 	Research Quantity
	Diphosphoramide, octamethyl-

	 	Research Quantity
	Diphosphoric acid, tetraethyl ester

	 	Research Quantity
	Dipropylamine

	 	Research Quantity
	Disulfoton

	 	Research Quantity
	Di-Tert-Butyl Dicarbonate

	 	Research Quantity
	Dithiobiuret

	 	Research Quantity
	Di-2,4-Diaminobutyric Acid Dihydrochloride

	 	Research Quantity
	Epichlorohydrin

	 	Research Quantity
	Ethanal

	 	Research Quantity
	Ethanamine, N,N-diethyl-

	 	Research Quantity
	Ethanamine, N-ethyl-N-nitroso-

	 	Research Quantity
	Ethane, 1,1,1,2-tetrachloro-

	 	Research Quantity
	Ethane, 1,1,1-trichloro-

	 	Research Quantity
	Ethane, 1,1,2,2-tetrachloro-

	 	Research Quantity
	Ethane, 1,1,2-trichloro-

	 	Research Quantity
	Ethane,
1,1’-[methylenebis (oxy)]bis[2-chloro-

	 	Research Quantity
	Ethane, 1,1-dichloro-

	 	Research Quantity
	Ethane, 1,1’ -oxybis-

	 	Research Quantity
	Ethane, 1,1’-oxybis[2-chloro-

	 	Research Quantity
	Ethane, 1,2-dibromo-

	 	Research Quantity
	Ethane, 1,2-dichloro-

	 	Research Quantity
	Ethane, hexachloro-

	 	Research Quantity
	Ethane, pentachloro-

	 	Research Quantity
	Ethanethioamide

	 	Research Quantity
	Ethanimidothioic acid, 2-(dimethylamino)-N-hydroxy-2-oxo-, methyl ester

	 	Research Quantity
	Ethanol, 2,2’-(nitrosoimino)bis-

	 	Research Quantity
	Ethanol, 2,2’-oxybis-, dicarbamate

	 	Research Quantity
	Ethanol, 2-ethoxy-

	 	Research Quantity

Page 16

 

Replidyne, Inc.

Active List of Reagents

August, 2005

	 	 	 
	Reagent Name	 	Amount*
	Ethanolamine

	 	Research Quantity
	Ethanone, 1-phenyl-

	 	Research Quantity
	Ethene, (2-chloroethoxy)-

	 	Research Quantity
	Ethene, 1,1-dichloro-

	 	Research Quantity
	Ethene, 1,2-dichloro-, (E)-

	 	Research Quantity
	Ethene, chloro-

	 	Research Quantity
	Ethene, tetrachloro-

	 	Research Quantity
	Ethene, trichloro-

	 	Research Quantity
	Ethoxyquin

	 	Research Quantity
	Ethyl (Methylthio)Acetate

	 	Research Quantity
	Ethyl 1-Methyl-5-Nitroimidazole-2-Carboxylate

	 	Research Quantity
	Ethyl 2-Ethylacetoacetate

	 	Research Quantity
	Ethyl 2-Phenylacetoacetate

	 	Research Quantity
	Ethyl 3-Phenylpropionate

	 	Research Quantity
	Ethyl 3-Pyridylacetate

	 	Research Quantity
	Ethyl acetate

	 	Research Quantity
	Ethyl acrylate

	 	Research Quantity
	Ethyl Alcohol, Absolute

	 	Research Quantity
	Ethyl Anthranilate

	 	Research Quantity
	Ethyl Bromoacetate

	 	Research Quantity
	Ethyl carbamate (urethane)

	 	Research Quantity
	Ethyl Chloroacetate

	 	Research Quantity
	Ethyl ether

	 	Research Quantity
	Ethyl Formate

	 	Research Quantity
	Ethyl methacrylate

	 	Research Quantity
	Ethyl methanesulfonate

	 	Research Quantity
	Ethyl Pyruvate

	 	Research Quantity
	Ethyl Sorbate

	 	Research Quantity
	Ethyl Trifluoroacetate

	 	Research Quantity
	Ethyl-1-Methyl-4-Nitroimidazole-2-Carboxylate

	 	Research Quantity
	Ethylene dibromide

	 	Research Quantity
	Ethylene dichloride

	 	Research Quantity
	Ethylene Glycol

	 	Research Quantity
	Ethylene glycol monoethyl ether

	 	Research Quantity
	Ethylene oxide

	 	Research Quantity
	Ethylenebisdithiocarbamic acid, salts & esters

	 	Research Quantity
	Ethylenediamine

	 	Research Quantity
	Ethyleneimine

	 	Research Quantity
	Ethylenethiourea

	 	Research Quantity
	Ethylidene dichloride

	 	Research Quantity
	Ethynyl P-Tolyl Sulfone

	 	Research Quantity
	Ethynylmagnesium Chloride

	 	Research Quantity
	Europium D-3-Trifluoroacetylcamphorate

	 	Research Quantity
	Exo-3,6-Epoxy-1,2,3,6-Tetrahydrophthalic Anhydride

	 	Research Quantity

Page 17

 

Replidyne, Inc.

Active List of Reagents

August, 2005

	 	 	 
	Reagent Name	 	Amount*
	Fluoranthene

	 	Research Quantity
	Fluorine

	 	Research Quantity
	Fluoroacetamide

	 	Research Quantity
	Fluoroacetic acid, sodium salt

	 	Research Quantity
	Fluoromethyl Phenyl Sulfone

	 	Research Quantity
	Formaldehyde

	 	Research Quantity
	Formetanate hydrochloride

	 	Research Quantity
	Formic acid

	 	Research Quantity
	Formparanate

	 	Research Quantity
	Fumaramide

	 	Research Quantity
	Fumaric Acid

	 	Research Quantity
	Fumaric Acid Monoethyl Ester

	 	Research Quantity
	Furan

	 	Research Quantity
	Furan, tetrahydro-

	 	Research Quantity
	Furfural

	 	Research Quantity
	Furfuran

	 	Research Quantity
	Furfurylamine

	 	Research Quantity
	Glucopyranose, 2-deoxy-2-(3-methyl-3-nitrosoureido)-, D-

	 	Research Quantity
	Glutathione, Reduced

	 	Research Quantity
	Glycidylaldehyde

	 	Research Quantity
	Glyoxylic Acid Monohydrate

	 	Research Quantity
	Guanidine, N-methyl-N'-nitro-N-nitroso-

	 	Research Quantity
	Hcl 2.0m In Ether

	 	Research Quantity
	Hcl 4.0 M In Dioxane

	 	Research Quantity
	H-D-Phg-Oh

	 	Research Quantity
	Hexachlorobenzene

	 	Research Quantity
	Hexachlorobutadiene

	 	Research Quantity
	Hexachlorocyclopentadiene

	 	Research Quantity
	Hexachloroethane

	 	Research Quantity
	Hexachlorophene

	 	Research Quantity
	Hexachloropropene

	 	Research Quantity
	Hexaethyl tetraphosphate

	 	Research Quantity
	Hexafluorosilicic Acid

	 	Research Quantity
	Hexamethyldisilazane

	 	Research Quantity
	Hydrazine

	 	Research Quantity
	Hydrazine, 1,1-dimethyl-

	 	Research Quantity
	Hydrazine, 1,2-diethyl-

	 	Research Quantity
	Hydrazine, 1,2-dimethyl-

	 	Research Quantity
	Hydrazine, 1,2-diphenyl-

	 	Research Quantity
	Hydrazine, methyl-

	 	Research Quantity
	Hydrazinecarbothioamide

	 	Research Quantity
	Hydrochloric Acid

	 	Research Quantity
	Hydrofluoric acid

	 	Research Quantity
	Hydrogen fluoride

	 	Research Quantity

Page 18

 

 

EXHIBIT
E 

PERSONAL PROPERTY

 

 

EXHIBIT
E — 1 SECTION E2

PERSONAL PROPERTY

Hard Wall Offices, Conference Rooms and Common Areas 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Gray	 	 	 	 	 	 	 	 	 	 	 	 	 	3’x6’	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Blue,	 	3’Square,	 	Purple Pattern	 	Turquoise	 	Black	 	 	 	 	 	2 Dr	 	2 1/2’x5’	 	2 1/2x5’	 	 	 	 	 	Conference	 	pattern	 	 	 	 	 	Wall	 	 	 	 	 	Exec	 	 	 	 	 	2 1/2 x 5’	 	2 1/2’ x 5’	 	Mail Box	 	1 1/2 x 3’
	 	 	Easy	 	Low	 	Rolling	 	side	 	Rolling	 	3 shelf	 	Lateral	 	Table	 	Desk,	 	 	 	 	 	Room	 	rolling	 	 	 	 	 	Hung	 	Gray Side	 	Desk	 	Small	 	Table,	 	Credenza,	 	Cabinet,	 	Supply
	Space Locations	 	Chair	 	Table	 	Chair	 	chair	 	Chair	 	Bookcase	 	File	 	Blond	 	Blond	 	PC Stand	 	Table	 	chair	 	Coal rack	 	Paintings	 	Chair	 	Blond	 	Refrigerator	 	, Gray	 	Gray	 	Gray	 	Cabinet
	Lobby Area
	 	 	4	 	 	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	4	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	3	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Hornet C.R.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	1	 	 	 	1	 	 	 	12	 	 	 	1	 	 	 	2	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Mammoth C.R.
	 	 	 	 	 	 	 	 	 	 	2	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Break Area
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	2	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Mail Area
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 
	Rest Room Lobby
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	8	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Off 1E2-315
	 	 	 	 	 	 	 	 	 	 	3	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Off 1E2-316
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Off 1E2-319
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	2	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Off 1E2-320
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	2	 	 	 	1	 	 	 	 	 	 	 	 	 	 	 	1	 	 	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Off 1E2-321
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	2	 	 	 	1	 	 	 	 	 	 	 	1	 	 	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Off 1E2-322
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	2	 	 	 	1	 	 	 	1	 	 	 	2	 	 	 	1	 	 	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Off 1E2-323
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	2	 	 	 	1	 	 	 	1	 	 	 	2	 	 	 	1	 	 	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Off 1E2-324
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	2	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Off 1E2-325
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	4	 	 	 	1	 	 	 	1	 	 	 	2	 	 	 	1	 	 	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

Cubicles
8’ X 10’ Total of 21 — Herman Miller Panel System

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Cubicle #	 	 	 	 	 	1	 	2	 	3	 	4	 	5	 	6	 	7	 	8	 	9	 	10	 	11	 	12	 	13	 	14	 	15	 	16	 	17	 	18	 	19	 	20	 	21
	Furniture
	 	Abbrev.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Flippers
	 	FL	 	 	2	 	 	 	2	 	 	 	2	 	 	 	2	 	 	 	2	 	 	 	2	 	 	 	1	 	 	 	2	 	 	 	2	 	 	 	2	 	 	 	2	 	 	 	1	 	 	 	2	 	 	 	2	 	 	 	2	 	 	 	2	 	 	 	2	 	 	 	2	 	 	 	2	 	 	 	2	 	 	 	2	 
	Black Rolling Chair
	 	BC	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	0	 	 	 	1	 	 	 	1	 	 	 	0	 	 	 	0	 	 	 	0	 	 	 	0	 	 	 	0	 	 	 	0	 	 	 	0	 	 	 	0	 	 	 	1	 	 	 	0	 	 	 	1	 
	Turquois Side Chair
	 	TC	 	 	0	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	2	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	0	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	0	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 
	2 Dr. Lat File
	 	 	2F	 	 	 	1	 	 	 	1	 	 	 	0	 	 	 	2	 	 	 	0	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	2	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	2	 	 	 	2	 	 	 	1	 
	Box, Box, File Ped.
	 	BBF	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	2	 	 	 	1	 	 	 	1	 	 	 	0	 	 	 	2	 
	Corner Surface
	 	CS	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	2	 	 	 	1	 	 	 	1	 	 	 	0	 	 	 	1	 
	2 1/2’
x 4’ Flat Surf
	 	FS	 	 	2	 	 	 	2	 	 	 	2	 	 	 	2	 	 	 	2	 	 	 	2	 	 	 	2	 	 	 	2	 	 	 	2	 	 	 	2	 	 	 	2	 	 	 	2	 	 	 	2	 	 	 	2	 	 	 	2	 	 	 	2	 	 	 	1	 	 	 	2	 	 	 	2	 	 	 	2	 	 	 	2	 
	White Board
	 	WB	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	0	 	 	 	0	 	 	 	1	 	 	 	2	 	 	 	1	 
	Cork Board
	 	CB	 	 	0	 	 	 	1	 	 	 	0	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 	 	 	1	 
	Gray Side Chair
	 	GSC	 	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Secretary Shelf
	 	SS	 	 	 	 	 	 	 	 	 	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	1	 	 	 	 	 	 	 	 	 	 	 	1	 
	Blue Rolling Chair
	 	BRC	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Book Shelf
	 	BS	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Silver Side Chair
	 	SSC	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Gray Rolling Chair
	 	GRC	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Short Flat Surface
	 	SFS	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Magenta Rolling Chair
	 	MRC	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 

 

EXHIBIT
E — 2 SECTION S1

Hard Wall Offices, Conference Rooms and Common Areas

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Purple	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	2 1/2’ X 6’	 	Box,	 	 	 	 	 	 
	 	 	2 1/2’ X 2 1/2’	 	3’ Round,	 	3’ Round,	 	4’ Round,	 	5’ Round,	 	1 1/2’	 	 	 	2 1/2’ X 5’	 	2 1/2’ X 5’	 	Pattern	 	Maroon	 	Black	 	Turquolse	 	Blue	 	 	 	2 Dr	 	4 Dr	 	Conference	 	Wall	 	Credenza,	 	Box,	 	 	 	2 1/2’ X 5’	 	Mall Box
	 	 	Blond	 	Blond	 	Gray	 	Blond	 	Blond	 	Round	 	2' Round	 	Table,	 	Desk,	 	Rolling	 	Rolling	 	Rolling	 	Side	 	Easy	 	3-Shelf	 	Lateral	 	Lateral	 	Room	 	Hung	 	Blond with	 	File	 	Large	 	Credenza,	 	Cabinet,
	Space Locations	 	Table	 	Table	 	Table	 	Table	 	Table	 	Table	 	Table	 	Blond	 	Blond	 	Chair	 	Chair	 	Chair	 	Chair	 	Chair	 	Bookcase	 	File	 	File	 	Table	 	Paintings	 	book shelf	 	Pedestal	 	Refrigerator	 	Gray	 	Gray
	Corridor to S1
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	2	 	 	 	 	 	 	 	 	 	 
	Lobby/Open Area
	 	 	 	4	 	1	 	 	 	 	 	 	 	1	 	2	 	 	 	11	 	 	 	 	 	 	 	5	 	8	 	3	 	1	 	 	 	3	 	 	 	1	 	 	 	 	 	 
	Pastuer-Tempes C.R.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	13	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	1	 	3	 	 	 	 	 	 	 	 	 	 
	Ehrlich C.R.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	7	 	 	 	 	 	 	 	 	 	 	 	 	 	1	 	 	 	1	 	 	 	 	 	 	 	 
	Off. 152
	 	1	 	 	 	 	 	 	 	1	 	 	 	 	 	2	 	 	 	5	 	 	 	1	 	 	 	 	 	2	 	1	 	 	 	 	 	1	 	 	 	 	 	 	 	 	 	 
	Off. 153
	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 	1	 	1	 	 	 	2	 	1	 	 	 	 	 	1	 	1	 	1	 	 	 	2	 	 	 	 	 	 	 	 	 	 
	Off. 154
	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 	1	 	1	 	 	 	 	 	2	 	2	 	 	 	1	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Off. 155
	 	1	 	 	 	 	 	 	 	 	 	1	 	 	 	1	 	1	 	 	 	 	 	1	 	2	 	1	 	1	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Off. 156
	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 	1	 	1	 	 	 	 	 	2	 	3	 	 	 	1	 	1	 	 	 	 	 	1	 	 	 	 	 	 	 	 	 	 
	Off. 157
	 	1	 	 	 	 	 	 	 	 	 	1	 	 	 	1	 	1	 	 	 	 	 	1	 	2	 	 	 	2	 	1	 	 	 	 	 	2	 	 	 	 	 	 	 	 	 	 
	Off. 158
	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 	1	 	1	 	 	 	 	 	1	 	2	 	 	 	2	 	1	 	 	 	 	 	1	 	 	 	 	 	 	 	 	 	 
	Off. 159
	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 	1	 	1	 	 	 	 	 	1	 	2	 	 	 	2	 	2	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Off. 160
	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 	1	 	1	 	2	 	 	 	1	 	 	 	 	 	1	 	1	 	1	 	 	 	1	 	 	 	 	 	 	 	 	 	 
	Off. 161
	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 	1	 	1	 	2	 	 	 	1	 	 	 	 	 	1	 	1	 	 	 	 	 	 	 	 	 	1	 	 	 	 	 	 
	Off. 162
	 	1	 	 	 	 	 	1	 	 	 	 	 	 	 	1	 	1	 	3	 	 	 	1	 	 	 	 	 	3	 	1	 	 	 	 	 	1	 	 	 	 	 	 	 	 	 	 
	Kitchen
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	7	 	 	 	 	 	 	 	 	 	 	 	 	 	1	 	 	 	 
	Mail Room
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	1	 	1

 

EXHIBIT E — 3 SECTION S1

PERSONAL PROPERTY

Cubicles
8’ X 10’ Total of 39 — Herman Miller Panel System

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Cubicle #	 	 	 	1	 	2	 	3	 	4	 	5	 	6	 	7	 	8	 	9	 	10	 	11	 	12	 	13	 	14	 	15	 	16	 	17	 	18	 	19	 	20	 	21	 	22
	Furniture
	 	Abbrev.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Flippers
	 	FL	 	2	 	2	 	2	 	2	 	2	 	2	 	2	 	2	 	2	 	2	 	2	 	1	 	2	 	2	 	2	 	2	 	1	 	2	 	2	 	2	 	2	 	2
	Black Rolling Chair
	 	BC	 	1	 	1	 	1	 	2	 	1	 	1	 	2	 	2	 	2	 	2	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	2
	Turquois Side Chair
	 	TC	 	1	 	1	 	1	 	1	 	1	 	2	 	1	 	1	 	1	 	1	 	1	 	0	 	1	 	1	 	1	 	1	 	1	 	1	 	0	 	1	 	0	 	1
	2 Dr. Lat File
	 	2F	 	1	 	1	 	0	 	1	 	1	 	1	 	1	 	1	 	1	 	0	 	1	 	0	 	1	 	1	 	1	 	0	 	1	 	1	 	0	 	1	 	1	 	1
	Box, Box, File Ped.
	 	BBF	 	2	 	1	 	2	 	1	 	2	 	2	 	1	 	1	 	1	 	0	 	2	 	0	 	2	 	2	 	2	 	2	 	2	 	1	 	1	 	2	 	1	 	1
	Corner Surface
	 	CS	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1
	2 1/2’
x 4’ Flat Surf
	 	FS	 	2	 	2	 	1	 	2	 	2	 	2	 	2	 	2	 	2	 	2	 	2	 	1	 	2	 	2	 	2	 	2	 	2	 	2	 	2	 	2	 	2	 	2
	White Board
	 	WB	 	0	 	1	 	0	 	0	 	1	 	1	 	0	 	0	 	0	 	0	 	1	 	0	 	1	 	1	 	1	 	0	 	1	 	1	 	0	 	1	 	1	 	0
	Cork Board
	 	CB	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	2	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1
	Gray Side Chair
	 	GSC	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Secretary Shelf
	 	SS	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Book Shelf
	 	BS	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Silver Side Chair
	 	SSC	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Blue Rolling Chair
	 	BRC	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Gray Rolling Chair
	 	GRC	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Short Flat Surface
	 	SFS	 	 	 	 	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Magenta Rolling Chair
	 	MRC	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Blue Easy Chair
	 	BEC	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Short Flipper
	 	SFL	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Pink Side Chair
	 	PSC	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Purple Rolling Chair
	 	PRC	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	1	 	 	 	 	 	 
	4 Dr. Lat File
	 	4F	 	 	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	1	 	 	 	 	 	 
	Blue Side Chair
	 	BSC	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Red Rolling Chair
	 	RRC	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Black Side Chair
	 	BlkSC	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Marron Rolling Chair
	 	MSC	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	1	 	 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Cubicle #	 	 	 	23	 	24	 	25	 	26	 	27	 	28	 	29	 	30	 	31	 	32	 	33	 	34	 	35	 	36	 	37	 	38	 	39
	Furniture
	 	Abbrev.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Flippers
	 	FL	 	2	 	2	 	2	 	2	 	2	 	2	 	2	 	2	 	2	 	2	 	2	 	2	 	2	 	2	 	2	 	2	 	1
	Black Rolling Chair
	 	BC	 	2	 	2	 	2	 	2	 	2	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1
	Turquois Side Chair
	 	TC	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1
	2 Dr. Lat File
	 	2F	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	0
	Box, Box, File Ped.
	 	BBF	 	1	 	1	 	1	 	1	 	1	 	1	 	2	 	2	 	2	 	2	 	2	 	2	 	2	 	1	 	2	 	2	 	0
	Comer Surface
	 	CS	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1	 	1
	2 1/2’
x 4’ Flat Surf
	 	FS	 	2	 	2	 	2	 	2	 	2	 	2	 	2	 	2	 	2	 	2	 	2	 	2	 	2	 	2	 	2	 	2	 	2
	White Board
	 	WB	 	0	 	0	 	0	 	0	 	0	 	1	 	1	 	1	 	1	 	0	 	1	 	1	 	1	 	1	 	1	 	1	 	1
	Cork Board
	 	CB	 	1	 	1	 	1	 	1	 	1	 	0	 	1	 	0	 	1	 	1	 	1	 	2	 	1	 	1	 	1	 	1	 	1
	Gray Side Chair
	 	GSC	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Secretary Shelf
	 	SS	 	 	 	 	 	 	 	 	 	 	 	1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Book Shelf
	 	BS	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Silver Side Chair
	 	SSC	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Blue Rolling Chair
	 	BRC	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Gray Rolling Chair
	 	GRC	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Short Flat Surface
	 	SFS	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Magenta Rolling Chair
	 	MRC	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Blu Easy Chair
	 	BEC	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Short Flipper
	 	SFL	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Pink Side Chair
	 	PSC	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Purple Rolling Chair
	 	PRC	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	4 Dr. Lat File
	 	4F	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Blue Side Chair
	 	BSC	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	3	 	 	 	 	 	 	 	 	 	 
	Red Rolling Chair
	 	RRC	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Black Side Chair
	 	BlkSC	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Marron Rolling Chair
	 	MSC	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

 

EXHIBIT F

RULES ANDEGULATIONS

	1.	 	The sidewalks, halls, passages, exits, entrances, elevators, and
stairways of the Building
shall not be obstructed by any of the tenants or used by them for any
purpose other than
for ingress to and egress from their respective Premises. The halls,
passages, exits,
entrances, elevators, and stairways are not for the general public, and
Landlord shall in all
cases retain the right to control and prevent access thereto of all
persons whose presence
in the judgment of Landlord would be prejudicial to the safety,
character, reputation and
interests of the Building and its tenants. No Tenant and no employee or
invitee of any
Tenant shall go upon the roof of the Building.
	 
	2.	 	All visitors and employees that do not have appropriate
identification or access badges
shall check-in and register at the main reception area of the Building.
	 
	3.	 	Tenants shall not bring any bicycles, motorcycles, or
similar vehicles into the building,
and will park such vehicles only in areas specified by Landlord.
	 
	4.	 	No birds, fish or other animals (other than seeing eye
dogs) shall be brought into or kept
in, on or about the Building.
	 
	5.	 	Tenants shall cooperate with Landlord to assure, and to
abide by all reasonable
regulations and requirements that Landlord may require for the proper
functioning and
protection of the HVAC, electrical, security, plumbing, fire and other
systems serving the
Premises. Tenants shall comply with all laws, statutes, ordinances
and governmental
rules and regulations now in force or which may later be enacted or
promulgated in
connection with building services furnished to the Premises,
including, without
limitation, any governmental rule or regulation relating to the heating
and cooling of the
Premises
	 
	6.	 	No sign, placard, picture, name, advertisement or notice
visible from the exterior of any
Tenant’s Premises shall be inscribed, painted, affixed or otherwise
displayed by any
Tenant on any part of the Building without the prior written consent of
Landlord.
Landlord will adopt and furnish to tenants general guidelines relating
to signs inside the
Building on the office floors. Each Tenant shall conform to such
guidelines, but may
request approval of Landlord for modifications, which approval shall be
at Landlord’s
sole discretion. All approved signs or lettering on doors shall be
printed, painted, affixed
or inscribed at the expense of the Tenant by a person approved by
Landlord, which
approval will not be unreasonably withheld. Material visible from
outside the Building
will not be permitted (except for signage permitted by the Lease).
	 
	7.	 	No Tenant shall employ any person or persons other than
Landlord’s janitorial service for
the purpose of cleaning the Premises, unless otherwise approved by
Landlord. No person
or persons other than those approved by Landlord shall be permitted to
enter the Building
for the purpose of cleaning the same. No Tenant shall cause any
unnecessary labor by
reason of such Tenant’s carelessness or indifference in the
preservation of good order and

F-1

 

	 	 	cleanliness. Janitor service will not be furnished on nights
when rooms are occupied after 8:00 P.M. unless, by prior arrangement
with Landlord, service is extended to a later hour for specifically
designated rooms with any additional cost to be paid by the
requesting Tenant. Tenants shall provide adequate waste and rubbish
receptacles, cabinets, book cases, map cases and the like necessary
to prevent unreasonable hardship to landlord in discharging its
obligation regarding cleaning service.

	8.	 	Landlord will furnish Tenant with electronic access key
cards, at Tenant’s expense, as
well as keys to all standard tumbler locks (in the amount of two (2)
per key lock) in the
Premises. Tenant shall pay to Landlord a nominal deposit for all
additional keys or key
cards that are provided by Landlord at the request of Tenant. Each
Tenant, upon the
termination of its tenancy, shall return to Landlord all keys and key
cards which have
been furnished to or made by the Tenant. Tenant shall be liable for the
reasonable cost of
replacement for all keys or key cards not so returned. No Tenant shall
change any lock
without the express written consent of the Landlord, and shall in such
case furnish
Landlord with a key for any such lock.
	 
	9.	 	Landlord shall have the right to prescribe the weight,
size and position of all equipment,
materials, furniture or other property brought into the Building.
Heavy objects shall, if
considered necessary by Landlord, shall be supported as is necessary
properly to
distribute the weight. Landlord will not be responsible for loss of or
damage to any such
property from any cause, and all damage done to the Building by moving
or maintaining
such property shall be repaired at the expense of the Tenant.
	 
	10.	 	Except as otherwise specifically permitted in the
Lease, no Tenant shall use or keep in the
Premises or the Building any kerosene, gasoline or inflammable or
combustible fluid or
material, or, without Landlord’s prior approval, use any method of
heating or air
conditioning other than that supplied by Landlord. No Tenant shall use
or keep or permit
to be used or kept any foul or noxious gas or substance in the
Premises, or permit or
suffer the Premises to be occupied or used in a manner offensive or
objectionable to
Landlord or other occupants of the Building by reason of noise, odors
or vibrations, or
interfere in any way with other tenants or those having business
therein.
	 
	11.	 	Landlord shall have the right, exercisable without
liability to any Tenant to change the
name and street address of the Building.
	 
	12.	 	Landlord reserves the right to exclude from the
Building between the hours of 6:00 P.M.
and 8:00 A.M. and at all hours on Saturdays, Sundays and legal holidays
all persons who
do not present a proper access card or other identification as an
employee of Tenant or
who do not otherwise present proper authorization by Tenant for access
to the Premises.
Tenant shall be responsible for all persons for whom it authorizes
access and shall be
liable to Landlord for all acts of such persons. Landlord shall in no
case be liable for
damages for any error with regard to the admission to or exclusion from
the Building of
any person. In the case of invasion, mob, riot, public excitement or
other circumstances
rendering such action advisable in Landlord’s opinion, Landlord
reserves the right to
prevent access to the Building during the continuance of the same by
such action as
Landlord may deem appropriate.

F-2

 

	13.	 	No curtains, draperies, blinds, shutters, shades, screens or
other coverings, hangings or
decorations shall be attached to, hung or placed in, or used in
connection with any
exterior window in the Building without the prior consent of Landlord.
If consented to
by Landlord, such items shall be installed on the office side of the
standard window
covering and shall in no way be visible from the exterior of the
Building.
	 
	14.	 	Messenger services and suppliers of bottled water,
food, beverages, and other products or
services shall be subject to such reasonable regulations as may be
adopted by Landlord.
Landlord may establish a central receiving station in the Building for
delivery and pick-up by all messenger services.
	 
	15.	 	Each Tenant shall see that the doors of its Premises
are closed and locked and that all
water faucets or apparatus, microwave ovens, and office equipment
(excluding office
equipment required to be operative at all times) are shut off before the Tenant or its
employees leave the Premises at night, so as to prevent waste or
damage, and for any
default or carelessness in this regard the Tenant shall be responsible
for any damage
sustained by other tenants or occupants of the Building or Landlord.
All tenants shall
keep the doors to the Building corridors closed at all times except for
ingress and egress.
	 
	16.	 	The toilets, urinals, wash bowls and other restroom
facilities shall not be used for any
purpose other than that for which they were constructed, no foreign
substance of any kind
whatsoever shall be thrown therein and the expense of any breakage,
stoppage or damage
resulting from the violation of this rule shall be borne by the Tenant
who, or whose
employees or invitees, shall have caused it.
	 
	17.	 	Parking

	 	17.1	 	Tenants shall not park in spaces allocated to other tenants.
	 
	 	17.2	 	No vehicles shall be permitted to be parked for more than 24 hours at a time.
	 
	 	17.3	 	Parking areas shall be used only for parking by vehicles no longer than full size,
passenger automobiles.
	 
	 	17.4	 	Users of the parking area will obey all posted signs.
	 
	 	17.5	 	The maintenance, washing, waxing or cleaning of vehicles in the parking area is
prohibited.
	 
	 	17.6	 	Tenants shall be responsible for seeing that all of its employees, agents and
invitees comply with the applicable parking rules, regulations,
laws and agreements.

	18.	 	No Tenant shall install any antenna, loudspeaker, or
any other device on the roof or
exterior walls of the Building without the express written consent by
Landlord, which
consent may be withheld in Landlord’s sole discretion.

F-3

 

	19.	 	There shall not be used in any portion of the Building, by
any Tenant or its invitees, any
hand trucks or other material handling equipment except those equipped
with rubber tires
and side guards unless otherwise approved by Landlord.
	 
	20.	 	No material shall be placed in the refuse boxes or
receptacles if such material is of such
nature that it may not be disposed of in the ordinary and customary
manner of removing
and disposing of refuse in the City of Louisville without being in
violation of any law or
ordinance governing such disposal. All refuse disposal shall be made
only through
entryways and elevators provided for such purposes and at such times
as Landlord shall
designate.
	 
	21.	 	Smoking in all portions of the Building is prohibited,
and each Tenant shall cooperate to
prevent the same.
	 
	22.	 	Loading docks shall be used only for the temporary
loading and unloading of materials.
Each Tenant shall endeavor to promptly remove all delivered materials
and to keep the
loading docks empty. The overnight storage of materials at the loading
docks is strictly
prohibited.
	 
	23.	 	Landlord may waive any one or more of these Rules and
Regulations for the benefit of
any particular Tenant or tenants, but no such waiver by Landlord shall
be construed as a
waiver of such Rules and Regulations in favor of any other Tenant or
tenants, nor prevent
Landlord from thereafter enforcing any such Rules and Regulations
against any or all of
the tenants of the Building.
	 
	24.	 	These Rules and Regulations are in addition to, and
shall not be construed to in any way
modify or amend, in whole or in part, the terms, covenants, agreements
and conditions of
any sublease of premises in the Building.
	 
	25.	 	Landlord reserves the right to make such other and
reasonable rules and regulations as in
its judgment may from time to time be needed for the safety, care and
cleanliness of the
Building, and for the preservation of good order therein.

F-4

 

EXHIBIT G

DEPICTION OF SECOND REFUSAL SPACE

OFFICE SPACE E1 10,476 RSF

 

 

ASSIGNMENT AND ASSUMPTION OF LEASES

     FOR AND IN CONSIDERATION of the sum of Ten Dollars ($10.00) and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, TRIUMPH 1450 LLC, a
Colorado limited liability company, having an office at 9605 Kingston Court, Suite 160, Englewood,
Colorado 80112 (“Assignor”), hereby sells, transfers, assigns and sets over to TRIUMPH 1450, LLC,
a Delaware limited liability company, as to an undivided 50% interest, and MRA DESERT VILLAS, LLC,
a Delaware limited liability company, as to an undivided 50% interest, as tenants-in-common,
having an office at 9605 Kingston Court, Suite 160, Englewood, Colorado 80112 (“Assignee”), all of
Assignor’s right, title and interest in and to those certain leases referred to in Exhibit
A annexed hereto and made a part hereof (the “Leases”) and any security deposits held by
Assignor in connection therewith, which Leases affect and relate to the real properties commonly
known as 1450 Infinite Drive and 1450 Centennial Court in the City of Louisville, Boulder County,
Colorado, from and after the date hereof.

     TO HAVE AND TO HOLD the same unto Assignee, its successors and assigns, forever, subject to
the terms, covenants, conditions and provisions of the Leases.

     Assignee hereby accepts said assignment and assumes and agrees to perform and comply with all
of the covenants, duties and obligations of Assignor as landlord under the Leases to be performed
from and after the date hereof.

     This Assignment shall be binding upon and inure to the benefit of the parties hereto and their
respective successors and assigns.

     IN
WITNESS WHEREOF, the parties hereto have executed this Assignment as
of the
25th
day of October, 2005.

	 	 	 	 	 	 	 	 	 
	ASSIGNOR:	 	 	 	ASSIGNEE:
	 
	 	 	 	 	 	 	 	 
	TRIUMPH 1450 LLC,	 	 	 	TRIUMPH 1450, LLC,
	a Colorado limated liability company 	 	 	 	a Delaware limited liability company
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Ronald D. Boraks
	 	 	 	By:
	 	/s/ Ronald D. Boraks
	 

	 	 
	 	 	 	 	 	 
	Name: RONALD D. BORAKS	 	 	 	Name: RONALD D. BORAKS
	Its: MANAGER	 	 	 	Its: MANAGER
	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	MRA DESERT VILLAS, LLC,
	 	 	 	 	 	 	a Delaware limited liability company
	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	By:
	 	/s/ Ronald D. Boraks
	 

	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Name: RONALD D. BORAKS
	 	 	 	 	 	 	Its: MANAGER

1

 

Exhibit A

 Leases

	1.	 	Lease by and between Assignor, as landlord, and Replidyne, Inc., as tenant.
	 
	2.	 	Lease by and between Assignor, as landlord, and Globelmmune, Inc., as tenant.
	 
	3.	 	Lease by and between Assignor, as landlord and Storage Technology Corporation, as
tenant.

2

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	Liquids=	 	 	 	 	 	 	 	 
	Irritant
	 	TEMED	 	IC	 	110-18-9	 	S	 	100	 	gm	 	365	 	0.22	 	M	 	F	 	1
	 
	 	Coomassie Plus Protien Assay	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Irritant
	 	Reagent	 	 	 	None	 	L	 	950	 	ml	 	365	 	0.2	 	M	 	I	 	1
	Irritant
	 	DMSO	 	 	 	67-68-5	 	L	 	1	 	L	 	365	 	2.1	 	M	 	I	 	1
	Irritant
	 	Ecoscint-O	 	 	 	None	 	L	 	12	 	L	 	365	 	25.8	 	M	 	D	 	1
	Irritant
	 	Gylcerin	 	 	 	56-81-5	 	L	 	40	 	L	 	365	 	86.0	 	M	 	D	 	1
	Irritant
	 	Nonidet P-40	 	 	 	9036-19-5	 	L	 	500	 	ml	 	365	 	1.1	 	M	 	I	 	1
	Irritant
	 	Picogreen	 	 	 	None	 	L	 	4	 	ml	 	365	 	0.01	 	M	 	I	 	1
	Irritant
	 	Tris-glycine-SDS	 	 	 	None	 	S	 	400	 	g	 	365	 	0.88	 	M	 	I	 	1
	Irritant
	 	Triton X-1  00	 	 	 	9002-93-1	 	L	 	500	 	ml	 	365	 	1.1	 	M	 	I	 	1
	Irritant
	 	Ammonium Sulfate	 	 	 	7783-20-2	 	S	 	10	 	kg	 	365	 	0.54	 	M	 	I	 	1
	Irritant
	 	Bis	 	 	 	2716-10-1	 	S	 	1500	 	g	 	365	 	3.30	 	M	 	D	 	1
	Irritant
	 	Boric Acid	 	 	 	10043-35-3	 	S	 	10	 	g	 	365	 	0.02	 	M	 	D	 	1
	Irritant
	 	Bromophenol Blue Aqueous	 	 	 	252-17-0	 	S	 	500	 	g	 	365	 	1.10	 	M	 	D	 	1
	Irritant
	 	Calcium Sulfate	 	 	 	7778-18-9	 	S	 	500	 	g	 	365	 	1.10	 	M	 	D	 	1
	Irritant
	 	Citric Acid Anhydrous	 	 	 	77-82-9	 	S	 	2000	 	g	 	365	 	4.41	 	M	 	I	 	1
	Irritant
	 	Deoxycholic Acid, Sodium Salt	 	 	 	302-95-4	 	S	 	100	 	g	 	365	 	0.22	 	M	 	I	 	1
	Irritant
	 	Dextrose	 	 	 	50-99-7	 	S	 	500	 	g	 	365	 	1.10	 	M	 	D	 	1
	Irritant
	 	Drierite	 	 	 	7778-18-9	 	S	 	3	 	kg	 	365	 	0.16	 	M	 	D	 	1
	Irritant
	 	D-Sorbitol	 	 	 	50-70-4	 	S	 	5	 	kg	 	365	 	0.27	 	M	 	I	 	1
	Irritant
	 	EDTA	 	 	 	60-00-4	 	S	 	500	 	g	 	365	 	1.10	 	M	 	D	 	1
	Irritant
	 	Glucose	 	 	 	50-99-7	 	S	 	1	 	kg	 	365	 	0.05	 	M	 	D	 	1
	Irritant
	 	Glycine	 	 	 	56-40-6	 	S	 	4	 	kg	 	365	 	0.22	 	M	 	D	 	1
	Irritant
	 	HEPES	 	 	 	7365-45-9	 	S	 	500	 	g	 	365	 	1.10	 	M	 	I	 	1
	Irritant
	 	Lysozyme	 	 	 	None	 	S	 	100	 	g	 	365	 	0.22	 	M	 	I	 	1
	Irritant
	 	Magnesium Acetate	 	 	 	76030-84-7	 	S	 	1000	 	g	 	365	 	2.20	 	M	 	I	 	1
	Irritant
	 	Magnesium Chloride	 	 	 	232-094-6	 	S	 	500	 	g	 	365	 	1.10	 	M	 	I	 	1
	Irritant
	 	MES	 	 	 	4432-31-9	 	S	 	100	 	g	 	365	 	0.22	 	M	 	D	 	1
	Irritant
	 	n-Octyl-B-D-glucopyranoside	 	 	 	29836-26-8	 	S	 	5	 	g	 	365	 	0.01	 	M	 	I	 	1
	Irritant
	 	Potassium Acetate	 	 	 	127-08-2	 	S	 	3	 	kg	 	365	 	0.16	 	M	 	I	 	1
	Irritant
	 	Potassium chloride	 	 	 	7447-40-7	 	S	 	3	 	kg	 	365	 	0.16	 	M	 	I	 	1
	Irritant
	 	potassium- phosphate dibasic	 	 	 	7758-11-4	 	S	 	3	 	kg	 	365	 	0.16	 	M	 	I	 	1
	Irritant
	 	potassium- phosphate monobasic	 	 	 	7778-77-0	 	S	 	3	 	kg	 	365	 	0.16	 	M	 	I	 	1
	Irritant
	 	Protamine Sulfate	 	 	 	9007-31-2	 	S	 	5	 	g	 	365	 	0.01	 	M	 	I	 	1
	Irritant
	 	Silica Gel Desiciant	 	 	 	None	 	S	 	2.5	 	kg	 	365	 	0.14	 	M	 	D	 	1
	Irritant
	 	Sodium Bicarbonate	 	 	 	144-55-8	 	S	 	500	 	g	 	365	 	1.10	 	M	 	I	 	1
	Irritant
	 	Sodium Chloride	 	 	 	7647-14-5	 	S	 	3	 	kg	 	365	 	0.16	 	M	 	I	 	1
	Irritant
	 	Sodium citrate	 	 	 	6132-05-4	 	S	 	1500	 	g	 	365	 	3.30	 	M	 	I	 	1
	Irritant
	 	Sodium Pyrophosphate	 	 	 	7722-88-5	 	S	 	9	 	kg	 	365	 	0.49	 	M	 	I	 	1

 19

 

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Irritant

	 	Sodium Sulfate
	 	7757-82-6
	 	S
	 	 	500	 	 	 	g	 	 	 	365	 	 	 	1.10	 	 	M
	 	I
	 	 	1	 
	Irritant

	 	Tricina
	 	5704-04-1
	 	S
	 	 	500	 	 	 	g	 	 	 	365	 	 	 	1.10	 	 	M
	 	I
	 	 	1	 
	Irritant

	 	Tris
	 	77-86-1
	 	S
	 	 	10	 	 	kg
	 	 	365	 	 	 	0.54	 	 	M
	 	I
	 	 	1	 
	 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	Total Irritants=	 	 	144.51	 	 	Ibs.  	 	 	 	 	 	 
	N/A

	 	Count Off
	 	N/A
	 	L
	 	 	2	 	 	 	L	 	 	 	365	 	 	 	0.5	 	 	M
	 	D
	 	 	1	 
	N/A

	 	Streptavidin_alkaline Phosphatase Conjugate
	 	None
	 	L
	 	 	4	 	 	ml
	 	 	365	 	 	 	0.00	 	 	M
	 	I
	 	 	1	 
	N/A

	 	Carbowax PEG 8000
	 	25322-68-3
	 	S
	 	 	12	 	 	kg
	 	 	365	 	 	 	0.65	 	 	M
	 	D
	 	 	1	 
	N/A

	 	Casitone Media
	 	N/A
	 	S
	 	 	500	 	 	 	g	 	 	 	365	 	 	 	1.10	 	 	M
	 	D
	 	 	1	 
	N/A

	 	IPTG
	 	N/A
	 	S
	 	 	100	 	 	 	g	 	 	 	365	 	 	 	0.22	 	 	M
	 	D
	 	 	1	 
	N/A

	 	L-glutmaic acid
	 	N/A
	 	S
	 	 	1	 	 	kg
	 	 	365	 	 	 	0.05	 	 	M
	 	D
	 	 	1	 
	N/A

	 	Lysol I.C.
	 	N/A
	 	S
	 	 	1	 	 	gal
	 	 	365	 	 	 	1	 	 	M
	 	D
	 	 	1	 
	N/A

	 	polyoxyethylene 20 cetyl Ether
	 	9004-95-9
	 	S
	 	 	500	 	 	 	g	 	 	 	365	 	 	 	1.10	 	 	M
	 	D
	 	 	1	 
	N/H

	 	Blue Dextran
	 	None
	 	L
	 	 	10	 	 	 	g	 	 	 	365	 	 	 	0.02	 	 	M
	 	D
	 	 	1	 
	N/H

	 	M13mp18 RF DNA
	 	N/A
	 	L
	 	 	10	 	 	mg
	 	 	365	 	 	 	0.00002	 	 	M
	 	D
	 	 	0	 
	N/H

	 	Murine IgG Immunoglogulin
	 	N/A
	 	L
	 	 	1	 	 	ml
	 	 	365	 	 	 	0.0	 	 	M
	 	D
	 	 	0	 
	N/H

	 	pH standard Buffers
	 	N/A
	 	L
	 	 	2000	 	 	ml
	 	 	365	 	 	 	0.5	 	 	M
	 	D
	 	 	1	 
	N/H

	 	Rabbit IgG Immunoglogulin
	 	N/A
	 	L
	 	 	1	 	 	ml
	 	 	365	 	 	 	0.00	 	 	M
	 	D
	 	 	0	 
	N/H

	 	Radioactive Decontaminant
	 	N/A
	 	L
	 	 	8	 	 	oz
	 	 	365	 	 	 	N/A	 	 	M
	 	D
	 	 	0	 
	N/H

	 	SYBR Gold
	 	None
	 	L
	 	 	1	 	 	ml
	 	 	365	 	 	 	0.00	 	 	M
	 	D
	 	 	1	 
	N/H

	 	T4 Polynucleotide kinase
	 	N/A
	 	L
	 	 	200	 	 	Units
	 	 	365	 	 	 	N/A	 	 	M
	 	D
	 	 	0	 
	N/H

	 	T7 DNA polymerase
	 	N/A
	 	L
	 	 	200	 	 	Units
	 	 	365	 	 	 	N/A	 	 	M
	 	D
	 	 	0	 
	N/H

	 	Adenosine 5’-Triphosphate
	 	9000-83-3
	 	S
	 	 	5	 	 	 	g	 	 	 	365	 	 	 	0.01	 	 	M
	 	D
	 	 	1	 
	N/H

	 	Adenosine-5’-O-(3-thiotriphosphate)
	 	93839-8905
	 	S
	 	 	200	 	 	mmol
	 	 	365	 	 	 	N/A	 	 	M
	 	D
	 	 	0	 
	N/H

	 	Calf thymus DNA
	 	N/A
	 	S
	 	 	250	 	 	mg
	 	 	365	 	 	 	0.0000	 	 	M
	 	D
	 	 	0	 
	N/H

	 	Cytidine-5’-triphosphate
	 	N/A
	 	S
	 	 	5	 	 	 	g	 	 	 	365	 	 	 	0.01	 	 	M
	 	D
	 	 	0	 
	N/H

	 	Deoxyadenosine-5’-triphosphate
	 	N/A
	 	S
	 	 	5	 	 	 	g	 	 	 	365	 	 	 	0.01	 	 	M
	 	D
	 	 	0	 
	N/H

	 	Deoxycytidine-5’-triphosphate
	 	N/A
	 	S
	 	 	5	 	 	 	g	 	 	 	365	 	 	 	0.01	 	 	M
	 	D
	 	 	0	 
	N/H

	 	Deoxyguanosine-5’-triphosphate
	 	N/A
	 	S
	 	 	5	 	 	 	g	 	 	 	365	 	 	 	0.01	 	 	M
	 	D
	 	 	0	 
	N/H

	 	DNA replication enzymes
	 	N/A
	 	S
	 	 	3	 	 	 	g	 	 	 	365	 	 	 	0.01	 	 	M
	 	D
	 	 	0	 
	N/H

	 	DNA, various sources
	 	N/A
	 	S
	 	 	100	 	 	mg
	 	 	365	 	 	 	0.00022	 	 	M
	 	D
	 	 	0	 
	N/H

	 	Dnase I
	 	9003-98-9
	 	S
	 	 	100	 	 	mg
	 	 	365	 	 	 	0.00022	 	 	M
	 	D
	 	 	0	 
	N/H

	 	Guanosine-5’-triphosphate
	 	N/A
	 	S
	 	 	5	 	 	 	g	 	 	 	365	 	 	 	0.01	 	 	M
	 	D
	 	 	0	 
	N/H

	 	Poly (dA-dC)Poly (dG-dT)
	 	N/A
	 	S
	 	 	5	 	 	Units
	 	 	365	 	 	 	N/A	 	 	M
	 	D
	 	 	0	 
	N/H

	 	Polydeoxyadenylic acid
	 	N/A
	 	S
	 	 	25	 	 	Units
	 	 	365	 	 	 	N/A	 	 	M
	 	D
	 	 	0	 
	N/H

	 	Prateose peptone #3
	 	N/A
	 	S
	 	 	500	 	 	 	g	 	 	 	365	 	 	 	1.10	 	 	M
	 	D
	 	 	1	 
	N/H

	 	Restriction enzymes
	 	N/A
	 	S
	 	 	5000	 	 	Units
	 	 	365	 	 	 	N/A	 	 	M
	 	D
	 	 	0	 
	N/H

	 	Sucrose
	 	57-50-1
	 	S
	 	 	6	 	 	kg
	 	 	365	 	 	 	0.33	 	 	M
	 	D
	 	 	1	 
	N/H

	 	Tetracycline
	 	60-54-8
	 	S
	 	 	5	 	 	 	g	 	 	 	365	 	 	 	0.01	 	 	M
	 	D
	 	 	1	 
	N/H

	 	THAM
	 	77-86-1
	 	S
	 	 	2	 	 	kg
	 	 	365	 	 	 	0.11	 	 	M
	 	D
	 	 	1	 
	N/H

	 	Thymidine-5’-triphosphate
	 	N/A
	 	S
	 	 	5	 	 	 	g	 	 	 	365	 	 	 	0.01	 	 	M
	 	D
	 	 	0	 

 20

 

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	N/H

	 	Todd Hewitt Broth
	 	None
	 	S
	 	 	10	 	 	kg
	 	 	365	 	 	 	0.54	 	 	M
	 	D
	 	 	1	 
	N/H

	 	Topoisomerase IV
	 	N/A
	 	S
	 	 	5	 	 	mg
	 	 	365	 	 	 	0.00001	 	 	M
	 	D
	 	 	0	 
	N/H

	 	Trypticase Soy Broth
	 	None
	 	S
	 	 	1000	 	 	g
	 	 	365	 	 	 	2.20	 	 	M
	 	D
	 	 	1	 
	N/H

	 	Tryptone Peptone
	 	N/A
	 	S
	 	 	3	 	 	kg
	 	 	365	 	 	 	0.16	 	 	M
	 	D
	 	 	1	 
	N/H

	 	Uridine-5’-triphosphate
	 	None
	 	S
	 	 	5	 	 	g
	 	 	365	 	 	 	0.01	 	 	M
	 	D
	 	 	0	 
	N/H

	 	Yeast Extract
	 	8013-01-2
	 	S
	 	 	10	 	 	kg
	 	 	365	 	 	 	0.54	 	 	M
	 	I
	 	 	1	 
	NH

	 	1 step NBT/BCIP
	 	N/A
	 	L
	 	 	250	 	 	ml
	 	 	365	 	 	 	0.06	 	 	M
	 	D
	 	 	1	 
	NH

	 	Agarose
	 	N/A
	 	S
	 	 	750	 	 	g
	 	 	365	 	 	 	1.65	 	 	M
	 	D
	 	 	1	 
	NH

	 	Albumin, Bovine
	 	N/A
	 	S
	 	 	200	 	 	g
	 	 	365	 	 	 	0.44	 	 	M
	 	D
	 	 	1	 
	NH

	 	Alumina
	 	1344-28-1
	 	S
	 	 	500	 	 	g
	 	 	365	 	 	 	1.10	 	 	M
	 	I
	 	 	1	 
	NH

	 	Ammonium Bicarbonate
	 	1066-33-7
	 	S
	 	 	500	 	 	g
	 	 	365	 	 	 	1.10	 	 	M
	 	I
	 	 	1	 
	NH

	 	Bacto-Argar
	 	None
	 	S
	 	 	500	 	 	g
	 	 	365	 	 	 	1.10	 	 	M
	 	I
	 	 	1	 
	NH

	 	Bentonite
	 	1302-78-9
	 	S
	 	 	500	 	 	g
	 	 	365	 	 	 	1.10	 	 	M
	 	D
	 	 	1	 
	NH

	 	Brain Heart Infusion
	 	None
	 	S
	 	 	500	 	 	g
	 	 	365	 	 	 	1.10	 	 	M
	 	D
	 	 	1	 
	 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	Total Non-hazardous=	 	 	17.95	 	Ibs.  	 	 	 	 	 	 
	OX

	 	Ammonium Persulfate
	 	7727-54-0
	 	S
	 	 	200	 	 	g
	 	 	365	 	 	 	0.44	 	 	M
	 	I
	 	 	1	 
	OX

	 	Sodium Borate
	 	10332-33-9
	 	S
	 	 	500	 	 	g
	 	 	365	 	 	 	1.10	 	 	M
	 	I
	 	 	1	 
	 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	Total Oxidizers=	 	 	1.54	 	Ibs.  	 	 	 	 	 	 
	 

	 	 	 	79-06-1 ,110-	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	POISON

	 	30% Acrylamide/Bis 37.5:1
	 	26-9
	 	L
	 	 	1500	 	 	ml
	 	 	365	 	 	 	0.39	 	 	M
	 	D
	 	 	1	 
	 

	 	 	 	79-06-1, 110-	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	POISON

	 	30% Acrylamide/Bis29:1
	 	26-9
	 	L
	 	 	500	 	 	ml
	 	 	365	 	 	 	0.13	 	 	M
	 	D
	 	 	1	 
	 

	 	 	 	79-06-1, 110-	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	POISON

	 	40% Acrylamide/Bis 19:1
	 	26-9
	 	L
	 	 	500	 	 	ml
	 	 	365	 	 	 	0.13	 	 	M
	 	D
	 	 	1	 
	POISON

	 	Buffer-Saturated Phenol
	 	108-95-2
	 	L
	 	 	100	 	 	ml
	 	 	365	 	 	 	0.03	 	 	M
	 	D
	 	 	1	 
	POISON

	 	Chloroform
	 	67-66-3
	 	L
	 	 	208	 	 	L
	 	 	365	 	 	 	10.0	 	 	M
	 	I
	 	 	5	 
	POISON

	 	Formamide
	 	75-12-7
	 	L
	 	 	1	 	 	L
	 	 	365	 	 	 	0.3	 	 	M
	 	D
	 	 	1	 
	POISON

	 	Tween-20
	 	9005-64-5
	 	L
	 	 	500	 	 	ml
	 	 	365	 	 	 	0.13	 	 	M
	 	I
	 	 	1	 
	 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	Total Poisonous Liquids=	 	 	11.06	 	 	gals	 	 	 	 	 	 
	POISON

	 	Acrylamide 99.9%
	 	79-06-1
	 	S
	 	 	200	 	 	g
	 	 	365	 	 	 	0.44	 	 	M
	 	D
	 	 	1	 
	POISON

	 	Ammonium Chloride
	 	12125-02-9
	 	S
	 	 	1000	 	 	g
	 	 	365	 	 	 	2.20	 	 	M
	 	I
	 	 	1	 
	POISON

	 	Ammonium Foramte
	 	N/A
	 	S
	 	 	500	 	 	g
	 	 	365	 	 	 	1.10	 	 	M
	 	D
	 	 	1	 
	POISON

	 	Ammonium Formate
	 	540-69-2
	 	S
	 	 	500	 	 	g
	 	 	365	 	 	 	1.10	 	 	M
	 	I
	 	 	1	 
	POISON

	 	Ampicillin Sodium Salt
	 	69-52-3
	 	S
	 	 	400	 	 	g
	 	 	365	 	 	 	0.88	 	 	M
	 	I
	 	 	1	 
	POISON

	 	Benzamidine
	 	618-39-3
	 	S
	 	 	5	 	 	g
	 	 	365	 	 	 	0.01	 	 	M
	 	I
	 	 	1	 
	POISON

	 	Betaine
	 	107-43-7
	 	S
	 	 	500	 	 	g
	 	 	365	 	 	 	1.10	 	 	M
	 	I
	 	 	1	 
	POISON

	 	Calcium Chloride
	 	10043-52-4
	 	S
	 	 	500	 	 	g
	 	 	365	 	 	 	1.10	 	 	M
	 	D
	 	 	1	 
	POISON

	 	Cesium Chloride
	 	7647-17-8
	 	S
	 	 	1	 	 	kg
	 	 	365	 	 	 	0.05	 	 	M
	 	D
	 	 	1	 
	POISON

	 	Chloramphenicol
	 	56-75-7
	 	S
	 	 	100	 	 	g
	 	 	365	 	 	 	0.22	 	 	M
	 	D
	 	 	1	 
	POISON

	 	Crystal Violet
	 	548-52-9
	 	S
	 	 	25	 	 	g
	 	 	365	 	 	 	0.06	 	 	M
	 	I
	 	 	1	 
	POISON

	 	d-Biotin
	 	58-85-5
	 	S
	 	 	25	 	 	g
	 	 	365	 	 	0.06	 	M
	 	D
	 	 	1	 

 21

 

 

     HAZARDOUS
MATERIALS INVENTORY STATEMENT

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Annual
	 	 	 	 	UFC Fl.	 	 	 	 	 	Qty. on	 	 	 	Days	 	 	 	 	 	 	 	 	 	Waste
	 	 	 	 	Liq.	 	C.A.S	 	Physical	 	Hand (Max.	 	 	 	on	 	Qty. on Hand	 	 	 	SARA	 	Throughput
	Hazard Class	 	Common/ Trade Name	 	Class	 	Number	 	State	 	Avg.)	 	Units	 	Site	 	(Liquids=gals)(Solids=lbs.)	 	Storage Type	 	Class	 	(gals)
	COMB

	 	Mineral Oil
	 	 	 	8042-47-5
	 	L
	 	 	1	 	 	L
	 	 	365	 	 	 	0.3	 	 	M
	 	D
	 	 	1	 
	COMB

	 	Dichloromethane
	 	Comb
	 	75-09-2
	 	L
	 	 	208	 	 	L
	 	 	265	 	 	 	5.0	 	 	M
	 	D
	 	 	5	 
	COMB

	 	No count Radioactive

Decontaminant
	 	 	 	N/A
	 	L
	 	 	8	 	 	oz
	 	 	365	 	 	 	0.06	 	 	M
	 	D
	 	 	1	 
	 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	Total Combustible
Liquids	=	 	 	5.32	 	 	gals	 	 	 	 	 	 
	COR

	 	Acetic Acid
	 	 	 	69-19-7
	 	L
	 	 	8	 	 	L
	 	 	365	 	 	 	2.1	 	 	M
	 	I
	 	 	1	 
	COR

	 	Sodium Hydroxide 10 N Solution
	 	 	 	1310-73-2
	 	L
	 	 	3	 	 	L
	 	 	365	 	 	 	0.8	 	 	M
	 	I
	 	 	1	 
	 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	Total Corrosive
Liquids 	=	 	 	2.8	 	 	gals	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	COR

	 	Imidazole
	 	 	 	288-32-4
	 	S
	 	 	500	 	 	g
	 	 	365	 	 	 	1.10	 	 	M
	 	I
	 	 	1	 
	COR

	 	Sodium Hydroxide
	 	 	 	1310-73-2
	 	S
	 	 	500	 	 	g
	 	 	365	 	 	 	1.10	 	 	M
	 	I
	 	 	1	 
	COR

	 	Sodium phosphate
	 	 	 	7558-79-4
	 	S
	 	 	1	 	 	kg
	 	 	365	 	 	 	2.20	 	 	M
	 	I
	 	 	1	 
	COR

	 	Sodium phosphate
	 	 	 	7558-79-4
	 	S
	 	 	1	 	 	kg
	 	 	365	 	 	 	2.20	 	 	M
	 	I
	 	 	1	 
	COR

	 	Sodium phosphate, dibasic
	 	 	 	7558-79-4
	 	S
	 	 	1	 	 	kg
	 	 	365	 	 	 	2.20	 	 	M
	 	I
	 	 	1	 
	COR

	 	Spermidine
	 	 	 	124-20-9
	 	S
	 	 	200	 	 	g
	 	 	365	 	 	 	0.44	 	 	M
	 	D
	 	 	1	 
	COR

	 	Trichloroacetic Acid
	 	 	 	76-03-9
	 	S
	 	 	1	 	 	kg
	 	 	365	 	 	 	2.20	 	 	M
	 	I
	 	 	1	 
	 	 	 	 	 	 	 	 	Total Corrosive
Solids	=	 	 	11.45	 	 	Ibs.	 	 	 	 	 	 
	FLAM

	 	Diethyl ether
	 	IA
	 	60-29-7
	 	L
	 	 	208	 	 	L
	 	 	365	 	 	 	20.00	 	 	M
	 	F
	 	 	55	 
	 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	Total 1 A Flammable
Liquids	=	 	 	20.00	 	 	M	 	F	 	 	55	 
	FLAM

	 	1,4 Dioxane
	 	IB
	 	123-91-1
	 	L
	 	 	208	 	 	L
	 	 	365	 	 	 	53.70	 	 	M
	 	F
	 	 	55	 
	FLAM

	 	2-propanol (a.k.a.
isopropanol)
	 	IB
	 	67-63-0
	 	L
	 	 	208	 	 	L
	 	 	365	 	 	 	53.7	 	 	M
	 	F
	 	 	2	 
	FLAM

	 	Acetone
	 	IB
	 	67-64-1
	 	L
	 	 	208	 	 	L
	 	 	365	 	 	 	53.7	 	 	M
	 	F
	 	 	5	 
	FLAM

	 	Acetonitrile
	 	IB
	 	75-05-8
	 	L
	 	 	208	 	 	L
	 	 	365	 	 	 	53.7	 	 	M
	 	F
	 	 	8	 
	FLAM

	 	Ethanol
	 	IB
	 	64-17-5
	 	L
	 	 	208	 	 	L
	 	 	365	 	 	 	53.7	 	 	M
	 	F
	 	 	20	 
	FLAM

	 	Ethyl Acetate
	 	IB
	 	141-78-6
	 	L
	 	 	208	 	 	L
	 	 	365	 	 	 	53.7	 	 	M
	 	F
	 	 	55	 
	FLAM

	 	Hexanes
	 	IB
	 	—
	 	L
	 	 	208	 	 	L
	 	 	365	 	 	 	53.7	 	 	M
	 	F
	 	 	55	 
	FLAM

	 	Iso-Amyl Alcohol
	 	IB
	 	71-41-0
	 	L
	 	 	500	 	 	ml
	 	 	365	 	 	 	0.13	 	 	M
	 	F
	 	 	1	 
	FLAM

	 	Methanol
	 	IB
	 	67-56-1
	 	L
	 	 	208	 	 	L
	 	 	365	 	 	 	53.7	 	 	M
	 	F
	 	 	55	 
	FLAM

	 	Tetrahydrofuran
	 	IB
	 	109-99-9
	 	L
	 	 	208	 	 	L
	 	 	365	 	 	 	53.7	 	 	M
	 	F
	 	 	55	 
	FLAM

	 	Triethylamine	 	IB
	 	121-44-8
	 	L
	 	 	500	 	 	ml
	 	 	365	 	 	 	0.13	 	 	M
	 	F
	 	 	1	 
	FLAM

	 	Waste Flammable Liquid (n.o.s)
	 	IB
	 	N/A
	 	L
	 	 	110	 	 	gal
	 	 	365	 	 	 	110	 	 	M
	 	F
	 	 	3300	 
	 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	Total IB Flammable
Liquids	=	 	 	539.7	 	 	gals	 	 	 	 	 	 
	FLAM

	 	1 -Butanol
	 	IC
	 	71-36-3
	 	L
	 	 	500	 	 	ml
	 	 	365	 	 	 	0.13	 	 	M
	 	F
	 	 	4	 
	FLAM

	 	2-Mercaptoethanol
	 	IC
	 	60-24-2
	 	L
	 	 	250	 	 	ml
	 	 	365	 	 	 	0.06	 	 	M
	 	I
	 	 	0.5	 
	 	 	 	 	 	 	 	 	Total IC Flammable	 	 	 	0.19
	 	 	gals	 	 	 	 	 	 

18

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Annual
	 	 	 	 	UFC Fl.	 	 	 	 	 	Qty. on	 	 	 	Days	 	 	 	 	 	 	 	 	 	Waste
	 	 	 	 	Liq.	 	C.A.S	 	Physical	 	Hand (Max.	 	 	 	on	 	Qty. on Hand	 	 	 	SARA	 	Throughput
	Hazard Class	 	Common/ Trade Name	 	Class	 	Number	 	State	 	Avg.)	 	Units	 	Site	 	(Liquids=gals)(Solids=lbs.)	 	Storage Type	 	Class	 	(gals)
	POISON

	 	Dithiothreitol
	 	 	 	3483-12-3
	 	S
	 	 	1	 	 	kg
	 	 	365	 	 	 	0.05	 	 	M
	 	I
	 	 	1	 
	POISON

	 	Ethidium bromide
	 	 	 	1239-45-8
	 	S
	 	 	5	 	 	g
	 	 	365	 	 	 	0.01	 	 	M
	 	D
	 	 	1	 
	POISON

	 	Ferric Chloride
	 	 	 	7705-08-0
	 	S
	 	 	250	 	 	g
	 	 	365	 	 	 	0.55	 	 	M
	 	D
	 	 	1	 
	POISON

	 	Kanamycin
	 	 	 	25389-94-0
	 	S
	 	 	5	 	 	g
	 	 	365	 	 	 	0.01	 	 	M
	 	D
	 	 	1	 
	POISON

	 	Magnesium Sulfate
	 	 	 	231-298-2
	 	S
	 	 	1000	 	 	g
	 	 	365	 	 	 	2.20	 	 	M
	 	D
	 	 	1	 
	POISON

	 	Nickel Sulfate
	 	 	 	10101-97-0
	 	S
	 	 	100	 	 	g
	 	 	365	 	 	 	0.22	 	 	M
	 	D
	 	 	1	 
	POISON

	 	Phenylmethylsulfonyl-Fluoride
	 	 	 	329-98-6
	 	S
	 	 	5	 	 	g
	 	 	365	 	 	 	0.01	 	 	M
	 	I
	 	 	1	 
	POISON

	 	Rifampicin
	 	 	 	13292-46-1
	 	S
	 	 	100	 	 	mg
	 	 	365	 	 	 	0.00022	 	 	M
	 	D
	 	 	1	 
	POISON

	 	SDS
	 	 	 	151-21-3
	 	S
	 	 	500	 	 	g
	 	 	365	 	 	 	1.10	 	 	M
	 	D
	 	 	1	 
	POISON

	 	Sodium acetate
	 	 	 	127-09-3
	 	S
	 	 	500	 	 	g
	 	 	365	 	 	 	1.10	 	 	M
	 	D
	 	 	1	 
	POISON

	 	Sodium Azide
	 	 	 	26628-22-8
	 	S
	 	 	100	 	 	g
	 	 	365	 	 	 	0.22	 	 	M
	 	I
	 	 	1	 
	POISON

	 	Urea
	 	 	 	57-13-6
	 	S
	 	 	3	 	 	kg
	 	 	365	 	 	 	0.16	 	 	M
	 	I
	 	 	1	 
	POISON

	 	Xylene Cyanole FF
	 	 	 	2650-17-1
	 	S
	 	 	25	 	 	g
	 	 	365	 	 	 	0.06	 	 	M
	 	I
	 	 	1	 
	POISON

	 	Zinc Sulfate
	 	 	 	7446-20-0
	 	S
	 	 	1	 	 	kg
	 	 	365	 	 	 	0.05	 	 	M
	 	I
	 	 	1	 
	 	 	 	 	 	 	 	 	 	 	Total
Poisonous Solids	=	 	 	14.08	 	 	Ibs.	 	 	 	 	 	 
	RAD

	 	Radioactive Isotope C14
	 	 	 	N/A
	 	L
	 	 	1	 	 	mCi
	 	 	365	 	 	 	N/A	 	 	M
	 	D
	 	 	0	 
	RAD

	 	Radioactive Isotope H3
	 	 	 	N/A
	 	L
	 	 	1	 	 	mCi
	 	 	365	 	 	 	N/A	 	 	M
	 	D
	 	 	0	 
	RAD

	 	Radioactive Isotope P32
	 	 	 	N/A
	 	L
	 	 	1	 	 	mCi
	 	 	365	 	 	 	N/A	 	 	M
	 	D
	 	 	0	 
	RAD

	 	Radioactive Isotope S35
	 	 	 	N/A
	 	L
	 	 	1	 	 	mCi
	 	 	365	 	 	 	N/A	 	 	M
	 	D
	 	 	0	 
	 
	Other

	 	Hazardous Wastes Solid (n.o.s.)
	 	 	 	N/A
	 	S
	 	 	110	 	 	gal
	 	 	365	 	 	 	110	 	 	M
	 	 	 	 	660	 
	 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 

19

 

Replidyne, Inc. 

Active List of Reagents 

August, 2005

	 	 	 
	Reagent Name	 	Amount*
	M-Anisidine

	 	Research Quantity
	m-Dichlorobenzene

	 	Research Quantity
	Melphalan

	 	Research Quantity
	Mercury

	 	Research Quantity
	Mercury, (acetato-O)phenyl

	 	Research Quantity
	Methacrylic Acid

	 	Research Quantity
	Methacrylonitrile

	 	Research Quantity
	Methanamine, N-methyl-

	 	Research Quantity
	Methane, bromo-

	 	Research Quantity
	Methane, chloro-

	 	Research Quantity
	Methane, chloromethoxy-

	 	Research Quantity
	Methane, dibromo-

	 	Research Quantity
	Methane, dichloro-

	 	Research Quantity
	Methane, dichlorodifluoro-

	 	Research Quantity
	Methane, iodo-

	 	Research Quantity
	Methane, oxybis[chloro-

	 	Research Quantity
	Methane, tetrachloro-

	 	Research Quantity
	Methane, tetranitro-

	 	Research Quantity
	Methane, tribromo-

	 	Research Quantity
	Methane, trichloro-

	 	Research Quantity
	Methane, trichlorofluoro-

	 	Research Quantity
	Methanesulfonic acid, ethyl ester

	 	Research Quantity
	Methanethiol

	 	Research Quantity
	Methanethiol, trichloro-

	 	Research Quantity
	Methanol

	 	Research Quantity
	Methapyrilene

	 	Research Quantity
	Methoxycarbonylsulfenyl Chloride

	 	Research Quantity
	Methoxychlor

	 	Research Quantity
	Methyl 2-Acetamido-5-Bromobenzoate

	 	Research Quantity
	Methyl 2-Amino-4,5-Dimethoxybenzoate

	 	Research Quantity
	Methyl 2-Amino-4-Chlorobenzoate

	 	Research Quantity
	Methyl 2-Amino-5-lodobenzoate

	 	Research Quantity
	Methyl 2-Aminothiophene-3-Carboxylate

	 	Research Quantity
	Methyl 2-Bromopropionate

	 	Research Quantity
	Methyl 3,3-Dimethylacrylate

	 	Research Quantity
	Methyl 3-Aminothiophene-2-Carboxylate

	 	Research Quantity
	Methyl 4,5-Dibromo-3-Hydroxythiophene-2-Carboxylate

	 	Research Quantity
	Methyl 4-Aminobenzoate

	 	Research Quantity
	Methyl 4-Chloroacetoacetate

	 	Research Quantity
	Methyl 4-Fluorobenzoylacetate

	 	Research Quantity
	Methyl alcohol

	 	Research Quantity
	Methyl Anthranilate

	 	Research Quantity
	Methyl bromide

	 	Research Quantity
	Methyl Bromoacetate

	 	Research Quantity

Page 20

 

Replidyne, Inc.

Active
List of Reagents

August,
2005

	 	 	 
	Reagent Name	 	Amount*
	Methyl chloride

	 	Research Quantity
	Methyl chlorocarbonate

	 	Research Quantity
	Methyl Chlorodifluoroacetate

	 	Research Quantity
	Methyl chloroform

	 	Research Quantity
	Methyl Chloroformate

	 	Research Quantity
	Methyl Diphenyl Phosphine Oxide

	 	Research Quantity
	Methyl ethyl ketone

	 	Research Quantity
	Methyl ethyl ketone peroxide

	 	Research Quantity
	Methyl hydrazine

	 	Research Quantity
	Methyl Iodide

	 	Research Quantity
	Methyl isobutyl ketone

	 	Research Quantity
	Methyl isocyanate

	 	Research Quantity
	Methyl isothiocyanate

	 	Research Quantity
	Methyl methacrylate

	 	Research Quantity
	Methyl Nicotinoylacetate

	 	Research Quantity
	Methyl parathlon

	 	Research Quantity
	Methyl Tetrahydro-3-Thiophenone-4-Carboxylate

	 	Research Quantity
	Methyl-(1-Methyl-1h-Imidazoi-2-Ylmethyl)-Amine

	 	Research Quantity
	Methylene bromide

	 	Research Quantity
	Methylene chloride

	 	Research Quantity
	Methyllithium

	 	Research Quantity
	Methylthiouracil

	 	Research Quantity
	Methyltriphenylphosphonium Bromide

	 	Research Quantity
	Mitomycin C

	 	Research Quantity
	Molybdenum Hexacarbonyl

	 	Research Quantity
	Monomethyl Phthalate

	 	Research Quantity
	Mono-Methyl Succinate

	 	Research Quantity
	Mp-Tmt

	 	Research Quantity
	Myristic Acid

	 	Research Quantity
	N-(2-Hydroxyethyl)Morpholine

	 	Research Quantity
	N-(2-Hydroxyethyl)Piperidine

	 	Research Quantity
	N-(2-Methoxyethyl)Methylamine

	 	Research Quantity
	N-(2-Methoxyethyl)Urea

	 	Research Quantity
	N-(3-Aminopropyl)Morpholine

	 	Research Quantity
	N-(3-Methoxypropyl)Urea

	 	Research Quantity
	N,N’-Diethylhydrazine

	 	Research Quantity
	N,N-Diisopropylcarbodiimide

	 	Research Quantity
	N,N-Dimethylaniline

	 	Research Quantity
	N,N-Dimethylformamide Dimethyl Acetal

	 	Research Quantity
	Nafion(R), Trimethylsilylated

	 	Research Quantity
	Naphthalenamine, N,N’-bis(2-chloroethyl)-

	 	Research Quantity
	Naphthalene

	 	Research Quantity
	Naphthalene, 2-chloro-

	 	Research Quantity
	N-Bromosuccinimide

	 	Research Quantity

Page 21

 

Replidyne, Inc.

Active
List of Reagents 
August,
2005

	 	 	 
	Reagent Name	 	Amount*
	n-Butyl alcohol

	 	Research Quantity
	N-Butyllithium

	 	Research Quantity
	N-Cbz-S-Phenyl-L-Cysteine

	 	Research Quantity
	N-Hexylacetoacetic Acid Ethyl Ester

	 	Research Quantity
	Nicotine, & salts

	 	Research Quantity
	Ninhydrin

	 	Research Quantity
	Nipecotic Acid

	 	Research Quantity
	Nitric acid, thallium(1+) salt

	 	Research Quantity
	Nitrobenzene

	 	Research Quantity
	N-Methylisatoic Anhydride

	 	Research Quantity
	N-Methylmorpholine

	 	Research Quantity
	N-Methyl-N-Nitroso-P-Toluenesulfonamide

	 	Research Quantity
	N-Methylthiourea

	 	Research Quantity
	N-Nitrosodiethanolamine

	 	Research Quantity
	N-Nitrosodiethylamine

	 	Research Quantity
	N-Nitrosodi-n-butylamine

	 	Research Quantity
	N-Nitroso-N-ethylurea

	 	Research Quantity
	N-Nitroso-N-methylurea

	 	Research Quantity
	N-Nitroso-N-methylurethane

	 	Research Quantity
	N-Nitrosopiperidine

	 	Research Quantity
	N-Nitrosopyrrolidine

	 	Research Quantity
	N-Prop-2-Ynylurea

	 	Research Quantity
	n-Propylamine

	 	Research Quantity
	O,O-Diethyl O-pyrazinyl phosphorothioate

	 	Research Quantity
	O,O-Diethyl S-methyl dithiophosphate

	 	Research Quantity
	o-Chlorophenol

	 	Research Quantity
	o-Dichlorobenzene

	 	Research Quantity
	O-Phthalaldehyde

	 	Research Quantity
	Osmium oxide OsO4, (T-4)-

	 	Research Quantity
	Osmium tetroxide

	 	Research Quantity
	o-Toluidine

	 	Research Quantity
	o-Toluidine hydrochloride

	 	Research Quantity
	Oxirane

	 	Research Quantity
	Oxirane, (chloromethyl)-

	 	Research Quantity
	Oxiranecarboxyaldehyde

	 	Research Quantity
	Palladium

	 	Research Quantity
	Palladium On Carbon %

	 	Research Quantity
	P-Anisaldehyde

	 	Research Quantity
	P-Anisidine

	 	Research Quantity
	Paraformaldehyde

	 	Research Quantity
	Paraldehyde

	 	Research Quantity
	p-Benzoquinone

	 	Research Quantity
	p-Chloroaniline

	 	Research Quantity
	p-Chloro-m-cresol

	 	Research Quantity

Page 22

 

Replidyne, Inc.

Active
List of Reagents
 August,
2005

	 	 	 
	Reagent Name	 	Amount*
	p-Dichlorobenzene

	 	Research Quantity
	p-Dimethylaminoazobenzene

	 	Research Quantity
	Pentachlorobenzene

	 	Research Quantity
	Pentachloroethane

	 	Research Quantity
	Pentachloronitrobenzene

	 	Research Quantity
	Pentachlorophenol

	 	Research Quantity
	Pentanol, 4-methyl-

	 	Research Quantity
	Periodic Acid

	 	Research Quantity
	Phenacetin

	 	Research Quantity
	Phenol

	 	Research Quantity
	Phenol, 2-(1-methylethoxy)-,methylcarbamate

	 	Research Quantity
	Phenol, 2,2’-methylenebis[3,4,6-trichloro-

	 	Research Quantity
	Phenol, 2,3,4,6-tetrachloro-

	 	Research Quantity
	Phenol, 2,4,5-trichloro-

	 	Research Quantity
	Phenol, 2,4,6-trichloro-

	 	Research Quantity
	Phenol, 2,4-dichloro-

	 	Research Quantity
	Phenol, 2,4-dimethyl-

	 	Research Quantity
	Phenol, 2,4-dinitro

	 	Research Quantity
	Phenol, 2,6-dichloro-

	 	Research Quantity
	Phenol, 2-chloro-

	 	Research Quantity
	Phenol, 4,4’-(1,2-diethyl-1,2-ethenedlyl)bis-, (E)-

	 	Research Quantity
	Phenol, 4-chloro-3-methyl-

	 	Research Quantity
	Phenol, 4-nitro-

	 	Research Quantity
	Phenol, methyl-

	 	Research Quantity
	Phenol, pentachloro-

	 	Research Quantity
	Phenylacetaldehyde

	 	Research Quantity
	Phenylacetic Acid

	 	Research Quantity
	Phenylacetylene

	 	Research Quantity
	Phenylguanidine Carbonate

	 	Research Quantity
	Phenylurea

	 	Research Quantity
	Phosphoric acid, diethyl 4-nitrophenyl ester

	 	Research Quantity
	Phosphoric acid, lead(2+) salt (2:3)

	 	Research Quantity
	Phosphorodithioic
acid, O,O-diethyl S-methyl ester

	 	Research Quantity
	Phosphorus Pentachloride

	 	Research Quantity
	Phosphorus sulfide

	 	Research Quantity
	Phosphorus Tribromide

	 	Research Quantity
	Phosphorus Trichloride

	 	Research Quantity
	Phthalic anhydride

	 	Research Quantity
	Physostigmine, salicylate

	 	Research Quantity
	Piperazine-2-Carboxylic Acid Dihydrochloride

	 	Research Quantity
	Piperidine

	 	Research Quantity
	Piperidine, 1-nitroso-

	 	Research Quantity
	p-Nitroaniline

	 	Research Quantity
	p-Nitrophenol

	 	Research Quantity

Page 23

 

Replidyne, Inc. 
Active
List of Reagents 
August,
2005

	 	 	 
	Reagent Name	 	Amount*
	Poly(Ethylene Glycol) Mn(400)

	 	Research Quantity
	Potassium Cyanate

	 	Research Quantity
	Potassium Hydroxide

	 	Research Quantity
	Potassium Iodide

	 	Research Quantity
	Potassium Nitrosodisulfonate

	 	Research Quantity
	Potassium Permanganate

	 	Research Quantity
	Potassium Sodium Tarirate Tetrahydrate

	 	Research Quantity
	Potassium Tert-Butoxide 1.0m In Thf

	 	Research Quantity
	Potassium Thiocyanate

	 	Research Quantity
	P-Phenetidine

	 	Research Quantity
	Pronamide

	 	Research Quantity
	Propane, 1,2-dibromo-3-chloro-

	 	Research Quantity
	Propane, 1,2-dichloro-

	 	Research Quantity
	Propane, 2,2’-oxybis[2-chloro-

	 	Research Quantity
	Propane, 2-nitro-

	 	Research Quantity
	Propanedinitrile

	 	Research Quantity
	Propanoic acid, 2-(2,4,5-trichlorophenoxy)-

	 	Research Quantity
	Propargyl Alcohol Tetrahydro-2h-Pyran Ether

	 	Research Quantity
	Propham

	 	Research Quantity
	Propionitrile

	 	Research Quantity
	Propionyl Chloride

	 	Research Quantity
	Propoxur

	 	Research Quantity
	Propranolol Hydrochloride

	 	Research Quantity
	Propylene dichloride

	 	Research Quantity
	Propyne

	 	Research Quantity
	Prosulfocarb

	 	Research Quantity
	Ps-Benzaldehyde

	 	Research Quantity
	P-Toluenesulfonic Acid Monohydrate

	 	Research Quantity
	p-Toluidine

	 	Research Quantity
	Pyrazinamide

	 	Research Quantity
	Pyridine

	 	Research Quantity
	Pyridine, 2-methyl-

	 	Research Quantity
	Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)-, & salts

	 	Research Quantity
	Pyridinium Chlorochromate

	 	Research Quantity
	Pyridinium P-Toluenesulfonate

	 	Research Quantity
	Pyrrole-2-Carboxaldehyde

	 	Research Quantity
	Pyrrolidine

	 	Research Quantity
	Pyrrolidine, 1-nitroso-

	 	Research Quantity
	Quinoline

	 	Research Quantity
	Rarechem Ah Bs 0111

	 	Research Quantity
	Reserpine

	 	Research Quantity
	Resorcinol

	 	Research Quantity
	Rhodanine

	 	Research Quantity
	Saccharin, & salts

	 	Research Quantity

Page 24

 

Replidyne, Inc. 
Active
List of Reagents 
August,
2005

	 	 	 
	Reagent Name	 	Amount*
	Safrole

	 	Research Quantity
	Salicylaldehyde

	 	Research Quantity
	Salicylic Acid

	 	Research Quantity
	Scandium
(iii) Trifluoromethanesulfonate

	 	Research Quantity
	Sec-Butyllithium

	 	Research Quantity
	Selenious acid

	 	Research Quantity
	Selenium dioxide

	 	Research Quantity
	Selenium sulfide

	 	Research Quantity
	Selenourea

	 	Research Quantity
	Silvex (2,4,5-TP)

	 	Research Quantity
	Sodium

	 	Research Quantity
	Sodium Acetate Trihydrate

	 	Research Quantity
	Sodium Dicyanamide

	 	Research Quantity
	Sodium Ethoxide

	 	Research Quantity
	Sodium Hydride 60% In Mineral Oil

	 	Research Quantity
	Sodium Hypophosphite

	 	Research Quantity
	Sodium Iodide

	 	Research Quantity
	Sodium Methoxide

	 	Research Quantity
	Sodium Nitrite

	 	Research Quantity
	Sodium Periodate

	 	Research Quantity
	Sodium Tert-Butoxide

	 	Research Quantity
	Stannous Chloride

	 	Research Quantity
	Streptozotocin

	 	Research Quantity
	S-Trioxane

	 	Research Quantity
	Succinic Anhydride

	 	Research Quantity
	Sulfur phosphide

	 	Research Quantity
	Sulfuric acid, dimethyl ester

	 	Research Quantity
	Sulfuryl Chloride

	 	Research Quantity
	Taurine

	 	Research Quantity
	Tert-Butyl 2,2,2-Trichloroacetimidate

	 	Research Quantity
	Tert-Butyl Acetoacetate

	 	Research Quantity
	Tert-Butyl Bromoacetate

	 	Research Quantity
	Tert-Butyl Glycidyl Ether

	 	Research Quantity
	Tert-Butyl Isocyanate

	 	Research Quantity
	Tert-Butyl N-(2-Oxoethyl)Carbamate

	 	Research Quantity
	Tert-Butylacetyl Chloride

	 	Research Quantity
	Tert-Butylamine

	 	Research Quantity
	Tert-Butyldimethylchlorosilane

	 	Research Quantity
	Tetrabutylammonium Bromide

	 	Research Quantity
	Tetrabutylammonium Chloride

	 	Research Quantity
	Tetrabutylammonium Iodide

	 	Research Quantity
	Tetrachloroethylene

	 	Research Quantity
	Tetraethoxysilane

	 	Research Quantity
	Tetrahydrofuran

	 	Research Quantity

Page 25

 

Replidyne, Inc.

Active
List of Reagents 
August,
2005

	 	 	 
	Reagent Name	 	Amount*
	Tetrapropylammonium Perruthenate

	 	Research Quantity
	Thallium chloride TICI

	 	Research Quantity
	Thalllum(l) acetate

	 	Research Quantity
	Thallium(l) carbonate

	 	Research Quantity
	Thallium(l) chloride

	 	Research Quantity
	Thallium(l) nitrate

	 	Research Quantity
	Thioacetamide

	 	Research Quantity
	Thiodicarb

	 	Research Quantity
	Thiomethanol

	 	Research Quantity
	Thioperoxydicarbonic diamide [(H2N)C(S)]2S2, tetramethyl-

	 	Research Quantity
	Thiophanate-methyl

	 	Research Quantity
	Thiophene-2-Boronic Acid

	 	Research Quantity
	Thiophene-3-Boronic Acid

	 	Research Quantity
	Thiophosgene

	 	Research Quantity
	Thiourea

	 	Research, Quantity
	Thiram

	 	Research Quantity
	Tin

	 	Research Quantity
	Titanium Dioxide

	 	Research Quantity
	Titanium Ethoxide

	 	Research Quantity
	Toluene

	 	Research Quantity
	Toluene diisocyanate

	 	Research Quantity
	Toluenediamine

	 	Research Quantity
	Triallate

	 	Research Quantity
	Tribromoacetaldehyde

	 	Research Quantity
	Trichloroethylene

	 	Research Quantity
	Trichloromonofluoromethane

	 	Research Quantity
	Trichlorosilane

	 	Research Quantity
	Triethanolamine

	 	Research Quantity
	Triethylamine

	 	Research Quantity
	Trielhylamine Trihydrofluoride

	 	Research Quantity
	Triethylammonium Acetate

	 	Research Quantity
	Triethylchlorosilane

	 	Research Quantity
	Triethylenediamine

	 	Research Quantity
	Trifluoroacetic Anhydride

	 	Research Quantity
	Trifluoromethanesulfonic Acid

	 	Research Quantity
	Triisopropyl Borate

	 	Research Quantity
	Trimethyl Borate

	 	Research Quantity
	Trimethyl Orthoacetate

	 	Research Quantity
	Trimethyl Orthoformate

	 	Research Quantity
	Trimethyl(Phenyl)Tin

	 	Research Quantity
	Trimethylaluminum

	 	Research Quantity
	Trimethylamine N-Oxide Dihydrate

	 	Research Quantity
	Trimethylchlorosilane

	 	Research Quantity
	Trimethylsilyl Polyphosphate

	 	Research Quantity

Page 26

 

Replidyne, Inc.
 Active
List of Reagents 
August,
2005

	 	 	 
	Reagent Name	 	Amount*
	Trimethylsilyl Trifluoromethanesulfonate

	 	Research Quantity
	Trimethylsilyldiazomethane

	 	Research Quantity
	Tri-N-Butyltin Chloride

	 	Research Quantity
	Triphenylphosphine Resin

	 	Research Quantity
	Triphosgene

	 	Research Quantity
	Tris(2,3-dibromopropyl) phosphate

	 	Research Quantity
	Tri-Tert-Butylphosphine

	 	Research Quantity
	Trypan blue

	 	Research Quantity
	Uracil mustard

	 	Research Quantity
	Urea, N-ethyl-N-nitroso-

	 	Research Quantity
	Urea, N-methyl-N-nitroso-

	 	Research Quantity
	Vinyl chloride

	 	Research Quantity
	Warfarin

	 	Research Quantity
	Warfarin, & salts

	 	Research Quantity
	Xylene (l)

	 	Research Quantity
	Zinc phosphide Zn3P2

	 	Research Quantity

 

	
	*
	 
	
 Research Quantity generally means < 500 g for solids and < 10 L for
liquids. Listed amounts represent quantities intended for actual use or storage
on the Premises. The maximum quantity of each reagent in use or in storage at
the Premises at any given time, is approximately four times the listed amount.
The maximum annual quantity of each reagent used and stored on the Premises is
approximately ten times the listed amount. This list is not meant to be
exhaustive.

Page 27

 

Replidyne, Inc.

Active List of Solvents

August, 2005

	 	 	 
	Solvent Name	 	Amount*
	Acetone
	 	55 gal
	Methanol
	 	55 gal
	Ethanol
	 	55 gal
	Isopropanol
	 	55 gal
	Acetonitrile
	 	55 gal
	Dichloromethane
	 	55 gal
	Chloroform
	 	55 gal
	Ethyl Acetate
	 	55 gal
	Hexanes
	 	55 gal
	Diethyl Ether
	 	55 gal
	Tetrahydrofuran
	 	55 gal
	1,4-Dioxane
	 	55 gal

 

			
	*	 	Listed amounts represent quantities intended for actual use or storage on the
Premises. The maximum quantity of each reagent in use or in storage at the Premises at
any given time, is approximately four times the listed amount. The maximum annual
quantity of each reagent used and stored on the Premises is approximately ten times
the listed amount. This list is not meant to be exhaustive.

Page 1

 

Hazardous Substance Management Plan

for

Replidyne, Inc.

Louisville, Colorado

Revised: August 18, 2005

	 	 	 
	 

	 	

 

 

EXHIBIT D

SUBTENANT’S HAZARDOUS SUBSTANCE MANAGEMENT PLAN

 

 

Hazardous Substance Management Plan

For

Replidyne, Inc.

Louisville, Colorado

Revised: August 18, 2005

	 	 	 	 	 	 	 
	Prepared by:
	 	 	 	 	 	 
	 

	 	 

Dean M. Calhoun, CIH
	 	 

Date
	 	 
	 

	 	President and Principal Consultant	 	 	 	 
	 

	 	Affygility Solutions, L.L.C.	 	 	 	 

 

 

Table of Contents

	 	 	 	 	 	 	 
	Owner and Facility Information	 	 	1	 
	 
	 	 	 	 	 	 
	.I

	 	Introduction
	 	 	2	 
	 
	 	 	 	 	 	 
	.II

	 	Facility Description
	 	 	2	 
	 
	 	 	 	 	 	 
	.III

	 	Hazardous Materials Inventory Statements
	 	 	2	 
	 
	 	 	 	 	 	 
	.IV

	 	Separation and Monitoring
	 	 	2	 
	 
	 	 	 	 	 	 
	 

	 	General Storage and Safe Work Practices 
	 	 	2	 
	 

	 	Inspection Procedures 
	 	 	3	 
	 
	 	 	 	 	 	 
	.V

	 	Waste Disposal
	 	 	3	 
	 
	 	 	 	 	 	 
	 

	 	BIOHAZARDOUS WASTE
	 	 	3	 
	 

	 	Hazardous Wastes Generator Status 
	 	 	3	 
	 

	 	Collection and Disposal of Liquid Hazardous Wastes 
	 	 	3	 
	 

	 	Collection and Disposal of Solid Hazardous Wastes 
	 	 	4	 
	 

	 	Shipment, Transportation, and Disposal of Hazardous Wastes 
	 	 	4	 
	 

	 	Collection and Disposal of Radioactive Wastes 
	 	 	4	 
	 

	 	          Discharges to the POTW
	 	 	4	 
	 

	 	          Disposal of Scintillation Vials and Dry Wastes
	 	 	4	 
	 

	 	          Records of Radioactive Wastes Disposal
	 	 	4	 
	 

	 	Collection, Storage, and Disposal of Biohazardous Wastes 
	 	 	5	 
	 
	 	 	 	 	 	 
	.VI

	 	Rccordkeeping
	 	 	5	 
	 
	 	 	 	 	 	 
	.VII

	 	y Response PlanEmcrgenc
	 	 	5	 
	 
	 	 	 	 	 	 
	.VIII

	 	Emergency Response Training Plan
	 	 	6	 
	 
	 	 	 	 	 	 
	.IX

	 	Site Closure
	 	 	6	 
	 
	 	 	 	 	 	 
	Appendixes	 	 	7	 
	 
	 	 	 	 	 	 
	 

	 	Appendix l — Definitions and Acronyms 
	 	 	8	 
	 

	 	Appendix
2 — Emergency Exits 
	 	 	9	 
	 

	 	Appendix
3 — Forms 
	 	 	10	 
	 

	 	          Laboratory EH&S Assessment Checklist
	 	 	11	 
	 

	 	          Hazardous Wastes Inspection Log
	 	 	13	 
	 

	 	          Employee Training Record
	 	 	14	 
	 

	 	          New Employee Orientation Checklist
	 	 	15	 
	 

	 	Appendix 4 — Site Closure Issues to Consider 
	 	 	16	 
	 

	 	Appendix
5 — Hazardous Materials Inventory Statements 
	 	 	17	 

ii

 

Owner and Facility Information

Ownership Information

	 	 	 	 	 	 	 
	Business Name:

	 	Replidyne, Inc.
	 	Phone:
	 	303-996-0000
	Address:	 	1450 Infinite Drive, Louisville, Colorado 80027	 	 
	 
	 	 	 	 	 	 
	Person responsible for the Business:	 	 	 	 
	Name/Title:

	 	Nebojsa Janjic/ VP of R&D
	 	Phone:
	 	303-996-5502

Emergency Contacts

	 	 	 	 	 	 	 	 	 	 	 
	Primary:

	 	Chris Ewing
	 	Wk. Phone:
	 	303-996-5530
	 	Cell Phone:
	 	720-938-6272
	1st Alternate:

	 	Joe Guiles
	 	Wk. Phone:
	 	303-996-5549
	 	Cell Phone:
	 	303-817-7553

Operational Information

	 	 	 	 	 	 	 
	Principal Business Activity:	 	Biotechnology Research and Development	 	 
	 
	Number
of Employees:           ~ 50

	 	 	 	Primary Hrs. of Operation :
	 	8:00 AM to 6:00 PM M-F
	SIC Code:                      8731

	 	 	 	Dun and Bradstreet Number:
	 	Currently applied for.

Declaration

I certify that the information above and on the following parts is true and correct to the best of my
knowledge.

	 	 	 	 	 	 	 	 	 
	Signature:

	 	 	 	 	 	Date:	 	 
	 

	 	 

	 	 
	 	 	 	 
 
	 
	 	 	 	 	 	 	 	 
	Print Name:

	 	 	 	 	 	Title:	 	 
	 

	 	 

(must be signed by owner/operator or designated representative)
	 	 
	 	 	 	 
 

 1

 

 

I. Introduction

This plan was developed to satisfy requirements for storage and handling of hazardous substances
and materials specified by the following regulation:

	•	 	Uniform Fire Code, 1991 Edition, Article 80, Sections 80.103 (b) and (c), and Appendix II-E.

In addition, the following references were consulted in the development of this plan:

	•	 	State of Colorado, Colorado Code of Regulations, 6 CCR 1007-1, Pan 4 Standards for the Protection against Radiation
	 
	•	 	State of Colorado, Colorado Code of Regulations, 6 CCR 1007-3, Hazardous Wastes
	 
	•	 	Colorado Department of Public Health and Environment
(April, 1998), Hazardous Waste Guidance — Personnel Training & Emergency Response/Preparedness and Prevention for Small Quantity Generators.

II. Facility Description

The Replidyne facility is located at 1450 Infinite Drive, Louisville, Colorado, 80027. The
facility is approximately 30,000 square feet consisting of support space, office space, and
laboratories. Replidyne’s primary business activities consist of research and development
bench-scale activities for the purpose of screening research materials for potential lead drug
compounds. Materials used include a variety of organic solvents, proteins, salts, and other
reagents in small containers.

III Hazardous Materials Inventory Statements

An inventory of all wastes and non-waste hazardous materials sorted alphabetically and by
hazard class is included in Appendix 5 of this plan.

IV. Separation and Monitoring

General Storage and Safe Work Practices

The following safe work practices will be followed for the storage of hazardous substances:

	•	 	Appropriate personal protective equipment will be worn when handling or using
hazardous materials.

	•	 	All laboratory personnel will be trained in safe work practices.

	•	 	Portable fire extinguishers will be available throughout the facility.

	•	 	Flammable liquids will be stored in approved flammable liquid storage cabinets
located
under laboratory hoods.

	•	 	Reagent bottles will not be stored on the floor.

	•	 	Incompatible materials will be stored separately.

	•	 	Hazardous wastes will be stored in labeled and approved containers.

 2

 

 

Inspection Procedures

All laboratory areas will be visually inspected on a quarterly basis. As part of the inspection
process, the proper storage of hazardous substances and materials will be verified. All inspections
will be documented on the “Laboratory Assessment” form contained in Appendix 3 of this plan. Any
observed deficiencies in storage practices will be corrected in a timely manner.

Areas used for the storage of hazardous wastes will be inspected on a weekly basis. Inspections
will be documented on the “Hazardous Waste Accumulation Inspection Log” contained in Appendix 3 of
this plan.

V. Waste Disposal

The following procedures shall apply regarding the collection, storage and disposal of hazardous,
biohazardous, and radioactive wastes at the Replidyne facilities.

Biohazardous Wastes

All biohazardous wastes will be collected in approved containers provided by the vendor. Sharps
containers will be labeled as Biohazardous Waste. Sharps will be collected in approved biohazardous
containers. On a biweekly basis the biohazard waste will be picked up by an approved vendor and
transported to an off-site location for proper disposal.

Hazardous Wastes Generator Status

The generation, storage, and disposal of hazardous waste are governed by the regulations of the
Colorado Department of Public Health and Environment Hazardous contained in 6 CCR 1007-3. It is
anticipated that Replidyne will initially be a Small Quantity Generator (SQG) of regulated
hazardous wastes (greater than 100 kg/month But <1000kg/month) as defined by 6 CCR 1007-3
-260.10.

Collection and Disposal of Liquid Hazardous Wastes

NO CHARACTERISTIC OR LISTED HAZARDOUS WASTES WILL BE DISCHARGED TO SINK DRAINS OR
THE POTW.

Liquid hazardous waste will be collected in approved and labeled containers strategically located
at “satellite accumulation” points throughout the lab. These containers will be in the form of NFPA
approved 5-gallon safety cans. Once these containers are full, laboratory personnel will transfer
the liquid waste into 55 gallon, DOT approved drum(s) located in the hazardous waste and flammable
liquid storage room. These drums will be kept closed except when adding or removing wastes.

 3

 

 

Collection and Disposal of Solid Hazardous Wastes

Solid hazardous wastes consisting of laboratory bench paper, kimwipes, cleanup materials,
contaminated gloves and personal protective equipment, and other debris will be collected in
approved step cans located at satellite accumulation points throughout the facility. Once these
containers are full, the waste will be transferred to DOT approved, open top, fiber drams for
subsequent off-site incineration. These containers will be kept closed except when adding or
removing wastes.

Shipment, Transportation, and Disposal of Hazardous Wastes

Full drums will be periodically transported off-site by a licensed transporter to an approved
treatment, storage, and disposal facility. Hazardous wastes manifests, land disposal restriction
notices, and other records of disposal will be maintained on-site.

Collection and Disposal of Radioactive Wastes

The generation, storage, and disposal of radioactive wastes are governed by the regulations of the
Colorado Department of Public Health and Environment’s Standards for Protection against Radiation
contained in 6 CCR 1007-1.

Discharges to the POTW

Replidyne proposes to dispose less than 5 mCi/month to the Publicly Owned Treatment Works (POTW).
All disposal and recordkeeping will be performed in accordance with the Colorado Department of
Public Health and Environment’s Standards for Protection against Radiation contained in Colorado
Code of Regulations 6 CCR 1007-1, Part 4, RH.35

Disposal of Scintillation Vials and Dry Wastes

Waste scintillation vials and dry waste containing radioactive material will be collected in
labeled and shielded radioactive waste containers strategically located in the laboratory areas.
All containers will be kept closed except when adding or removing wastes. Once full, the material
will be transfer to a 55 gallon drum in the radioactive waste storage room. Radioactive wastes with
half lives less than 120 days will be decayed on-site. Radioactive wastes with half lives greater
than 120 days will be picked up and disposed of by a radioactive waste broker possessing a NRC
licenses (Environmental Management and Controls, RML licenses #3546-50). A permit “To Dispose of
Low-Level Radioactive Waste” at the commercial low-level radioactive waste disposal site at
Richland, Washington will be obtained. Replidyne, Inc. will also register with US Ecology, Inc.
prior to the shipment of radioactive waste.

Records of Radioactive Wastes Disposal

Records of radioactive wastes disposal will be maintained in accordance with 6 CCR 1007-1,
Part 4, RH.4.48

 4

 

 

Collection, Storage, and Disposal of Biohazardous Wastes

Laboratory operations will generate small amounts of material classified as biohazardous
wastes. All biohazardous wastes will be collected in appropriately label containers provided by the
biohazardous wastes vendor. Replidyne contracted with an approved biohazardous waste vendor to
collect full and partially full containers of biohazardous wastes on a biweekly basis. All
biohazardous wastes will be transported by a licensed vendor to a permitted facility for final
treatment and disposal. All containers stored on-site will be covered and securely sealed to
prevent spillage or leakage.

	VI.	 	Recordkeeping

The following records will be maintained on-site:

	•	 	A copy of the Hazardous Substance Management Plan;
	 
	•	 	Regulatory records, including permits, licensees, and inspection reports;
	 
	•	 	Records of biohazardous, hazardous, and radioactive wastes disposal;
	 
	•	 	Accident and incident records;
	 
	•	 	Employee training records;
	 
	•	 	Laboratory inspection records; and
	 
	•	 	Hazardous waste accumulation area inspection logs.
	 
	VII.	 	Emergency Response Plan

In the event of a spill or release of a hazardous substance the following steps will be taken:

WARNING: ODOR IS NOT AN ADEQUATE INDICATOR OF HAZARD. MANY SUBSTANCES HAVE ODOR THRESHOLDS
SIGNIFICANTLY ABOVE HAZARDOUS CONCENTRATIONS.

WARNING: HAZARDOUS MATERIALS SPILLS MUST ONLY BE CLEANED UP BY PROPERLY TRAINED AND EQUIPPED
PERSONAL. FAILURE TO ADHERE TO THIS WARNING CAN CAUSE SERIOUS INJURY OR DEATH.

	1.	 	Isolate the area and deny entry. Ensure that all personnel evacuate the immediate area
of the spill. A facility map depicting the emergency exits are shown in Appendix 2.
Isolation of the area can be performed by closing all laboratory doors, and blocking off
entry with either barricade tape or posting signs labeled “Warning — Do Not Enter.
Hazardous Materials Spill” on all doors to the impacted area.
	 
	2.	 	Establish command until relieved by either security or the Emergency Response Team.
Establish command means using others to isolate the area and contact security.
	 
	3.	 	Contact Security. Contact the security guard(s) at the main entrance, they have the list
of all emergency personnel and will alert appropriate personnel. In addition, the security
guards have access to material safety data sheets for materials that are under the control
of Replidyne.

5

 

	4.	 	From a safe location Await further instruction to be issued by either security or
the Emergency Response Team.
	 
	VIII.	 	Emergency Response Training Plan

All employees will be trained in the procedures and actions to be taken in the event of a
spill or release of a hazardous substance(s).

All laboratory employees will be trained in the following topics:

	•	 	Emergency response procedures;
	 
	•	 	General Safety Rules and Practices;
	 
	•	 	Replidyne’s Chemical Hygiene Plan;
	 
	•	 	Radiation Safety; and
	 
	•	 	Procedures for the proper disposal of biohazardous, hazardous, and radioactive wastes.

All training will be documented and records of such training will be kept on-site.

	IX.	 	Site Closure

Replidyne will submit a plan to the facility owner to terminate storage, dispensing, handling
or use of hazardous materials at least 30 days prior to facility closure. This plan shall
demonstrate that hazardous materials which were stored, dispensed, handled, or used in the facility
have been transported, disposed of or reused in a manner compliant with Federal, State, and local
environmental regulations. Items to be considered in this plan are included in Appendix 3.

6

 

Appendixes

7

 

Appendix 1
— Definitions and Acronyms

	 	 	 
	Acutely hazardous

wastes

	 	An acutely hazardous waste exhibits any of the
characteristics identified in 6 CCR 1007-3, Section 261,
Subpart C and is fatal to humans or animals in low doses or can
cause or contribute to an
increase in serious irreversible, or incapacitating
reversible illness. All P listed wastes are acutely hazardous
wastes.
	 
	 	 
	CCR

	 	Colorado Code of Regulations
	 
	 	 
	CDPHE

	 	Colorado Department of Public Health and Environment
	 
	 	 
	Conditionally Exempt

Small Quantity

Generator

	 	A generator that generates no more than 100 kilograms
(about 220 pounds or 25 gallons) of hazardous wastes and no
more than 1 kilogram (about 2.2 pounds) of acutely hazardous
waste in any calendar month.
	 
	 	 
	DOT

	 	Department of Transportation
	 
	 	 
	Large Quantity

Generator

	 	A generator of hazardous waste that generates 1,000
kilograms (about 2,200 pounds or about 250 gallons) or more of
hazardous waste, or more than one kilogram (about 2.2 pounds)
of acutely hazardous wastes, in any one calendar month, or who
has greater than 6,000 kilograms of non-acutely hazardous waste
on-site at any one time (about thirty 55-gallon drums).
	 
	 	 
	NFPA

	 	National Fire Protection Association
	 
	 	 
	POTW

	 	Publicly Owned Treatment Works.
	 
	 	 
	Small Quantity

Generator

	 	A generator of hazardous waste that generates no more than
1000 kilograms (about 2,200 pounds or about 250 gallons) or
more than one kilogram (about 2.2 pounds) of acutely hazardous
wastes, in any one calendar month, or who has greater than
6,000 kilograms of non-acutely hazardous waste on-site at any
one time (about thirty 55-gallon drums).
	 
	 	 
	TSDF

	 	Treatment, Storage, and Disposal Facility.

8

 

Appendix 2 — Emergency Exits

9

 

Appendix 3 — Forms

10

 

Laboratory EH&S Assessment Checklist

Date:                                                              Assessment Team:                                                                                 

Department: 
                                                                                                                                                                  

Indicate for each item: YES — NO — N/A for not applicable. Each NO must be explained in the
comments section.

GENERAL
SAFETY/MAINTENANCE

	1.	 	First-aid kits are available in the laboratory and well stocked.
	 
	2.	 	Spill kit(s) available in laboratory and well stocked
	 
	3.	 	Sinks are not cluttered with dirty glassware.
	 
	4.	 	Generally good housekeeping (e.g. unobstructed aisles, floors clean and dry)
	 
	5.	 	Appropriate waste receptacles for (non-biohazardous) broken glass provided
	 
	6.	 	All electrical appliances properly grounded (i.e. 3rd prong in place, no adapters)
	 
	7.	 	Electrical wires free from tangling, obstructing aisles, and corroding
	 
	8.	 	All electrical extension cords used for temporary operations only.
	 
	9.	 	Outlet strips are plugged directly into an outlet. No “daisy chaining” of outlet strips.
	 
	10.	 	All exit lights and emergency lighting are in working order.

SAFETY EQUIPMENT

	11.	 	Unobstructed eyewash and safety showers
	 
	12.	 	Eyewash and safety showers flow tested within past month
	 
	13.	 	Safety glasses available at entrance to lab and provided to visitors upon entering
	 
	14.	 	Personal protective equipment available, and in good condition

RADIATION SAFETY

	15.	 	Handheld meters have adequate charge and have been calibrated within past year.
	 
	16.	 	No contamination present in the immediate area.
	 
	17.	 	Waste properly disposed and no evidence of hot material in “public trash” receptacle.
	 
	18.	 	TLD badges being worn.
	 
	19.	 	Proper shielding of radioactive materials utilized.
	 
	20.	 	Freezer door sheets are properly recorded and maintained.
	 
	21.	 	Bench log books/inventory records completed.

FUME HOODS

	22.	 	Hoods are uncluttered; chemicals are not stored in hood.
	 
	23.	 	Long-term storage of chemicals in fume hood is prohibited
	 
	24.	 	Fume hood velocities have been tested as required by site-specific SOP.
	 
	25.	 	Low face velocity alarms are in working condition

11

 

CHEMICAL SAFETY

	26.	 	No more than 10 gallons of flammable liquids are stored outside of safety cans or cabinet.
	 
	27.	 	Flammables stored in flammable side of storage cabinet.
	 
	28.	 	Approved explosion proof refrigerators used for cold storage of flammable liquids
	 
	29.	 	Flammables stored at least 18” away from ignition sources
	 
	30.	 	Flammables not stored with oxidizers and corrosives.
	 
	31.	 	Hazardous materials stored away from exits
	 
	32.	 	Glass containers of flammable and corrosive chemicals (above 6 molar concentration) stored off
of floor AND on shelves below five feet.
	 
	33.	 	All chemicals in original containers properly labeled with chemical name (no abbreviations),
and all hazards.
	 
	34.	 	All chemicals removed from original containers and placed in
reagent bottles or other containers are labeled with chemical name
(no abbreviations or formulas), and all hazards. Color coded
labels to show health, flammability, reactivity, etc. are
appropriate.
	 
	35.	 	Chemicals and food stored/handled separately. No evidence of food waste in lab trash cans.
	 
	36.	 	Incompatibles stored separately.
	 
	37.	 	Light reactives (e.g. hydrogen and chlorine) stored away from light.
	 
	38.	 	Water reactives (e.g. sodium, potassium, lithium) store away from water
	 
	39.	 	Peroxidizable chemicals (e.g. ethers/thf) have dates of receipt
AND opening; Containers was opened OR peroxide strip testing was
performed within six months of the date of inspection.
	 
	40.	 	All refrigerators are labeled “Not for storage of food or drink”.
	 
	41.	 	Excessive amount of round-bottom flasks not stored in refrigerators.
	 
	42.	 	Hazardous waste is properly labeled with the words
“Hazardous Waste”. Container is closed except when adding waste.

GAS CYLINDERS

	42.	 	Gas cylinders properly labeled with the name of the contents
	 
	43.	 	Compressed gas cylinders (whether full or empty) secured
	 
	44.	 	Incompatible gas cylinders kept segregated
	 
	45.	 	Protective caps in place on cylinders which are not in use.

FIRE PREVENTION/SAFETY

	46.	 	All exits maintained to provide free and unobstructed access
	 
	47.	 	Boxes/materials not stored with 18” of ceiling or sprinkler heads.
	 
	48.	 	Portable space heaters are not present.
	 
	49.	 	Is there at least 32” clearance in front of electrical panels/breaker boxes?
	 
	50.	 	Combustible materials not stored in electrical closets.
	 
	51.	 	Fire ext. not blocked.
	 
	52.	 	Fire ext. fully charged and has been inspected within the last month.

12

 

Hazardous
Wastes Inspection Log

	 	 	 
	Location:
	 	 
	 

	 	 

Use format mm/dd/yy for date and “ü” for items to be inspected. Once completed log must be

retained for one year.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Leaks or	 	 	 	 	 	 	 
	 	 	Inspector	 	 	No. of	 	 	 	 	 	 	Aisle	 	 	Accum	 	 	Damaged	 	 	Spill	 	 	Comments or Corrective	 
	Date	 	Initials	 	 	Drums	 	 	Labeling	 	 	Space	 	 	Dates	 	 	Containers	 	 	Equipment	 	 	Action	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

13

 

Replidyne, Inc.

Employee Training Record

	 	 	 
	 

	 	Louisville, Colorado
	 
	 	 
	(name of employee)
	 	(facility location)
	 	 	 
	 
	 	Laboratory Personnel
	 
	 	 
	(employee social security number)
	 	(job title)

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	INSTRUCTOR	 	EMPLOYEE
	DATE	 	HOURS	 	SUBJECT	 	INITIALS	 	INITIALS
	     /     /

	 	 	0.5	 	 	Tour of the Facility (I)	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	     /     /

	 	 	0.1	 	 	EH&S Policy (I)	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	     /     /

	 	 	0.7	 	 	Chemical Hygiene Program Introduction (U)	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	     /     /

	 	 	0.1	 	 	Responding to Chemical Releases (A)	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	     /     /

	 	 	0.2	 	 	Evacuation Procedures (A)	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	     /     /

	 	 	0.2	 	 	Response to Fires (A)	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	     /     /

	 	 	0.2	 	 	Other Emergency Procedures (I)	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	     /     /

	 	 	0.2	 	 	General Laboratory Safety Rules and
Procedures (U)	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	     /     /

	 	 	0.1	 	 	Declaration of Pregnancy (I)	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	     /     /

	 	 	0.2	 	 	Access to Medical & Chemical Exposure
Records (A)	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	     /     /

	 	 	0.3	 	 	Hazardous Waste Disposal Procedures/Requirements (A)	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	     /     /

	 	 	0.3	 	 	Personal Protective Equipment (U)	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	     /     /

	 	 	1.0	 	 	Bloodborne Pathogens (A)	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	     /     /

	 	 	0.1	 	 	Hazardous Waste Job Description (I)	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	     /     /

	 	 	0.1	 	 	Occupational Radiation Dose Release
Form (I)	 	 	 	 

 

			
	(I)	 	= Initial Training Only    (A) = Initial and Annual
Refresher Training    (U) = Initial and Update as necessary.

14

 

Replidyne, Inc.

New Employee Orientation Checklist

	 	 	 
	o

	 	Location of exits and fire alarm pull boxes. Discuss evacuation routes.
	o

	 	Location of first-aid kits.
	o

	 	Location of spill control kits. Discuss procedures to follow in the event of a spill.
	o

	 	Location of fire extinguishers in their specific area.
	o

	 	Location of and operation of eye wash stations and emergency showers.
	o

	 	Location of Material Safety Data Sheets.
	 
	 	 
	Radiological Items
	 
	o

	 	Location of “hot sinks” and sink disposal log book procedures.
	o

	 	Location of radioactive waste containers.
	o

	 	Brief demonstration and overview of radiation meters.
	o

	 	Procedures when working with Radioactive Materials.
	o

	 	Discussion of restrictions while awaiting radiological badges.
	o

	 	Whole Body Monitor Badge Ordered.
	o

	 	Ring Badge Ordered (for P32 users).
	 
	 	 
	Biological Items
	 
	o

	 	Location of biowaste containers.
	 
	 	 
	Hazardous Waste/Chemical Storage
	 
	o

	 	Location of satellite accumulation areas.
	o

	 	Describe procedures for handling “In Process Waste.”
	o

	 	Describe procedures for contaminated rags, kim wipes, absorbent, etc.
	o

	 	Describe procedures for misc. outdated, off-specification, reagents and wastes.
	o

	 	Location of main accumulation area. Description of 3 container procedure for waste
disposal.
	 
	 	 
	Introduction to Key EH&S Personnel
	 
	o

	 	 Radiation Safety Officer
	o

	 	 Chemical Hygiene Officer
	o

	 	 Biological Safety Officer

	 	 	 	 	 	 	 
	Tour(s) conducted by:	 	Date:	 	 
	 

	 	
 

	 	 	 	 
	 
	 	 	 	 	 	 
	Employee

	 	 	 	Date:	 	 
	Signature:

	 	 	 	 	 	 
	 

	 	 
	 	 	 	 
	 
	 	 	 	 	 	 
	Comments: 
	 	 	 	 	 	 
	 	 	 

15

 

 

Appendix 4 — Site Closure Issues to Consider 

At least 30 days prior to expected closure of the facility, perform the following steps:

	•	 	Perform a complete laboratory cleanup. This includes freezers, cabinets under laboratory hoods,
chemical storage shelves.
	 
	•	 	Place reagents intended for disposal in plastic tubs.
	 
	•	 	Collect all hazardous wastes, biohazardous wastes, and radioactive wastes and arrange for offsite
shipment.
	 
	•	 	Submit decontamination and contamination survey plan to the Colorado Department of Public
Health
and Environment Radiation Control Division. Include sinks drains and traps, and ventilation
systems.
	 
	•	 	After hazardous wastes have been shipped to the appropriate TSDFs, notify the Colorado
Department
of Public Health and Environment Hazardous Wastes Division to deactivate the hazardous waste
generator’s I.D. number.
	 
	•	 	After all radioactive wastes have been shipped to the appropriate TSDF; notify the Rocky Mountain
Low-Level Waste Board (RMLLWB) to deactivate the RMLLWD permit.
	 
	•	 	Decontaminate all laboratory hoods, and chemical storage areas.

All documentation should be assembled in a comprehensive closure plan and retained for future
reference.

16

 

 

Appendix 5 — Hazardous Materials Inventory Statements

17exv10w18

 

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act Of 1933, as amended.

Exhibit 10.18

COLLABORATION AND COMMERCIALIZATION AGREEMENT

          This Collaboration and Commercialization Agreement (the “Agreement”) is entered into
as of February 10, 2006 (the “Effective Date”) by and among Replidyne, Inc., a Delaware
corporation (“Replidyne”), having its principal place of business at 1450 Infinite Drive,
Louisville, Colorado 80027, and Forest Laboratories Holdings Limited, an Irish corporation
(“Forest”), having its principal place of business at Milner House, 18 Parliament Street, Hamilton
HM11, Bermuda.

Recitals

          Whereas, Replidyne and Daiichi Asubio Pharmaceutical, Inc. (“DAP”)
(successor-in-interest to Daiichi Suntory Pharma Co., Ltd.) entered into a License Agreement dated
March 15, 2004 as may be amended in accordance with its terms (the “DAP Agreement”), pursuant to
which DAP granted to Replidyne an exclusive license to certain patents and know-how to develop and
commercialize faropenem medoxomil (formerly designated as faropenem daloxate) in the Field (as
defined below) in specified countries;

          Whereas, Forest develops, manufactures and markets pharmaceutical products, and in
particular, has expertise in promoting pharmaceutical products to primary care physicians;

          Whereas, Replidyne develops anti-infective and other pharmaceutical products and is
building an organization to promote pharmaceutical products to specialist physicians;

          Whereas, Forest and Replidyne desire to collaborate on the further development of
faropenem medoxomil for the treatment of community-acquired infectious diseases in the Territory
(as defined below), with the intent that Forest will market and promote the product(s) primarily to
primary care physicians, and Replidyne will market and promote the product(s) primarily to certain
medical specialists, including pediatricians;

          Whereas, Forest desires to acquire, and Replidyne is willing to grant to Forest,
certain licenses under patents and know-how controlled by Replidyne to develop and commercialize
faropenem medoxomil in the Field in the Territory (as defined below), in accordance with foregoing
and the terms and conditions set forth in this Agreement.

Agreement

          Now, Therefore, in consideration of the foregoing premises and the mutual covenants
contained herein and other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the parties agree as follows:

	1.	 	Definitions

          1.1 “ADEs” has the meaning provided in Section 5.12.

          1.2 “Administrator” has the meaning provided in Section 14.2.

 1.

 

          1.3 “Affiliate” means any company or entity controlled by, controlling, or under common
control with a party hereto. For this purpose, the term “control” shall mean the direct or
indirect ownership of more than 50% of the voting stock or other ownership interests of that
entity, or the power, directly or indirectly to cause the direction of the management and policies
of such entity.

          1.4 “AECB Indication” means a separate, labeled use for the treatment of acute exacerbations
of chronic bronchitis in humans.

          1.5 “ANDA” shall mean an Abbreviated New Drug Application filed with the FDA (as more fully
defined in 21 USC §355(j)).

          1.6 “ANDA Proceeding” has the meaning provided in Section 9.4(b).

          1.7 “AOM Indication” means a separate, labeled use for the treatment of acute otitis media in
humans.

          1.8 “API Supply Agreement” means the agreement setting forth the terms and conditions for the
supply of Drug Substance from NISSO through DAP to Replidyne dated December 20, 2004, as the same
may be amended or assigned to Forest as contemplated in Section 6.2 hereof.

          1.9 “Applicable Laws” means all applicable laws, rules and regulations that apply to the
development, manufacturing or commercialization of Product in the Territory or the performance of
either party’s obligations under this Agreement, including without limitation any rules,
regulations, guidelines or other requirements of the FDA, that may be in effect from time to time.

          1.10 “Arbitrators” has the meaning provided in Section 14.2.

          1.11 “Bayer” means Bayer AG, a prior licensee of the DAP Know-How and DAP Patents pursuant to
a license agreement with Suntory Ltd., Tokyo, Japan, a predecessor in interest to DAP, dated June
28, 1999, which was terminated November 19, 2003.

          1.12 “Bayer Know-How” means the data, information, documentation, know-how and technology,
relating to Drug Substance and/or Products that was generated or acquired by Bayer and/or its
Affiliates and actually provided to Replidyne by DAP.

          1.13 “Calendar Quarter” means each respective period of three (3) consecutive months ending on
March 31, June 30, September 30 and December 31.

          1.14 “Canadian Rights” has the meaning provided in Section 5.9(b).

          1.15 “Ciba-Geigy Patents” means the patents owned by Ciba-Geigy (currently
Novartis) as listed in Exhibit A hereof.

          1.16 “Claim” has the meaning provided in Section 14.2.

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

 2.

 

          1.17 “[ *** ] Threshold” has the meaning provided in Section 7.3(d).

          1.18 “Combination Product” means a Product containing one or more other therapeutically active
ingredients in addition to the Drug Substance.

          1.19 “Commercially Reasonable Efforts” means, with respect to the development or
commercialization of the Product, except as otherwise explicitly set forth in this Agreement, the
level of efforts required to carry out such obligation in a sustained manner consistent with the
efforts a biotechnology company or pharmaceutical company, as the case may be, devotes to a product
of similar market potential, profit potential or strategic value resulting from its own research
efforts, based on market conditions then prevailing, consistent with the exercise of prudent
scientific and/or business judgment in accordance with generally accepted practices in the
pharmaceutical industry. Commercially Reasonable Efforts shall be determined without regard to the
particular circumstances of a party, including any other product opportunities of such party.
Commercially Reasonable Efforts requires, with respect to such an obligation, that the party: (a)
promptly assign responsibility for such obligation to specific employee(s) who are held accountable
for progress and monitor such progress on an on-going basis; (b) set and consistently seek to
achieve specific, meaningful and measurable objectives for carrying out such obligation; and (c)
consistently make and implement decisions and allocate resources designed to advance progress with
respect to such objectives. The term “commercially reasonable” has the corresponding meaning.

          1.20 “Competitive Product” has the meaning set forth in Section 5.10.

          1.21 “Confidential Information” has the meaning provided in Section 11.1.

          1.22 “Control” means, with respect to any information, Patent or other intellectual property
right, possession by a party of the ability (whether by ownership, license or otherwise) to grant
access, a license or a sublicense to such information, Patent or intellectual property right
without violating the terms of any agreement or other arrangement with any Third Party.

          1.23 “Cost of Goods” for any dosage strength and formulation of the Product for any period
shall mean actual direct out-of-pocket cost incurred by a party for the acquisition of Drug
Substance and actual direct out-of-pocket costs incurred by a party for the acquisition,
manufacture, shipping from the manufacturer to Forest’s initial distribution site, storage at such
site, and final labeling and packaging of the Product for such period, including the cost of
commercially reasonable strategies for hedging of exchange rate risk (in each case, to the extent
not already deducted in the calculation of Net Sales or included in Distribution Costs), as
recognized and recorded in accordance with US GAAP.

          1.24 “Cost of Goods Committee” or “CGC” means the committee formed pursuant to Section 3.3.

          1.25 “DAP Improvement” means any and all developments, enhancements, modifications, inventions
or discoveries in the Field relating to Products for use in the Field, that are developed or
created by or on behalf of DAP (other than by Replidyne, its Affiliates, licensees and
sublicensees, and their respective employees, agents, consultants, subcontractors

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

 3.

 

and other
representatives) at any time during the term of the DAP Agreement, whether patentable or not,
including but not limited to, developments, inventions or discoveries intended to enhance the
safety or efficacy of Drug Substance and/or Products, and all intellectual property rights thereto
which are necessary or useful for Forest to exercise the rights licensed to it under Section 2.1 of
this Agreement, but excluding those related specifically to manufacturing of Drug Substance.

          1.26 “DAP Know-How” means any and all data, information, documentation, know-how and
technology, whether patentable or not, relating to Drug Substance and/or Products, including,
without limitation, information regarding their stability, pharmacology, toxicology, clinical use,
compositions and formulations for administration, and any scientific information and data developed
by Wyeth relating to Drug Substance and to Products; in each case that was generated or acquired by
DAP and/or its Affiliates prior to the effective date of the DAP Agreement or is generated by DAP
and/or its Affiliates during the term of the DAP Agreement, but excluding data, information,
documentation, know-how and technology, whether patentable or not, related specifically to
manufacturing of Drug Substance.

          1.27 “DAP Logogram” means the logogram adopted by DAP at any time during the term of the DAP
Agreement.

          1.28 “DAP Patents” means the patent applications and patents listed in Exhibit B attached
hereto, and patents issuing from such patent applications, and any and all patents and patent
applications covering DAP Improvements, in each case including any continuations,
continuations-in-part, provisionals, divisionals, reissues, reexaminations, extensions,
substitutions, restorations, additions, revalidations, registrations, confirmations, renewals and
counterparts thereof in the Territory that are necessary or useful for the use, development,
manufacture, marketing, promotion, distribution, sale and/or commercialization of Products in the
Territory for use in the Field.

          1.29 “Detail” means an interactive face-to-face contact of a sales representative, who is
fully equipped with, and knowledgeable of, applicable promotional materials and product labeling
for the Product, with a target physician or other medical professional licensed to prescribe drugs
or other healthcare professional that has a significant impact or influence on prescribing
decisions, during which relevant characteristics of the Product are described by the sales
representative. Details shall be deemed to include only presentations in the first or second
position in a sales presentation and shall not be deemed to include “tertiary” or “reminder”
details, in each case as such terms are generally understood in the pharmaceutical industry.
“Detailing” shall have a corresponding meaning.

          1.30 “Detailing Commencement Date” means the first day following NDA Approval on which
Detailing of the Product by Replidyne begins, as determined by the JMC.

          1.31 “Detailing Year” means, with respect to the first Detailing Year, the twelve (12) month
period commencing on the Detailing Commencement Date, and with respect to subsequent Detailing
Years, each successive twelve (12) month period thereafter.

          1.32 “Detail Reports” means a report of Details performed by a party during the

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

 4.

 

Calendar
Quarter covered by such statement containing such information and in such format as determined by
the JMC.

          1.33 “Development Costs” means with respect to a particular Product the sum of all internal
costs, including to the extent allocated to the foregoing directly related overhead (but not
general or corporate overhead), and direct out-of-pocket costs, in each case incurred by a party
and/or its Affiliates in connection with the conduct of the activities assigned to it by the JDC
pursuant to the Development Plan, including, without limitation, FTE costs (which fairly reflect
the actual FTE costs of each party for its personnel in the applicable functional areas (but
excluding senior executives), to be discussed and agreed upon by the parties respective finance
departments), costs of preparation of regulatory filings, costs of clinical supply of Product, and
any other activities conducted under the Development Plan that support obtaining or maintaining NDA
Approval of Product in the Territory, such as surveillance studies and pharmacovigilance.
Development Costs shall be determined in accordance with US GAAP and in accordance with the
relevant party’s accounting standards applied on a consistent basis.

          1.34 “Development Information” means any and all information generated by a party (or a
party’s Affiliates or any Third Party on behalf of a party) in the development of the Drug
Substance and/or Product for the Territory as provided in this Agreement, including, without
limitation, protocols, analysis plans, annotated case report forms per study, analysis datasets,
programs, raw data and other relevant documentation used for the study reporting efforts, FDA
outputs relating to the development of, and/or filing of NDAs for, Drug Substance and/or Product in
the Territory (including, without limitation, all substantive correspondence with the FDA,
responses from the FDA, requests for information from the FDA, briefing documents and other
materials relating to interactions with the FDA, and summaries of outputs resulting from
substantive correspondence/ conversations or meetings with the FDA), and information from clinical
advisory boards and investigators.

          1.35 “Development Plan” means the plan and related budget for conducting research and
development of the Drug Substance and Products in the Field in the Territory, as amended from time
to time by the JDC. The initial outline of the Development Plan has been agreed upon by the
parties in writing as of the Effective Date.

          1.36 “Development Program” means a research and development program carried out by Replidyne
and, as applicable, Forest pursuant to Article 4, as more fully described in the Development Plan.

          1.37 “Distribution Costs” for any dosage strength and formulation of the Product for any
period shall mean a reasonable estimate of the direct out-of-pocket costs of shipping, handling and
other Product-specific logistical costs, including, without limitation, quality
assurance and quality control procedures and regulatory reporting obligations, related to
distribution of the Product from Forest’s initial distribution site to Forest’s customers (to the
extent not already deducted in the calculation of Net Sales or included in Costs of Goods) as
recognized and recorded in accordance with US GAAP. The parties’ finance departments will mutually
agree upon a simple rule for Distribution Costs (e.g., as a percentage of Net Sales) after mutual
review and discussion of Forest’s actual Distribution Costs from time to time.

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

 5.

 

          1.38 “Drug Substance” means the chemical substance identified as faropenem medoxomil as its
generic name (formerly designated as faropenem daloxate) and having the chemical structure:
(5-Methyl-2-oxo-1, 3-dioxolen-4-yl) methyl (5R,
6S)-6-[(R)-1-hydroxyethyl]-2-[(R)-2-tetrahydro-furyl] penem-3-carboxylate.

          1.39 “FDA” means the United States Food and Drug Administration, or any successor agency
thereto having the administrative authority to regulate the marketing of human pharmaceutical
products or biological therapeutic products, delivery systems and devices in the United States of
America.

          1.40 “Field” means the treatment, amelioration or prevention of infectious diseases in humans
and all other pharmaceutical uses and indications for the Product.

          1.41 “First Commercial Sale” means, with respect to any Product, the first sale for end use or
consumption of such Product in the United States after NDA Approval. Sale to an Affiliate or
sublicensee shall not constitute a First Commercial Sale unless the Affiliate or sublicensee is the
end user of the Product.

          1.42 “Forest Costs” has the meaning provided in Section 7.3(d).

          1.43 “Forest Indemnitee” has the meaning provided in Section 13.1.

          1.44 “Forest Inventions” has the meaning provided in Section 9.1.

          1.45 “Forest Know-How” means any and all data, information, documentation, know-how and
technology Controlled by Forest or any of its Affiliates on the Effective Date or during the Term
that is useful for purposes of the Development Program or necessary or useful for the manufacture
of Product (including Drug Substance) anywhere in the world, or the commercialization or use of the
Drug Substance or Product in the Field in the Territory, including, without limitation, all such
data, information, documentation, know-how and technology that is developed or acquired by Forest
or any of its Affiliates in the course of performance of, or pursuant to any right granted under,
this Agreement, but excluding the Forest Patents and the Joint Patents.

          1.46 “Forest Patents” means all Patents Controlled by Forest or any of its Affiliates on the
Effective Date or during the Term to the extent useful for purposes of the Development Program or
necessary or useful for the manufacture of Product (including Drug Substance) anywhere in the
world, or the commercialization or use of the Drug Substance or Product in the Field in the
Territory, including, without limitation, any Patents that claim or disclose any Forest
Invention, but excluding the Joint Patents.

          1.47 “Forest Sales Force” means those members of Forest’s sales force (whether Forest
employees, contractors or agents), who promote Product in the Field in the Territory, but excluding
the Replidyne Pediatrician Sales Force and Replidyne Specialty Sales Force, together with
field-based sales managerial personnel having direct and sole responsibility for the management of
such sales force.

 [ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

 6.

 

          1.48 “Forest Technology” means the Forest Patents and Forest Know-How.

          1.49 “FTE” means the equivalent of the work time of an employee or consultant of Replidyne or
Forest (or their Affiliates, as applicable) with appropriate qualifications performing work under
the Development Plan on a full-time basis over a 12-month period (including normal vacations, sick
days and holidays).

          1.50 “Generic Equivalent” shall mean, on a Product-by-Product basis, a product that is
therapeutically equivalent to a Product and that: (a) is pharmaceutically equivalent to such
Product (contains the same active ingredient(s) and has the same dosage form, route of
administration and strength); and (b) has gained market approval through an ANDA filed in
accordance with 505(j) of the U.S. Food Drug & Cosmetic Act and prepared in accordance with 21 CFR
314.94 or through any equivalent mechanism under any successor law or regulation in the United
States.

          1.51 “Generic Profits” shall mean, with respect to a generic Product sold by Forest, its
Affiliates or permitted sublicensees, on a Product-by-Product basis, an amount, which shall not be
less than zero (0) for purposes of this Agreement, equal to (a) Net Sales of such generic Product,
minus (b) Cost of Goods, Distribution Costs and sales and marketing costs (such as trade
advertising) of Forest for such generic Product in the Territory.

          1.52 “IND” means an Investigational New Drug Application filed with the FDA, or the equivalent
application or filing filed with any equivalent agency or governmental authority outside the United
States of America (including any supra-national agency such as in the European Union) necessary to
commence human clinical trials in such jurisdiction.

          1.53 “Initial Period” means the first [ *** ] months of the Replidyne Specialist Promotion
Period.

          1.54 “Inventions” has the meaning provided in Section 9.1.

          1.55 “Joint Development Committee” or “JDC” means the committee formed pursuant to Section
3.1.

          1.56 “Joint Inventions” has the meaning provided in Section 9.1.

          1.57 “Joint Marketing Committee” or “JMC” means the committee formed pursuant to Section 3.2.

          1.58 “Joint Patents” means all Patents in the Territory that claim or disclose a Joint
Invention.

          1.59 “Joint Supply Committee” or “JSC” means the committee formed pursuant to Section 6.1.

          1.60 “Licensed Know-How” means any and all data, information, documentation, know-how and
technology Controlled by Replidyne as of the Effective Date or during the Term that is useful for
purposes of the Development Program or necessary or useful for the

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

 7.

 

manufacture of Product
(including Drug Substance) anywhere in the world (excluding, with respect to the DAP Know-How,
rights in Japan, except to the extent rights in Japan are included in the rights granted to
Replidyne under the DAP Agreement), or the commercialization or use of Drug Substance or Product in
the Field in the Territory, including, without limitation, the DAP Know-How and the Bayer Know-How,
but excluding the Licensed Patents and the Joint Patents.

          1.61 “Licensed Patents” means the Replidyne Patents, the Ciba-Geigy Patents and the DAP
Patents.

          1.62 “Licensed Technology” means the Licensed Patents and Licensed Know-How.

          1.63 “Losses” has the meaning provided in Section 13.1.

          1.64 “Manufacturing Technology” means all information and documentation necessary or advisable
to enable Replidyne or its designee to manufacture Drug Substance, including without limitation,
NISSO’s standard operating procedures, NISSO’s Improvements, and the Drug Master File sections
relevant to chemical manufacturing, testing and release, Sensitive Manufacturing Information, and
all updates thereto.

               (a) “NISSO’s Improvements” means all information, documents and tangible and intangible
materials which result from or are related to the performance by NISSO of the services contemplated
by the API Supply Agreement (including, without limitation, data, test results, measurements,
quantitative and qualitative analyses, processes, samples, inventions, discoveries, improvements,
intellectual property, derivative works, technology and/or any other work product, whether
patentable or not) developed under the API Supply Agreement by NISSO or on behalf of NISSO by any
of its representatives relating to the Drug Substance or the Products.

               (b) “Drug Master File” means the drug master file, as defined in 21 CFR Section 314.420 or
successor provision, filed with the FDA with respect to the Drug Substance, which permits NISSO to
authorize others to rely on the information in such file to support an NDA for the Products.

               (c) “Sensitive Manufacturing Information” means the confidential manufacturing information
that is included in the Drug Master File.

          1.65 “Marketing and Sample Expense” means, generally, the external, out-of-pocket
costs which are incurred by a party or for its account attributable to the marketing of any
dosage strength and formulation of the Product in the Territory, including, without limitation, the
sum of Advertising, Consumer and Physician Promotion, Education, Market and Consumer Research,
Phase IV Programs, Promotional Management and Trade Promotion Expenses, each of which is specified
below. To the extent multiple products are involved and some of such products are not Product,
then such expenses will be allocated on a pro rata basis based upon net sales of each respective
product by such party during the most recent Calendar Quarter. The costs of activities which
promote a party’s business as a whole without being product specific (such as corporate image
advertising) are specifically excluded from Marketing and Sample Expense.

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

 8.

 

               (a) “Advertising” means all media costs associated with advertising the Product in the
Territory including, but not limited to the following: production expense/artwork including set
up; design and art work for an advertisement; advertising agency fees; the cost of securing print
space, air time and the like in newspapers, magazines, trade journals, television, radio,
billboards and other media.

               (b) “Consumer and Physician Promotion” means the expenses associated with programs to promote
the Product in the Territory directly to the prescriber or end user, including, but not limited to,
expenses associated with promoting products directly to the professional community such as
professional samples (including Cost of Goods of samples), professional literature, promotional
material costs, patient aids and detailing aids.

               (c) “Education” means expenses associated with professional education with respect to the
Product in the Territory through any means not covered under subsections (a) and (b) above,
including, but not limited to, articles appearing in journals, newspapers, magazines or other
media; seminars, lunch and dinner programs, CME programs and professional society programs,
scientific exhibits, and conventions; and symposia, advisory boards and opinion leader development
activities.

               (d) “Market and Consumer Research” means payments to Third Parties related to conducting and
monitoring professional and consumer appraisals of existing, new or proposed Product in the
Territory, such as market share services (e.g., IMS data), special research testing, focus groups,
as well as qualitative and quantitative research studies.

               (e) “Phase IV Programs” means payments to Third Parties and the directly allocable internal
costs of a party (including directly related overhead but not corporate or general overhead) for
functions (such as data collection and analysis) that a party performs internally on a reasonably
cost-effective basis compared to Third Party costs for such functions, in each case for Phase IV
marketing studies of the Product in the Territory, including, but not limited to, the cost of
clinical grants and the cost of clinical research organizations.

               (f) “Promotional Management” means payments to Third Parties for development or management of
marketing or promotional strategies, planning and programs for the Product in the Territory,
including, but not limited to, costs associated with developing overall sales and marketing
strategies (e.g., product line or customer segment), and planning and
programs for the Product in the Territory, including, but not limited to, launch sales force
meetings, promotional meetings, other meetings scheduled solely for the Product (but not periodic
sales force meetings of a party), conventions and seminars. In addition, payments to Third Parties
in connection with Trademark selection, filing, prosecution and enforcement in the Territory are
included in this category.

               (g) “Trade Promotion” means the allowances given to retailers, brokers, distributors, hospital
buying groups and similar groups for purchasing, promoting, and distribution of the Product in the
Territory, including, but not limited to, purchasing, advertising, new distribution, and display
allowances as well as free goods, wholesale allowances and reasonable field sales samples (to the
extent not already deducted in the calculation of Net Sales).

 [ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

 9.

 

          1.66 “Marketing Expense Ratio” has the meaning set forth in Section 5.3(e).

          1.67 “Marketing Plan” means the annual marketing and commercial plan for the Product in the
Field in the Territory that includes the related budget for Marketing and Sample Expense, as the
same is from time to time in effect in accordance with the terms hereof.

          1.68 “NDA” means a New Drug Application (as more fully defined in 21 C.F.R. 314.5 et seq.) and
all amendments and supplements thereto filed with the FDA, including all documents, data, and other
information concerning a pharmaceutical product which are necessary for gaining approval to market
such pharmaceutical product in the United States.

          1.69 “NDA Acceptance” means the submission of a NDA for Product to the FDA and filing of such
NDA by the FDA.

          1.70 “NDA Approval” means the issuance by the FDA of an action letter indicating that an NDA
for Product is approved. For avoidance of doubt, NDA Approval does not mean that the FDA issues an
action letter indicating that an NDA for Product is approvable.

          1.71 “Net Sales” means, for the applicable period, the gross amount invoiced for sales or
other transfers of the Products (including, for purposes of Section 7.5, any generic Product) by
Forest and its Affiliates and permitted sublicensees to Third Parties that are not Affiliates or
permitted sublicensees of Forest (and to any Affiliate or sublicensee of Forest if such Affiliate
or sublicensee is the final user of and does not further sell such Product, in which case the
amount billed therefor shall be deemed to be the amount that would be billed to an independent
Third Party in an arm’s length transaction), less the following items as allocable to such
Products, all as recorded in accordance with US GAAP and in a manner consistent with Forest’s
revenue recognition policies from the sale of pharmaceutical products consistently applied:

               (a) trade discounts, credits or allowances, including without limitation, discounts provided
by means of chargebacks, rebates and administrative fees charged by customers or health care
organizations determined based upon sales;

               (b) credits or allowances additionally granted upon returns, rejections or recalls (except
where any such recall arises out of Forest’s or its Affiliate’s gross negligence,
willful misconduct or fraud);

               (c) freight, shipping and insurance charges;

               (d) taxes, duties or other governmental tariffs (other than income taxes); and

               (e) rebates, discounts or other payments on sales of Product that are mandated by the
government.

          In the case of the Combination Products, the Net Sales shall be calculated by multiplying
actual Net Sales of the Combination Product (calculated as if such Combination Product did not
contain other therapeutically active ingredients) by the fraction A/(A+B) where A is the invoice
price of a Product containing only Drug Substance, if sold separately, and B is the total invoice
price of the other active ingredient or ingredients in the combination, if sold separately. If the

 [ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

 10.

 

other active ingredient or ingredients in the Combination Product are not sold separately in the
Territory, Net Sales shall be calculated by multiplying actual Net Sales thereof by the fraction
A/C where A is the invoice price of a Product containing only Drug Substance, if sold separately,
and C is the invoice price of the Combination Product.

          If the Product containing only Drug Substance is not sold separately in the Territory, the
parties shall, in good faith, negotiate and agree upon how to calculate the Net Sales on sales of
the Combination Product, with a view to achieving to the greatest extent possible the economic
balance and mutual understanding established between the parties for calculation of Net Sales on
the Combination Product as reflected in this section.

          1.72 “NISSO” means Nippon Soda Co., Ltd., which is the contract manufacturer of the Drug
Substance for Replidyne as of the Effective Date.

          1.73 “Oral Suspension” means a finished pharmaceutical preparation containing the Drug
Substance as an active ingredient, consisting of a dosage formulation of the Drug Substance
suspended in a liquid for delivery by mouth.

          1.74 “Patents” means: (a) an unexpired patent which has not been held invalid or
unenforceable by a court of competent jurisdiction from which no appeal can be taken or has been
taken within the required time period, including without limitation any substitution, extension,
registration, confirmation, reissue, re-examination, renewal or any like filing thereof; and (b)
pending patent applications, including without limitation any provisional, converted provisional,
continued prosecution application, continuation, divisional or continuation-in-part thereof.

          1.75 “Pediatrician” means a physician specializing in the development, care, and treatment of
children from birth through adolescence and board certified in pediatrics.

          1.76 “Pediatrician Promotion Option” has the meaning set forth in Section 5.5.

          1.77 “Pediatrician Promotion Rights” has the meaning set forth in Section 5.5, as
further described in Schedule 5.5.

          1.78 “Phase 2 Clinical Trial” means a human clinical trial that would satisfy the requirements
for a Phase 2 study as defined in 21 C.F.R. 312.21(b) (or its successor regulation).

          1.79 “Phase 3 Clinical Trial” means a human clinical trial that would satisfy the requirements
for a Phase 3 study as defined in 21 C.F.R. 312.21(c) (or its successor regulation).

          1.80 “Pre-Launch Period” means, with respect to a Product, the twelve (12) month period
preceding the anticipated Detailing Commencement Date for such Product.

          1.81 “Primary Care Physician” or “PCP” means a physician, such as a general practitioner or
internist, chosen by an individual to serve as his or her health-care professional and capable of
handling a variety of health-related problems, of keeping a medical history and medical records on
the individual, and of referring the person to Specialists as needed.

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

 11.

 

          1.82 “Product” means a finished pharmaceutical preparation containing the Drug Substance as an
active ingredient, in any dosage or formulation, including but not limited to a Tablet or an Oral
Suspension.

          1.83 “Replidyne Indemnitee” has the meaning provided in Section 13.2.

          1.84 “Replidyne Inventions” has the meaning provided in Section 9.1.

          1.85 “Replidyne Patents” means all Patents Controlled by Replidyne as of the Effective Date or
during the Term that are useful for purposes of the Development Program or necessary or useful for
the manufacture of Product (including Drug Substance) anywhere in the world, or the
commercialization or use of Drug Substance or Product in the Field in the Territory, including,
without limitation, any Patents that claim or disclose any Replidyne Invention, but excluding the
Ciba-Geigy Patents, the DAP Patents and the Joint Patents.

          1.86 “Replidyne Pediatrician Sales Force” means those members of Replidyne’s sales force
(subject to the provisions of Section 2.4(b) of Schedule 5.5, whether Replidyne employees,
contractors or agents), who promote Product to Pediatricians in the Territory pursuant to
Replidyne’s exercise of the Pediatrician Promotion Option, together with field-based sales
managerial personnel having direct and sole responsibility for the management of such sales force.

          1.87 “Replidyne Specialist Promotion Period” means the period beginning on the Detailing
Commencement Date and ending on the last day of the fifth (5th) Detailing Year, unless
extended by mutual agreement of the parties or sooner terminated in accordance with the terms of
this Agreement.

          1.88 “Replidyne Specialty Sales Force” means those members of Replidyne’s sales force (subject
to the provisions of Section 5.4(a), whether Replidyne employees, contractors or agents), who
promote Product to Target Specialists in the Field in the Territory pursuant to Section 5.2, together with field-based sales managerial personnel having direct and sole
responsibility for the management of such sales force.

          1.89 “Royalty Payments” shall have the meaning provided in Section 7.5(a).

          1.90 “Royalty Term” means, in the case of any Product in the Territory (on a
Product-by-Product basis), the period of time commencing on the First Commercial Sale of such
Product in the Territory and, subject to the provisions of Section 7.5, ending upon the later of:
(a) the expiration of the last to expire valid claim of the Licensed Patents, Forest Patents or
Joint Patents claiming the manufacture, use or sale of such Product in the Territory, including any
period of extended commercial exclusivity for the Product granted under any such Licensed Patent,
Forest Patent or Joint Patent or under any other laws or regulations in the Territory, (b) the
commercial introduction by a Third Party of a Generic Equivalent to such Product in the Territory;
and (c) twelve (12) years after the date of First Commercial Sale of such Product in the Territory.

          1.91 “Sales Force Expense” means the salaries, bonuses, other cash compensation payments and
benefits provided by Replidyne to the Replidyne Specialty Sales Force, together

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

 12.

 

with direct
out-of-pocket expenses of Replidyne in utilizing the Replidyne Specialty Sales Force in the
Detailing of the Product (such as automobile, travel and lodging, equipment and other support
costs) recognized and recorded in accordance with US GAAP. In addition, “Sales Force Expense”
shall include out-of-pocket costs of activities in support of the Replidyne Specialist Sales Force
(for example, training and technology support services), provided that Replidyne shall first
consult with Forest to determine whether such support services may be provided by Forest (in which
case Forest shall have the option to provide such services and Replidyne shall utilize such
services if so provided by Forest) and to the extent not so available from Forest, such costs shall
only be included in Sales Force Expense to the extent such costs do not exceed the incremental
costs Forest would have incurred in providing such services to its own sales force. Promptly
following the Effective Date, the JMC will develop a mutually agreed protocol consistent with this
definition to more specifically identify and standardize the components of Sales Force Expense to
facilitate the reimbursement of such expense as contemplated by this Agreement.

          1.92 “Specialists” means physicians whose practices are limited to treating a specific
disease, specific parts of the body, a specific age group or specific procedures, who are potential
prescribers of the Products.

          1.93 “Standstill Period” has the meaning provided in Section 15.1.

          1.94 “Supply Transition” means the period of time, commencing on the Effective Date, during
which the parties shall transition responsibility from Replidyne to Forest under the API Supply
Agreement and Replidyne’s other agreements with Third Party contract manufacturers for the Product.

          1.95 “Tablet” means a finished pharmaceutical preparation containing the Drug Substance as an
active ingredient, consisting of a solid dosage formulation for delivery by mouth
intended to be swallowed whole and to dissolve in the gastrointestinal tract.

          1.96 “Target Specialists” means infectious disease specialists, otolaryngologists, and such
other Specialists (other than Pediatricians) as to which the JMC may agree warrant Detailing of the
Product.

          1.97 “Term” has the meaning provided in Section 12.1.

          1.98 “Territory” means the United States of America, and its territories and possessions,
including Puerto Rico irrespective of political status.

          1.99 “Third Party” means any entity other than Replidyne or Forest or an Affiliate of
Replidyne or Forest.

          1.100 “Trademark” means any trade names or trademarks for the Product that are selected for
use in the marketing and promotion of the Product in the Territory in accordance with the terms
hereof (but not including trademarks or trade names of general use in a party’s business and not
specifically related to the Product).

 [ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

 13.

 

          1.101 “US GAAP” means generally recognized accounting principles in the United States of
America.

          1.102 “Wyeth” means Wyeth-Ayerst, a prior licensee of the DAP Know-How and DAP Patents
pursuant to a license agreement with Suntory Ltd., Tokyo, Japan, a predecessor in interest to DAP,
dated May 27, 1992, which was terminated March 22, 1996.

	2.	 	Licenses

          2.1 License Grants. Subject to the terms and conditions of this Agreement, Replidyne hereby
grants to Forest during the Term:

               (a) a co-exclusive license (or sublicense, as the case may be) under the Licensed Technology,
with the right to sublicense to Affiliates under Section 2.2, to conduct development of Product in
the Field in the Territory pursuant to the Development Plan;

               (b) an exclusive license (or sublicense, as the case may be) under the Licensed Technology,
with the right to sublicense to Affiliates under Section 2.2, to make and have made anywhere in the
world, excluding Japan (except to the extent rights in Japan are included in the rights granted to
Replidyne under the DAP Agreement), Product for the Territory from Drug Substance supplied by a
Third Party approved by Replidyne;

               (c) a co-exclusive license (or sublicense, as the case may be) under the Licensed Technology,
with the right to sublicense under Section 2.2, to use, market and promote Product in the Field in
the Territory;

               (d) an exclusive license (or sublicense, as the case may be) under the Licensed
Technology, with the right to sublicense under Section 2.2, to sell, offer for sale and import
Product in the Field in the Territory; and

               (e) a co-exclusive license (or sublicense, as the case may be) with the right to sublicense
under Section 2.2, to use and display the Trademarks and the DAP Logogram in connection with the
promotion, marketing and commercialization of Product in the Field in the Territory.

          The licenses (or sublicenses, as the case may be) granted in Section 2.1(a), (c) and (e) shall
be co-exclusive with Replidyne, meaning that Forest and Replidyne will share such rights, on an
exclusive basis as to Third Parties, with respect to Products in the Territory as set forth in this
Agreement. The licenses (or sublicenses, as the case may be) granted in Section 2.1(b) and (d)
shall be exclusive, meaning that such rights with respect to Products in the Territory are
exclusive, even as to Replidyne, its Affiliates and any Third Parties, but subject to the rights of
Replidyne as set forth in this Agreement.

          In addition, in the event the launch of a Generic Equivalent to a Product (on a
Product-by-Product basis) by a Third Party [ *** ], the licenses granted to Forest pursuant to this
Agreement shall be deemed to include the sale and distribution by Forest of such Product as a
generic Product subject to Section 7.5. For purpose of this Agreement, references to “generic

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

 14.

 

Product” means a product having the same active ingredient(s), dosage form, route of administration
and strength as the Product, but is sold by Forest without use of the Trademark [ *** ] in a manner
typical of the generic industry.

          Forest shall not exercise the foregoing license if it appears that the Generic Equivalent [
*** ]. However, Forest or its Affiliates or sublicensees may nevertheless exercise the foregoing
license if, [ *** ]. If sales of the Generic Equivalent terminate for any reason, then Forest will
promptly cease the sale and distribution of its generic Product or, to the extent to do so would be
prohibited by law or would violate best industry practices, cease the active promotion for sale of
the generic Product.

          2.2 Sublicenses. Forest shall have the right to grant sublicenses of the rights granted to it
under this Agreement (a) to its Affiliates upon prior written notice to Replidyne and (b) to Third
Parties with the prior written consent of Replidyne in its sole discretion, and Forest shall have
no other right to sublicense. Sublicenses granted by Forest to its Affiliates under this Agreement
shall not permit the further grant of sublicenses unless agreed to in writing by Replidyne in its
sole discretion. Any sublicense granted by Forest under this Agreement shall be subject and
subordinate to, and consistent with, the terms and conditions of this Agreement. Forest shall
remain fully responsible for the conduct of its Affiliates and Third Party sublicensees under the
terms of this Agreement, including any breach of the terms hereof by such Affiliates or
sublicensees, and any action or inaction by such Affiliate or Third Party sublicensee shall be
considered the action or inaction of Forest under this Agreement (including, without limitation,
for purposes of the definition of Net Sales). In the event of a material default by an Affiliate
or Third Party under a sublicense agreement with Forest, Forest will inform Replidyne and take such
action as necessary or appropriate to cure such default.

          2.3 Grant to Replidyne by Forest. Subject to the terms and conditions of this Agreement,
Forest hereby grants to Replidyne and its Affiliates, during the Term, (a) a non-exclusive,
worldwide, [ *** ] license under the Forest Technology to: (i) perform Replidyne’s obligations
under the Development Plan (with no right to sublicense); and (ii) to develop, make, have made,
use, sell, offer for sale and import the Product outside the Territory (with the right to
sublicense to the extent and during any period that Replidyne has the necessary licenses from DAP
with respect to territories outside the Territory); and (b) a fully paid, royalty-free license
under the Forest Technology, with the right to sublicense only to Affiliates of Replidyne, to use,
market and promote the Product in the Field in the Territory in accordance with Replidyne’s
promotion rights and obligations under this Agreement. Notwithstanding the preceding, in the event
that [ *** ].

     2.4 Related Compounds. If a party proposes to develop or acquire rights to any analogs,
homologues, derivatives, salts, metabolites, esters, isomers, enantiomers, polymorphs or pro-drugs
of Drug Substance during the Term, the parties agree to work together with regard to such
activities and shall discuss and agree upon matters regarding intellectual property rights and
payment for costs prior to the development or acquisition of the foregoing. Any rights developed
or acquired by a party during the Term as to any analogs, homologues, derivatives, salts,
metabolites, esters, isomers, enantiomers, polymorphs or pro-drugs of Drug Substance shall be
included in the definition of Drug Substance and shall be deemed governed by and subject to the
terms and conditions hereof (i.e., irrespective of which party acquires such rights, all
intellectual

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

 15.

 

property rights relating thereto shall be deemed included in Licensed Technology
licensed to Forest pursuant to Section 2.1 or in Forest Technology licensed to Replidyne pursuant
to Section 2.3, and any finished pharmaceutical product containing such compound shall be deemed a
“Product” for all purposes of this Agreement). No such product shall be commercialized in the
Territory during the term without the mutual agreement of the parties.

          2.5 Trademark and Trade Dress Matters.

               (a) Sale under Trademarks. In the Territory, Forest and its Affiliates will sell
Products exclusively under the Trademark in accordance with the terms and conditions set forth in
this Agreement. The Trademark has been selected by Replidyne and submitted to the FDA prior the
Effective Date. If the FDA does not approve the use of such submitted Trademark or if either party
determines to use an alternate Trademark in the Territory, the parties shall select by mutual
agreement an alternate Trademark for use with the Product. The Trademark shall be owned by
Replidyne, subject to the license granted to Forest herein.

               (b) Use of Names and Logos on Product and Related Materials. Subject to Applicable
Laws, all packaging and labels and all sales, advertising and promotional literature and other
materials used in connection with Products in the Territory shall indicate that the Product is sold
under license from Replidyne and shall bear the names and logos of both Replidyne and Forest. As
used in this Agreement, “labels” or “labeling” means labels and other written, printed or graphic
matter, including without limitation artwork upon the Products or any container utilized with the
Products, and “packaging” means containers, cartons, shipping cases,
package inserts or other similar material used in packing or accompanying the Products. The
place and manner of use of the names and logos of Replidyne and Forest shall be determined by
Forest in consultation with Replidyne, but in any event shall be of equal size and prominence.

               (c) Use of DAP Name and DAP Logogram. Subject to Applicable Laws and provided that
there is adequate space, Forest and its Affiliates shall specify on certain packaging and labels
used in connection with Products, as mutually agreed (but not including any sales, advertising or
promotional literature or other materials), that Products are manufactured and sold under a license
from Daiichi Asubio Pharmaceutical, Inc., Tokyo Japan, and Forest and its Affiliates shall use on
Products and certain of their labels, packaging, literature, advertising and other printed
materials as mutually agreed the DAP Logogram. The place and manner of such information and DAP
Logogram shall be subject to agreement with DAP, such approval not to be withheld if such
information and DAP Logogram are used in accordance with DAP’s normal practices.

               (d) Trademark Use. The manner of use of the Trademarks shall be subject to periodic
review by the JMC. Forest shall not use the Trademarks in a way that would diminish their value,
and Forest shall not use a trademark confusingly similar to one of the Trademarks with any of its
other products or use the Trademarks in combination with Forest’s other trademarks in a manner
which would create combination marks. Forest shall comply with reasonable policies for usage of
Trademarks, as approved by the JMC from time to time. Replidyne shall utilize the Trademarks
within the Territory only in accordance with this Agreement. Replidyne may utilize the Trademarks
outside the Territory, except that, if there is a reasonable likelihood of a negative impact from
parallel imports of Product (or corresponding

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

 16.

 

Generic Equivalents) using the Trademark from outside
the Territory into the Territory, then Replidyne may utilize such Trademark outside the Territory
only with Forest’s prior written approval, which shall not be unreasonably withheld or delayed in
light of Replidyne’s proposals to address such negative impact from parallel imports. If Forest
reasonably withholds its approval of the use of the Trademark outside the Territory, Replidyne
shall not authorize the use of the Trademark by DAP outside the Territory. If DAP nevertheless
uses the Trademark outside the Territory, Replidyne shall be responsible, in its sole discretion,
to enforce its rights with respect to the Trademark under the DAP Agreement. Replidyne shall hold
Forest harmless from any direct damages incurred by Forest as a result of parallel imports of
Product attributable to DAP’s un-authorized use of the Trademark outside the Territory or as a
result of other actions taken by DAP directly resulting from Replidyne’s refusal to permit DAP to
use the Trademark outside the Territory, subject to Section 10.5.

          2.6 Sales Outside the Territory. To the extent not otherwise prohibited by law, neither
Forest nor its Affiliates or permitted sublicensees shall sell Product to customers outside the
Territory or to any Third Party in the Territory that Forest has reasonable grounds to believe are
likely to export Product outside the Territory. If Forest becomes aware that a Third Party in the
Territory is exporting Products acquired from Forest to a country outside the Territory, then
Forest shall use Commercially Reasonable Efforts within its legal rights and the remedies afforded
by Applicable Laws to deter such Third Party from continuing such exportation, including, without
limitation by ceasing or limiting the supply of Product to such
Third Party. All inquiries or orders received by Forest for Products to be delivered outside
of the Territory shall be referred to Replidyne. To the extent not otherwise prohibited by law,
neither Replidyne nor its Affiliates or licensees will sell Product to customers inside the
Territory or to any Third Party that Replidyne has reasonable grounds to believe are likely to
import Product into the Territory. If Replidyne becomes aware that a Third Party outside the
Territory is exporting Product acquired from Replidyne or any Affiliate or licensee to a country
within the Territory, then Replidyne shall use Commercially Reasonable Efforts within its legal
rights and the remedies afforded by Applicable Laws to deter such Third Party from continuing such
exportation, including, without limitation, by ceasing or limiting the supply of Product to such
Third Party. All inquiries or orders received by Replidyne for Products to be distributed within
the Territory shall be referred to Forest.

     2.7 Retained Rights; No Implied Licenses. For avoidance of doubt, the licenses granted in
Section 2.1 shall not in any way be interpreted as granting Forest a license to manufacture or have
manufactured Drug Substance or to sell the Drug Substance, except to the extent included in rights
granted to Replidyne under the DAP Agreement, the API Supply Agreement or otherwise included in the
Licensed Patents and Licensed Know-How. Replidyne hereby expressly reserves the right to practice,
and to grant licenses under, the Licensed Patents, the Joint Patents and the Licensed Know-How for
any and all purposes except to the extent that Forest has been granted a license under Section 2.1
and reserves such rights to practice intellectual property rights, including the Manufacturing
Technology, to which it may obtain a license under the API Supply Agreement except to the extent
that Forest may be granted a license under Section 6.5. No right or license under any Patents or
other intellectual property rights of either party is granted or shall be granted by implication to
the other, and each party agrees not to practice any Patents or other intellectual property rights
of the other party except

 [ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

 17.

 

pursuant to the licenses expressly granted in this Agreement or any other
written agreement between the parties. All such rights or licenses are or shall be granted only as
expressly provided in the terms of this Agreement.

	3.	 	Collaboration Governance

          3.1 Joint Development Committee.

               (a) Formation. Promptly after the Effective Date, the parties will form a Joint
Development Committee (the “JDC”) comprised of three (3) representatives of each of Forest and
Replidyne. One (1) member of the JDC shall be selected to act as the chairperson of the JDC, with
each chairperson acting for a term of twelve (12) months. The chairperson shall be selected
alternately by Replidyne and Forest, and Replidyne shall designate the first chairperson. The JDC
shall meet at least four (4) times per year or at such greater frequency as the JDC agrees. Such
meetings may be conducted by videoconference, teleconference or in person, as agreed by the parties
(except that at least two (2) of such meetings per year shall be conducted in person), and the
parties shall agree upon the time of meetings. Within thirty (30) days after each meeting, the JDC
chairperson will prepare and distribute to the other members of the JDC for review and comment
reasonably detailed minutes of such meeting, which will be approved as the first order of business
at the immediately succeeding JDC meeting. Subject to
prior coordination with the other party, a reasonable number of additional representatives of
a party may attend meetings of the JDC in a non-voting capacity, consistent with the agendas and
purposes for such meetings.

               (b) Responsibilities. The JDC shall oversee and manage the development (including
clinical and non-clinical activities) and regulatory approval of the Product in the Field in the
Territory. In addition to its general responsibilities, the JDC shall in particular:

                    (i) encourage and facilitate communication between the parties with respect to the Development
Program;

                    (ii) establish, update, amend, review and approve the Development Plan for accomplishing the
goals of the Development Program;

                    (iii) oversee development and regulatory strategies for Products;

                    (iv) monitor progress of the Development Program and each party’s diligence in carrying out
its responsibilities thereunder; and

                    (v) carry out the other duties and responsibilities described for it in this Agreement.

               (c) JDC Decision-Making. Decisions of the JDC shall be made by unanimous vote, with
the Replidyne members collectively having one (1) vote and the Forest members collectively having
one (1) vote. No vote of the JDC may be taken unless at least two (2) of each party’s
representatives on the JDC are present to vote. If the JDC is unable to reach a unanimous vote on
any matter, then the matter shall be referred to the Chief Executive Officer of Replidyne

 [ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

 18.

 

and the
Chief Executive Officer of Forest’s corporate parent, Forest Laboratories, Inc. (“Forest Parent”)
for further discussion and resolution. These individuals shall as soon as practicable attempt in
good faith to resolve the matter and thereby make the decision on behalf of the JDC. These
individuals may obtain the advice of other employees or consultants as they deem necessary or
advisable in order to make the decision.

               (d) Limits on Authority. The JDC will have only such powers as are specifically
delegated to it in this Agreement, and will have no power to amend this Agreement or waive a
party’s rights or obligations under this Agreement.

          3.2 Joint Marketing Committee.

               (a) Formation. Promptly after the Effective Date, the parties will form a Joint
Marketing Committee (the “JMC”) comprised of three (3) representatives of each of Forest and
Replidyne. The chairperson of the JMC shall be selected by Forest. The JMC shall meet at least
four (4) times per year or at such greater frequency as the JMC agrees. Such meetings may be
conducted by videoconference, teleconference or in person, as agreed by the parties (except that at
least two (2) of such meetings per year shall be conducted in person), and
the parties shall agree upon the time of meetings. Within thirty (30) days after each
meeting, the JMC chairperson will provide the parties with a written report describing, in
reasonable detail, the status of the parties’ activities under the Marketing Plan, a summary of the
results and progress to date, the issues requiring resolution, and the agreed resolution of
previously reported issues. Subject to prior coordination with the other party, a reasonable
number of additional representatives of a party may attend meetings of the JMC in a non-voting
capacity, consistent with the agendas and purposes for such meetings. Each party shall make
available personnel having responsibility for Product development for consultation with or
membership on the JMC at such times and to the extent the JMC is considering issues relating to
Phase IV or other clinical trials of the Product.

               (b) Responsibilities. The JMC shall oversee and manage the commercialization strategy
for Products in the Field in the Territory. In addition to its general responsibilities, the JMC
shall in particular:

                    (i) review and approve the Marketing Plan, including, without limitation, the portions
relating to marketing to Target Specialists and Pediatricians, and amendments and updates thereto;

                    (ii) develop strategies for conducting Phase IV clinical trials of Products following the
initial NDA Approval to support marketing the Product;

                    (iii) coordinate the parties selling activities among Primary Care Physicians and Specialists,
including Target Specialists and Pediatricians; and

                    (iv) carry out the other duties and responsibilities described for it in this Agreement.

               (c) JMC Decision Making. Decisions of the JMC shall be made by

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

 19.

 

unanimous vote, with
the Replidyne members collectively having one (1) vote and the Forest members collectively having
one (1) vote. No vote of the JMC may be taken unless at least two (2) of each party’s
representatives on the JMC are present to vote. If the JMC is unable to reach a unanimous vote on
any matter, including, without limitation, as to the approval or amendment of any Marketing Plan,
the matter shall be referred to the Chief Executive Officer of Replidyne and the Chief Executive
Officer of Forest Parent for further discussion and resolution. These individuals shall as soon as
practicable attempt in good faith to resolve the matter and thereby make the decision on behalf of
the JMC. These individuals may obtain the advice of other employees or consultants as they deem
necessary or advisable in order to make the decision. Except as provided in the following two
sentences, if the Chief Executive Officer of Replidyne and the Chief Executive Officer of Forest
Parent are unable to reach agreement on any such matter, including, without limitation, as to the
approval or amendment of any Marketing Plan (including the determination of aggregate Marketing and
Sampling Expense and the allocation thereof among the various components of such expense, such as
medical education, sales aids, sample expense and journal advertising), the Chief Executive Officer
of Forest Parent shall have the final decision-making authority on such matter. If Replidyne is
then participating in
promotional activities with respect to Target Specialists, the strategic objectives and total
funding commitment and allocation thereof for promotional activities directed to Target Specialists
to be reflected in the Marketing Plan will be decided as above, however any matter relating to the
implementation of the strategic objectives of the Marketing Plan with respect to the promotion of
the Product to Target Specialists, including the specific uses of allocated funding, must be
resolved by the Chief Executive Officer of Replidyne and the Chief Executive Officer of Forest
Parent, which resolution must be consistent with the overall marketing strategy determined by the
JMC for the Tablets, as reflected in the Marketing Plan. If Replidyne has exercised the
Pediatrician Promotion Option and is then participating in promotional activities with respect to
Pediatricians, then any matter that relates to the pediatric portion of the Marketing Plan
(including its approval or amendment, provided, however, that such pediatric portion of the
Marketing Plan shall be consistent with the overall Marketing Plan) or its implementation
including, without limitation, marketing and Detailing of the Oral Suspension to Pediatricians and
non-Pediatricians, must be resolved by the Chief Executive Officer of Replidyne and the Chief
Executive Officer of Forest Parent.

               (d) Limits on Authority. The JMC will have only such powers as are specifically
delegated to it in this Agreement, and will have no power to amend this Agreement or waive a
party’s rights or obligations under this Agreement.

          3.3 Cost of Goods Committee.

               (a) Formation. Promptly after the Effective Date, the parties will form a Cost of
Goods Committee comprised of two (2) representatives of each of Forest and Replidyne, and the CGC
will be operative during any period that it appears reasonably likely, based upon objective
evidence discussed by the parties, that the Cost of Goods for a period will exceed [ *** ]. The
CGC shall oversee matters impacting the Cost of Goods for Products [ *** ]. For example, the CGC
shall review financial decisions for each formulation of the Product that relate to: (i) pricing
and discounting strategies; (ii) dosing and duration of therapy; and (iii) Drug Substance cost
reduction strategies, including hedging of exchange rate risk. The CGC shall meet at least two (2)
times per year or at such greater frequency as the CGC agrees. Such

 [ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

 20.

 

meetings may be conducted by
videoconference, teleconference or in person, as agreed by the parties (except that at least two
(2) of such meetings per year shall be conducted in person), and the parties shall agree upon the
time of meetings. Within thirty (30) days after each meeting, the CGC chairperson will provide the
parties with a written report describing, in reasonable detail, relevant matters pertaining to Cost
of Goods, any issues requiring resolution, and the agreed resolution of previously reported issues.
Subject to prior coordination with the other party, a reasonable number of additional
representatives of a party may attend meetings of the CGC in a non-voting capacity, consistent with
the agendas and purposes for such meetings.

               (b) CGC Decision Making. Decisions of the CGC shall be made by unanimous vote, with
the Replidyne members collectively having one (1) vote and the Forest members collectively having
one (1) vote. No vote of the CGC may be taken unless at least one (1) of each party’s
representatives on the CGC is present to vote. If the CGC is unable to reach a unanimous vote on
any matter, such matter shall instead be referred to the Chief Executive
Officer of Replidyne and the Chief Executive Officer of Forest Parent for further discussion
and resolution. These individuals shall as soon as practicable attempt in good faith to resolve
the matter and thereby make the decision on behalf of the CGC. These individuals may obtain the
advice of other employees or consultants as they deem necessary or advisable in order to make the
decision. If the Chief Executive Officer of Replidyne and the Chief Executive Officer of Forest
Parent are unable to reach agreement on any matter, the Chief Executive Officer of Forest Parent
shall have the final decision-making authority on such matter.

               (c) Limits on Authority. The CGC will have only such powers as are specifically
delegated to it in this Agreement, and will have no power to amend this Agreement or waive a
party’s rights or obligations under this Agreement.

	4.	 	Conduct of the Development Program

          4.1 Development Program Activities. Development and regulatory activities for Products in the
Field in the Territory will be conducted as outlined in the Development Plan. For clarification,
Phase IV marketing studies are not considered to be development activities. The JDC shall
determine on a Calendar Quarter basis the number of FTEs of each party that will work on the
Development Program during such Calendar Quarter. Any amendments or revisions to the Development
Plan shall be in writing and shall require unanimous approval of the JDC. Each party, as
applicable, will use Commercially Reasonable Efforts to execute and to perform, or cause to be
performed, the activities set forth in the Development Plan, in each case in compliance with the
terms of this Agreement and Applicable Laws. If a party proposes development activities for
Products in the Field in the Territory, but the JDC does not reach agreement to include such
development activities in the Development Plan, the parties will discuss and agree whether one
party can proceed with such development activities at its own expense and, if so, on what terms the
results of such development activities would be made available to the other party by the party that
conducts such development activities.

          4.2 Oral Suspension Development. As a specific activity under the Development Program, the
parties will collaborate to complete development of an Oral Suspension, with the goal of maximizing
efficiency and controlling Development Costs by utilizing the expertise and existing resources of
each of the parties. The JDC shall allocate tasks between the parties and to

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

 21.

 

Third Parties based
on the availability of expertise to conduct development activities cost effectively. The
allocation of each party’s responsibilities shall be set forth in the Development Plan.

          4.3 Technology and Information Transfer. Commencing promptly after the Effective Date and
from time to time thereafter during the Term, Replidyne shall disclose to Forest such Licensed
Technology in Replidyne’s possession as is reasonably necessary or useful to enable Forest to
exercise fully the licenses granted to Forest under Article 2. Commencing promptly after the
Effective Date and from time to time thereafter during the Term, Forest will disclose to Replidyne
such Forest Technology in Forest’s possession as is reasonably necessary or useful to enable
Replidyne to perform its Development Program activities hereunder in accordance with the
Development Plan and otherwise to exercise fully the licenses granted to
Replidyne under Article 2 hereof. Each party will, at no cost or expense to the other party,
provide such other party with copies of or access to any and all Development Information generated
or otherwise obtained in the development of Products as provided in this Section 4.3, all of which
Development Information may be used and referenced by or on behalf of Forest in the development,
manufacture and/or commercialization of Product in the Field in the Territory in accordance with
the terms of this Agreement and by or on behalf of Replidyne in the performance by Replidyne of the
development and commercialization activities with respect to the Product in the Field in the
Territory in accordance with the terms of this Agreement and (including, as appropriate and,
without limitation, by DAP) in the development, manufacture and/or commercialization of Product in
the Field outside the Territory, including, without limitation, in the preparation, submission,
filing, prosecution and maintenance of regulatory approvals in the applicable territory. Moreover,
upon reasonable written notice from a party, the other party will provide regulatory authorities
with access to any Development Information for inspection and/or review as may be required under
Applicable Law.

          4.4 Clinical Supply. The parties will utilize Replidyne’s Product facility for Development
Program purposes (e.g., Oral Suspension and Tablet formulation development) unless and until
alternative facilities are available, with the costs incurred for such activity treated as
Development Costs. Costs of manufacture and supply of Drug Substance and Product for development
activities, including clinical trials, shall be treated as a Development Cost. Subject to the
foregoing, the JSC (or if the JSC no longer exists, the party that is in charge of supply) shall be
responsible for arranging for the supply of Drug Substance necessary for producing required
clinical quantities of Product. Responsibility for packaging and labeling of clinical quantities
of Product shall be assigned in the Development Plan.

          4.5 Development Reports. Each party shall keep the other party fully informed as to all
discoveries and technical developments (including, without limitation, any Inventions) made in the
course of performing activities under the Development Program. In particular, each party shall
prepare, and distribute to all members of the JDC no later than ten (10) days prior to the next JDC
meeting, such report as the JDC may request setting forth such information regarding the results
and progress of performance of the Development Program. Nothing herein shall require a party to
disclose information received from or generated for a Third Party that remains subject to bona fide
confidentiality obligations to such Third Party; provided that neither party shall undertake any
such confidentiality obligations in favor of Third Parties to the extent such obligations could
reasonably be expected to prevent the sharing of information necessary or

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

 22.

 

useful for the efficient
conduct of the Development Program.

          4.6 Development Costs.

               (a) Allocation of Costs. Replidyne will bear [ *** ] percent ([ *** ]%) and Forest
will bear [ *** ] percent ([ *** ]%) of the Development Costs incurred by the parties under the
Development Plan, including without limitation Development Costs incurred for clinical development
necessary to support NDAs for a Tablet in a 600 mg dosage and an Oral Suspension.

               (b) Reports and Payments. Each party shall report to the other party within thirty
(30) days after the end of each Calendar Quarter the Development Costs incurred by such party
during such Calendar Quarter. Such report shall specify in reasonable detail all amounts included
in such Development Costs during such Calendar Quarter (broken down by activity) and shall be
accompanied by invoices or other appropriate supporting documentation for any payments made by such
party to Third Parties that individually exceed fifty thousand dollars ($50,000) or as may be
determined by the JDC. Within forty five (45) days after the end of each Calendar Quarter, the
party that has paid less than its share of such Development Costs as provided in Section 4.6(a)
shall make a reconciling payment to the other party to achieve the appropriate allocation of
Development Costs provided in Section 4.6(a). Each such report shall enable the receiving party to
compare the reported Development Costs against the Development Plan, on both a quarterly basis and
a cumulative basis for each activity. The parties shall seek to resolve any questions related to
such accounting statements within fifteen (15) days following receipt by each party of the other
party’s report hereunder.

          4.7 Registration Activities. Regulatory strategy for the Product and all decision-making with
respect thereto shall be determined by the JDC. Prior to the Effective Date, Replidyne has
prepared and submitted to the FDA a NDA for a Tablet in a 300 mg dosage. Replidyne and Forest will
collaborate to develop and prepare for submission any supplemental NDAs or additional NDAs for the
Products, with the specific responsibilities of each party’s personnel to be assigned by the JDC
based on the availability of expertise and resources within each party’s organization. Replidyne
shall hold the NDA for the Tablet and any subsequent supplemental NDAs for the Tablet until
approval of the NDA for the Tablet, at which time Forest will become the holder of such NDA. The
IND and NDA for the Oral Suspension will be filed in Replidyne’s name, and Replidyne shall hold the
NDA and any subsequent supplemental NDAs for the Oral Suspension until approval of the NDA for the
Oral Suspension, at which time Forest will become the holder of such NDA. Irrespective of which
party prepares any such NDA or portion thereof, the other party shall be given the opportunity to
review and provide comments on any such submission and no such NDA (including any supplemental NDA)
shall be submitted for filing to the FDA without the mutual agreement of Forest and Replidyne, such
consent not to be unreasonably withheld or delayed. Forest and Replidyne shall keep one another
fully informed of the registration process of Product through the Joint Development Committee.
Each party shall use Commercially Reasonable Efforts to obtain in a timely manner NDA Approvals for
Products.

          4.8 Meetings and Communications with the FDA. As of the date(s) to be mutually agreed by the
parties, but in any event within six (6) months after the Effective Date, Forest shall

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

 23.

 

be
designated as Replidyne’s agent for purposes of adverse event reporting, sample tracking and
submissions and interactions with the FDA’s Division of Drug Marketing, Advertising and
Communications with respect to Products in the Territory and shall have the primary responsibility
for the associated subject matters. Subject to the provisions of Section 4.7, Replidyne shall be
primarily responsible for and have the authority to conduct interactions with the FDA regarding NDA
approval matters until transfer of the NDA to Forest, following which Forest shall have such
primary contact responsibilities. Irrespective of which party has such primary contact
responsibility, the other party shall be notified in advance of any
substantive communications with the FDA and shall be afforded the opportunity to participate
in such communications. Subject to the preceding sentence, to the extent permitted by the FDA,
Replidyne and Forest shall mutually attend all meetings, participate in any oral communications and
agree upon any written communications with the FDA relating to Product and labeling discussions
with the FDA shall be conducted jointly by Forest and Replidyne.

          4.9 Subcontracts. Each party may perform some of their obligations under the Development Plan
through one (1) or more Affiliates or subcontractors; provided that (a) none of the rights of
either party hereunder are diminished or otherwise adversely affected as a result of such
subcontracting, and (b) the Affiliate or subcontractor undertakes in writing obligations of
confidentiality and non-use regarding Confidential Information which are substantially the same as
those undertaken by the parties pursuant to Article 11 hereof. If a party performs any of its
obligations under this Agreement through an Affiliate or subcontractor, then such party will at all
times be responsible for the performance and payment of such Affiliate or subcontractor and will
actively monitor and supervise the work of such Affiliate or subcontractor. Notwithstanding the
foregoing, in the event a party desires to use a subcontractor hereunder, it will first offer the
other party the opportunity to provide the affected services utilizing its internal resources to
the extent such other party possesses qualified resources to provide such services in a timely and
efficient manner and at a cost competitive to the use of Third Party resources.

          4.10 Materials Transfer. In order to facilitate the Development Program, either party may
provide to the other party certain biological materials or chemical compounds Controlled by the
supplying party (collectively, “Materials”) for use by the other party in furtherance of the
Development Program. Except as otherwise provided under this Agreement, all such Materials
delivered to the other party will remain the sole property of the supplying party, will be used
only in furtherance of the Development Program in accordance with this Agreement, will not be used
or delivered to or for the benefit of any Third Party without the prior written consent of the
supplying party, and will be used in compliance with all applicable laws, rules and regulations.
The Materials supplied under this Agreement must be used with prudence and appropriate caution in
any experimental work because not all of their characteristics may be known. Except as expressly
set forth herein, and provided that the materials shall comply with any certificate of analysis or
specifications provided by or on behalf of the supplying party, the Materials are provided “as
is” and without any representation or warranty, express or implied, including without limitation
any implied warranty of merchantability or of fitness for any particular purpose or any warranty
that the use of the Materials will not infringe or violate any patent or other proprietary rights
of any third party.

          4.11 Liability. In connection with the conduct of the Development Program, Replidyne will
bear [ *** ] and Forest will bear [ *** ] of any liability for personal injury or

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

 24.

 

property damage
arising in connection with the conduct of the clinical development activities and the
indemnification obligations of the parties set forth in Article 13 with respect to these matters
shall be applied in a manner consistent with such allocation of liability; provided, however, that
each party shall be responsible for, and hereby assumes, any and all risks of personal injury or
property damage attributable solely to the negligence or willful misconduct of
that party or its Affiliates, and their respective directors, officers, employees and agents.

	5.	 	Commercialization

          5.1 Forest General Commercial Responsibilities. Forest or its Affiliate shall be responsible,
at its own expense, for the conduct of all promotion, marketing, sampling, pre-launch, launch and
sales activities with respect to Products in the Field in the Territory, subject to Replidyne’s
promotion, marketing, sampling and sales activities with respect to Products to Target Specialists
in the Territory, as more fully described in Section 5.4, and if Replidyne exercises the
Pediatrician Promotion Option pursuant to Section 5.5, to Pediatricians in the Territory.

          5.2 Marketing Plans. Within a reasonable period of time after the Effective Date, Forest or
its Affiliate shall prepare and submit to the Joint Marketing Committee for review and approval a
Marketing Plan. The Marketing Plan for each Detailing Year shall include (a) marketing strategy,
(b) sales forecasts, (c) amounts budgeted for expenditures by Forest on Marketing and Sample
Expense for the Product in such Detailing Year, (d) a sampling plan with respect to the Product,
(e) the aggregate number and monthly or quarterly breakdown of Detailing calls with respect to the
Product that are projected in such Detailing Year, including the frequency of Details and the
proportion of Details to be provided in first and second positions, and (f) the percentage of the
total Detailing calls with respect to the Product to be performed by the Replidyne Specialty Sales
Force in such Detailing Year and shall be prepared with input from Replidyne, including
specifically, input as to those portions of the Marketing Plan describing activities directed to
Target Specialists, which shall be consistent with the overall Marketing Plan for non-Target
Specialists. A separate Marketing Plan shall be prepared for each Product subsequently launched,
the initial version of which shall be submitted to the JMC for review and approval not later than
three (3) months after NDA Acceptance for such Product. The Marketing Plan shall be updated on an
annual basis approximately [ *** ] months in advance of the beginning of the next applicable
Detailing Year. The JMC shall then discuss and agree upon such updated Marketing Plan within
thirty (30) days after submission of such Marketing Plan to the JMC.

          5.3 Diligence.

               (a) Forest shall use Commercially Reasonable Efforts to promote, market and sell Product in
the Field in the Territory in accordance with the Marketing Plan.

               (b) The launch of the Tablet in a 300 mg dosage by Forest or its Affiliates in the Territory
shall take place within no more than six (6) months following NDA Approval of such Product,
including, for this purpose, FDA approval of labeling and product launch promotional materials for
such Product (provided that such that such NDA Approval includes approval for use in (i) acute
sinusitis and (ii) and one of the following: (A) community acquired

 [ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

25.

 

pneumonia; or (B) the AECB Indication, unless the JMC determines that seasonality
considerations support extending the launch time by up to an additional three (3) months). In
addition, Forest’s obligation to launch is subject to having approved dating for the Product of at
least eighteen (18) months and having available launch supplies of Product having such dating (it
being agreed that Forest shall be required to order Drug Substance when it is commercially
reasonable to do so, with the understanding that receipt of an approvable letter from the FDA is
not necessary for a determination that it is commercially reasonable to order Drug Substance for
such Product supplies).

          (c) Without limiting the generality of the foregoing, Forest agrees that in each of the first
[ *** ] sales years following the First Commercial Sale of the first Tablet subject to NDA
Approval, Forest (i) will provide at least [ *** ] Details for the Tablet and (ii) will incur at
least [ *** ] dollars ($[ *** ]) in Marketing and Sample Expense; provided that if there is any
development (including Forest’s launch of the Product with only one approved respiratory
indication) that is material and adverse to the market potential for the Tablet or materially and
adversely affects the commercial value of Detailing efforts, and such specific commitment is no
longer commercially reasonable in light of such development, then the preceding specific commitment
shall be reduced to a commercially reasonable level mutually agreed by the parties.

          (d) Following launch of the first Oral Suspension, Commercially Reasonable Efforts with
respect to the promotion and marketing of the Product to all audiences in the Territory shall
require a significant increase over the level of resources applied to the promotion of the Tablets
alone in the preceding year to reflect the additional value of the Oral Suspension. Without
limiting the generality of the foregoing, the party responsible for promotional activities directed
toward Pediatricians (i.e., Replidyne, if Replidyne has exercised the Pediatrician Promotion
Option, and otherwise Forest) shall provide at least [ *** ] Details directed to Pediatricians
during each of the first [ *** ] sales years following the First Commercial Sale of the Oral
Suspension; provided that if there is any development (including launch of the Oral Suspension
without approval of the AOM Indication) that is material and adverse to the market potential for
the Oral Suspension or materially and adversely affects the commercial value of Detailing efforts,
and such specific commitment is no longer commercially reasonable in light of such development,
then the preceding specific commitment shall be reduced to a commercially reasonable level mutually
agreed by the parties.

          (e) Irrespective of which party performs Detailing activities directed toward Pediatricians,
the Marketing Plan will contain sections describing activities directed to Pediatricians, as well
as the marketing of the Oral Suspension to non-Pediatricians, which sections will be consistent
with the JMC’s overall marketing strategy for the Product in the Territory and with the overall
Marketing Plan. The Marketing Plan shall establish goals for Detailing of the Product to
Pediatricians and Detailing of the Oral Suspension to non-Pediatricians for each Detailing Year,
including establishing the number and frequency of Details to be provided and the proportion of
Details to be provided in first and second positions. In addition, the Marketing Plan for each
Detailing Year shall also specify the proportion of Marketing and Sample Expense for efforts
directed to Primary Care Physicians and other non-Pediatricians, on the one hand, to Marketing and
Sample Expense for efforts directed to Pediatricians, on the other hand (the “Marketing Expense
Ratio”), with the JMC allocating Forest’s Marketing and Sample Expense directed to Primary Care
Physicians and other non-

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

26.

 

Pediatricians on a reasonable basis between the Tablet and the Oral Suspension so that such
Marketing and Sample Expense related to the Oral Suspension may be used as the Non-Pediatrician
Suspension Marketing and Sample Expense, and shall specify minimum marketing contributions to be
made by Forest and Replidyne (if Replidyne has exercised the Pediatrician Promotion Option),
respectively, based on the Marketing Expense Ratio. In the absence of objective evidence to the
contrary, the Marketing Expense Ratio shall assume an equal per physician value of promotion to
Pediatricians and non-Pediatricians. In addition, whether or not Replidyne has exercised the
Pediatrician Promotion Option, the party performing promotional activities directed to
Pediatricians will use Commercially Reasonable Efforts to execute such activities and the diligence
requirements of Section 2.3 of Schedule 5.5 shall apply to such promotional activities.

     5.4 Replidyne Commercial Activities for Target Specialists. Forest shall, through Forest
Parent, engage Replidyne to perform all marketing and promotion-related activities for the Products
directed to Target Specialists. Replidyne will promptly notify Forest at any time that it appears
reasonably likely that Replidyne will not be able to substantially achieve required levels of
Detailing over any significant period or in any significant area. Following any such notice, the
parties will meet and confer in good faith to develop a plan to achieve such required levels of
Detailing as promptly as practicable, including through the reallocation of Replidyne personnel, if
practicable and without adversely affecting Replidyne’s Detailing efforts, and the utilization of
Forest sales force personnel as reasonably required to achieve the required levels of Detailing.
Following the development of such plan, Forest shall have the right to call on Target Specialists
as provided by the plan, in which case the JMC will coordinate the efforts of each of Forest and
Replidyne with respect to the Detailing of Product to Target Specialists by each party. In
addition, if (a) Replidyne elects not to provide Details of the Product to certain Target
Specialists (e.g., due to a particular geographical location), the Detail Reports indicate that
Replidyne’s Detailing has not achieved material Detailing requirements to be performed by Replidyne
as targeted by the Marketing Plan (as to number or position of Details) over a significant period
or (b) the JMC determines, prior to a formal annual update to the Marketing Plan, that Detailing
efforts to Target Physicians in addition to those in the then current Marketing Plan are
appropriate and authorizes additional funds, if required (subject to the maximum funding set forth
in Section 7.10(c)), to support such additional Detailing efforts to Target Physicians, the parties
will meet and confer in the manner set forth above to develop a plan to address the provision of
additional Details, which plan will be based on the considerations, and implemented by the parties,
as provided above. In any such event requiring the utilization of Forest sales force personnel,
the parties will cooperate to transition Detailing efforts to Replidyne as promptly as practicable
in light of the need to assure a smooth transition of Detailing activities once Replidyne possesses
adequate resources to provide Detailing efforts targeted by the Marketing Plan. During the
Replidyne Specialist Promotion Period, Replidyne will use its Commercially Reasonable Efforts to
provide Detailing to Target Specialists in accordance with the Marketing Plan through the Replidyne
Specialty Sales Force.

     (a) Organization of Replidyne Specialty Sales Force. The JMC will determine the
number of Target Specialists to be on the call plan, call frequency and other matters necessary to
determine the size of the Replidyne Specialty Sales Force. The JMC will also determine what
ancillary personnel and activities, if any, are needed to enhance Target

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

27.

 

Specialist promotional efforts and which are to be: (i) provided by Replidyne at Replidyne’s
cost; (ii) provided in-kind by Forest for Replidyne’s use; or (iii) provided by Replidyne but
reimbursed by Forest. For purposes of determining the size and geographical distribution of the
Replidyne Specialty Sales Force, the call plan will contemplate approximately [ *** ] Target
Specialists and a call frequency of an average of [ *** ] Details per Detailing Year; provided that
in any event, the Replidyne Specialty Sales Force will be comprised of at least fifty (50) sales
representatives, each having a sales territory that allows such sales representative to call upon a
reasonable number of Target Specialists within a reasonable geographic area (i.e., without
overly-burdensome travel requirements). During the Pre-Launch Period, Replidyne shall use its
Commercially Reasonable Efforts to engage and organize the Replidyne Specialty Sales Force. The
Replidyne Specialty Sales Force will be organized by Replidyne under the general recommendations
and supervision of the JMC as to numbers and qualifications of sales representatives and
field-based sales managerial personnel and the timing of hiring in light of the then-current
Marketing Plan. Such sales representatives shall have qualification and experience at least
comparable to Forest’s sales representatives and shall be entitled to incentive compensation with
respect to the marketing of the Product on a basis not materially less favorable to the Product
than provided by Forest to its sales representatives. During the Initial Period, the Replidyne
Specialty Sales Force may be comprised of personnel provided by a contract sales organization;
provided that at the end of the first [ *** ] of the Initial Period, the JMC shall determine
whether:

               (i) the Replidyne Specialty Sales Force has delivered [ *** ] percent ([ *** ]%) of the
Details set forth in the Marketing Plan for that time period;

               (ii) at least [ *** ] percent ([ *** ]%) of the Details performed by Replidyne Specialty Sales
Force during that time period were delivered to Target Specialists on the call panel and with the
frequency and Detail position established by the JMC; and

               (iii) the performance by the Replidyne Specialty Sales Force meets the metrics previously
established by the JMC to be measured in an ImpactRX report obtained at the [ *** ] benchmark
point.

     If the Replidyne Specialty Sales Force fails to meet the foregoing requirements, Replidyne
will provide written notice to Forest within [ *** ] of such determination by the JMC, indicating
whether Replidyne will (A) transition to a sales force comprised of personnel who are full-time
employees of Replidyne and coordinate Detailing to Target Specialists together with Forest’s sales
representatives pending the achievement of a full-time employee trained and qualified sales force
or (B) terminate its promotional efforts with respect to Target Specialists, in each case over the
course of the [ *** ] month period immediately following such notice.

          (b) Training Materials and Sessions. Forest shall provide Replidyne with training
materials Forest provides to the Forest Sales Force, sufficient in quantity and quality to allow
Replidyne to train the Replidyne Specialty Sales Force in Product-specific sales skills and to
Detail the Product in a manner consistent with the Detailing performed by the Forest Sales Force.
Replidyne will prepare or have prepared any supplementary training materials required for Detailing
the Product to the Target Specialists, consistent with the applicable Marketing Plan. Forest will
permit Replidyne sales representatives to participate in training sessions of the Forest

 [ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

28.

 

Sales Force in Product-specific sales skills with respect to the Product and the indications
for the Product and will provide reasonable advance notice to Replidyne of scheduled training
events. Without limiting the generality of the foregoing, the parties intend that the Replidyne
Specialty Sales Force will participate in the initial Product launch and subsequent sales force
meetings to the extent related to the Product.

          (c) Promotional Materials. Forest shall provide Replidyne with sales and promotional
materials reasonably sufficient to permit Replidyne to perform Detailing calls in a manner
consistent with the Detailing calls performed by the Forest Sales Force. Replidyne will create or
have created on its behalf such additional sales and promotional materials intended to be specific
to the Target Specialist audience as called for under, and consistent with, the Marketing Plan.
The project managers of each party will share with one another any such materials, and no such
materials may be utilized until completion of Forest’s regulatory and compliance review.

          (d) Sampling. Forest shall provide Replidyne with Product samples reasonably
sufficient to permit Replidyne to perform Detailing calls in accordance with the Marketing Plan.
Replidyne shall be responsible for accounting for sample distribution by the Replidyne Specialty
Sales Force and shall maintain all records with respect to sample distribution as required by
applicable laws and regulations. Within thirty (30) days after the end of each month, Replidyne
shall provide to Forest a written report summarizing samples distributed by the Replidyne Specialty
Sales Force for such calendar month. In addition, Replidyne shall ensure, through appropriate
routine monitoring and auditing standards which conform with current good industry practices, that
sampling of the Product is carried out by Replidyne in a manner which is in compliance with all
Applicable Laws. Replidyne shall immediately advise Forest of its discovery of any act or omission
of Replidyne regarding sample distribution that could violate or require reporting under applicable
law. Forest shall be solely responsible for the filing of any necessary reports to FDA in
connection with sampling. Within thirty (30) days after the expiration or termination of the
Replidyne Specialist Promotion Period, Replidyne shall return, or otherwise dispose of in
accordance with written instructions from Forest, all remaining samples and will provide Forest
with a certified statement that all remaining samples have been returned or otherwise properly
disposed of in accordance with Forest’s instructions and that Replidyne is no longer in possession
or control of any samples in any form or fashion.

          (e) Funding. Forest will reimburse Replidyne for the Sales Force Expense and
Marketing and Sampling Expense incurred by Replidyne in the performance of the activities to be
conducted by the Replidyne Specialty Sales Force and ancillary personnel of Replidyne in accordance
with the Marketing Plan, as provided in Section 7.10. If Replidyne engages a contract sales
organization rather than hiring its own employees for purposes of forming the Replidyne Specialty
Sales Force, [ *** ]. Replidyne shall not be obligated to incur expenses for any marketing or
promotional activities directed at Target Specialists, other than those expenses that are Sales
Force Expense and Marketing and Sampling Expense to be reimbursed by Forest, unless Replidyne
elects in its sole discretion to do so, provided that, unless Replidyne elects to cease promotional
activities to Target Specialists and to transition such activities to Forest within a six-month
period, Replidyne shall be responsible for the ancillary costs of the Replidyne Specialty Sales
Force which are not Sales Force Expense. If at any time during the Replidyne

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

29.

 

Specialist Promotion Period, the limits on Forest’s reimbursement of the Sales Force Expense
and Marketing and Sampling Expense as set forth in Section 7.10 are such that Forest’s funding of
the Replidyne activities directed to Target Specialists falls below the level sufficient to execute
the Marketing Plan with respect to Target Specialists, except to the extent of the ancillary costs
referred to in the preceding sentence, Replidyne shall not be obligated to supplement the funding
to meet the goals of the Marketing Plan with respect to Target Specialists.

          (f) Additional Support. Forest will offer to Replidyne, free of charge, but at no
additional out-of-pocket cost to Forest, reasonable access to Forest’s personnel and technology
infrastructure as may be available to provide support for Replidyne’s marketing and promotion to
Target Specialists (including without limitation, External Scientific Affairs and trainers,
information technology support personnel and personnel responsible for accounting for sample
distribution, database access, and access to Forest sample ordering systems).

          (g) Extension; Termination. The Replidyne Specialist Promotion Period shall be
subject to renewal or extension by the written agreement of the parties. Replidyne reserves the
right to terminate its promotional efforts under Section 5.4 at any time during the Replidyne
Specialist Promotion Period, effective upon twelve (12) months written notice to Forest. If
Replidyne exercises the foregoing right, Replidyne shall provide such transition activities as and
for such period as Forest may reasonably request, including, without limitation, arranging for
meetings between members of the Replidyne Specialty Sales Force and sales representatives of
Forest, to assure a smooth transition of marketing to Target Specialists, subject to Forest’s
payment of Sales Force Expense and Marketing and Sample Expense incurred by Replidyne with respect
to such transition activities during any such transition period.

          (h) Forest Termination Right. If Forest ceases the promotion, sale or distribution of
the Product in the Territory under the circumstances permitted under this Agreement, then upon
written notice to Replidyne, Forest may terminate the Replidyne Specialist Promotion Period,
effective within a reasonable period of time in light of the circumstances underlying any such
cessation by Forest. In addition, Forest reserves the right to terminate the Replidyne Specialist
Promotion Period, effective upon [ *** ] written notice to Replidyne in the event that the Detail
Reports for at least [ *** ] indicate that Replidyne’s Detailing has not achieved at least [ *** ]
percent ([ *** ]%) of the Detailing to be performed by Replidyne as targeted by the Marketing Plan
(as to number or position of Details) for each such Calendar Quarter or upon the failure by
Replidyne to achieve at least [ *** ] percent ([ *** ]%) of the Detailing to be performed by
Replidyne as targeted by the Marketing Plan (as to numbers or portions of Details) in the aggregate
over a period of [ *** ], unless in either case, during such [ *** ] period Replidyne develops and
implements a program of increased Detailing which provides, to Forest’s reasonable satisfaction,
assurance that Detail shortfalls will not again occur. Failure of Replidyne to meet the number of
Details required under the Marketing Plan with respect to promotion efforts directed to Target
Specialists shall not be deemed a material breach under this Agreement and, notwithstanding Section
12.8, shall not entitle Forest to claim any damages, compensation or relief except as provided in
this Section 5.4(h) and Section 7.10(c)(ii).

     5.5 Pediatrician Promotion Option. Forest hereby grants to Replidyne an exclusive

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

30.

 

option (the “Pediatrician Promotion Option”) to promote the Products on an exclusive basis to
Pediatricians in the Territory through the Replidyne Pediatrician Sales Force (the “Pediatrician
Promotion Rights”), exercisable by written notice to Forest at any time before the date that is six
(6) months prior to the projected date determined by the JDC for the submission of the first NDA
for an Oral Suspension. If Replidyne exercises the Pediatrician Promotion Option, the terms and
conditions of Schedule 5.5 shall apply with respect to the launch, promotion, marketing, sampling
and sale of Products in the Field in the Territory to Pediatricians and shall take precedence over
any provision of this Agreement to the contrary to the extent applicable to the launch, promotion,
marketing, sampling and sale of the Product to Pediatricians in the Field in the Territory.

     5.6 Product Management; Distribution; Returns.

          (a) Forest shall have sole responsibility for the distribution, sale and invoicing of the
Product in the Field in the Territory. All orders for the Product in the Field in the Territory
shall be subject to acceptance by Forest. Forest shall have sole discretion to make pricing and
discounting decisions with respect to the Product, provided that material pricing and discount
strategies will be reviewed and discussed by the JMC.

          (b) Forest will have the exclusive right and responsibility at its cost to (i) receive and
fill order for the Product in the Territory, (ii) warehouse and distribute the Product in the
Territory, (iii) control invoicing, order processing and collection of accounts receivable for the
Product in the Territory, and (iv) engage in all other activities relating to the ordering and
distribution of the Product in the Territory.

          (c) If quantities of the Product sold in the Territory are returned to Replidyne, Replidyne
shall notify Forest in writing and ship them to the facility designated by Forest, with any
reasonable or authorized shipping or other cost to be paid by Forest. Replidyne, at its option,
may advise the customer who made the return that the Product has been returned to Forest, but shall
take no other steps in respect of any such return without the written consent of Forest.

     5.7 Medical Inquiries; Product Complaints.

          (a) Forest shall be responsible for formulating responses and answering medical questions and
inquiries from members of the medical and paramedical professions and consumers regarding the
Product in the Territory. Replidyne shall comply with the reasonable directions and policies
established by Forest in connection therewith, including, but not limited to, that all requests for
written responses to medical inquiries shall be routed to and answered by Forest.

          (b) Replidyne shall refer all Product complaints (e.g., tampering, contamination, mix-up,
discoloration, incorrect quantities) in the Territory to Forest promptly after notice thereof (but
in any event within one (1) business day). Product complaints shall be handled by Forest in the
ordinary course of its business and, subject only to Replidyne’s right to comply with all
applicable laws and regulations, Replidyne shall not otherwise handle any such Product complaints
in the Territory.

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

31.

 

          (c) If Replidyne has exercised the Pediatrician Promotion Right, Forest shall consult with
Replidyne regarding standardized responses to medical inquiries and product complaints involving
the Oral Suspension (as may be updated from time to time), and shall give good faith consideration
to any comments provided by Replidyne with respect thereto. On a periodic basis, Forest will
provide Replidyne with copies of product technical complaints regarding the Oral Suspension and the
results of Forest’s investigations of such complaints.

     5.8 Compliance with Law.

          (a) Each party shall comply in all material respects with Applicable Laws with respect to its
obligations under this Article 5 and shall maintain all licenses, permits, approvals and other
authorizations applicable to it in order to enable it to perform its obligations under this Article
5. Forest shall adopt and maintain compliance standards consistent with guidelines announced by
the Office of Inspector General of the Department of Health and Human Services, the American
Medical Association and other recognized medical or pharmaceutical organizations. With respect to
its marketing and promotion-related activities for the Products directed to Target Specialists,
Replidyne shall comply with Forest’s compliance standards. Forest will periodically inform
Replidyne of such compliance standards and issues may be submitted to the JMC for resolution by
Forest’s compliance function.

          (b) Forest shall be responsible for accounting for sample distribution by the Forest Sales
Force and shall maintain all records with respect to sample distribution as required by applicable
laws and regulations. In addition, Forest shall ensure, through appropriate routine monitoring and
auditing standards which conform with current good industry practices, that sampling of the Product
is carried out by Forest and its Affiliates in a manner which is in compliance with all Applicable
Laws. Forest shall immediately advise Replidyne of its discovery of any act or omission of Forest
with respect to Products that could violate or require reporting under applicable law.

          (c) Neither party shall make any claims or statements with respect to the Product that are not
strictly consistent with the sales and marketing materials approved for use pursuant to the
Marketing Plan.

     5.9 Commercialization Outside the Territory.

     (a) Subject to the coordination of worldwide Phase IV programs and publications pursuant to
Section 5.13, Replidyne shall have full control, authority and responsibility for the
commercialization of Product outside the Territory, subject to its agreements with Third Parties,
including, without limitation, pricing and reimbursement for Product, Product advertising and
promotional materials, Product packaging, sales force training and all interactions with regulatory
authorities regarding the commercialization of Product. The parties acknowledge that parallel
imports of the Product from Canada into the Territory at a substantially lower price than Product
is sold in the Territory could have a detrimental effect on the marketplace in the Territory.
Accordingly, Replidyne shall not: (i) sublicense rights to commercialize the Product in Canada; or
(ii) itself implement a launch plan for the Product in Canada, in each case without first
conferring with Forest regarding Replidyne’s or its sublicensee’s plans for mitigating the negative
impact of parallel imports of Product into the

 [ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

32.

 

Territory. Forest’s approval of such sublicense or
launch plan shall be required, which approval may be withheld only if Forest can reasonably
demonstrate that the plans to mitigate parallel imports of the Product (or corresponding generic
equivalents) from Canada into the Territory are inadequate for that purpose.

          (b) In the event that Replidyne proposes to sublicense rights to commercialize the Product in
the Field in Canada (the “Canadian Rights”) to any Third Party, Replidyne shall first provide
Forest with written notice thereof and hereby grants Forest the first right of negotiation with
respect to the Canadian Rights in accordance with this Section 5.9(b). Forest shall within [ *** ]
days after receipt of such notice notify Replidyne in writing either that (i) Forest is interested
in negotiating for the Canadian Rights; or (ii) Forest is not interested in negotiating the
Canadian Rights and therefore waives the right of first negotiation with respect to the Canadian
Rights. If Forest notifies Replidyne in writing within [ *** ] days that Forest is interested in
negotiating for the Canadian Rights, the parties shall negotiate in good faith the terms of the
Canadian Rights for up to [ *** ] days from such notification, it being understood that
the financial terms for the Canadian Rights shall be based on the value of the market for the
Product in Canada only (without valuing any expected sales into the United States market). Failure
by Forest to give written notice of its interest or lack of interest in negotiating for the
Canadian Rights within [ *** ] days after receipt of written notice from Replidyne shall be deemed
a waiver by Forest of its first right of negotiation with respect to the Canadian Rights. If
Forest waives or otherwise fails to exercise its first right of first negotiation with respect the
Canadian Rights, or if the parties fail to agree to the terms of the grant of the Canadian Rights
to Forest within such [ *** ] day negotiation period, then Replidyne shall be free to
grant the Canadian Rights to any Third Party and Forest shall have no further rights with respect
to the Canadian Rights, except as provided in Section 5.9(a), and except that Replidyne shall not
grant the Canadian Rights to any Third Party on terms which are less favorable to Replidyne than
those last offered to Replidyne by Forest without first offering the Canadian Rights to Forest on
such terms for a period of at least [ *** ] days. If Forest notifies Replidyne in writing within
such [ *** ] day period that Forest accepts such terms, the parties shall enter into an agreement
on such terms within thirty (30) days after such notice from Forest. If Forest does not notify
Replidyne in writing within such sixty (60) day period that Forest accepts such terms, then
Replidyne shall be free, subject only to the requirements of Section 5.9(a) (which shall be
addressed, if possible, during the period of negotiation under this Section 5.9(b)), to grant the
Canadian Rights to any Third Party on such terms, and Forest shall have no further rights with
respect to the Canadian Rights.

     5.10 Competitive Products. The parties agree that (i) from the Effective Date until the [ ***
] anniversary of the Effective Date, neither party shall, directly or indirectly, itself or through
one or more Affiliates or Third Parties, conduct or cause to be conducted clinical development of a
Competitive Product (including, without limitation, under any collaboration, license or similar
agreement), and (ii) from the Effective Date until the [ *** ] anniversary of the First Commercial
Sale, both parties agree that they shall not, directly or indirectly, itself or through one or more
Affiliates or Third Parties, market or sell any Competitive Product in the Field in the Territory.
For purposes of this Section 5.10, “Competitive Product” means exclusively any product, other than
a Product, that is [ *** ] an antibiotic having [ *** ] and directed to [ *** ]. The foregoing
restriction shall not prevent either party from marketing or

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

33.

 

selling a [ *** ] antibiotic for [ ***
]. If, after the [ *** ] anniversary of the First Commercial Sale, either party proposes to market
or sell a Competitive Product in the Territory, (a) such party must first consult with the other
party and provide reasonable assurances that such activities will not impair promotion and sale
efforts for the Product in the Territory, and (b) subject to subsection (a), such party may market
and sell a Competitive Product in the Territory; provided that such activities do not in fact
impair promotion and sales efforts with respect to Product in the Territory. At either party’s
request, the other party will provide documentation and other objective evidence to substantiate
that the marketing and sale of such Competitive Product will not impair promotion and sales efforts
for the Product. Further, at either party’s request, Forest and Replidyne will meet to discuss
such matters, and Forest agrees that DAP shall be permitted to attend such meeting. If either
party proposes to market or sell [ *** ] antibiotic in the Territory prior to the the [ *** ]
anniversary of the First Commercial Sale, it must first consult with the other party and provide
reasonable assurances that such activities will not impair promotion and sale efforts for the
Product in the Territory. Subject to the preceding sentence, either party may market and sell [
*** ] antibiotic in the Territory prior to the [ *** ] anniversary of the First Commercial Sale;
provided that such activities do not in fact impair promotion and sales efforts with respect to
Product in the Territory. Notwithstanding the foregoing, a party shall not be deemed in breach of
subsection (i) of this Section 5.10 if such party is subject to a Change in Control and promptly
following such Change in Control implements firewall mechanisms which assure to the reasonable
satisfaction of the other party that investment, clinical development efforts and subsequent sales
and promotion efforts with respect to the Product will not be adversely affected by such Change in
Control, and a party shall not be deemed in breach of subsection (ii) of this Section 5.10 if it
acquires a Competitive Product through a merger or acquisition by or of a Third Party and the
surviving entity (x) does not (or promptly ceases to) promote the Competitive Product actively, (y)
promptly announces its intention to divest such Competitive Product and thereafter completes such
divestment within [ *** ] months, or (z) promptly implements firewall mechanisms (including
separate sales forces and marketing management) which assure to the reasonable satisfaction of the
other party that sales and promotional efforts with respect to the Product will not be adversely
affected by such merger or acquisition.

     5.11 Phase IV and Publication Strategy. Neither party will undertake, or permit its
Affiliates or (sub)licensees to undertake, whether within or outside the Territory, any
pre-clinical or clinical marketing studies of the Product, including, without limitation, Phase IV
marketing studies, but excluding any studies required for registration or imposed by regulatory
authority in a country within a party’s territory, without consultation with, and approval of, the
JMC (which shall consult with appropriate development personnel of the parties for this purpose).
Forest agrees that it shall be subject to the same requirement of consultation with, and approval
of, Replidyne, DAP or their (sub)licensees outside the Territory, with regard to marketing studies
of the Product by Forest.

     The parties will also coordinate worldwide publication strategy and activities related to
scientific conferences inside and outside the Territory, including through delegation to
appropriate working groups of the parties. Each party shall be afforded the opportunity to review
and approve any scientific paper or presentation with respect to the Product proposed for
publication, presentation or distribution by the other party or its Affiliates and shall have no
more

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

34.

 

than ten (10) days to complete such review and approval. The party proposing publication or
presentation shall not unreasonably reject comments furnished by the other party, will comply with
the other party’s request to delete references to the its Confidential Information in any such
publication or presentation and will delay publication for such reasonable period requested by the
other party to permit the filing of patent applications concerning any Licensed Technology, Forest
Technology or Joint Inventions disclosed in material proposed for such publication or presentation.
In no event will Confidential Information of a party be published without the consent of such
party.

     The parties will coordinate the disclosure of the initiation and results of clinical studies
performed pursuant to the Development Plan to the extent required by law or best industry
practices; provided that all proposed disclosures and publications will be submitted for
expeditious review by the JDC and due regard will be given to the comments of each party, the
maintenance of confidentiality of Confidential Information of each party and allowing time for
intellectual property registrations as provided under Article 9. Nothing set forth herein shall be
deemed to limit or restrict either party from disclosing the results of clinical trials (whether
performed by the parties or by Third Parties) to the extent required by law or best industry
practices. The parties intend that the provisions of this Section 5.11 shall apply to the parties
and their respective Affiliates and (sub)licensees, as well as DAP and its licensees.

     5.12 Adverse Events. For purposes of this Section, adverse drug experiences (“ADEs”) shall
mean any adverse medical occurrence in a patient to whom the Product has been administered and
which does not necessarily have a casual relationship with the treatment (as defined by 21 C.F.R.
312.32, 314.80 and any other applicable definitions in regulations promulgated by the FDA or ICH)
which are required to be reported to the FDA or to international regulatory agencies. The parties
will cooperate to develop, as promptly as possible (and in any event within six (6) months
following the Effective Date), an ADE information exchange protocol to provide each party with such
information as it may require to comply with legal and regulatory ADE reporting standards. Pending
finalization of such protocol, each of the parties hereto shall disclose to the other party all
safety reports and other information which they may from time to time receive or obtain whether
from sources within or without the Territory with respect to any adverse experiences with respect
to the Product. Specifically, all serious adverse events and reactions occurring in a patient to
whom the Product has been administered, whether believed due to the Product or not, will be
transmitted to the other party as promptly as possible and in any event within ten (10) calendar
days of first knowledge of the event/reaction, except for deaths which will be transmitted within
five (5) calendar days. All aggregate reports of ADEs (i.e., IND annual reports, NDA periodic
reports, PSURs etc.) submitted to a Regulatory Authority will be transmitted to the other party
within five (5) calendar days of transmission to the Regulatory Authority. All questions from and
responses to a health authority regarding ADEs will be transmitted to the other party within five
(5) days of receipt/transmission. Each party will use its best efforts to obtain in a timely
manner from Third Parties (including without limitation, DAP and its licensees) who are developing
or commercializing the Product or other forms of faropenem outside of the Territory all such
information regarding adverse events and reactions with respect to the Product or other forms of
faropenem required by regulatory authorities in the Territory.

     5.13 Recalls or Other Corrective Actions. If the FDA issues or requests a recall or

 [ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

35.

 

takes
similar action in connection with the Product or in the event either party determines that an
event, incident or circumstance has occurred that may result in the need for a recall or market
withdrawal of the Product in the Territory, the party notified of or desiring such recall or
similar action shall, within twenty-four (24) hours, advise the other party thereof by telephone
(and confirmed by email or facsimile), email or facsimile. Forest shall have sole responsibility
and shall make all decisions with respect to any recall, market withdrawals or any other corrective
action related to the Product in the Territory, including the right to cease all sales of Product
in the Territory or the promotion and Detailing of the Product in the Territory. At Forest’s
request, Replidyne shall use Commercially Reasonable Efforts to assist Forest in conducting such
recall, market withdrawal or other corrective action with respect to Target Specialists, and any
documented out-of-pocket costs incurred by Replidyne with respect to participating in such recall,
market withdrawal or other corrective action shall be reimbursed by Forest as Sales Force Expense
hereunder.

     5.14 Product Liability. In connection with the commercialization of the Products, Forest will
be responsible for any liability for personal injury or property damage arising in connection with
use of the Product; provided, however, that in any event each party shall be responsible for, and
hereby assumes, any and all risks of personal injury or property damage to the extent attributable
to the negligence or willful misconduct of that party or its Affiliates or licensees (excluding, in
the case of Replidyne, Forest and its Affiliates and sublicensees), and their respective directors,
officers, employees and agents.

6. Supply Matters

     6.1 Joint Supply Committee. Promptly after the Effective Date, the parties will form a Joint
Supply Committee (the “JSC”) comprised of two (2) representatives of each of Forest and Replidyne,
which shall oversee manufacturing activities for the Drug Substance and Product for use in the
Territory during the Supply Transition. The JSC shall meet at least four (4) times per year during
the Supply Transition or at such greater frequency as the JSC agrees. Such meetings may be
conducted by videoconference, teleconference or in person, as agreed by the parties, and the
parties shall agree upon the time of meetings. Subject to coordination with the other party, a
reasonable number of additional representatives of a party may attend meetings of the JSC in a
non-voting capacity, consistent with the agendas and purposes for such meetings. Decisions of the
JSC shall be made by unanimous vote, with the Replidyne members collectively having one (1) vote
and the Forest members collectively having one (1) vote. No vote of the JSC may be taken unless at
least one (1) of each party’s representatives on the JSC are present to vote. If the JSC is unable
to reach a unanimous vote on any matter, then Forest shall have the tie-breaking vote. The JSC
will have no power to amend this Agreement or waive a party’s rights or obligations under this
Agreement.

     6.2 Supply Transition. As soon as practicable and subject to the further provisions hereof,
Forest will take over responsibility for the obligations in the API Supply Agreement and existing
supply contracts for manufacture and packaging of the Product in the Territory, [ *** ].

     6.3 Launch Delay Compensation.

          (a) Provided that Forest is in compliance with its obligations under this

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

36.

 

Agreement, Replidyne
shall be responsible for all compensation that may accrue under Section 3.3 of the API Supply
Agreement for any period ending on or prior to [ *** ]. Forest shall be responsible for the
payment of all compensation that may become due under Section 3.3 of the API Supply Agreement other
than as provided in the preceding sentence.

          (b) With respect to the supply contract with Tropon GmbH existing as of the Effective Date for
the manufacture and packaging of Tablets, Replidyne shall be responsible for the maintenance and
qualification fees incurred under such agreement for any period ending prior to December 31, 2005.
With respect to any credits accrued by Replidyne under such agreement prior to that date, Forest
will apply such credits at the first opportunity and thereafter promptly reimburse Replidyne for
such credited amounts (other than credits accrued with respect to payments made under Section 3.3
of the Tropon/Replidyne supply contract as in effect immediately prior to the Effective Date, for
which Forest will reimburse Replidyne only if Forest either is not required to produce additional
registration batches of Tablets or is able to use for commercial distribution any such additional
registration batches of Tablets produced for Forest). Replidyne shall also be responsible for any
charge incurred with respect to minimum purchase obligations for calendar year 2006 that is not
creditable against future payments pursuant to the terms of such agreement, and Forest shall be
responsible for any such charges incurred under such agreement other than such charges for which
Replidyne is responsible.

     6.4 Supply Costs. Subject to Section 6.3, all costs incurred after October 1, 2005 related to
manufacture, packaging and distribution of Drug Substance and Product will be borne by Forest;
provided, however, that, [ *** ]. Replidyne has provided Forest a reconciliation of all costs
accrued since October 1, 2005 through December 31, 2005 under the API Supply Agreement and existing
supply agreements for the manufacturing and packaging of Product. If the API Supply Agreement and
Replidyne’s other existing Third Party supply agreements for manufacture and packaging of Product
are not assigned to Forest, Forest’s required quantities of Drug Substance and Product will be
supplied to Forest by Replidyne at Replidyne’s cost under the API Supply Agreement and other
applicable Third Party agreements. Forest will bear the risk and have the benefit of currency
fluctuations applied to Drug Substance and Product purchases in foreign currencies. Following the
Effective Date, Replidyne shall not incur FTE costs for the account of Forest with respect to
Replidyne personnel participating in activities related to the manufacture, packaging and
distribution of Drug Substance, without prior mutual agreement of the parties to a plan for such
activities.

     6.5 Manufacturing Rights. Unless and until Forest becomes an assignee of the API Supply
Agreement and existing supply contracts for manufacture and packaging of the Product in the
Territory (or enters into a separate agreement with the parties to such agreements providing for
supply of Drug Substance and for manufacture and packaging of the Product in the Territory),
Replidyne will use Commercially Reasonable Efforts to make available to Forest the benefits
available to Replidyne under such agreements. In particular, if Replidyne is granted a license
pursuant to Section 8.2 of the API Supply Agreement (thus triggering the grant of manufacturing
rights under the DAP Agreement), Replidyne grants to Forest or its Third Party manufacturing
designee during the Term, a non-exclusive worldwide license to manufacture the Drug Substance,
under all patents, know-how and other intellectual property rights, including, without limitation,
the Manufacturing Technology and the patents and patent applications listed in Attachment 8.2 of
the API Supply Agreement and all foreign counterparts thereof and any

 [ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

37.

 

intellectual property rights
pertaining to the manufacture of Drug Substance under the DAP Agreement, that are Controlled by
NISSO and/or DAP, to (i) research, develop, make, have made and use Drug Substance and Products
anywhere in the world, and (ii) promote, offer to sell, sell, have sold and otherwise commercialize
the Drug Substance and Products in the Territory. Such license shall be royalty free except to the
extent of any amounts due to NISSO and DAP pursuant to the API Supply Agreement in connection
therewith. In addition, unless and until Forest becomes an assignee of the API Supply Agreement
and existing supply contracts for manufacture and packaging of the Product in the Territory (or
enters into separate agreements relating to such matters), to the extent necessary to preserve
Forest’s economic interest as provided in this Agreement, Replidyne shall (i) perform its
obligations under such agreements in accordance with their terms, (ii) [ *** ].

     6.6 Manufacturing Transfer Compensation. After the initial NDA filing for the Product, if
Forest transfers responsibility for manufacturing Drug Substance to a Third Party manufacturer in
accordance with the API Supply Agreement, then, provided that NISSO and DAP are then in full
compliance with the API Supply Agreement, [ *** ].

     6.7 Supply Chain Management. Replidyne will retain responsibility for supply chain management
with respect to its requirements of Drug Substance and the Product outside of the Territory;
provided however, that the parties will work together in good faith to establish and coordinate a
mutually acceptable global supply chain (including, without limitation, the coordination of
forecasts and orders) for the manufacture of Drug Substance and Product.

7. Fees and Payments

     7.1 Upfront Fee. Forest shall pay to Replidyne a non-refundable, non-creditable upfront fee
equal to fifty million dollars ($50,000,000) within five (5) days of the Effective Date.

     7.2 Milestone Payments.

          (a) Forest shall pay Replidyne the following non-refundable, non-creditable payments within [
*** ] after the occurrence of each of the following milestone events with respect to Product in the
Territory:

	 	 	 	 	 
	Development Milestones	 	 	 
	Milestone Event	 	Milestone Payment	 
	First NDA Acceptance for a Tablet
	 	$	10,000,000	 
	[ *** ](1)
	 	$	[ *** ]	 
	[ *** ](2)
	 	$	[ *** ]	 
	[ *** ](3)
	 	$	[ *** ]	 
	[ *** ](4)
	 	$	[ *** ]	 
	[ *** ](4)
	 	$	[ *** ]	 
	 
	 	 	 
	Total Potential Development Milestone Payments:
	 	$	[ *** ]	 

 [ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

38.

 

	 	 	 	 	 
	Commercial Milestones	 	 	 
	Milestone Event	 	Milestone Payment(5)(6)	 
	The first time Net Sales in the Territory for
Tablets exceed $[ *** ] in any consecutive twelve
(12) month period during the first [ *** ]
following First Commercial Sale of the first Tablet
	 	$	[ *** ]	 
	 
	 	 	 	 
	The first time Net Sales in the Territory for
Tablets exceed $[ *** ] in any consecutive twelve
(12) month period during the first [ *** ]
following First Commercial Sale of the first Tablet
	 	$	[ *** ]	 
	 
	 	 	 	 
	The first time Net Sales in the Territory for Oral
Suspension exceed $[ *** ] in any consecutive
twelve (12) month period during the first [ *** ]
following First Commercial Sale of the first Oral
Suspension
	 	$	[ *** ]	 
	 
	 	 	 	 
	The first time Net Sales in the Territory for Oral
Suspension exceed $[ *** ] in any consecutive
twelve (12) month period during the first [ *** ]
following First Commercial Sale of the first Oral
Suspension
	 	$	[ *** ]	 
	 
	 	 	 	 
	Total Potential Commercialization Milestone Payments
	 	$	[ *** ]	 

 

			
	(1)	 	[ *** ]
	 
	(2)	 	[ *** ]
	 
	(3)	 	[ *** ]
	 
	(4)	 	[ *** ]
	 
	(5)	 	[ *** ]
	 
	(6)	 	[ *** ]

          (b) Each of the milestone payments described in this Section 7.2 shall be payable one (1)
time and only for the first time that the corresponding milestone is achieved, regardless of how
many times such milestone is achieved, and no milestone payments will be owed for a milestone which
is not reached. All payments made to Replidyne pursuant to this Section 7.2 are non-refundable and
may not be credited against any other payments payable by Forest to Replidyne under this Agreement.

     7.3 Royalties. Forest shall pay to Replidyne royalties on Net Sales of Products as follows
(references to Net Sales of Products in this Section exclude Net Sales of any generic Product,
which are subject to compensation under Section 7.5 below):

          (a) during the [ *** ] year period commencing with First Commercial Sale of the first Product
in the Territory, a royalty on annual Net Sales of all Products equal to [ *** ] percent ([ ***
]%);

          (b) during the [ *** ] year period commencing on the [ *** ] anniversary of the First
Commercial Sale of the first Product in the Territory, a royalty on annual Net Sales of

 [ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

39.

 

all
Products equal to [ *** ] percent ([ *** ]%); and

     (c) after the [ *** ] anniversary of the First Commercial Sale of the first Product in the
Territory, a royalty on Net Sales of all Products equal to:

               (i) [ *** ] percent ([ *** ]%) of that portion of total Net Sales of Products in each sales
year that is less than or equal to $[ *** ] (which threshold shall be reduced to $[ *** ] if no NDA
Approval has been granted for a Product [ *** ] by the end of calendar year [ *** ]); and

               (ii) [ *** ] percent ([ *** ]%) of that portion of total Net Sales of Products in each sales
year that is greater than $[ *** ] (which threshold shall be reduced to $[ *** ] if no NDA Approval
has been granted for a Product [ *** ] by the end of calendar year [ *** ]).

          (d) If Forest’s [ *** ] for Product in the Territory (the “Forest Costs”) exceeds (i) [ *** ]
(on a Calendar Quarter basis) at any time prior to the [ *** ] anniversary of the First Commercial
Sale or (ii) [ *** ] during any Calendar Quarter thereafter (the “[ *** ] Threshold”), the royalty
payable by Forest to Replidyne under this Section 7.3 for such Calendar Quarter shall be reduced by
an amount equal to [ *** ]% of the amount by which the Forest Costs for such Calendar Quarter
exceeds the [ *** ] Threshold, but in no event by more than [ *** ] for such Calendar Quarter. To
the extent that, after giving effect to any such reduction in royalties, Forest Costs continue to
exceed [ *** ] Threshold, [ *** ].

     7.4 Payments to DAP. Replidyne will be responsible for payment of all milestone payments and
royalty payments owed to DAP pursuant to the DAP Agreement.

     7.5 Royalty Term; Generic Product. The payments specified in Section 7.3 (collectively,
“Royalty Payments”) shall be payable on a Product-by-Product basis for a period equal to the
Royalty Term for such Product.

          (a) Branded Product When Generic Equivalent is Sold. If during the Term, a Third
Party introduces and commercializes in the Territory a Generic Equivalent to a Product, then (i)
the royalty rate applicable to the Net Sales of such Product (excluding Net Sales of any Generic
Equivalent to such Product which are subject to Section 7.5(b)) shall be reduced to [ *** ] percent
([ *** ]%) of the royalty rates set forth in Section 7.3, and (ii) the Royalty Term for such
Product shall instead end on the later of (A) the expiration of the last to expire valid claim of
those Licensed Patents that are issued as of the Effective Date claiming the manufacture, use or
sale of such Product in the Territory, including any period of extended commercial exclusivity for
the Product under any such Licensed Patent granted under any laws or regulations in the Territory,
(B) twelve (12) years after the date of First Commercial Sale of such Product in the Territory or
(C) five (5) years after the First Commercial Sale of the Generic Equivalent to such Product;
except that [ *** ].

     (b) Generic Product Sold by Forest. In consideration of the rights granted to Forest
under this Agreement with regard to generic Product, Forest shall pay to Replidyne, on each generic
Product an amount equal to [ *** ] percent ([ *** ]%) of Generic Profits so long as

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

40.

 

such generic
Product is sold or transferred in the Territory.

     7.6 Bioterror Applications. If a Product is developed for the treatment of Bacillus anthracis
or other bioterrorism and biowarfare applications with the intent to sell the Product to government
and military agencies for military or civilian use for such applications, then (a) notwithstanding
Section 4.6(a) and references to Section 4.6(a) in this Agreement, the Development Costs and other
expenses specific to the development and commercialization of the Product for such purpose shall be
shared by the parties such that Replidyne shall bear [ *** ]% and Forest shall bear [ *** ]%, and
(b) in lieu of Royalty Payments under Section 7.3 on sales of the Product to government and
military agencies for military or civilian use for such applications, Forest shall pay Replidyne [
*** ]% of the profit margin on such sales of the Product, where profit margin is equal to such
sales of the Product to the government or military agencies for military or civilian use for such
applications, less Cost of Goods and Distribution Costs for such Product and royalties owed to DAP
on such sale. Forest shall be responsible for paying the Cost of Goods and Distribution Costs for
such Product and will pay to Replidyne the royalties owed to DAP, which Replidyne shall pass
through to DAP. Any other sales of the Product for bioterrorism and biowarfare applications shall
remain subject to the Royalty Payments as provided in Section 7.3.

     7.7 Other Royalty Adjustments. In the event that the parties develop a modified or sustained
release formulation of the Product, royalties payable pursuant to Section 7.3 in respect of such
formulation of the Product shall be [ *** ].

     7.8 Acknowledgment of Replidyne Contribution. The parties hereby acknowledge that the value
contributed by Replidyne to any Product developed and/or commercialized by or on behalf of Forest
and its Affiliates is the access to the Licensed Technology and that the up front, milestone and
Royalty Payments described above in this Article 7 will be payable by Forest in accordance with the
terms and conditions hereof regardless of whether or not a Product is covered by a Licensed Patent,
Forest Patent and/or Joint Patent.

     7.9 Reimbursement of Development Costs. Each party shall be responsible for its share of
Development Costs as provided under Section 4.6(a). Reconciliation and reimbursement for
Development Costs shall be carried out pursuant to Section 4.6(b).

     7.10 Reimbursement of Replidyne Target Specialist Commercial Activities.

          (a) Reimbursement of Pre-Launch Period Sales Force Expense. Forest agrees to
reimburse Sales Force Expense incurred by Replidyne during the Pre-Launch Period in an amount not
to exceed an aggregate of [ *** ] dollars ($[ *** ]). Replidyne shall provide a statement to
Forest within thirty (30) days of the end of each Calendar Quarter during the Pre-Launch Period
setting forth the Sales Force Expense incurred for the preceding Calendar Quarter and identifying
the components thereof in such detail as determined by the JMC. Subject to the maximum limitation
set forth above, Forest will provide reimbursement of the Sales Force Expense reflected in the
statement for each such Calendar Quarter within thirty (30) days of the receipt thereof by Forest.

          (b) Reimbursement of Marketing and Sample Expense. In consideration for

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

41.

 

the marketing
and promotional activities directed to Target Specialists to be provided by Replidyne hereunder,
Forest shall reimburse Replidyne for all actual Marketing and Sample Expense incurred by Replidyne
during each Detailing Year of the Replidyne Specialist Promotion Period, not to exceed the amount
of Marketing and Sample Expense to be incurred by Replidyne as budgeted under the Marketing Plan
for the applicable Detailing Year unless otherwise agreed in writing by the parties; provided that,
if the Marketing and Sample Expense that Replidyne would have to incur to achieve the objectives
set forth in the Marketing Plan exceeds the amount of the Marketing and Sample Expense to be
incurred by Replidyne as budgeted under the Marketing Plan (unless Forest agrees to reimburse such
amount to Replidyne and adjust the Marketing Plan accordingly), Replidyne shall not be obligated to
incur such amount of Marketing and Sample Expense in excess of the amount budgeted under the
Marketing Plan, unless it decides to do so in its sole discretion, and, if it does not incur such
excess Marketing and Sample Expense, Replidyne shall not be responsible to the extent that it does
not achieve the objectives set forth in the Marketing Plan. Replidyne shall provide a statement to
Forest within thirty (30) days of the end of each Calendar Quarter during the Replidyne Specialist
Promotion Period setting forth the Marketing and Sample Expense incurred for the preceding Calendar
Quarter and identifying the components thereof in such detail as determined by the JMC. Forest
will provide reimbursement of the Marketing and Sample Expense reflected in each statement for such
Calendar Quarter within thirty (30) days of the receipt thereof by Forest.

          (c) Reimbursement of Sales Force Expense. In consideration for the Details to be
provided by Replidyne to Target Specialists hereunder, Forest shall reimburse Replidyne for Sales
Force Expense in accordance with the following:

               (i) With respect to the Initial Period, Forest shall reimburse one hundred percent (100%) of
Sales Force Expense up to an aggregate maximum per Detailing Year equal to [ *** ] dollars ($[ ***
]) and with the expectation that such amount will be sufficient, at a minimum, to support Detailing
by the Replidyne Specialty Sales Force to approximately [ *** ] Target Specialists at an average
frequency of [ *** ] Details per Detailing Year. Reimbursement shall be made on a Calendar Quarter
basis against receipt of statements from Replidyne on the same basis provided in Section 7.10(a)
above, together with a Detail Report. With respect to each Detailing Year during the remainder of
the Replidyne Specialist Promotion Period following the Initial Period, Forest shall reimburse
Sales Force Expense as follows:

                    (1) [ *** ] percent ([ *** ]%) of Sales Force Expense shall be multiplied by the percentage of
first position Details to total Details required to be provided by Forest pursuant to the Marketing
Plan with respect to Forest’s own Detailing of the Product; and

                    (2) [ *** ] percent ([ *** ]%) of Sales Force Expense shall be multiplied by the percentage of
second position Details to total Details required to be provided by Forest pursuant to the
Marketing Plan with respect to Forest’s own Detailing of the Product,

     subject to an aggregate maximum per Detailing Year equal to [ *** ] dollars ($[ *** ]) as
proportionately reduced to reflect the change in Forest’s reimbursement of Sales Force Expense from
one hundred percent (100%) of Sales Force Expense in the Initial Period to a percentage of

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

42.

 

Sales
Force Expense based on the application of the foregoing Detail weighting scheme after the Initial
Period (subject to further adjustment pursuant to Section 7.10(d)(ii)).

     The total of the amounts so determined shall be the amount of Sales Force Expense to be
reimbursed by Forest (i.e., for example, if the Marketing Plan for a Detailing Year requires that
fifty percent (50%) of Forest’s Details be in first position, Forest shall reimburse a total of
fifty percent (50%) of Sales Force Expense (consisting of the sum of [ *** ] percent ([ *** ]%) x
fifty percent (50%) (reflecting Forest’s first position obligation) and [ *** ] percent ([ *** ]%)
x fifty percent (50%) (reflecting Forest’s second position obligation)). Reimbursement shall be
made on a Calendar Quarter basis against receipt of statements and Detail Reports from Replidyne in
the same manner as provided above.

               (ii) In the event that Detailing actually provided by Replidyne for a given Detailing Year did
not achieve at least [ *** ] percent ([ *** ]%) of the Detailing targeted by the Marketing Plan (as
to number of weighted Details, with Details at second position weighted at fifty percent (50%) of a
first position Detail), Forest may credit an amount determined within sixty (60) days of the end of
such Detailing Year against the reimbursement of Sales Force Expense in the next Detailing Year
(which may, to the extent the amount of such credit exceeds Sales Force Expense in such next
Detailing Year, be carried forward and applied in a subsequent Detailing Year or applied to reduce
royalties if no further Sales Force Expense remains payable by Forest). The amount of such credit
shall be equal to (A) the amount by which the Detailing actually provided by Replidyne as a
percentage of the Detailing to be provided by Replidyne as targeted by the Marketing Plan for the
applicable Detailing Year is less than one hundred percent (100%), multiplied by (B) the actual
Sales Force Expense reimbursed by Forest for such Detailing Year.

          (d) Additional Adjustments. Notwithstanding the provisions of Section 7.10(c), the
reimbursement of Sales Force Expense is subject to the following:

               (i) In the event that, during the Initial Period or thereafter, the Replidyne Specialty Sales
Force commences the detailing of pharmaceutical products other than the Product, the parties shall
negotiate in good faith as to a reduction in the percentage of Sales Force Expense subject to
reimbursement by Forest taking into account the percentage of Replidyne Specialty Sales Force
detailing activity proposed to be devoted to such new product.

               (ii) Within sixty (60) days following the expiration of the Initial Period, the JMC will
evaluate the productivity of Detailing to Target Specialists in terms of prescriptions and sales
generated through such efforts (based upon IMS Xponent data or other mutually-agreed generally
recognized prescription data source). In the event that the JMC recommends a significantly reduced
level of Details to Target Specialists, Forest reserves the right to reduce the total Sales Force
Expense subject to reimbursement in accordance with the terms hereof in proportion to the reduction
in Detailing to Target Specialists for the immediately preceding Detailing Year as so recommended
by the JMC, with a commensurate reduction in the aggregate maximum amount of Sales Force Expense
subject to reimbursement in such Detailing Year as provided in Section 7.10(c)(i). Replidyne shall
only be obligated to perform the number of Details to Target Specialists corresponding to the
recommendation of the JMC.

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

43.

 

8. Payment; Records; Audits

     8.1 Payment; Reports. Royalty Payments shall be calculated and reported for each Calendar
Quarter. All payments due to Replidyne under this Agreement shall be paid within forty-five (45)
days of the end of each Calendar Quarter, unless otherwise specifically provided herein. Each
payment shall be accompanied by [ *** ] and Net Sales of Products by Forest and its Affiliates,
each in sufficient detail to permit confirmation of the accuracy of the payment made, including,
without limitation and on a Product-by-Product basis, the number of Products sold, the gross sales
and Net Sales of such Products, the Royalty Payments and other payments payable and the method used
to calculate the Royalty Payments and other payments. [ *** ].

     8.2 Manner and Place of Payment. All payments hereunder shall be payable in U.S. dollars.
All payments owed under this Agreement shall be made by wire transfer in immediately available
funds to a bank and account designated in writing by Replidyne, unless otherwise specified in
writing by Replidyne.

     8.3 Income Tax Withholding. Replidyne will pay any and all taxes levied on account of any
payments made to it under this Agreement. If any taxes are required to be withheld by Forest,
Forest will: (a) deduct such taxes from the payment made to Replidyne; (b) timely pay the taxes to
the proper taxing authority; and (c) send proof of payment to Replidyne and certify its receipt by
the taxing authority (to the extent the taxing authority provides such certification to Forest)
within thirty (30) days following such payment.

     8.4 Financial Records.

          (a) Both parties shall, and shall cause their respective Affiliates to, keep complete and
accurate books and records pertaining to Development Costs. Such books and records shall be
retained by both parties and their Affiliates until three (3) years after the end of the period to
which such books and records pertain, or for such longer period as may be required by Applicable
Laws.

          (b) Forest shall keep, and shall cause its Affiliates to keep, complete and accurate records
pertaining to the sale or other disposition of Products in sufficient detail to permit Replidyne to
confirm [ *** ] and the accuracy of all Royalty Payments due hereunder. In addition, Forest shall
maintain accurate records relating to its promotion obligations hereunder (including, without
limitation, records relating to the performance of Details by Forest (including records of
physicians called on, frequency of calls and other data which underlies the Detail Reports required
by Section 8.1) which records shall be kept available for three (3) years following the Detailing
Year to which such records relate unless a longer period is otherwise required by Applicable Laws.

          (c) Replidyne shall maintain accurate records relating to its promotion obligations hereunder
(including, without limitation, records relating to the performance of Details by Replidyne
(including records of physicians called on, frequency of calls and other data which underlies the
Detail Reports required by Section 7.10(c)(i)), and records supporting the determination of Sales
Force Expense and Marketing and Sample Expense) which records shall be kept available for three (3)
years following the Detailing Year to which such records

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

44.

 

relate unless a longer period is otherwise
required by Applicable Laws.

     8.5 Audits. At the request of either party, the other party shall, and shall cause its
Affiliates to, permit the requesting party to cause an independent auditor or other representative,
at reasonable times and upon reasonable notice, to examine the books and records maintained
pursuant to Section 8.4. Such examinations may not: (a) be conducted for any Calendar Quarter
ended more than three (3) years prior to the date that such request is made; (b) be conducted more
than once in any twelve (12) month period or (c) be repeated for any Calendar Quarter; provided,
however, that audits may be conducted more frequently or for such periods as may be reasonable in
the event a party has good cause, based upon objective evidence, to perform such additional audits.
Except as provided below, the cost of this examination shall be borne by the party that requested
the examination, unless the audit reveals a variance of more than five percent (5%) from the
reported amounts covering a period of at least twelve (12) months, in which case the audited party
shall bear the cost of the audit. If such audit concludes that additional payments were owed or
that excess payments were made during such period, the paying party shall pay the additional
payments or the receiving party shall reimburse such excess payments, within sixty (60) days after
the date on which such written audit report is delivered to the parties.

     8.6 Late Payments. If any payment due under this Agreement is not made when due, the payment
shall accrue interest from the tenth day following the furnishing by Replidyne of written notice of
such late payment, unless payment is made during such 10 day period, at the prime rate of interest,
as adjusted monthly, plus one percent (1%) per month; provided, however, that in no event shall
such rate exceed the maximum legal annual interest rate. In addition, interest shall not accrue as
to the portion of any payment which is being disputed diligently and in good faith until from and
after an amount is awarded by arbitration in accordance with Article 14 hereof, unless the
Arbitrators elect to award interest in light of the circumstances. The payment of such interest
shall not limit a party from exercising any other rights it may have as a consequence of the
lateness of any payment.

9. Intellectual Property

     9.1 Ownership of Inventions. Inventorship of inventions conceived of and reduced to practice
in the course of the Development Program (“Inventions”) shall be determined in accordance with the
rules of inventorship under United States patent laws. Replidyne shall own all Inventions
conceived of and reduced to practice in the course of the Development Program solely by its
employees and contractors (“Replidyne Inventions”), and all Replidyne Patents. Forest shall own
all Inventions conceived of and reduced to practice in the course of the Development Program solely
by its or its Affiliate’s employees and contractors (“Forest Inventions”), and all Forest Patents.
All Inventions conceived of and reduced to practice in the course of the Development Program
jointly by one or more employees or contractors of Forest or its Affiliate and one or more
employees or contractors of Replidyne (“Joint Inventions”), and all Joint Patents, shall be owned
jointly by Forest and Replidyne. Forest’s interest in Joint Patents shall be deemed Forest
Technology for purposes of the rights granted to Replidyne in Section 2.3.

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

45.

 

     9.2 Patent Prosecution and Maintenance.

          (a) DAP Patents. Forest acknowledges that DAP is responsible for prosecution and maintenance
of all DAP Patents under the DAP Agreement. Replidyne shall keep Forest informed of progress with
regard to the prosecution and maintenance of the DAP Patents by providing Forest with all copies of
official actions, amendments and responses with respect to such prosecution and will exercise its
rights under the DAP Agreement to require DAP to provide all such documents and related information
for purposes of this Section. Replidyne shall exercise its rights under the DAP Agreement to
require DAP to consult with Replidyne in the prosecution and maintenance of the DAP Patents in the
Territory and will request that DAP include Forest in such consultation (or will make such comments
to DAP as requested by Forest in the course of such consultation). Without limiting the generality
of the foregoing, Replidyne will communicate to DAP Forest’s comments on any related document that
DAP intends to file or to cause to be filed with the relevant governmental authority in advance of
such filing and shall exercise its rights under the DAP Agreement to require DAP not to
unreasonably deny or delay any actions recommended by Forest in its comments.

          (b) Replidyne Patents. Replidyne shall be responsible for the preparation, filing,
prosecution and maintenance of the Replidyne Patents at its own expense. Replidyne shall keep
Forest informed of progress with regard to the preparation, filing, prosecution and maintenance of
Replidyne Patents and consider in good faith the requests and suggestions of Forest with respect to
strategies for filing and prosecuting the Replidyne Patents. In the event that Replidyne
determines that the patent costs exceed the value of any Replidyne Patent claiming the manufacture,
use or sale of a Product being developed or commercialized by or on behalf of Forest pursuant to a
license granted under this Agreement, Replidyne shall (i) provide reasonable prior written notice
to Forest of such determination (which notice shall, in any event, be given no later than sixty
(60) days prior to the next deadline for any action that may be taken with respect to such
Replidyne Patent with the U.S. Patent & Trademark Office or any foreign patent office) and (ii) at
Forest’s election with regard to any Replidyne Patent, Replidyne will continue to prosecute and
maintain such Replidyne Patent at Forest’s expense and direction.

          (c) Forest Patents. Forest shall be responsible for the preparation, filing, prosecution and
maintenance of the Forest Patents at Forest’s expense. Forest shall keep Replidyne informed of
progress with regard to the preparation, filing, prosecution and maintenance of Forest Patents and
consider in good faith the requests and suggestions of Replidyne with respect to strategies for
filing and prosecuting the Forest Patents. In the event that Forest desires to abandon any Forest
Patent claiming the manufacture, use or sale of a Product being developed or commercialized by or
on behalf of Forest pursuant to a license granted under this Agreement, Forest shall provide
reasonable prior written notice to Replidyne of such intention to abandon (which notice shall, in
any event, be given no later than sixty (60) days prior to the next deadline for any action that
may be taken with respect to such Forest Patent with the U.S. Patent & Trademark Office or any
foreign patent office) and provide Replidyne an opportunity to assume, at Replidyne’s cost,
responsibility for such Forest Patent. At Replidyne’s request, Forest shall permit Replidyne to
submit foreign equivalents of any Patents filed by Forest in the Territory with claims relating
exclusively to the Product, at Replidyne’s expense, using counsel reasonably acceptable to Forest.

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

46.

 

          (d) Joint Patents. The parties shall mutually determine which party shall be responsible for
the preparation, filing, prosecution and maintenance of Joint Patents, in appropriate countries
throughout the world. Replidyne and Forest shall share equally the costs for preparation, filing,
prosecuting and/or maintaining Joint Patents, except as provided below. The prosecuting party
shall consult with the other party as to the preparation, filing, prosecution and maintenance of
the Joint Patents reasonably prior to any deadline or action with the U.S. Patent & Trademark
Office or any foreign patent office, and shall furnish to the other party copies of all relevant
documents reasonably in advance of such consultation. If the prosecuting party desires to abandon
any Joint Patent for which it is responsible, or if the prosecuting party later declines
responsibility for any Joint Patent, the prosecuting party shall provide reasonable prior written
notice to the other party of such intention to abandon or decline responsibility (which notice
shall, in any event, be given no later than sixty (60) days prior to the next deadline for any
action that may be taken with respect to such Joint Patent with the U.S. Patent & Trademark Office
or other patent office in the Territory), and the other party shall have the right, at its expense,
to prepare, file, prosecute, and maintain such Joint Patent, in which case the prosecuting party
shall assign all of its right, title and interest in such Joint Patent to the other party, and,
upon such assignment, such Joint Patent(s) shall become the sole property of the other party,
subject only to the licenses granted herein.

          (e) Patent Strategy. Notwithstanding anything to the contrary set forth herein, strategic
decisions relating to the prosecution (including decisions relating to reexamination or reissue of
issued patents) of DAP Patents, Replidyne Patents or Forest Patents in the Territory and material
components of the implementation of such decisions shall require the consensus of Forest, Replidyne
and DAP (as to DAP, to the extent provided by the DAP Agreement).

     9.3 Cooperation of the Parties. Each party agrees to cooperate fully in the preparation,
filing, prosecution and maintenance of any Patents under this Agreement and in the obtaining and
maintenance of any patent extensions, supplementary protection certificates and the like with
respect to any Patent claiming a Product being developed or commercialized in accordance with this
Agreement. Such cooperation includes, but is not limited to:

          (a) executing all papers and instruments, or requiring its employees or contractors, to
execute such papers and instruments, so as to effectuate the ownership of Inventions set forth in
Section 9.1, and the ownership of Patents as provided in this Agreement, and to enable the other
party to apply for and to prosecute patent applications in any country; and

          (b) promptly informing the other party of any matters coming to such party’s attention that
may affect the preparation, filing, prosecution or maintenance of any such patent applications.

     9.4 Infringement by Third Parties.

     (a) Notification. Replidyne and Forest shall promptly notify the other in writing of any
alleged or threatened infringement in the Territory of any Licensed Patent, Forest Patent, Joint
Patent or Trademark of which they become aware. Both parties shall use their commercially
reasonable efforts in cooperating with each other to terminate such infringement

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

47.

 

without
litigation, if appropriate.

          (b) Licensed Patents, Forest Patents and Joint Patents. Subject to mutual agreement of the
parties with respect to litigation strategy and consultation by Forest with Replidyne with respect
to all material decisions, [ *** ] shall have the first right to bring and control any action or
proceeding with respect to infringement of any of the Licensed Patents, Joint Patents or Forest
Patents, including any action or proceeding filed in connection with an ANDA filed by a Third Party
(an “ANDA Proceeding”) related to the Licensed Patents, Joint Patents or Forest Patents, in the
Territory, subject to this Section 9.4(b). [ *** ] shall manage the action or proceeding on a
day-to-day basis and shall keep [ *** ] updated regarding the status and costs of such action or
proceeding. [ *** ] shall have the right to be represented in any such action or proceeding by
counsel of its own choice. [ *** ] may enter into a financial settlement or other compromise in
connection with an action or proceeding it brings; provided, that [ *** ] shall be required to
obtain [ *** ]’s prior written consent before entering into any such settlement or other compromise
that involves a grant of rights under the Licensed Patents or Joint Patents or that otherwise
diminishes the rights or interests of [ *** ] in any manner, such consent not to be unreasonably
withheld. If [ *** ] fails to bring such an action or proceeding within (i) [ *** ] days following
the notice of alleged infringement or (ii) [ *** ] days before the time limit, if any, set forth in
the Applicable Laws for the filing of such actions or the waiver of any legal rights associated
therewith, whichever comes first, [ *** ] shall have the right to bring and control any such action
and by counsel of its own choice, and [ *** ] shall have the right, at its own expense, to be
represented in any such action by counsel of its own choice. If [ *** ] brings any such action or
proceeding, [ *** ] shall keep [ *** ] updated regarding the status and costs of such action or
proceeding. Irrespective of which party brings and controls any such action or proceeding, [ ***
]. If the party that brings such action or proceeding finds it legally necessary to join DAP as a
party to such action or proceeding, Replidyne will exercise its rights under the DAP Agreement
(including the Letter Agreement) to cause DAP to be joined as a party plaintiff to any such action
or proceeding or will permit by Forest to enforce Replidyne’s rights under the DAP Agreement to do
so. Forest acknowledges that, if neither Forest nor Replidyne commences an infringement suit or
action or settlement negotiations with the alleged infringer within [ *** ] days after (A)
Replidyne receives notification from DAP of any such infringement or (B) Replidyne sends notice to
DAP of such action, as applicable, DAP may bring an appropriate suit or action against the Third
Party infringer.

          (c) Cooperation. In the event a party brings an infringement action in accordance with this
Section 9.4, the other party shall cooperate fully, including, if required to bring such action,
the furnishing of a power of attorney or being named as a party. Neither party shall have the
right to settle any patent infringement litigation under this Section 9.4 relating to any Patent
claiming the manufacture, use or sale of the Products being developed or commercialized pursuant to
this Agreement without the prior written consent of such other party, such consent not to be
unreasonably withheld. [ *** ].

     9.5 Infringement of Third Party Rights. Each party shall promptly notify the other in writing
of any allegation by a Third Party that the activity of either of the parties pursuant to this
Agreement infringes or may infringe the intellectual property rights of such Third Party. Forest
shall have the sole right, subject to the following provisions of this Section, to control the
defense of any such claim involving alleged infringement of Third Party rights by the sale of the

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

48.

 

Product, [ *** ] by counsel of its own choice, and Replidyne shall have the right, at its own
expense, to be represented in any such action by counsel of its own choice. Forest will keep
Replidyne fully informed of the status of and developments with respect to any such action and will
consult with Replidyne as to strategic decisions with respect thereto. The parties shall cooperate
in the defense of any such claim, [ *** ]. Neither party shall have the right to settle any patent
infringement litigation under this Section 9.5 in a manner that diminishes the rights or interests
of the other party without the written consent of such other party (which shall not be unreasonably
withheld).

     9.6 Privileged Communications. In furtherance of this Agreement, it is expected that Forest
and Replidyne will, from time to time, disclose to one another privileged communications with
counsel, including opinions, memoranda, letters and other written, electronic and verbal
communications. Such disclosures are made with the understanding that they shall remain
confidential, they will not be deemed to waive any applicable attorney-client privilege and that
they are made in connection with the shared community of legal interests existing between Replidyne
and Forest, including the community of legal interests in avoiding infringement of any valid,
enforceable patents of Third Parties and maintaining the validity of Patents included in Licensed
Technology, Forest Patents and Joint Patents.

10. Representations and Warranties

     10.1 Mutual Representations and Warranties. Each party represents and warrants to the other
that:

          (a) it is duly organized and validly existing under the laws of its jurisdiction of
incorporation or formation, and has full corporate or other power and authority to enter into this
Agreement and to carry out the provisions hereof;

          (b) it is duly authorized to execute and deliver this Agreement and to perform its obligations
hereunder, and the person or persons executing this Agreement on its behalf has been duly
authorized to do so by all requisite corporate or partnership action;

          (c) this Agreement is legally binding upon it, enforceable in accordance with its terms, and
does not conflict with any agreement, instrument or understanding, oral or written, to which it is
a party or by which it may be bound, nor violate any material law or regulation of any court,
governmental body or administrative or other agency having jurisdiction over it; and

          (d) neither party nor its Affiliates has engaged any investment banker, broker or finder that
would impose any liability on the other party for fees, commissions or other charges in connection
with the execution of this Agreement, and any such fees, commissions or other charges are the sole
responsibility of the engaging party.

     10.2 Replidyne Representations and Warranties. Replidyne represents and warrants to Forest
that, as of the Effective Date:

     (a) Replidyne Controls the Licensed Patents and the Licensed Know-How and has the right to
grant the licenses to the Licensed Technology as provided in Section 2.1 and

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

49.

 

Section 6.5.
Replidyne has not received, to Replidyne’s knowledge, any written or oral claim of ownership,
inventorship or patent infringement from any Third Party (including, without limitation, by current
or former employees, consultants or other Replidyne personnel) with respect to the Licensed
Patents, and Replidyne is not aware that DAP, Wyeth or Bayer has received any such claim and is not
aware of any reasonable basis for any such claim. To Replidyne’s knowledge, the development,
manufacture or commercialization of the Product in the Field in the Territory, as currently
conducted or proposed to be conducted by Replidyne, does not infringe any issued patent of any
Third Party. Replidyne is not subject to any royalty or similar payment obligation to any Third
Party with respect to the grant of rights to Replidyne to practice the Licensed Technology, except
as set forth in the DAP Agreement (a true copy of which, with confidential information redacted,
has been provided to Forest).

          (b) The DAP Agreement remains in full force and effect and, to Replidyne’s knowledge, DAP is
not in material breach under the DAP Agreement. Replidyne has paid all amounts due and payable
under the DAP Agreement to the extent accrued on or before the Effective Date and is not in
material breach under the DAP Agreement.

     10.3 Debarment; Proceedings. During the Term, neither of the parties shall knowingly use any
employee, representative, agent, assistant or associate who has been debarred by the FDA pursuant
to 21 U.S.C. Section 335 (a) or (b) of the United States Federal Food Drug and Cosmetic Act (21
U.S.C. Section 301 et seq.), as amended from time to time, in connection with any of the activities
to be carried out under this Agreement. In addition, as of the Effective Date, neither party is
subject to any proceeding by any regulatory authority having jurisdiction over the registration,
manufacture or marketing of pharmaceutical products which could reasonably be expected to prevent
or delay such party’s completion of its responsibilities under the Development Plan.

     10.4 Disclaimer. Except as expressly set forth herein, the technology and intellectual
property rights provided by each party hereunder are provided “as is” and each party expressly
disclaims any and all warranties of any kind, express or implied, including without limitation any
warranties of merchantability, fitness for a particular purpose, title, non-infringement of the
intellectual property rights of third parties, or arising from a course of dealing, usage or trade
practices, in all cases with respect thereto. Without limiting the generality of the
foregoing, neither party warrants (a) the success of any study or test commenced under the
Development Program or (b) the safety or usefulness for any purpose of the technology it provides
hereunder.

     10.5 Limitation of Liability. EXCEPT FOR FRAUDULENT BREACHES OF THE REPRESENTATIONS
AND WARRANTIES IN Article 10 or liability for breach of Section 2.1 or Article 11,
neither party shall be entitled to recover from the other party any special, incidental,
consequential or punitive damages in connection with this agreement or any license granted
hereunder; provided, however, that this Section 10.5 shall not be construed to limit either party’s
indemnification obligations under Article 13. The Parties agree that payments accrued and payable
under Article 7 are general (not special, incidental, consequential or punitive) damages.

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

50.

 

11. Confidentiality

     11.1 Confidential Information. Except to the extent expressly authorized by this Agreement or
otherwise agreed in writing by the parties, the parties agree that, during the Term and for five
(5) years thereafter, the receiving party shall keep confidential and shall not publish or
otherwise disclose and shall not use for any purpose other than as expressly provided for in this
Agreement any data, information, documentation, know-how and technology furnished to it by the
other party pursuant to this Agreement or developed as part of the Development Program hereunder
(collectively, “Confidential Information”). Each party may use such Confidential Information only
to the extent required to accomplish the purposes of this Agreement. Each party will use at least
the same standard of care as it uses to protect proprietary or confidential information of its own
to ensure that its employees, agents, consultants and other representatives do not disclose or make
any unauthorized use of the Confidential Information. Each party will promptly notify the other
upon discovery of any unauthorized use or disclosure of the Confidential Information.

     11.2 Exceptions. Confidential Information shall not include any information which the
receiving party can prove by competent written evidence:

          (a) is now, or hereafter becomes, through no act or failure to act on the part of the
receiving party, generally known or available;

          (b) is known by the receiving party at the time of receiving such information, as evidenced by
its records;

          (c) is hereafter furnished to the receiving party by a Third Party, as a matter of right and
without restriction on disclosure;

          (d) is independently discovered or developed by the receiving party without the use of
Confidential Information belonging to the disclosing party; or

          (e) is the subject of a written permission to disclose provided by the disclosing party.

     11.3 Authorized Disclosure. Each party may disclose Confidential Information belonging to the
other party to the extent such disclosure is reasonably necessary in the following instances:

          (a) filing or prosecuting Patents as permitted by this Agreement;

          (b) regulatory filings for Products such party has a license or right to develop hereunder or
otherwise conducting development and/or commercialization activities in accordance with this
Agreement;

          (c) prosecuting or defending litigation as permitted by this Agreement;

          (d) complying with applicable court orders or governmental regulations; and

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

51.

 

          (e) disclosure to Affiliates, sublicensees, licensors (including DAP), contractors, employees,
consultants, bankers, lawyers, accountants, agents or other Third Parties in connection with due
diligence or similar investigations by such Third Parties, and disclosure to potential Third Party
investors in confidential financing documents; provided, in each case, that any such Affiliate,
sublicensee, contractor, employee, consultant, banker, lawyer, accountant, agent or Third Party
agrees to be bound by terms of confidentiality and non-use comparable in scope to those set forth
in this Article 11.

Notwithstanding the foregoing, in the event a party is required to make a disclosure of the other
party’s Confidential Information pursuant to Section 11.3(c) or (d), it will, except where
impracticable, give reasonable advance notice to the other party of such disclosure and use efforts
to secure confidential treatment of such information at least as diligent as such party would use
to protect its own confidential information, but in no event less than reasonable efforts. In any
event, the parties agree to take all reasonable action to avoid disclosure of Confidential
Information hereunder. The parties will consult with each other on the provisions of this
Agreement to be redacted in any filings made by the parties with the Securities and Exchange
Commission or as otherwise required by law.

     11.4 Publicity. It is understood that the parties intend to issue a joint press release
announcing the execution of this Agreement and agree that each party may desire or be required to
issue subsequent press releases relating to this Agreement or activities performed hereunder. The
parties agree to consult with each other reasonably and in good faith with respect to the text and
timing of such press releases prior to the issuance thereof; provided that a party may not
unreasonably withhold consent to such releases, and that either party may issue such press releases
as it determines, based on advice of counsel, are reasonably necessary to comply with laws or
regulations or for appropriate market disclosure. In addition, following the initial joint press
release announcing this Agreement, either party shall be free to disclose, without the other
party’s prior written consent, the existence of this Agreement, the identity of the other party and
those terms of the Agreement which have already been publicly disclosed in accordance herewith.
Forest acknowledges that Replidyne is required under the DAP Agreement to review with DAP certain
press releases relating to the DAP Agreement and may require that DAP-related information be
inserted or deleted from press releases proposed by the parties under this Agreement.

12. Term and Termination

     12.1 Term. The term of this Agreement shall commence on the Effective Date and continue until
the expiration of the last Royalty Term for any Product with respect to which Forest has a license,
unless earlier terminated pursuant to the further provisions hereof (the “Term”).

     12.2 Forest Right of Termination. Forest reserves the right to terminate this Agreement in
its entirety at any time effective upon [ *** ] days prior written notice to
Replidyne in the event Forest reasonably believes issues of safety or efficacy (which arise or
become more significant following the Effective Date) are reasonably likely to (a) prevent
regulatory approval of the Product in the United States, (b) materially delay such approval or (c)
substantially negatively impact the marketing potential of the Product in the United States, in

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

52.

 

each case without regard to the particular circumstances of Forest, including any other product
opportunities of Forest. Prior to any notice of termination under this Section 12.2, the parties
will discuss such issues for a period of up to [ *** ] days, which discussions shall include a
face-to-face meeting of the Chief Executive Officer of Replidyne and the Chief Executive Officer of
Forest Parent if requested by either party. Forest shall have no obligation to develop, promote or
sell the Product during [ *** ] notice period, if Forest’s intent to terminate is based upon safety
issues. Forest shall have no obligation to pay to Replidyne any milestone payment under Section
7.2 with respect to a milestone event achieved during such discussion period or notice period;
provided that Forest actually terminates the Agreement effective at the end of the [ *** ]-day
notice period.

     12.3 Termination for Material Breach.

          (a) Material Breach. Subject to Section 12.3(b), each party shall have the right to
terminate this Agreement and its obligations hereunder for material breach by the other party,
which breach remains uncured for sixty (60) days (ten (10) days in the event of failure to make any
payment when due), after written notice is provided to the breaching party specifying the nature of
the breach in reasonable detail and demanding its cure. In the case of a non-payment related
material breach, if such breach cannot be cured within the sixty (60) day cure period, this
Agreement shall not terminate if the breaching party has made diligent efforts to cure such breach
within the sixty (60) day period and this Agreement shall remain in effect for such period after
notice of breach as may be reasonable in the circumstances as long as the breaching party continues
to use diligent efforts to pursue the cure with a reasonable expectation that cure will be effected
as promptly as practicable thereafter. As an alternative to termination of this Agreement in its
entirety, in the case of any uncured material breach by Replidyne (other than a breach as described
in Section 12.3(b)), Forest may terminate the Replidyne Specialist Promotion Period and the
Pediatrician Promotion Rights, together with other operational rights, as more fully described, and
with consequences set forth, in Section 12.5(e). In the event the parties in good faith dispute
the existence of a material breach or a party’s diligence in attempting to cure a material breach,
termination of this Agreement shall not be deemed to occur unless and until such dispute has been
referred for resolution in accordance with Section 14 hereof, material breach of the Agreement or
failure to make diligent efforts to cure such breach has been established by an arbitration
thereunder and, if such breach can be cured by the payment of money or the taking of specific
remedial actions, the breaching party does not pay the amount so determined to be due within ten
(10) days of receipt of the arbitration decision or otherwise diligently undertake and complete
such remedial actions within the timeframe established by such arbitration decision.

          (b) Material Breach Regarding Target Specialist or Pediatrician Promotion Efforts. In
the event of an uncured material breach by Replidyne of this Agreement with respect to the conduct
of Replidyne’s promotion efforts directed to Target Specialists (other than as provided in Section
5.4(h)) or Replidyne’s performance of the Pediatrician Promotion Rights (other than as provided in
Section 2.4(g) of Schedule 5.5), after any dispute resolution in
accordance with Article 14, the remedy of termination shall only be effective with respect to
Replidyne’s continued performance of promotional efforts to Target Specialists as provided in
Section 5.4 and the Pediatrician Promotion Rights as provided in Schedule 5.5, and all other
provisions of this Agreement shall remain in full force and effect in accordance with their terms.

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

53.

 

     12.4 Termination for Insolvency. This Agreement may be terminated by either party upon at
least sixty (60) days’ prior written notice thereof if the other party makes a general assignment
for the benefit of creditors, is the subject of proceedings in voluntary or involuntary bankruptcy
instituted on behalf of or against such party, or has a receiver or trustee appointed for all or
substantially all of its property; provided that in the case of an involuntary bankruptcy
proceeding such right to terminate shall only become effective if the party consents to the
involuntary bankruptcy or such proceeding is not dismissed within ninety (90) days after the filing
thereof.

     12.5 Rights following Expiration of Term or Termination.

          (a) Expiry of Term Under Section 12.1. Upon expiration of the Term pursuant to
Section 12.1, Forest shall have a fully-paid, perpetual, non-exclusive license to the Licensed
Technology and, for so long as Forest continues to sell the Product in the Territory) a fully paid,
exclusive license to the Trademark in connection with the manufacture, marketing, sale and
distribution of the Product in or for purposes of the Territory.

          (b) Termination of this Agreement by Forest Under Section 12.2 or Replidyne Under Section
12.3(a) or 12.4. In the event of a termination by Forest pursuant to Section 12.2 or by
Replidyne pursuant to Section 12.3(a) or 12.4, Forest shall furnish Replidyne with reasonable
cooperation to assure a smooth transition of any or all aspects of the on-going Product programs
which Replidyne determines to continue, including without limitation, clinical studies, regulatory
activities, manufacture and supply and marketing and promotion, and Forest shall continue to
perform any of such activities (except under the circumstances regarding safety issues provided in
Section 12.2), as may be requested by Replidyne, for a period of up to six (6) months following
Forest’s notice of termination provided under Section 12.2. Such activities shall be performed
under the terms of this Agreement. However, if this results in a net loss to Forest over the
period from the 91st day to the end of the six (6) month transition period (i.e., income
attributable to such period less costs for such period), then Replidyne shall reimburse Forest to
the extent of such net loss, subject to receipt of supporting documentation. In addition,

               (i) all rights under the licenses granted under Sections 2.1, 2.3 and 6.5 shall automatically
terminate and revert to the granting party;

               (ii) Forest shall, and it hereby does (but only effective upon such termination), grant to
Replidyne a worldwide, exclusive (even as to Forest), perpetual, fully paid license, with the right
to sublicense, under the Forest Technology and Forest’s interest in the Joint Patents, to make,
have made, use, sell, have sold, offer for sale and import Products;

               (iii) Forest shall (A) transfer to Replidyne as soon as reasonably practicable all data and
information in Forest’s or its Affiliates’ possession relating to any Product as may be necessary
to enable Replidyne to practice the license granted under
Section 12.5(b)(ii), (B) transfer and assign to Replidyne all of its right, title and interest
in and to all INDs, NDAs, drug dossiers and master files with respect to any and all Products, (C)
assign and transfer to Replidyne all of Forest’s rights and obligations under any Third Party
manufacturing contracts entered into by Forest in connection with the Product, (D) sell to
Replidyne Forest’s remaining Product inventory, at a transfer price not to exceed Forest’s cost,

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

54.

 

and (E) take such other actions and execute such other instruments, assignments and documents as
may be necessary to effect the transfer of rights hereunder to Replidyne; and

               (iv) Forest will destroy or return all Replidyne Confidential Information to Replidyne.

Except as provided by this Section, Forest shall have no further obligation to Replidyne in respect
of the termination of this Agreement pursuant to this Section, including, without limitation, the
payment of any milestone payment the time for payment of which has not occurred as of the notice of
termination by Forest in accordance with Section 7.2 hereof.

          (c) Termination of this Agreement by Forest under Section 12.3(a) or Section 12.4.
Upon any termination of this Agreement by Forest pursuant to Section 12.3(a) or 12.4,

               (i) all rights under the licenses granted under Sections 2.1, 2.3 and 6.5 shall automatically
terminate and revert to the granting party; and

               (ii) Forest will destroy or return to Replidyne all Confidential Information of Replidyne, and
Replidyne shall destroy or return all Confidential Information of Forest to Forest.

          (d) Termination by Forest under Section 12.3(b). If Forest terminates the Replidyne
Specialist Promotion Period and the Pediatrician Promotion Rights pursuant to Section 12.3(b),
Forest shall assume responsibility for promotion of the Product to Target Specialists and
Pediatricians, and shall use Commercially Reasonable Efforts to do so in accordance with the terms
of this Agreement. Upon any termination of such rights by Forest pursuant to Section 12.3(b),
Replidyne shall provide such transition activities as Forest may reasonably request, for up to
ninety (90) days, including, without limitation, arranging for meetings between members of the
applicable Replidyne sales force and sales representatives of Forest, to assure a smooth transition
of marketing to Target Physicians and Pediatricians, as the case may be. In addition, Replidyne
shall destroy or return to Forest all Forest Confidential Information pertaining to such promotion
activities and will transfer to Forest, as soon as reasonably practicable, data in Replidyne’s or
its Affiliates possession comparable to the data referred to in subsection (b)(iii) above.

          (e) Termination by Forest Under Section 12.3(a). If Forest elects to terminate the
Replidyne Specialist Promotion Period, the Pediatrician Promotion Rights and other operational
rights pursuant to the penultimate sentence of Section 12.3(a), the following shall apply:

               (i) Such termination will be effected in the manner set forth in
subsection (d) above, Replidyne shall be obligated to perform the transitional activities
provided by such subsection and Forest shall assume the additional responsibilities for Product
promotion to the extent provided by such subsection;

               (ii) Replidyne’s rights to participate in the JDC, JMC or CGC shall

 [ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

55.

 

terminate; provided that
in any event Forest will continue to periodically provide information to Replidyne with respect to
manufacturing, development, intellectual property and commercialization matters to the extent
reasonably related to Replidyne’s continuing rights under the Agreement. Notwithstanding the
preceding, Replidyne shall not be obligated to incur or reimburse Development Costs accruing from
and after such termination, except for those Development Costs approved by the JDC with Replidyne’s
participation or to the extent of commercially reasonable development efforts consistent with the
previously agreed Development Plan;

               (iii) Each of the licenses granted to Forest by Section 2.1 shall be construed in such manner
so as to give effect to the termination of Replidyne’s promotional (and, if applicable, other
operational) rights; and

               (iv) Without limiting the generality of the termination of the Pediatrician Promotion Rights,
from and after such termination, Forest shall no longer be required to extend any further credit
pursuant to Section 4.1 of Schedule 5.5.

     12.6 Survival. Termination of this Agreement, in whole or in part, shall not relieve the
parties of any liability or obligation which accrued hereunder prior to the effective date of such
termination nor, except as otherwise specifically provided herein, preclude either party from
pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any
breach of this Agreement nor prejudice either party’s right to obtain performance of any
obligation. In addition, termination of this Agreement shall not terminate provisions which
provide by their respective terms for obligations or undertakings following the expiration of the
term of this Agreement.

     12.7 Exercise of Right to Terminate. The use by either party hereto of a termination right
provided for under this Agreement shall not give rise to the payment of damages or any other form
of compensation or relief to the other party with respect thereto.

     12.8 Damages; Relief. Subject to Section 12.7 above, termination of this Agreement shall not
preclude either party from claiming any other damages, compensation or relief that it may be
entitled to upon such termination.

     12.9 Rights in Bankruptcy. All rights and licenses granted under or pursuant to this
Agreement by Forest or Replidyne are, and will otherwise be deemed to be, for purposes of Section
365(n) of the U.S. Bankruptcy Code, licenses of right to “intellectual property” as defined under
Section 101 of the U.S. Bankruptcy Code. The parties agree that the parties, as licensees of such
rights under this Agreement, will retain and may fully exercise all of their rights and elections
under the U.S. Bankruptcy Code. The parties further agree that, in the event of the commencement
of a bankruptcy proceeding by or against either party under the U.S. Bankruptcy Code, the party
hereto that is not a party to such proceeding will be entitled to a
complete duplicate of (or complete access to, as appropriate) any such intellectual property
and all embodiments of such intellectual property, and same, if not already in their possession,
will be promptly delivered to them (i) upon any such commencement of a bankruptcy proceeding upon
their written request therefor, unless the party subject to such proceeding elects to continue to
perform all of its obligations under this Agreement, or (ii) if not delivered under (i) above,

 [ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

56.

 

following the rejection of this Agreement by or on behalf of the party subject to such proceeding
upon written request therefor by the non-subject party.

     12.10 Effect of Termination of DAP Agreement. All rights in the Bayer Know-How, Ciba-Geigy
Patents, DAP Know-How and DAP Patents that revert to DAP upon termination of the DAP Agreement in
accordance with its terms shall, in the event of termination of the DAP Agreement, cease to be
subject to this Agreement (other than the provisions of Article 11).

13. Indemnification

     13.1 Indemnification by Replidyne. Replidyne hereby agrees to save, defend and hold Forest
and its Affiliates and their respective directors, officers, employees and agents (each, a “Forest
Indemnitee”) harmless from and against (a) any and all liabilities, expenses and/or losses,
including reasonable legal expense and attorneys’ fees (collectively, “Losses”), to which any
Forest Indemnitee may become subject as a result of any claim, demand, action or other proceeding
by any Third Party to the extent such Losses arise directly or indirectly out of: (i) the practice
by Replidyne of any license granted to it hereunder, (ii) the development, manufacture, use,
handling, storage, promotion, marketing or sale or other disposition of any Product by Replidyne or
its Affiliates or sublicensees (other than Forest and its Affiliates and sublicensees), but
excluding any liability for personal injury or property damage arising in connection with the
Product in the Territory (except as provided in Section 13.1(a)(iii) and subject to Section 5 of
Schedule 5.5, if applicable), (iii) liability for personal injury or property damage arising in
connection with the Product in the Territory to the extent attributable to the negligence or
willful misconduct of Replidyne or its Affiliates or licensees (other than Forest and its
Affiliates and sublicensees) and their respective directors, officers, employees and agents, or
(iv) the breach by Replidyne of any warranty, representation, covenant or agreement made by
Replidyne in this Agreement; except, in each case, to the extent such Losses result from the
negligence or willful misconduct of any Forest Indemnitee or the breach by Forest of any warranty,
representation, covenant or agreement made by Forest in this Agreement, and (b) any Losses to which
Forest may become subject as a result of any claim, demand, action or other proceeding by DAP
against Forest as a result of Forest reasonably withholding consent to use of the Trademark outside
the Territory pursuant to Section 2.5(d).

     13.2 Indemnification by Forest. Forest hereby agrees to save, defend and hold Replidyne and
its Affiliates, DAP and its Affiliates and their respective directors, officers, employees and
agents (each, a “Replidyne Indemnitee”) harmless from and against any and all Losses to which any
Replidyne Indemnitee may become subject as a result of any claim, demand, action or other
proceeding by any Third Party to the extent such Losses arise directly or indirectly out of: (i)
the practice by Forest of any license granted to it hereunder, (ii) the development, manufacture,
use, handling, storage, promotion, marketing, sale or other disposition of any Product by Forest or
its Affiliates or sublicensees, (iii) any liability for
personal injury or property damage arising in connection with use of the Product in the
Territory (except as provided in Section 13.1(a)(iii) and subject to Section 5 of Schedule 5.5, if
applicable), or (iv) the breach by Forest of any warranty, representation, covenant or agreement
made by Forest in this Agreement; except, in each case, to the extent such Losses result from the
negligence or willful misconduct of any Replidyne Indemnitee or the breach by Replidyne of any
warranty, representation, covenant or agreement made by Replidyne in this Agreement.

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

57.

 

     13.3 Control of Defense. Any entity entitled to indemnification under this Article 13 shall
give notice to the indemnifying party of any Losses that may be subject to indemnification,
promptly after learning of such Losses, and the indemnifying party shall assume the defense of such
Losses with counsel reasonably satisfactory to the indemnified party. If such defense is assumed
by the indemnifying party with counsel so selected, the indemnifying party will not be subject to
any liability for any settlement of such Losses made by the indemnified party without its consent
(but such consent will not be unreasonably withheld or delayed), and will not be obligated to pay
the fees and expenses of any separate counsel retained by the indemnified party with respect to
such Losses.

     13.4 Insurance. Each party, at its own expense, shall maintain such types and amounts of
liability insurance (or self-insure) as are appropriate for the activities for which it is
responsible under this Agreement and consistent with industry standards during the Term and shall
name the other party to this Agreement as an additional insured with respect to such insurance.
The insured party shall provide a certificate of insurance (or evidence of self-insurance)
evidencing such coverage to the other party upon request.

14. Dispute Resolution

     14.1 Dispute Resolution. Any dispute arising under or relating to the parties rights and
obligations under this Agreement will be referred to the Chief Executive Officer of Replidyne and
the Chief Executive Officer of Forest, or the Chief Executive Officer of any Affiliate of Forest
that is primarily responsible for the activities of Forest under this Agreement, as directed by
Forest, for resolution. In the event the two Chief Executive Officers are unable to resolve such
dispute within (30) days of such dispute being referred to the officers, the dispute shall be
subject to arbitration, as provided in Section 14.2. Notwithstanding the preceding, the parties
acknowledge that the failure of the JMC, JDC, JSC or CGC to reach consensus as to any matter, which
failure does not involve a breach by a party of its obligations hereunder, shall not be deemed a
dispute which may be referred for resolution by arbitration hereunder.

     14.2 Arbitration.

               (a) Claims. Any claim, dispute, or controversy of whatever nature arising between the parties
out of or relating to this Agreement that is not resolved under Section 14.1 within the required
thirty (30) day time period, including without limitation, any action or claim based on tort,
contract, or statute (including any claims of breach or violation of statutory or common law
protections from discrimination, harassment and hostile working environment), or concerning the
interpretation, effect, termination, validity, performance and/or breach of this Agreement
(“Claim”), shall be resolved by final and binding arbitration before a panel of three experts with
relevant industry experience (the “Arbitrators”). One Arbitrator shall
be chosen by Replidyne and one Arbitrator shall be chosen by Forest within fifteen (15) days
from the notice of initiation of arbitration. The third Arbitrator shall be chosen by mutual
agreement of the Arbitrator chosen by Replidyne and the Arbitrator chosen by Forest within fifteen
(15) days of the date that the last of such Arbitrators were appointed. The Arbitrators shall be
administered by the International Chamber of Commerce (the “Administrator”) in accordance with its
then existing arbitration rules or procedures regarding commercial or business disputes. The
arbitration shall be held in Denver, Colorado if requested by Forest and in New York, New York

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

58.

 

if
requested by Replidyne. The arbitrators shall be instructed by the parties to complete the
arbitration within ninety (90) days after selection of the final Arbitrator.

               (b) Arbitrators’ Award. The Arbitrators shall, within fifteen (15) calendar days after the
conclusion of the arbitration hearing, issue a written award and statement of decision describing
the essential findings and conclusions on which the award is based, including the calculation of
any damages awarded. The decision or award rendered by the Arbitrators shall be final and
non-appealable, and judgment may be entered upon it in accordance with applicable law in the State
of New York or Colorado, as applicable, or any other court of competent jurisdiction. The
Arbitrators shall be authorized to award compensatory damages, but shall NOT be authorized (i) to
award non-economic damages, such as for emotional distress, pain and suffering or loss of
consortium, (ii) to award punitive damages, or (iii) to reform, modify or materially change this
Agreement or any other agreements contemplated hereunder; provided, however, that the damage
limitations described in parts (i) and (ii) of this sentence will not apply if such damages are
statutorily imposed.

               (c) Costs. Each party shall bear its own attorney’s fees, costs, and disbursements arising
out of the arbitration and the costs of the arbitrator selected by it, and shall pay an equal share
of the fees and costs of the third arbitrator; provided, however, the Arbitrators shall be
authorized to determine whether a party is the prevailing party, and if so, to award to that
prevailing party reimbursement for its reasonable attorneys’ fees, costs and disbursements
(including, for example, expert witness fees and expenses, photocopy charges, travel expenses,
etc.), and/or the fees and costs of the Administrator and the Arbitrators.

               (d) Compliance with this Agreement. Unless the parties otherwise agree in writing, during the
period of time that any arbitration proceeding is pending under this Agreement, the parties shall
continue to comply with all those terms and provisions of this Agreement that are not the subject
of the pending arbitration proceeding.

               (e) Injunctive or Other Equity Relief. Nothing contained in this Agreement shall deny any
party the right to seek injunctive or other equitable relief from a court of competent jurisdiction
in the context of a bona fide emergency or prospective irreparable harm, and such an action may be
filed and maintained notwithstanding any ongoing arbitration proceeding.

15. General Provisions

     15.1 Standstill. During the Term (the “Standstill Period”), a party will not, without the
prior written consent of the other party, in any manner, directly or indirectly:

          (a) make, effect, initiate, cause or participate in (i) any acquisition of beneficial
ownership of any securities of the other party or any securities of any Affiliate of such other
party (other than de minimus investments as part of normal cash management activities), (ii) any
acquisition of any assets of the other party or any assets of any Affiliate of such other party,
(iii) any tender offer, exchange offer, merger, business combination, recapitalization,
restructuring, liquidation, dissolution or extraordinary transaction involving the other party or
any Affiliate of such other party, or involving any securities or assets of the other party or any

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

59.

 

securities or assets of any Affiliate of such other party, or (iv) any “solicitation” of “proxies”
(as those terms are used in the proxy rules of the Securities and Exchange Commission) or consents
with respect to any securities of the other party;

          (b) form, join or participate in a “group” (as defined in the Securities Exchange Act of 1934
and the rules promulgated thereunder) with respect to the beneficial ownership of any securities of
the other party;

          (c) act, alone or in concert with others, to seek to control or influence the management,
board of directors or policies of the other party;

          (d) take any action that might require the other party to make a public announcement regarding
any of the types of matters set forth in Section 15.1(a);

          (e) agree or offer to take, or encourage or propose (publicly or otherwise) the taking of, any
action referred to in Section 15.1(a), (b), (c) or (d);

          (f) assist, induce or encourage any third party to take any action of the type referred to in
Section 15.1(a), (b), (c), (d) or (e);

          (g) enter into any discussions, negotiations, arrangement or agreement with any Third Party
relating to any of the foregoing.

     15.2 Governing Law. This Agreement shall be governed by and interpreted in accordance with
the laws of the State of New York, excluding application of any conflict of laws principles that
would require application of different law.

     15.3 Entire Agreement; Modification. This Agreement is both a final expression of the
parties’ agreement and a complete and exclusive statement with respect to all of its terms. This
Agreement supersedes all prior and contemporaneous agreements and communications, whether oral,
written or otherwise, concerning any and all matters contained herein. This Agreement may only be
modified or supplemented in a writing expressly stated for such purpose and signed by the parties
to this Agreement.

     15.4 Relationship Between the Parties. The parties’ relationship, as established by this
Agreement, is solely that of independent contractors. This Agreement does not create any
partnership, joint venture or similar business relationship between the parties. Neither party is
a legal representative of the other party, and neither party can assume or create any obligation,
representation, warranty or guarantee, express or implied, on behalf of the other party for any
purpose whatsoever.

     15.5 Non-Waiver. The failure of a party to insist upon strict performance of any provision of
this Agreement or to exercise any right arising out of this Agreement shall neither impair that
provision or right nor constitute a waiver of that provision or right, in whole or in part, in that
instance or in any other instance. Any waiver by a party of a particular provision or right shall
be in writing, shall be as to a particular matter and, if applicable, for a particular period of
time and shall be signed by such party.

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

60.

 

     15.6 Assignment; Change in Control. Except as expressly provided hereunder, neither this
Agreement nor any rights or obligations hereunder may be assigned or otherwise transferred by
either party without the prior written consent of the other party (which consent shall not be
unreasonably withheld); provided, however, that either party may assign this Agreement and its
rights and obligations hereunder without the other party’s consent:

          (a) in connection with the transfer or sale to a Third Party of all or substantially all of
the business of such party to which this Agreement relates, whether by merger, sale of stock, sale
of assets or otherwise; provided that the Third Party does not have a Competitive Product (except
under the circumstances provided under Section 5.10) and the Third Party provides a written
statement to the other party confirming that such Third Party is familiar with the terms of this
Agreement and will comply, or cause the acquired party or such other entity affiliated with the
Third Party that is the surviving entity in such transaction to comply, with the obligations of the
transaction party under this Agreement; and provided, further that in the event of such a
transaction (whether this Agreement is actually assigned or is assumed by the acquiring party by
operation of law (e.g., in the context of a reverse triangular merger)), intellectual property
rights of the acquiring party to such transaction (if other than one of the parties to this
Agreement) shall not be included in the intellectual property rights licensed hereunder; or

          (b) to an Affiliate, provided that the assigning party shall remain liable and responsible to
the non-assigning party hereto for the performance and observance of all such duties and
obligations by such Affiliate.

The rights and obligations of the parties under this Agreement shall be binding upon and inure to
the benefit of the successors and permitted assigns of the parties. Any assignment not in
accordance with this Agreement shall be void.

     Notwithstanding the preceding, in the event Forest is subject to a Change in Control (as
defined below) which has not been approved by the Board of Directors of Forest as constituted
immediately prior to such Change in Control, Replidyne shall have the right, but not the
obligation, to terminate this Agreement upon written notice furnished within sixty (60) days of
such Change in Control. In connection with any such termination by Replidyne pursuant to this
paragraph, Replidyne shall pay Forest the Fair Market Value of Forest’s rights under this Agreement
at such time, which payment shall be made in a lump-sum cash payment at the time of the
effectiveness of such termination or, if later, within thirty (30) business days following the
determination of Fair Market Value.

          (i) “Change of Control” shall mean (i) the acquisition, directly or indirectly, of beneficial
ownership of a percentage of the voting power of a party sufficient to exercise de
facto control over the policies and business decisions of a party or of all or
substantially all of the business or assets of such party (whether by way of merger, sale of stock,
sale of assets or otherwise) by any person or entity (including a “group” as defined in Section
13(d)-3 of the Securities Exchange Act of 1934 (the “Exchange Act”)) (provided that the acquisition
of less than fifty percent (50%) of such voting power shall not be deemed to constitute a “Change
of Control” for as long as the acquiror or “group” qualifies to report, and does in fact report,
its beneficial ownership on Schedule 13G in accordance with Rule 13(d)-1 promulgated under the

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

61.

 

Exchange Act) or (ii) individuals who, for a period of at least two (2) consecutive years prior to
such determination (together with any other individuals whose election was approved by a two-thirds
(2/3) vote of the directors then in office) shall cease to constitute at any time a majority of the
members of the Board of Directors of such party.

          (ii) “Fair Market Value” shall mean with respect to a valuation required by any provision
hereof, the price which a willing buyer would pay, on an arm’s length basis, for all rights and
related intellectual property assets which comprise the assets, data or rights being valued, in
light of the status of development and reasonably anticipated risks and costs of further
development and the market potential for the commercialization of such assets, data or rights. In
any case where Fair Market Value must be determined, the determination shall be made by mutual
agreement of the parties through good faith negotiations based upon objective data possessed and
disclosed by both parties; provided that if no agreement as to Fair Market Value is reached after a
period of sixty (60) days, Fair Market Value shall be determined by a panel of three experts with
experience in the valuation of pharmaceutical products in the Territory, two of whom shall be
chosen by the parties, and the third, who will serve as chairperson, shall be chosen by the experts
selected by the parties, whose decision shall be binding and conclusive upon the parties.

     15.7 No Third Party Beneficiaries. This Agreement is neither expressly nor impliedly made for
the benefit of any party other than those executing it; provided that the parties acknowledge and
agree that DAP is intended to be a Third Party beneficiary of all provisions in this Agreement
specifically referring to DAP or a licensor of Replidyne or to obligations applicable to any
sublicensee of Replidyne under the DAP Agreement.

     15.8 Severability. If, for any reason, any part of this Agreement is adjudicated invalid,
unenforceable or illegal by a court of competent jurisdiction, such adjudication shall not affect
or impair, in whole or in part, the validity, enforceability or legality of any remaining portions
of this Agreement. All remaining portions shall remain in full force and effect as if the original
Agreement had been executed without the invalidated, unenforceable or illegal part.

     15.9 Notices. Any notice to be given under this Agreement must be in writing and delivered
either in person, by any method of mail (postage prepaid) requiring return receipt, or by overnight
courier or facsimile confirmed thereafter by any of the foregoing, to the party to be notified at
its address(es) given below, or at any address such party has previously designated by prior
written notice to the other. Notice shall be deemed sufficiently given for all purposes upon the
earliest of: (a) the date of actual receipt; (b) if mailed, three days after the date of postmark;
or (c) if delivered by overnight courier, the next business day the overnight courier regularly
makes deliveries.

 [ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

62.

 

     If to Forest, notices must be addressed to:

Forest Laboratories Holdings Limited

Milner House

18 Parliament Street

Hamilton, HM11

Bermuda

Attention: Chief Executive Officer

Telephone: (441) 295-4630

Facsimile: (441) 292-7880

     With a required copy to:

Forest Laboratories, Inc.

909 Third Avenue

New York, New York 10022

Attention: Chief Executive Officer

Telephone: (212) 421-7850

Facsimile: (212) 224-6740

     If to Replidyne, notices must be addressed to:

Replidyne, Inc.

1450 Infinite Drive

Louisville, Colorado 80027

Attention: President and Chief Executive Officer

Telephone: (303) 996-5500

Facsimile: (303) 996-5599

     with a copy to:

Cooley Godward llp

380 Interlocken Crescent, Suite 900

Broomfield, Colorado 80021-8021

Attention: James C. T. Linfield

Telephone: (720) 566-4000

Facsimile: (720) 566-4099

     15.10 Force Majeure. Except for the obligation to make payment when due, each party shall be
excused from liability for the failure or delay in performance of any obligation under this
Agreement by reason of any event beyond such party’s reasonable control including but not limited
to Acts of God, fire, flood, explosion, earthquake, or other natural disaster, war, civil unrest,
accident, destruction or other casualty, any lack or failure of transportation facilities, or any
other event similar to those enumerated above. Such excuse from liability shall be effective only
to the extent and duration of the event(s) causing the failure or delay in performance and provided
that the party has not caused such event(s) to occur. Notice of a party’s failure or delay in
performance due to force majeure must be given to the other party
within ten (10) days after

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

63.

 

its occurrence. All delivery dates under this Agreement that have
been affected by force majeure shall be tolled for the duration of such force majeure. In no event
shall any party be required to prevent or settle any labor disturbance or dispute. Notwithstanding
the foregoing, should the event(s) of force majeure suffered by a party extend beyond a period of
one hundred eighty (180) days, the other party may then terminate this Agreement by written notice
to the non-performing party, with the consequences of such termination as set forth in Sections
12.3, 12.4 and 12.5, or, in lieu of such termination, may undertake the development, manufacturing,
marketing and other functions of a party whose performance has been affect by such event of force
majeure for the period of such force majeure and such additional period as may be reasonably
required to assure the smooth and uninterrupted transition of such activities.

     15.11 Interpretation.

          (a) Captions & Headings. The captions and headings of clauses contained in this Agreement
preceding the text of the articles, sections, subsections and paragraphs hereof are inserted solely
for convenience and ease of reference only and shall not constitute any part of this Agreement, or
have any effect on its interpretation or construction.

          (b) Singular & Plural. All references in this Agreement to the singular shall include the
plural where applicable, and all references to gender shall include both genders and the neuter.

          (c) Articles, Sections & Subsections. Unless otherwise specified, references in this
Agreement to any article shall include all sections, subsections, and paragraphs in such article;
references in this Agreement to any section shall include all subsections and paragraphs in such
sections; and references in this Agreement to any subsection shall include all paragraphs in such
subsection.

          (d) Days. All references to days in this Agreement shall mean calendar days, unless otherwise
specified.

          (e) Ambiguities. Ambiguities and uncertainties in this Agreement, if any, shall not be
interpreted against either party, irrespective of which party may be deemed to have caused the
ambiguity or uncertainty to exist.

          (f) English Language. This Agreement has been prepared in the English language and the
English language shall control its interpretation. In addition, all notices required or permitted
to be given hereunder, and all written, electronic, oral or other communications between the
parties regarding this Agreement shall be in the English language.

     15.12 Counterparts. This Agreement may be executed in two or more counterparts, each of which
shall be deemed an original document, and all of which, together with this writing, shall be deemed
one instrument.

     15.13 DAP Agreement. Replidyne shall not agree to any amendment or modification of the DAP
Agreement or waive any of its rights thereunder to the extent such amendment, modification or
waiver would adversely affect Forest’s interests under this
Agreement except

 [ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

64.

 

with Forest’s prior written consent, which shall not be unreasonably withheld
or delayed.

     Replidyne agrees to exercise its rights and perform its obligations under the DAP Agreement to
the extent necessary to preserve Forest’s interests under this Agreement and the then current plans
of the JDC or JMC. [ *** ]

     Replidyne shall promptly notify Forest of [ *** ] to the extent material to Forest’s interest
in the development, regulatory approval or commercialization of Product in the Territory and
including, without limitation, [ *** ]. Replidyne hereby affirms that Forest shall have the right,
but not the obligation, to cure any material breach by Replidyne under the DAP Agreement (but
excluding any such breach caused by Forest) at any time during [ *** ] prior to the final effective
date of termination pursuant to the terms provided under Section 16.2 of the DAP Agreement, all to
the extent necessary for Forest to preserve its interests under this Agreement. In the event
Forest is required, acting in good faith, [ *** ].

     In the event of a breach by DAP of the DAP Agreement, Replidyne shall have the right to first
discuss the matter with DAP and to attempt to reach a resolution; [ *** ]. If, with respect to
such breach by DAP, Replidyne institutes an arbitration pursuant to Article 25 of the DAP
Agreement, [ *** ]

     Replidyne hereby affirms that Forest shall have the right, but not the obligation, to assume
the obligations of Replidyne under the DAP Agreement in order to preserve Forest’s sublicense under
the DAP Agreement on the terms provided in Section 16.5 of the DAP Agreement regarding insolvency
or bankruptcy of Replidyne.

     Replidyne and Forest agree that they will meet together with DAP up to twice per year to
review and discuss among the three companies the progress of development and commercial efforts for
Products.

[Remainder of this page intentionally left blank.]

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

65.

 

     In Witness Whereof, the parties hereto have duly executed this Collaboration and
Commercialization Agreement as of the Effective Date.

	 	 	 	 	 	 	 
	Replidyne, Inc.	 	Forest Laboratories Holdings Limited
	 
	 	 	 	 	 	 
	By:

	 	/s/ Kenneth Collins
	 	By:
	 	/s/ Howard Solomon
	 

	 	 
	 	 	 	 
	Name:

	 	 	 	Name:	 	 
	 

	 	 
	 	 	 	 
	Title:

	 	 	 	Title:	 	 
	 

	 	 
	 	 	 	 

Collaboration and Commercialization Agreement

Signature Page

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

66.

 

EXHIBIT A

Ciba-Geigy Patents

6-substituted thia-aza compounds (Ciba-Geigy)

	 	 	 	 	 	 	 	 	 	 	 	 	 
	Country	 	Application Date	 	Patent No.	 	Expiration Date
	U.S.A

	 	 	1989.08.21	 	 	 	4952690	 	 	 	2007.08.28	 

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

Exhibit A-1

 

 

EXHIBIT B

DAP Patents

     1. Composition of Matter of faropenem daloxate:

	 	 	 	 	 	 	 	 	 
	Country	 	Application Date	 	Patent No.	 	Registration Date	 	Expiration Date
	U.S.A
	 	1991.08.16	 	5830889	 	1998.11.03	 	2015.11.03
	U.S.A (divisional)
	 	1991.08.16	 	5885981	 	1999.03.23	 	2015.11.03

     2. Sustained Release Formulation:

	 	 	 	 	 	 	 	 	 
	Application	 	Publication	 	Pub. Date	 	Filed	 	Title
	US2004000791270

	 	US20050169984A1
	 	2005-08-04
	 	2004-03-03
	 	Pharmaceutical hard

capsule containing

inorganic substance

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

Exhibit B-1

 

 

SCHEDULE 5.5

Pediatrician Promotion Rights

SCHEDULE 5.5

Terms and Conditions for Pediatrician Promotion Rights

Upon Replidyne’s exercise of the Pediatrician Promotion Option pursuant to Section 5.5 of this
Agreement, the provisions of this Schedule 5.5 shall apply, notwithstanding anything to the
contrary in the Agreement. Forest shall cause Forest Parent to perform the obligations of Forest
specified in this Schedule 5.5.

     1. Definitions. All terms defined in the Agreement shall have the meaning given such
terms in the Agreement. For purposes of this Schedule 5.5, the following terms shall have
the respective meanings set forth below:

          1.1. “Non-Pediatrician Suspension Cost of Goods” for any dosage strength of the Oral
Suspension for any period, shall mean the Cost of Goods for the units of such dosage strength of
the Oral Suspension included in the Non-Pediatrician Suspension Net Sales for such period.

          1.2. “Non-Pediatrician Suspension Distribution Costs” for any dosage strength of the Oral
Suspension for any period, shall mean the Distribution Costs for the units of such dosage strength
of the Oral Suspension included in the Non-Pediatrician Suspension Net Sales for such period.

          1.3. “Non-Pediatrician Suspension Marketing and Sample Expense” for any dosage strength of the
Oral Suspension for any period, shall mean a reasonable allocation of Marketing and Sample Expense
attributable to the marketing and promotion of the Oral Suspension to non-Pediatricians, as
determined by the JMC.

          1.4. “Non-Pediatrician Suspension Marketing Margin” for any dosage strength of the Oral
Suspension for any period, shall mean the amount equal to:

	 	(a)	 	Non-Pediatrician Suspension Net Sales, minus
	 
	 	(b)	 	all of the following:

	 	(i)	 	Non-Pediatrician Suspension Cost of Goods;
	 
	 	(ii)	 	Non-Pediatrician Suspension Royalty;
	 
	 	(iii)	 	Non-Pediatrician Suspension Distribution Costs; and
	 
	 	(iv)	 	Non-Pediatrician Suspension Marketing and Sample Expense.

In the event that the Non-Pediatrician Suspension Marketing Margin for a period is a negative
amount, such amount shall be referred to as a “Non-Pediatrician Suspension Loss,” and
“Non-Pediatrician Suspension Losses” shall have the corresponding meaning.

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

Schedule 5.5-1

 

 

          1.5. “Non-Pediatrician Suspension Net Sales” for any dosage strength of the Oral Suspension
for any period, shall mean (a) the Net Sales for such dosage strength for such period, less (b)
Pediatrician Net Sales for such dosage strength of the Oral Suspension for such period.

          1.6. “Non-Pediatrician Suspension Royalty” for any dosage strength of the Oral Suspension for
any period, shall mean the Royalty Payments to Replidyne for the units of such dosage strength and
formulation of the Oral Suspension included in the Non-Pediatrician Suspension Net Sales for such
period.

          1.7. “Pediatrician Cost of Goods” for any dosage strength and formulation of the Product for
any period, shall mean the Cost of Goods for the units of such dosage strength and formulation of
the Product included in the Pediatrician Net Sales for such period.

          1.8. “Pediatrician Distribution Costs” for any dosage strength and formulation of the Product
for any period, shall mean the Distribution Costs for the units of such dosage strength and
formulation of the Product included in the Pediatrician Net Sales for such period.

          1.9. “Pediatrician Marketing and Sample Expense” for any dosage strength and formulation of
the Product for any period, shall mean the Marketing and Sample Expense for the units of such
dosage strength and formulation of the Product included in the Pediatrician Net Sales for such
period.

          1.10. “Pediatrician Marketing Margin” for any dosage strength and formulation of the Product
for any period, shall mean the amount equal to:

	 	(a)	 	Pediatrician Net Sales, minus
	 
	 	(b)	 	all of the following:

	 	(i)	 	Pediatrician Cost of Goods;
	 
	 	(ii)	 	Pediatrician Royalty;
	 
	 	(iii)	 	Pediatrician Distribution Costs; and
	 
	 	(iv)	 	Pediatrician Marketing and Sample Expense.

In the event that the Pediatrician Marketing Margin for a period is a negative amount, such amount
shall be referred to as a “Pediatrician Loss,” and “Pediatrician Losses” shall have the
corresponding meaning.

          1.11. “Pediatrician Net Sales” for any dosage strength and formulation of the Product for any
period, shall mean (a) the Net Sales for such dosage strength or formulation for such period,
multiplied by (b) the percentage that the units of such dosage strength and formulation included in
Net Sales which are represented by prescriptions originating from Pediatricians represent of the
total units of such dosage strength and formulation included in Net Sales represented by all
prescriptions for such period based upon IMS Xponent data or other mutually-agreed generally
recognized prescription data source.

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

Schedule 5.5-2

 

 

          1.12. “Pediatrician Promotion Fee” shall have the meaning assigned to such term in Section
4.3(a).

          1.13. “Pediatrician Promotion Period” shall mean the period beginning on the date on which
Replidyne exercises the Pediatrician Promotion Option and ending on the earlier of: (a) the
expiration of the last to expire valid claim of the Licensed Patents, Forest Patents or Joint
Patents claiming the manufacture, use or sale of the Oral Suspension in the Territory, including
any period of extended commercial exclusivity for the Oral Suspension under any Licensed Patent,
Forest Patent or Joint Patent granted under any laws or regulations in such country; and (b) date a
Third Party commences the distribution of a generic equivalent to the Oral Suspension in the
Territory, unless sooner terminated in accordance with the terms of this Agreement.

          1.14. “Pediatrician Royalty” for any dosage strength and formulation of the Product for any
period, shall mean the Royalty Payments to Replidyne for the units of such dosage strength and
formulation of the Product included in the Pediatrician Net Sales for such period.

     2. Pediatrician Promotion Rights.

          2.1. Promotion to Pediatricians. During the Pediatrician Promotion Period, Forest and
Replidyne agree to promote the Product in the Field in the Territory in accordance with the
Agreement, as modified by the terms and conditions of this Schedule 5.5.

          2.2. Marketing Plan. Replidyne shall draft and submit to the JMC for review and
approval those portions of the Marketing Plan describing activities directed to Pediatricians, and
Forest shall draft and submit to the JMC for review and approval those portions of the Marketing
Plan describing activities directed to marketing the Oral Suspension to non-Pediatricians, both of
which shall be consistent with the JMC’s overall marketing strategy for the Product in the
Territory and with the overall Marketing Plan.

          2.3. Diligence. The parties acknowledge that additional promotional efforts following
the First Commercial Sale of an Oral Suspension is warranted to increase awareness of the
commercial availability of that additional Product. Subject to the minimum promotional efforts
required by Section 5.3(d) of the Agreement, such efforts shall be Commercially Reasonable Efforts
as established by the JMC pursuant to the Marketing Plan. Forest’s promotional efforts to
non-Pediatricians with respect to the Oral Suspension will be performed in conjunction with the
promotion of the Tablet to such physicians. Accordingly, the JMC will establish for each Detailing
Year objectives specifically for the promotion of the Oral Suspension by Forest to
non-Pediatricians, such as the priority of the Oral Suspension relative to the Tablet in Details to
Primary Care Physicians, the list of non-Pediatricians that warrant detailing of the Oral
Suspension and the positioning of the Oral Suspension relative to the Tablet in marketing
campaigns.

          2.4. Replidyne Commercial Activities for Pediatricians. During the Pediatrician
Promotion Period, Replidyne shall perform all marketing and promotion-related activities for the
Products directed to Pediatricians. Replidyne will promptly notify Forest at any

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

 Schedule 5.5-3

 

 

time that it appears reasonably likely that Replidyne will not be able to substantially
achieve required levels of Detailing over any significant period or in any significant area.
Following any such notice, the parties will meet and confer in good faith to develop a plan to
achieve such required levels of Detailing as promptly as practicable, including through the
reallocation of Replidyne personnel, if practicable and without adversely affecting Replidyne’s
Detailing efforts, and the utilization of Forest sales force personnel as reasonably required to
achieve the required levels of Detailing. Following the development of such plan, Forest shall
have the right to call on Pediatricians as provided by the plan, in which case the JMC will
coordinate the efforts of each of Forest and Replidyne with respect to the Detailing of Product to
Pediatricians by each party. In addition, if (a) Replidyne elects not to provide Details of the
Product to certain Pediatricians (e.g., due to a particular geographical location), the Detail
Reports indicate that Replidyne’s Detailing has not achieved material Detailing requirements to be
performed by Replidyne as targeted by the Marketing Plan (as to number or position of Details) over
a significant period or (b) the JMC determines, prior to a formal annual update to the Marketing
Plan, that Detailing efforts to Pediatricians in addition to those in the then current Marketing
Plan are appropriate and authorizes additional funds, if required to support such additional
Detailing efforts to Pediatricians, the parties will meet and confer in the manner set forth above
to develop a plan to address the provision of additional Details, which plan will be based on the
considerations, and implemented by the parties, as provided above. In any such event requiring the
utilization of Forest sales force personnel, the parties will cooperate to transition Detailing
efforts to Replidyne as promptly as practicable in light of the need to assure a smooth transition
of Detailing activities once Replidyne possesses adequate resources to provide Detailing efforts
targeted by the Marketing Plan.

               (a) Marketing. During the Pediatrician Promotion Period and subject to the minimum
requirements set forth in Section 5.3(d) of the Agreement, Replidyne will use its Commercially
Reasonable Efforts to execute on the activities under the Marketing Plan regarding marketing and
promotion to Pediatricians. Forest will reimburse Replidyne for expenses incurred by Replidyne in
performing such activities as provided in Section 4.3(b) of this Schedule 5.5. Forest will share
with Replidyne any market research or other marketing information or materials relevant to
marketing and promotion to Pediatricians that Forest possesses, as requested by Replidyne.

               (b) Organization of Replidyne Pediatrician Sales Force. The JMC will determine the
minimum number of Pediatricians to be on the call plan and minimum frequency. During the
Pre-Launch Period with respect to the Oral Suspension, Replidyne shall use its Commercially
Reasonable Efforts to engage and organize the Replidyne Pediatrician Sales Force in accordance with
strategic plans agreed to by the JMC and provided in the Marketing Plan. To form the Replidyne
Pediatrician Sales Force, Replidyne may expand its then-existing sales force by engaging personnel
provided by a contract sales organization; provided that personnel of a contract sales organization
shall make up no more than [ *** ] of the Replidyne Pediatrician Sales Force; and provided, further
that Replidyne will transition to a Replidyne Pediatrician Sales Force comprised entirely of
personnel who are full-time employees of Replidyne by the [ *** ] anniversary of the Detailing
Commencement Date for the Oral Suspension. At the end of the first [ *** ] following the Detailing
Commencement Date for the Oral Suspension, if the

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

Schedule 5.5-4

 

 

Replidyne Pediatrician Sales Force is then comprised of personnel provided by a contract sales
organization, the JMC shall determine whether:

                    (i) the Replidyne Pediatrician Sales Force has delivered [ *** ] percent ([ *** ]%) of the
Details set forth in the Marketing Plan for that time period;

                    (ii) at least [ *** ] percent ([ *** ]%) of the Details performed by Replidyne Pediatrician
Sales Force during that time period were delivered to Pediatricians on the call panel and with the
frequency and Detail position established by the JMC; and

                    (iii) the performance by the Replidyne Pediatrician Sales Force meets the metrics previously
established by the JMC to be measured in an ImpactRX report obtained at the [ *** ] benchmark
point.

               If the Replidyne Pediatrician Sales Force fails to meet the foregoing requirements, Replidyne
will provide written notice to Forest within [ *** ] of such determination by the JMC, indicating
whether Replidyne will (A) transition to a sales force comprised of personnel who are full-time
employees of Replidyne and coordinate Detailing to Pediatricians together with Forest’s sales
representatives pending the achievement of a full-time employee trained and qualified sales force
or (B) terminate the Pediatrician Promotion Period, in each case over the course of the [ *** ]
month period immediately following such notice.

               (c) Training Materials and Sessions. Forest shall provide Replidyne with the training
materials Forest provides to the Forest Sales Force, sufficient in quantity and quality to allow
Replidyne to train the Replidyne Pediatrician Sales Force in Product-specific sales skills and to
Detail the Product in a manner consistent with the Detailing performed by the Forest Sales Force.
Replidyne will prepare or have prepared any supplementary training materials required for Detailing
the Product to Pediatricians, consistent with the applicable Marketing Plan. Forest will permit
Replidyne sales representatives to participate in training sessions of the Forest Sales Force with
respect to the Product and will provide reasonable advance notice to Replidyne of scheduled
training events, provided the Replidyne salary and out-of-pocket travel and related expenses of
such attendance shall be for the account of Replidyne. Without limiting the generality of the
foregoing, the parties intend that the Replidyne Pediatrician Sales Force will participate in the
initial Oral Suspension launch and subsequent sales force meetings to the extent related to the
Oral Suspension. Training sessions or modules specific to promotion to Pediatricians will be the
responsibility and at the cost of Replidyne.

               (d) Promotional Materials. Forest shall provide Replidyne with sales and promotional
materials reasonably sufficient to permit Replidyne to perform Detailing calls to Pediatricians in
a manner consistent with the Detailing calls performed by the Forest Sales Force. Replidyne will
create or have created on its behalf such additional sales and promotional materials intended to be
specific to the Pediatrician audience as called for under the Marketing Plan. The project managers
of each party will share with one another any such materials. No such materials shall be used
until they have been approved by the regulatory and compliance functions of each party.

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

Schedule 5.5-5

 

 

               (e) Sampling. Forest shall provide Replidyne with Product samples as requested by
Replidyne to permit Replidyne to perform Detailing calls to Pediatricians in accordance with the
Marketing Plan. Replidyne shall be responsible for accounting for sample distribution by the
Replidyne Pediatrician Sales Force and shall maintain all records with respect to sample
distribution as required by Applicable Laws. Within thirty (30) days after the end of each month,
Replidyne shall provide to Forest a written report summarizing samples distributed by the Replidyne
Pediatrician Sales Force for such calendar month. In addition, Replidyne shall ensure, through
appropriate routine monitoring and auditing standards which conform with current good industry
practices, that sampling of the Product is carried out by Replidyne in a manner which is in
compliance with all Applicable Laws. Replidyne shall immediately advise Forest of its discovery of
any act or omission of Replidyne regarding sample distribution that could violate or require
reporting under Applicable Laws. Forest shall be solely responsible for the filing of any
necessary reports to FDA in connection with sampling. Within thirty (30) days after the expiration
or termination of the Pediatrician Promotion Period, Replidyne shall return, or otherwise dispose
of in accordance with written instructions from Forest, all remaining samples and will provide
Forest with a certified statement that all remaining samples have been returned or otherwise
properly disposed of in accordance with Forest’s instructions and that Replidyne is no longer in
possession or control of any samples in any form or fashion.

               (f) Termination. Replidyne reserves the right to terminate its Pediatrician Promotion
Rights at any time during the Pediatrician Promotion Period, effective upon eighteen (18) months
written notice to Forest, or immediately upon written notice to Forest if Replidyne believes that a
recall, market withdrawal or other corrective action related to the Oral Suspension is warranted in
the Territory. If Replidyne exercises the foregoing right, Replidyne shall provide such transition
activities as and for such period as Forest may reasonably request, including, without limitation,
arranging for meetings between members of the Replidyne Pediatrician Sales Force and sales
representatives of Forest, to assure a smooth transition of marketing to Pediatricians.

               (g) Forest Right of Termination. If Forest ceases the promotion, sale or distribution
of the Product in the Territory under the circumstances permitted under this Agreement, then upon
written notice to Replidyne, Forest may terminate the Pediatrician Promotion Period, effective
within a reasonable period of time in light of the circumstances underlying any such cessation by
Forest. In addition, Forest reserves the right to terminate the Pediatrician Promotion Period,
effective upon [ *** ] written notice to Replidyne in the event that the Detail Reports for at
least [ *** ] indicate that Replidyne’s Detailing has not achieved at least [ *** ] percent ([ ***
]%) of the Detailing to be performed by Replidyne as targeted by the Marketing Plan (as to number
or position of Details) for each such Calendar Quarter or upon the failure by Replidyne to achieve
at least [ *** ] percent ([ *** ]%) of the Detailing to be performed by Replidyne as targeted by
the Marketing Plan (as to numbers or portions of Details) in the aggregate over a period of [ ***
], unless in either case, during such [ *** ] period Replidyne develops and implements a program of
increased Detailing which provides, to Forest’s reasonable satisfaction, assurance that Detail
shortfalls will not again occur. Failure of Replidyne to meet the number of Details required under
the Marketing Plan with respect to promotion efforts directed to Pediatrician shall not be deemed a
material breach under this

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

Schedule 5.5-6

 

 

Agreement and, notwithstanding Section 12.8, shall not entitle Forest to claim any damages,
compensation or relief except as provided in this Section 2.4(g) and Section 4.3(e).

          2.5. Market Withdrawals. Each party shall have the right to determine whether a
market withdrawal of the Oral Suspension in the Territory is warranted. If Replidyne makes such a
determination, it shall have the right to cease the promotion and Detailing of the Oral Suspension
in the Territory immediately upon written notice to Forest. If Forest makes such a determination,
it shall have the right to cease all sales of Oral Suspension in the Territory and the promotion
and Detailing of the Oral Suspension in the Territory immediately upon written notice to Replidyne.
If Replidyne ceases promotion and Detailing of the Oral Suspension in the Territory and Forest
continues the sale of the Oral Suspension in Territory, Replidyne shall have no liability for sales
of Oral Suspension after the date that Replidyne discontinues its promotion and Detailing of the
Oral Suspension in the Territory.

     3. Supply Matters. During the Pediatrician Promotion Period, Forest shall keep
Replidyne advised of matters regarding the supply of the Oral Suspension in the Territory and shall
consult with Replidyne on strategic decisions to be made with respect thereto.

     4. Financial Matters.

          4.1. Credit Facility. Forest will extend a line of credit of sixty million dollars
($60,000,000) to Replidyne against which, beginning upon commencement of the Pediatrician Promotion
Period, Replidyne may draw down in one (1) or more installments such amounts as are necessary to
constitute and maintain the Replidyne Pediatrician Sales Force and conduct pre-launch, marketing
and other activities related to the exercise of the Pediatrician Promotion Rights. Replidyne
agrees to draw down on the line of credit only such amounts as expected to be needed to finance the
Pediatrician Promotion Rights by providing written notice to Forest that specifies the amount
requested and the reasons for the draw down with reasonable specificity. Any amounts owing by
Replidyne to Forest under the line of credit shall bear interest at the prime rate of interest, as
adjusted monthly, plus one percent (1%) and shall be repaid on a Calendar Quarter basis over a
period ending four (4) years from the date of the first draw, with no penalty for pre-payments.
The outstanding balance at any given time may be applied against Royalty Payments and milestone
payments due from Forest under this Agreement in the event of a default by Replidyne under the
loan, subject to a customary notice requirement and cure period to be provided for under the loan
documents and Replidyne shall grant Forest a security interest in Replidyne’s interest in the
Royalty Payments and milestone payments receivable by Replidyne under this Agreement to the extent
necessary to further secure Replidyne’s obligations in connection with the loan. At the time of
execution of the loan documents, Replidyne’s rights to receive Royalty Payments or milestone
payments under the Agreement shall be free from any pledge, hypothecation, security interest or
other encumbrance in an amount necessary to secure Replidyne’s repayment obligations under the
loan. Other standard loan terms will be negotiated in good faith by the parties.

          4.2. Reporting. Within forty-five (45) days after each Calendar Quarter during a
Detailing Year, each party shall provide to the other a report, in a form specified by the JMC,
summarizing (a) information regarding such party’s actual performance of marketing and promotional
activities, as compared to marketing and promotional commitments set forth in the

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

Schedule 5.5-7

 

 

Marketing Plan, including, without limitation, the number and frequency of Details of Oral
Suspension provided by such party, including the proportion of Details in first and second
position, and Marketing and Sample Expense incurred by such party during the Calendar Quarter, and
(b) such information as is necessary to allow calculation of the Non-Pediatrician Suspension
Marketing Margin and the Pediatrician Marketing Margin.

          4.3. Compensation to Replidyne.

               (a) Pediatrician Promotion Fee. In addition to the Royalty Payments and other
payments due to Replidyne under Section 7 of the Agreement (including, without limitation,
development and commercial milestones for the Oral Suspension and royalties on all sales of the
Oral Suspension), subject to adjustment in accordance with subsections (d) and (e) below, Forest
shall pay to Replidyne a fee (the “Pediatrician Promotion Fee") equal to the sum of:

                    (i) [ *** ] percent ([ *** ]%) of the Pediatrician Marketing Margin; and

                    (ii) [ *** ] percent ([ *** ]%) of the Non-Pediatrician Suspension Marketing Margin.

               (b) Reimbursement of Replidyne’s Marketing and Sample Expense. Together with each
payment of the Pediatrician Promotion Fee, Forest shall reimburse Replidyne for the Pediatrician
Marketing and Sample Expense incurred by Replidyne and, if applicable, any Non-Pediatrician
Suspension Marketing and Sample Expense incurred by Replidyne as provided for under the Marketing
Plan, as well as any other expenses related to the Oral Suspension that are incurred by Replidyne
but are to be borne by Forest under this Agreement (such as Cost of Goods and Distribution Costs),
which are reported to Forest for the Calendar Quarter to which such payment relates.

               (c) Payment. Within forty-five (45) days of the end of each Calendar Quarter during
the Pediatrician Promotion Period, Forest shall pay Replidyne an amount equal to the Pediatrician
Promotion Fee earned by Replidyne for such Calendar Quarter. In the event that the Pediatrician
Promotion Fee for a Calendar Quarter is negative, Replidyne shall pay Forest the amount by which
such Pediatrician Promotion Fee is negative within forty-five (45) days of the end of such Calendar
Quarter.

               (d) Annual Adjustment. With respect to the payment of the Pediatrician Promotion Fee
for the fourth Calendar Quarter of a Detailing Year, Forest shall calculate the actual Pediatrician
Promotion Fee payable for the entire such Detailing Year and Forest shall make payment (or receive
a credit), as appropriate, for the balance of the Pediatrician Promotion Fee due for such Detailing
Year (taking into account any payments by Replidyne to Forest of negative amounts).

               (e) Additional Adjustment. If the Detailing actually provided by Replidyne to
Pediatricians for a given Detailing Year fails to achieve at least [ *** ] percent ([ *** ]%) of
the Detailing targeted by the Marketing Plan (as to number or position of Details), the

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

Schedule 5.5-8

 

 

percentage of Pediatrician Marketing Margin used in calculating the Pediatrician Promotion Fee
shall be reduced [ *** ].

               (f) Records. Each party shall maintain accurate records relating to its obligations
hereunder (including, without limitation, records relating to the performance of Details (including
records of physicians called on, frequency of calls and other data which underlies the Detail
Reports required by Section 3.2, and the calculation of Pediatrician Marketing Margin and
Suspension Marketing Margin), which records shall be kept available for three (3) years following
the Detailing Year to which such records relate unless a longer period is otherwise required by
Applicable Laws. The audit provisions of Section 8.5 of the Agreement shall apply to such records.

     5. Product Liability. In connection with the commercialization of the Oral
Suspension, Forest and Replidyne will share responsibility equally for any liability for personal
injury or property damage arising in connection with use of the Oral Suspension; provided, however,
that in any event each party shall be responsible for, and hereby assumes, any and all risks of
personal injury or property damage attributable solely to the gross negligence or willful
misconduct of that party or its Affiliates, and their respective directors, officers, employees and
agents.

     6. Intellectual Property Matters.

          6.1. Infringement by Third Parties. With regard to any action or proceeding with
respect to infringement of any of the Licensed Patents, Joint Patents or Forest Patents pertaining
to the Oral Suspension, including any ANDA Proceeding related to such Licensed Patents, Joint
Patents or Forest Patents, in the Territory during the Pediatrician Promotion Period, the parties
shall cooperate in bringing and shall share control of such action or proceeding with counsel
mutually acceptable to the parties. In any such action or proceeding that relates to the Oral
Suspension during the Pediatrician Promotion Period, the parties will share equally the costs
associated with such action or proceeding, unless otherwise agreed in writing by the parties.

          6.2. Infringement of Third Party Rights. With regard to the defense of any claim by a
Third Party alleging that the activity of either of the parties pursuant to this Agreement with
respect to the Oral Suspension infringes or may infringe the intellectual property rights of such
Third Party during the Pediatrician Promotion Period, the parties shall cooperate in and shall
share control of the defense of such claim with counsel mutually acceptable to such parties and
shall share equally the costs associated with the defense of such claim, unless otherwise agreed in
writing by the parties.

[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.

Schedule 5.5-9

 

 

Table Of Contents

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	Page	 
	1.	 	DEFINITIONS	 	 	1	 
	2.	 	LICENSES	 	 	14	 
	 	 	2.1	 	License Grants	 	 	14	 
	 	 	2.2	 	Sublicenses	 	 	15	 
	 	 	2.3	 	Grant to Replidyne by Forest	 	 	15	 
	 	 	2.4	 	Related Compounds	 	 	16	 
	 	 	2.5	 	Trademark and Trade Dress Matters	 	 	16	 
	 
	 	 	 	(a)	 	Sale under Trademarks	 	 	16	 
	 
	 	 	 	(b)	 	Use of Names and Logos on Product and Related Materials	 	 	16	 
	 
	 	 	 	(c)	 	Use of DAP Name and DAP Logogram	 	 	16	 
	 
	 	 	 	(d)	 	Trademark Use	 	 	17	 
	 	 	2.6	 	Sales Outside the Territory	 	 	17	 
	 	 	2.7	 	Retained Rights; No Implied Licenses	 	 	17	 
	3.	 	COLLABORATION GOVERNANCE	 	 	18	 
	 	 	3.1	 	Joint Development Committee	 	 	18	 
	 
	 	 	 	(a)	 	Formation	 	 	18	 
	 
	 	 	 	(b)	 	Responsibilities	 	 	18	 
	 
	 	 	 	(c)	 	JDC Decision-Making	 	 	19	 
	 
	 	 	 	(d)	 	Limits on Authority	 	 	19	 
	 	 	3.2	 	Joint Marketing Committee	 	 	19	 
	 
	 	 	 	(a)	 	Formation	 	 	19	 
	 
	 	 	 	(b)	 	Responsibilities	 	 	19	 
	 
	 	 	 	(c)	 	JMC Decision Making	 	 	20	 
	 
	 	 	 	(d)	 	Limits on Authority	 	 	20	 
	 	 	3.3	 	Cost of Goods Committee	 	 	20	 
	 
	 	 	 	(a)	 	Formation	 	 	20	 
	 
	 	 	 	(b)	 	CGC Decision Making	 	 	21	 
	 
	 	 	 	(c)	 	Limits on Authority	 	 	21	 
	4.	 	CONDUCT OF THE DEVELOPMENT PROGRAM	 	 	21	 
	 	 	4.1	 	Development Program Activities	 	 	21	 

-i-

 

Table Of Contents

(continued)

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	Page	 
	 	 	4.2	 	Oral Suspension Development	 	 	22	 
	 	 	4.3	 	Technology and Information Transfer	 	 	22	 
	 	 	4.4	 	Clinical Supply	 	 	22	 
	 	 	4.5	 	Development Reports	 	 	22	 
	 	 	4.6	 	Development Costs	 	 	23	 
	 
	 	 	 	(a)	 	Allocation of Costs	 	 	23	 
	 
	 	 	 	(b)	 	Reports and Payments	 	 	23	 
	 	 	4.7	 	Registration Activities	 	 	23	 
	 	 	4.8	 	Meetings and Communications with the FDA	 	 	24	 
	 	 	4.9	 	Subcontracts	 	 	24	 
	 	 	4.10	 	Materials Transfer	 	 	24	 
	 	 	4.11	 	Liability	 	 	25	 
	5.	 	COMMERCIALIZATION	 	 	25	 
	 	 	5.1	 	Forest General Commercial Responsibilities	 	 	25	 
	 	 	5.2	 	Marketing Plans	 	 	25	 
	 	 	5.3	 	Diligence	 	 	26	 
	 	 	5.4	 	Replidyne Commercial Activities for Target Specialists	 	 	27	 
	 
	 	 	 	(a)	 	Organization of Replidyne Specialty Sales Force	 	 	28	 
	 
	 	 	 	(b)	 	Training Materials and Sessions	 	 	29	 
	 
	 	 	 	(c)	 	Promotional Materials	 	 	29	 
	 
	 	 	 	(d)	 	Sampling	 	 	29	 
	 
	 	 	 	(e)	 	Funding	 	 	29	 
	 
	 	 	 	(f)	 	Additional Support	 	 	30	 
	 
	 	 	 	(g)	 	Extension; Termination	 	 	30	 
	 
	 	 	 	(h)	 	Forest Termination Right	 	 	30	 
	 	 	5.5	 	Pediatrician Promotion Option	 	 	31	 
	 	 	5.6	 	Product Management; Distribution; Returns	 	 	31	 
	 	 	5.7	 	Medical Inquiries; Product Complaints	 	 	32	 
	 	 	5.8	 	Compliance with Law	 	 	32	 
	 	 	5.9	 	Commercialization Outside the Territory	 	 	33	 

-ii-

 

Table Of Contents

(continued)

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	Page	 
	 	 	5.10	 	Competitive Products	 	 	34	 
	 	 	5.11	 	Phase IV and Publication Strategy	 	 	35	 
	 	 	5.12	 	Adverse Events	 	 	35	 
	 	 	5.13	 	Recalls or Other Corrective Actions	 	 	36	 
	 	 	5.14	 	Product Liability	 	 	36	 
	6.	 	SUPPLY MATTERS	 	 	36	 
	 	 	6.1	 	Joint Supply Committee	 	 	36	 
	 	 	6.2	 	Supply Transition	 	 	37	 
	 	 	6.3	 	Launch Delay Compensation	 	 	37	 
	 	 	6.4	 	Supply Costs	 	 	38	 
	 	 	6.5	 	Manufacturing Rights	 	 	38	 
	 	 	6.6	 	Manufacturing Transfer Compensation	 	 	39	 
	 	 	6.7	 	Supply Chain Management	 	 	39	 
	7.	 	FEES AND PAYMENTS	 	 	39	 
	 	 	7.1	 	Upfront Fee	 	 	39	 
	 	 	7.2	 	Milestone Payments	 	 	39	 
	 	 	7.3	 	Royalties	 	 	41	 
	 	 	7.4	 	Payments to DAP	 	 	42	 
	 	 	7.5	 	Royalty Term; Generic Product	 	 	42	 
	 
	 	 	 	(a)	 	Branded Product When Generic Equivalent is Sold	 	 	42	 
	 
	 	 	 	(b)	 	Generic Product Sold by Forest	 	 	42	 
	 	 	7.6	 	Bioterror Applications	 	 	42	 
	 	 	7.7	 	Other Royalty Adjustments	 	 	43	 
	 	 	7.8	 	Acknowledgment of Replidyne Contribution	 	 	43	 
	 	 	7.9	 	Reimbursement of Development Costs	 	 	43	 
	 	 	7.10	 	Reimbursement of Replidyne Target Specialist Commercial Activities	 	 	43	 
	 
	 	 	 	(a)	 	Reimbursement of Pre-Launch Period Sales Force Expense	 	 	43	 
	 
	 	 	 	(b)	 	Reimbursement of Marketing and Sample Expense	 	 	43	 
	 
	 	 	 	(c)	 	Reimbursement of Sales Force Expense	 	 	44	 
	 
	 	 	 	(d)	 	Additional Adjustments	 	 	45	 

-iii-

 

Table Of Contents

(continued)

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	Page	 
	8.	 	PAYMENT; RECORDS; AUDITS	 	 	46	 
	 	 	8.1	 	Payment; Reports	 	 	46	 
	 	 	8.2	 	Manner and Place of Payment	 	 	46	 
	 	 	8.3	 	Income Tax Withholding	 	 	46	 
	 	 	8.4	 	Financial Records	 	 	46	 
	 	 	8.5	 	Audits	 	 	47	 
	 	 	8.6	 	Late Payments	 	 	47	 
	9.	 	INTELLECTUAL PROPERTY	 	 	47	 
	 	 	9.1	 	Ownership of Inventions	 	 	47	 
	 	 	9.2	 	Patent Prosecution and Maintenance	 	 	48	 
	 
	 	 	 	(a)	 	DAP Patents	 	 	48	 
	 
	 	 	 	(b)	 	Replidyne Patents	 	 	48	 
	 
	 	 	 	(c)	 	Forest Patents	 	 	48	 
	 
	 	 	 	(d)	 	Joint Patents	 	 	49	 
	 
	 	 	 	(e)	 	Patent Strategy	 	 	49	 
	 	 	9.3	 	Cooperation of the Parties	 	 	49	 
	 	 	9.4	 	Infringement by Third Parties	 	 	49	 
	 
	 	 	 	(a)	 	Notification	 	 	49	 
	 
	 	 	 	(b)	 	Licensed Patents, Forest Patents and Joint Patents	 	 	50	 
	 
	 	 	 	(c)	 	Cooperation	 	 	50	 
	 	 	9.5	 	Infringement of Third Party Rights	 	 	51	 
	 	 	9.6	 	Privileged Communications	 	 	51	 
	10.	 	REPRESENTATIONS AND WARRANTIES	 	 	51	 
	 	 	10.1	 	Mutual Representations and Warranties	 	 	51	 
	 	 	10.2	 	Replidyne Representations and Warranties	 	 	52	 
	 	 	10.3	 	Debarment; Proceedings	 	 	52	 
	 	 	10.4	 	Disclaimer	 	 	52	 
	 	 	10.5	 	Limitation of Liability	 	 	53	 
	11.	 	CONFIDENTIALITY	 	 	53	 
	 	 	11.1	 	Confidential Information	 	 	53	 

-iv-

 

Table Of Contents

(continued)

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	Page	 
	 	 	11.2	 	Exceptions	 	 	53	 
	 	 	11.3	 	Authorized Disclosure	 	 	54	 
	 	 	11.4	 	Publicity	 	 	54	 
	12.	 	TERM AND TERMINATION	 	 	55	 
	 	 	12.1	 	Term	 	 	55	 
	 	 	12.2	 	Forest Right of Termination	 	 	55	 
	 	 	12.3	 	Termination for Material Breach	 	 	55	 
	 
	 	 	 	(a)	 	Material Breach	 	 	55	 
	 
	 	 	 	(b)	 	Material Breach Regarding Target Specialist or Pediatrician Promotion Efforts	 	 	56	 
	 	 	12.4	 	Termination for Insolvency	 	 	56	 
	 	 	12.5	 	Rights following Expiration of Term or Termination	 	 	56	 
	 
	 	 	 	(a)	 	Expiry of Term Under Section 12.1	 	 	56	 
	 
	 	 	 	(b)	 	Termination of this Agreement by Forest Under Section 12.2 or Replidyne Under Section 12.3(a) or 12.4	 	 	56	 
	 
	 	 	 	(c)	 	Termination of this Agreement by Forest under Section 12.3(a) or Section 12.4	 	 	57	 
	 
	 	 	 	(d)	 	Termination by Forest under Section 12.3(b)	 	 	57	 
	 
	 	 	 	(e)	 	Termination by Forest Under Section 12.3(a)	 	 	58	 
	 	 	12.6	 	Survival	 	 	58	 
	 	 	12.7	 	Exercise of Right to Terminate	 	 	58	 
	 	 	12.8	 	Damages; Relief	 	 	58	 
	 	 	12.9	 	Rights in Bankruptcy	 	 	59	 
	 	 	12.10	 	Effect of Termination of DAP Agreement	 	 	59	 
	13.	 	INDEMNIFICATION	 	 	59	 
	 	 	13.1	 	Indemnification by Replidyne	 	 	59	 
	 	 	13.2	 	Indemnification by Forest	 	 	59	 
	 	 	13.3	 	Control of Defense	 	 	60	 
	 	 	13.4	 	Insurance	 	 	60	 
	14.	 	DISPUTE RESOLUTION	 	 	60	 
	 	 	14.1	 	Dispute Resolution	 	 	60	 

-v-

 

Table Of Contents

(continued)

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	Page	 
	 	 	14.2	 	Arbitration	 	 	60	 
	 
	 	 	 	(a)	 	Claims	 	 	60	 
	 
	 	 	 	(b)	 	Arbitrators’ Award	 	 	61	 
	 
	 	 	 	(c)	 	Costs	 	 	61	 
	 
	 	 	 	(d)	 	Compliance with this Agreement	 	 	61	 
	 
	 	 	 	(e)	 	Injunctive or Other Equity Relief	 	 	61	 
	15.	 	GENERAL PROVISIONS	 	 	62	 
	 	 	15.1	 	Standstill	 	 	62	 
	 	 	15.2	 	Governing Law	 	 	62	 
	 	 	15.3	 	Entire Agreement; Modification	 	 	62	 
	 	 	15.4	 	Relationship Between the Parties	 	 	62	 
	 	 	15.5	 	Non-Waiver	 	 	63	 
	 	 	15.6	 	Assignment; Change in Control	 	 	63	 
	 	 	15.7	 	No Third Party Beneficiaries	 	 	64	 
	 	 	15.8	 	Severability	 	 	64	 
	 	 	15.9	 	Notices	 	 	64	 
	 	 	15.10	 	Force Majeure	 	 	65	 
	 	 	15.11	 	Interpretation	 	 	66	 
	 	 	15.12	 	Counterparts	 	 	66	 
	 	 	15.13	 	DAP Agreement	 	 	67	 

-vi-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00101-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00101-of-00352.parquet"}]]